Prof. Dr. med. Christoph U. Correll

Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters Charité – Universitätsmedizin Berlin Campus Virchow Augustenburger Platz 1 (Intern: Mittelallee 5a, 2. Stock) 13353 Berlin Tel.: 0049/30-450-566202 Fax: 0049/30-450-566921 Email: Christoph.Correll@charite.de

Website: https://kinder-und-

jugendpsychiatrie.charite.de/

The Zucker Hillside Hospital Department of Psychiatry Northwell Health The Zucker Hillside Hospital 75-59 263rd Street Glen Oaks, NY 11004 Telephone: (718) 470-4812 Fax: (718) 343-1659 Email: ccorrell@northwell.edu

Website: http://www.feinsteininstitute.org/faculty/christoph-u-correll-md/

BIRTH PLACE Hamburg, Germany

NATIONALITY German ACADEMIC AND CLINICAL POSITION

10/2017- CURRENT Professor and Director of the Department of Child and Adolescent

Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow,

Augustenburger Platz 1, 13353 Berlin, Germany 09/2017-10/2017 Guest Professor, Department of Neurology and Psychiatry,

Sapienza University of Rome Viale dell'Università, 30 – 00185 Rome, Italy 06/2013 - CURRENT Professor of Psychiatry and Molecular Medicine The Donald and Barbara Zucker School of Medicine at

Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, New York 11549, USA 12/2012 – 12/2016 Guest Professor, Klinik und Poliklinik für Psychiatrie und

Psychotherapie, Universitätsklinikum Carl Gustav Carus, Technische Universität,

Fetscherstraße 74, 01307 Dresden, Germany

01/2011 - CURRENT Investigator, Center for Psychiatric Neuroscience Feinstein Institute for Medical Research 350 Community Dr, Manhasset, New York 11030, USA

01/2011 – 12.2017 Adjunct Associate Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine 1300 Morris Park Ave, Bronx, New York 10461, USA

07/2010 – 05/2013 Associate Professor of Psychiatry and Molecular Medicine Hofstra North Shore-LIJ School of Medicine, 500 Hofstra Blvd, Hempstead, New York 11549, USA

01/2010 - CURRENT Co-Director, Laboratory of Child and Adolescent Psychiatry, Psychiatric Neuroscience Center of Excellence Feinstein Institute for Medical Research, 350 Community Dr, Manhasset, New York 11030, USA

Curriculum Vitae Christoph U. Correll, M.D. Page 2

07/2008 -12/2010 Associate Professor of Psychiatry and Behavioral Sciences Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, New York 10461, USA

01/2006 - CURRENT Medical Director, The Zucker Hillside Hospital Recognition and Prevention (RAP) Program, 75-59 263rd Street, Glen Oaks, New York 11004, USA

07/2005 – 10/2017 Director, Adverse Events Assessment and Prevention Unit, The Zucker Hillside Hospital Advanced Center for Intervention and Services Research,

75-59 263rd Street, Glen Oaks, New York 11004, USA

7/2005 - 12/2005 Associate Medical Director, The Zucker Hillside Hospital Recognition and Prevention (RAP) Program, 75-59 263rd Street, Glen Oaks, New York 11004, USA

03/2005 – 10/2017 Director, Core Laboratory Unit, The Zucker Hillside Hospital Advanced Center for Intervention and Services Research,

75-59 263rd Street, Glen Oaks, New York 11004, USA

10/2004 – 10/2017 Co-director, Research Knowledge Transfer Unit, The Zucker Hillside Hospital Advanced Center for Intervention and Services Research,

75-59 263rd Street, Glen Oaks, New York 11004, USA

10/2004 – 10/2017 Co-director, Clinical Assessment Strategies Unit, The Zucker Hillside Hospital Advanced Center for Intervention and Services Research,

75-59 263rd Street, Glen Oaks, New York 11004, USA

07/2003 - 06/2008 Assistant Professor of Psychiatry and Behavioral Sciences Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, New York 10461, USA

07/03 - CURRENT Staff Psychiatrist, The Zucker Hillside Hospital North Shore – Long Island Jewish Medical Center Division of Psychiatry Research, 75-59 263rd Street, Glen Oaks, New York 11004, USA EDUCATION 1985 - 1993 Free University of Berlin, Germany (Medical Studies) 1990 - 1991 Dundee University, Great Britain (Medical Studies) SUB-INTERNSHIPS 10/1992-01/1993 Psychiatry: St. Vincent’s Hospital and Medical Center of New York, New

York, U.S.A 02/1993-05/1993 Surgery: Universidad Austral de Chile, Instituto de Cirugia, Valdivia, Chile 06/1993-09/1993 Medicine: Universidad de Valparaiso, Hospital Van Buren, Valparaiso,

Chile MEDICAL DISSERTATION 1991-1996 “Presentation of psychotropic drugs in medical and non-medical media:

impact and quality assurance of the audit system press”. Medical dissertation (PhD), Free University of Berlin, Berlin, Germany, 1996 (Supervisor: Prof. Dr. Michael Linden).

Curriculum Vitae Christoph U. Correll, M.D. Page 3

UNITED STATES MEDICAL LICENSING EXAM

07/1994 Step one 05/1994 Step two 12/1998 Step three

UNITED STATES NATIONAL PROVIDER IDENTIFICATION (NPI) NUMBER

1053475954 UNITED STATES NATIONAL DRUG ENFORCEMENT ADMINISTRATION (DEA) NUMBER

BC8642793 RESIDENCY 01/1995-06/1997 Neurology Neurologische Klinik Bad Neustadt GmbH Von-Guttenberg-Straße 10, 97616 Bad Neustadt, Germany 07/1997-06/1998 Psychiatry PGY-1 Beth Israel Medical Center 16th Street at 1st Avenue New York, NY 10003, USA 07/1998-06/2001 Psychiatry PGY-2, PGY-3, Chief and Research Residency Hillside Hospital North Shore - Long Island Jewish Health System 75-59 263rd Street, Glen Oaks, NY 11004, USA

07/2001-06/2003 Child and Adolescent Psychiatry Fellow

Schneider Children’s Hospital North Shore - Long Island Jewish Health System 269-01 76th Avenue New Hyde Park, NY 11040, USA MEDICAL LICENSE 02/11/02-2/10/05 Indiana State License: 01055722 (inactive) 10/31/03-10/30/06 New York State Limited License: 002031 (inactive) 10/31/06-12/31/12 New York State Limited License: 002766 (inactive) 01/16/13-present New York State License: 268331 (valid until 05/31/2020) BOARD CERTIFICATIONS 05/2002 Diplomate, Psychiatry, American Board of Psychiatry and Neurology 11/2003 Diplomate, Child and Adolescent Psychiatry, American Board of

Psychiatry and Neurology

Curriculum Vitae Christoph U. Correll, M.D. Page 4

AWARDS AND HONORS

1. U.S. Psychiatric & Mental Health Congress Eli Lilly Fellowship Award (2000)

2. Pfizer Psychiatry Resident of the Year Award (2001)

3. New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award for outstanding research submission (2001)

4. Charlotte Marker Zitrin, MD Paper Award for best research paper (2001)

5. Hillside Hospital Department of Psychiatry Outstanding Resident Award (2001)

6. American Association of Directors of Psychiatric Residency Training (AADPRT) International Medical Graduate Mentorship Program Award in Psychiatry (Mentor: Judith Rapoport, M.D.) (2001)

7. Long Island Jewish Medical Center First Prize for Outstanding Achievement in Medical Writing (2001)

8. American Academy of Child and Adolescent Psychiatry (AACAP)/Pfizer Travel Award (2001)

9. American Association of Directors of Psychiatric Residency Training (AADPRT) Peter Henderson, M.D., Memorial Paper Award for best paper in the area of child and adolescent psychiatry (2002)

10. Seventh Annual American Psychiatric Association (APA) Research Colloquium for Junior Investigators Award (2002)

11. Clinical Research Methodology Workshop American Society of Clinical Psychopharmacology (ASCP) Fellowship Award (2002)

12. 11th Biennial Winter Workshop on Schizophrenia Young Scientist Award for excellence in scientific research (2002)

13. American Psychiatric Association (APA)/Lilly Resident Research Award for exceptional unpublished manuscript (2002)

14. American Academy of Child and Adolescent Psychiatry (AACAP) Presidential Scholar Award for outstanding research achievements (Mentor: Barbara Geller, M.D.) (2002)

15. American Association of Directors of Psychiatric Residency Training (AADPRT) George Ginsberg Fellowship Award for outstanding achievement in education and teaching (2003)

16. American Federation for Medical Research (AFMR) Clinical Research 2003 Conference Travel Award (2003)

17. American Federation for Medical Research (AFMR) Henry Christian Award for the most outstanding abstract in each category (2003)

18. Clinical Research Methodology Workshop American Society of Clinical Psychopharmacology (ASCP) Fellowship Award (2003)

19. 156th Annual American Psychiatric Association (APA) Resident and Staff Physician Fellow Correspondent Program Award (2003)

20. Long Island Jewish Medical Center First Prize for Outstanding Achievement in Medical Writing (2003)

21. Long Island Jewish Medical Center Second Prize for Outstanding Achievement in Medical Writing (2003)

22. John and Maxine Bendheim Fellowship Award for Research (2003)

23. Ninth Annual American Psychiatric Association (APA) Research Colloquium for Junior Investigators Award (2004)

24. American Academy of Child and Adolescent Psychiatry (AACAP) 2004 Pilot Research Award (2004)

25. North Shore - Long Island Jewish Research Institute Faculty Research Award (2004)

26. American College of Neuropsychopharmacology (ACNP) Travel Award (2005)

27. International Congress on Schizophrenia Research (ICOSR) Young Investigator Award (2005)

Curriculum Vitae Christoph U. Correll, M.D. Page 5

28. First NIMH-sponsored Career Development Institute for Bipolar Disorder Fellowship Award (2005)

29. First Neuroleptic Malignant Syndrome Information Service (NMSIS) 2004-2005 Promising New Investigators award (2005)

30. National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigators Award (2007)

31. American College of Neuropsychopharmacology (ACNP) Membership (2010)

32. John and Maxine Bendheim Fellowship Award for Research (2013)

33. American Academy of Child and Adolescent Psychiatry (AACAP) Outstanding Mentor Award (2014)

34. International Society for Bipolar Disorders (ISBD) Best Paper Award - 1st place for the best paper published in Bipolar Disorders in 2015: Correll CU, Hauser M, Penzner JB, Auther AM, Kafantaris V, Saito E, Olvet D, Carrión RE, Birmaher B, Chang KD, Delbello MP, Singh MK, Pavuluri M, Cornblatt BA. Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. Bipolar Disord. Aug;16(5):478-92. (2015)

35. Psychiatry Editor's Choice: Best articles of 2015 - Ranked, sorted, and summarized by MDLinx editors from the latest literature: Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015 Jun;14(2):119-136. (2015)

https://snt147.mail.live.com/?tid=cmlHdWHKCu5RGfhgAhWteyLA2&fid=flinbox

36. NYCCC Advisory Council Award, 40th Lauretta Bender Honored Lecturer (2016)

37. Northwell Health and the Feinstein Institute Excellence in Research Award for the paper: John M Kane, Delbert G Robinson, Christoph Correll, Patricia Marcy and Majnu John; “Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-year Outcomes From the NIMH RAISE Early Treatment Program.” Am J Psychiatry 173(4):362-372, 2016.

38. “Outstanding Research Partner” Award to the “MOBILITY Research Team of Christoph Correll, Northwell Health” by the North Shore Child & Family Guidance Center, 64th Annual Meeting of the North Shore Child & Family Guidance Center, NY, June 13, 2017

39. Excellence in Research Award by the Feinstein Institute for Medical Research, Manhasset, NY, presented to Christoph U Correll, MD, Jose M Rubio, MD and John M Kane, MD for the published paper, entitled “What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17(2):149-160, 2018” for highlighting new paradigms that will lead to improved diagnosis, treatment and prevention of human disease through research (2018)

EXPERT RANKING 2014

1. Listing by Web of Science as one of “The most influential scientific minds 2014” and “top 1% cited scientists in the area of psychiatry”

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CB4QFjAA&url=http%3A%2F%2Fsciencewatch.com%2Fsites%2Fsw%2Ffiles%2Fsw-article%2Fmedia%2Fworlds-most-influential-scientific-minds-2014.pdf&ei=lnDZU-a5OdGzyASFkIGACg&usg=AFQjCNEnGNfIdAineRp1nfq023_pRcMdBw&sig2=k7Q7D_zg0VF-SXBHyG6hbA&bvm=bv.72185853,d.aWw

2015

1. Listing by Web of Science as one of “The most influential scientific minds 2015” and “top 1% cited scientists in the area of psychiatry”

http://stateofinnovation.thomsonreuters.com/worlds-most-influential-scientific-minds-report-2015?utm_term=jan&utm_content=hcr-congrats&utm_campaign=12772-HCR_WMISM-27815&utm_medium=email&utm_source=Eloqua

Curriculum Vitae Christoph U. Correll, M.D. Page 6

2016

1. Listing by Web of Science as one of “The most influential scientific minds 2016” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com)

2017

1. Ranked number 1 among world’s experts on the topic of psychotropic drugs (11/2017) (http://expertscape.com/ex/psychotropic+drugs)

2. Ranked number 1 among world’s experts on the topic of schizophrenia (11/2017) (http://expertscape.com/ex/schizophrenia)

3. Ranked number 1 among world’s experts on the topic of weight gain, out of 54,268 ranked scientists (11/2017) (http://expertscape.com/ex/weight+gain)

4. Ranked number 13 among world’s experts on the topic of bipolar disorder (11/2017) (http://expertscape.com/ex/bipolar+disorder)

5. Listing by Web of Science as one of “The most influential scientific minds 2017” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com)

2018

1. Ranked number 1 among world’s experts on the topic of psychotropic drugs, out of 121,791 ranked scientists (12/2018) (http://expertscape.com/ex/psychotropic+drugs)

2. Ranked number 1 among world’s experts on the topic of schizophrenia, out of 66,205 ranked scientists (12/2018) (http://expertscape.com/ex/schizophrenia)

3. Ranked number 1 among world’s experts on the topic of antipsychotics, out of 52,280 ranked scientists (12/2018) (http://expertscape.com/ex/antipsychotics)

4. Ranked number 2 among world’s experts on the topic of weight gain, out of 57,426 ranked scientists (12/2018) (http://expertscape.com/ex/weight+gain)

5. Ranked number 6 among world’s experts on the topic of clozapine, out of 8,832 ranked scientists (12/2018) (http://expertscape.com/ex/clozapine

6. Ranked number 20 among world’s experts on the topic of bipolar disorder out of 33,924 ranked scientists (12/2018) (http://expertscape.com/ex/bipolar+disorder)

7. Listing by Web of Science as one of “The most influential scientific minds 2017” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com)

2019 (23 topics as World Expert = Top 0.1%; 14 topics ranked as expert = top 1% cited experts)

1. Ranked number 1 among world’s experts on the topic of central nervous system agents, out of 285,553 ranked scientists (05/2019) (http://expertscape.com/ex/central+nervous+system+agents)

2. Ranked number 1 among world’s experts on the topic of central nervous system depressants, out of 216,420 ranked scientists (05/2019)

(http://expertscape.com/ex/central+nervous+system+depressants)

3. Ranked number 1 among world’s experts on the topic of psychotropic drugs, out of 127,321 ranked scientists (05/2019) (http://expertscape.com/ex/psychotropic+drugs)

4. Ranked number 1 among world’s experts on the topic of tranquilizing agents, out of 71,280 ranked scientists (05/2019) (http://expertscape.com/ex/tranquilizing agents)

5. Ranked number 1 among world’s experts on the topic of schizophrenia, out of 69,752 ranked scientists (05/2019) (http://expertscape.com/ex/schizophrenia)

6. Ranked number 1 among world’s experts on the topic of antipsychotics, out of 54,452 ranked scientists (05/2019) (http://expertscape.com/ex/antipsychotics)

7. Ranked number 1 among world’s experts on the topic of weight gain, out of 59,948 ranked scientists (05/2019) (http://expertscape.com/ex/weight+gain)

Curriculum Vitae Christoph U. Correll, M.D. Page 7

8. Ranked number 6 among world’s experts on the topic of clozapine, out of 9,330 ranked scientists (05/2019) (http://expertscape.com/ex/clozapine)

9. Ranked number 8 among world’s experts on the topic of heterocyclic compounds, 3-ring, out of 219,981 ranked scientists (05/2019) (http://expertscape.com/ex/heterocyclic+compounds+3-ring)

10. Ranked number 11 among world’s experts on the topic of behavioral disciplines and activities out of 266,443 ranked scientists (05/2019) (http://expertscape.com/ex/behavioral+disciplines+activities)

11. Ranked number 12 among world’s experts on the topic of delayed-action preparations out of 63,868 ranked scientists (05/2019) (http://expertscape.com/ex/delayed-action+preparations)

12. Ranked number 16 among world’s experts on the topic of mental disorders out of 289,517 ranked scientists (05/2019) (http://expertscape.com/ex/mental+disorders)

13. Ranked number 21 among world’s experts on the topic of bipolar disorder out of 35,735 ranked scientists (05/2019) (http://expertscape.com/ex/bipolar+disorder)

MEDIA 2003 - present Interviews and coverage by local, national and international newspapers, radio

and television, including AP Radio Network Washington DC; Associated Press; Baltimore Sun; Behavioral Health Central; Bloomberg News; BP Magazine; CBS Evening News; Chicago Tribune; Clinical Psychiatry News; Correio Braziliense; dailyRx News; Disability Scoop; Doctor’s Guide; Forbes Magazine; Frankfurter Allgemeine Zeitung; Glen Oaks Ledger; Health.com; HealthDay; Healthline; Medscape Psychiatry; Nervenheilkunde; Newsday; New York Times; National Public Radio (NPR); Psychiatric News; Psychiatric Times; ReachMD Radio; Schizophrenia Research Forum; Science; Science Magazine; Sirius XM Satellite Radio; The New York Times; The Philadelphia Inquirer; Times.com; USA TODAY; Veritas Medicine; and the Wall Street Journal.

2004 Listing in the “Guide to America’s Top Psychiatrists” by the Consumers’ Research Council of America

2005, 2006 Listing in Marquis’ 60th and 61st edition of “Who is Who in America”

2008/2009 Listing in Cambridge Who’s Who Registry Among Executives and Professionals in the field of Research, Medicine and Healthcare

2010 Healthcare Channel TV Interview http://currentmedicine.tv/?s=correll

TEACHING ACTIVITY/CLINICAL SUPERVISION 1995 - 1997 Teaching clinical neurology to nurses, physical therapists and

neurorehabilitation staff at the Neurologische Klinik Bad Neustadt

1996 - 1997 Teaching and supervision of incoming residents during their mandatory rotation as chief resident of the neurological ICU, Neurologische Klinik Bad Neustadt

1996 - 1997 Assistant teaching position at the School for Physiotherapy, Bad Neustadt, Germany, teaching the neurology curriculum to first- and second-year physical therapists

1997 - 1998 Teaching and supervision of third- and fourth-year medical students as well as physician assistants during their clinical rotations as a PGY-1 at Beth Israel Medical Center, NY

Curriculum Vitae Christoph U. Correll, M.D. Page 8

1998 - 1999 Supervision of third- and fourth-year medical students as a PGY-2 at Hillside Hospital

2000 - 2001 Supervision of third- and fourth-year medical students as well as first- and second-year residents at Hillside Hospital during inpatient chief residency

2000 - 2007 Tutor and supervisor of undergraduate and medical student awardees of the Stanley Scholar Research Fellowship in psychiatric research

2001 - 2003 Development of an annual educational workshop on research for residents of the adult and child and adolescent psychiatry programs at Long Island Jewish Medical Center

2003 - 2006 Course director, The Zucker Hillside Hospital Research Seminar for psychiatry residents

2003 - 2006 Course director and lecturer, The Zucker Hillside Hospital Psychopharmacology Teaching Course for second year psychiatry residents

2003 - present Comprehensive Psychiatric Care supervisor for fourth year psychiatry residents

2003 - present Lecturer of the Schneider Children’s Hospital Child and Adolescent Psychiatry Psychopharmacology Teaching Course for first year child and adolescent psychiatry residents

2003 - present Psychiatry Research Elective supervisor for third- and fourth-year psychiatry residents

2003 - present Psychopharmacology supervisor for final year adult psychiatry residents

2003 - present Psychopharmacology supervisor for first-and second-year child and adolescent psychiatry fellows

2004 - 2006 Course director of the Zucker Hillside Hospital Scientific Journal Club Meeting

2006 – 2010 External psychopharmacology lecturer for third-and fourth-year psychiatry residents at Coney Island Hospital, New York.

2007 - present Course co-director and lecturer, The Zucker Hillside Hospital Psychobiology and Neuroscience Course for second- and third-year psychiatry residents

2007 - present Course director and lecturer, The Zucker Hillside Hospital Mood Disorder Component of the Psychobiology and Neuroscience Course for second-and third-year psychiatry residents

2010- present External clinical research supervisor for first year child and adolescent psychiatry fellows at North Shore University Medical Center, New York.

DEPARTMENTAL/HOSPITAL SERVICE

1999 - 2001 Member, Psychiatric Residency Retreat Committee

2000 - 2001 Member, Journal Club Committee

2000 - 2001 Resident Representative to the Department of Psychiatry Executive Committee

2000 - 2001 Department of Psychiatry Comprehensive Review of Psychiatry Editorial Committee

1999 - 2001 Resident Representative, The Zucker Hillside Hospital Pharmacy and Therapeutics Committee

2000 - 2001 Member, LIJ Resident’s Council

Curriculum Vitae Christoph U. Correll, M.D. Page 9

Member, LIJ House Staff Affairs Committee

2001 - 2002 Member, American Academy of Child and Adolescent Psychiatry Early Investigators Group Organizational Committee

2001 - 2003 Child Psychiatry Fellow Representative, The Zucker Hillside Hospital Pharmacy and Therapeutics Committee

2001 - 2017 Member, The Zucker Hillside Hospital Research Protocol Committee

2003 - 2017 Member, The Zucker Hillside Hospital Pharmacy and Therapeutics Committee

2003 - 2005 Member, Center for Weight Management Medical Oversight Committee

2004 - 2005 Member, Long Island Jewish Medical Center Bariatric Surgery Performance Improvement Committee

2004 - 2012 Alternate Member, the North Shore - Long Island Jewish Health System Institutional Review Board (IRB)

2004 - 2011 Member, Research Network Development Unit of the NIMH-funded Zucker Hillside Hospital Advanced Center for Intervention and Services Research

2004 – 2017 Member, the Zucker Hillside Hospital Research Training Committee of the Advanced Center for Intervention and Services Research Training Committee

2004 – 2017 Co-director, Knowledge Transfer Unit of the NIMH-funded Zucker Hillside Hospital Advanced Center for Intervention and Services Research

2004 – 2017 Co-director, Clinical Assessment Strategies Unit of the NIMH-funded Zucker Hillside Hospital Advanced Center for Intervention and Services Research

2005 – 2017 Director, Research Core Laboratory Unit, The Zucker Hillside Hospital Division of Psychaitry Research

2005 – 2017 Director, Adverse Events Assessment Unit of the NIMH-funded Zucker Hillside Hospital Advanced Center for Intervention and Services Research

2005 - 2006 Associate Medical Director, the NIMH-funded Zucker Hillside Hospital Recognition and Prevention (RAP) Program

2006 – 2017 Medical Director, the NIMH-funded Zucker Hillside Hospital Recognition and Prevention (RAP) Program

2006 – 2017 Co-director, Zucker Hillside Hospital Research Track in Child and Adolescent Psychiatry

2006 Member, the Zucker Hillside Hospital – North Shore University Hospital Education Policy Committee

2006 Co-chair, the Zucker Hillside Hospital – North Shore University Hospital Education Policy Committee’s Neurobiology and Biological Psychiatry Subcommittee

2009 Chair, Ad Hoc Committee for the Albert Einstein Committee on Appointments and Promotions for an applicant for promotion to Associate Professor of Clinical Medicine and Associate Professor of Clinical Family and Social Medicine

2009 – 2017 Co-director, Zucker Hillside Hospital Research Track in General Psychiatry

2009 – 2017 Director, Visiting Research Scientist and Fellowship Program

2010 – 2017 Director, Pediatric Diagnostic and Psychopharmacology Consultation Service

Curriculum Vitae Christoph U. Correll, M.D. Page 10

PROFESSIONAL SOCIETY MEMBERSHIPS

1997 - present Member, American Psychiatric Association (APA)

2000 - present Member, American Academy of Child and Adolescent Psychiatry (AACAP)

2001 - 2004 Member, American Academy of Child and Adolescent Psychiatry (AACAP) Early Investigators Group

2004 - present Fellow, CME Institute of Physicians Postgraduate Press

2005 - present Member, Schizophrenia International Research Society (SIRS)

2005 - present Board Member, American Society of Clinical Psychopharmacology (ASCP)

2005 - present Member, International Early Psychosis Association (IEPA)

2006 - 2011 Professional Advisory Council Member, Child & Adolescent Bipolar Foundation (CABF)

2006 - 2011 Senior Advisor, Young Investigators in Biological Child and Adolescent Psychiatry Group (YIBcap) http://www.yibcap.com/index.php?page_id=0604040001&lang=de

2010 - 2016 Member, American College of Neuropsychopharmacology (ACNP)

2011 - 2013 Professional Advisory Council Member, Balanced Mind Foundation

2011 - present Member, International Society for Bipolar Disorders (ISBD)

2012 – 2017 Fellow, New York Academy of Medicine (NYAM) [ID: 53131]

2013 - present Member, German Association of Child and Adolescent Psychiatry (DGKJP)

2014 - present Member, Faculty, Lundbeck International Neuroscience Foundation (LINF)

2016 - present Member, Société Médico-Psychologique

2016 - present Member, Scientific Advisory Board, Institue of clinical Research and Education in Medicine - I.R.E.M.

2016 - present Fellow and Board Member, American Society of Clinical Psychopharmacology (ASCP)

2016 - present Member, Board of Trustees, Lundbeck International Neuroscience Foundation (LINF)

2017 - present Fellow, American College of Neuropsychopharmacology (ACNP)

2018 - present Nordostdeutsche Gesellschaft für Psychiatrie, Psychotherapie und Psychosomatik des Kindes- und Jugendalters e. V.

Curriculum Vitae Christoph U. Correll, M.D. Page 11

OTHER EXTERNAL PROFESSIONAL ACTIVITIES US COMMITTEE, EXPERT AND CONSENSUS ACTIVITIES

November 2003 Observing Member, Consensus Development Conference on Antipsychotic

Drugs and Obesity and Diabetes, cosponsored by the American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity

2004 Member, Expert Consensus Panel on Atypical Antipsychotic Related Adverse Effects in Children and Adolescents (Chair: Elizabeth Pappadopulos, PhD)

2004 - 2008 Member, American Psychiatric Association Work Group on Diabetes and Second-generation Antipsychotic Agents

November 2005 Member, Advisory Board to the NIMH Negative Symptoms Initiative for the development of a new rating instrument for the assessment of negative symptoms in schizophrenia

March 2006 Member, Bipolar Disorder NOS Consensus Work Group, Satellite Symposium of the Fourth Annual NIMH Collaborative Pediatric Bipolar Disorder Conference, Chicago, IL, March 31, 2006.

2006 Member, “Consensus Survey of Outpatient Management of Aggressive Youth”, and the “Consensus Meeting on Outpatient Prescribing of Antipsychotics in Youth: Treatment Recommendations and Research Priorities”, Dallas, TX, 02.12 - 02.13.2006. (Co-Chairs: Peter Jensen, MD, and Elizabeth Pappadopulos, PhD)

2006 Member, Roadmap Expert Consensus Group on the Pharmacology and Use of Antipsychotics (Chair: Peter Weiden, MD)

2007 - 2009 Member, Steering Committee, New Drug Evaluation Unit (NCDEU) conference

2007 - 2012 Member, Steering Committee of the Centers for Education and Research on Therapeutics (CERTs), a research program administered by the Agency for Healthcare Research and Quality (AHRQ), in consultation with the Food and Drug Administration agencies within the United States Department of Health and Human Services (HHS) regarding the Treatment of Maladaptive Aggression in Youth (TMAY) Consensus Guideline development.

2008 - 2009 Member, Work Group on Research and Pediatric Psychopharmacology Initiative (PPI), American Academy of Child and Adolescent Psychiatry (AACAP) for the development of the Parents’ Medication Guide for Bipolar Disorder in Children and Adolescents (http://www.aacap.org/cs/BipolarDisorder.ResourceCenter; www.parentsmedguide.org)

2008 - 2011 Member, Pilot Research Award Selection Committee, American Academy of Child and Adolescent Psychiatry (AACAP)

2008 – 2017 Member, Work Group on Research, American Academy of Child and Adolescent Psychiatry (AACAP)

2009 Member, Planning Committee for the 50th Anniversary Meeting of the New Drug Evaluation Unit (NCDEU) conference

2011 Subject matter expert/Consultant, Antipsychotic Medication Decision Aid, developed by the US Department of Health and Human Services, Center for Mental Health Services (CMHS) in the federal Substance Abuse

Curriculum Vitae Christoph U. Correll, M.D. Page 12

and Mental Health Services Administration (SAMHSA) (http://archive.samhsa.gov/BRSS-TACS-Decision-Tool/DA_files/Intro_pg5_Acknowledgments.html)

2011 – 2012 Member, Program Committee of the annual New Drug Evaluation Unit (NCDEU) conference

2012 – present Member, Program Committee of the annual American Society of Clinical Psychopharmacology (ASCP) conference

2012 – 2013 Member, Clinical Expert Review Committee (CERC) for the FDA sponsored schizophrenia data standards development initiative as part of the Center for Drug Evaluation and Research (CDER) “55 in Five” program.

2012 - present Consultant, FDA-sponsored Mini-Sentinel and Metabolic Effects of Second-Generation Antipsychotics in Youth Work Group of the Rutgers University Center for Education Research and Therapeutics (CERTS) (http://mini-sentinel.org/assessments/medical_events/details.aspx?ID=203).

2012 – 2016 Member, Faculty of 1000, Post-publication Peer Review (F1000Trials; F1000Prime) (http://f1000.com/thefaculty/member/8347384589127120)

2014 Stakehoder, 2014 ROAMER's Survey on 'Priorities for mental health research in Europe' to orientate next calls of the EU's Horizon 2020 programme

2014 Subject matter expert, The National Institute for Child Health and Human Development (NICHD) Pediatric Adverse Event Working Group (AEWG) sponsored initiative to build a core set of pediatric adverse event concepts (terms, synonyms, and definitions) for clinical research, safety reporting, and medical practice in order to create a core library of harmonized pediatric terms that will enable clinical research, quality and safety reporting in the USA and internationally

2014 – present Co-chair, Treatment Response and Resistance in Psychosis (TRRIP) working group (co-chairs: O Howes, J Kane, C Correll)

2015 Member, Clinical Expert Review Committee (CERC) for the FDA sponsored bipolar disorder standard data elements development initiative as part of the Center for Drug Evaluation and Research (CDER) Data Standards program.

2016 Subject matter expert/Consultant, Update of the Antipsychotic Medication Decision Aid, developed by the US Department of Health and Human Services, Center for Mental Health Services (CMHS) in the federal Substance Abuse and Mental Health Services Administration (SAMHSA) (http://archive.samhsa.gov/BRSS-TACS-Decision-Tool/DA_files/Intro_pg5_Acknowledgments.html)

2016 Member, Clinical Expert Review Committee (CERC) for the FDA sponsored generalized anxiety disorder standard data elements development initiative as part of the Center for Drug Evaluation and Research (CDER) Data Standards program.

2017 Ad Hoc Member, Promotions Committtee for Full Professorship, Harvard Medical School, Boston, MA, USA.

2017 Content expert, “Good Outcome in Individuals at Ultra-High Risk (UHR) of Developing Psychosis: A Delphi Study”, led by The Psychosis Studies Department at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London (Natalia Petros, Andrea Mechelli, Philip McGuire, Polly Radcliffe and Paolo Fusar-Poli).

Curriculum Vitae Christoph U. Correll, M.D. Page 13

2017 - present Member, American College of Neuropsychopharmacology (ACNP) Program Committee

2017 – present Member, American Society of Clinical Psychopharmacology (ASCP) Task Force on Expert Consensus Guidelines

2017 Discussant, breakout session “Biopsychosocial and Behavioral Factors Associated with the Development of Severe Obesity” as part of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop on Developing Precision Medicine Approaches to the Treatment of Severe Obesity in Adolescents: Research Gaps and Opportunities, Rockville, MD, September 18-19, 2017 (https://www.niddk.nih.gov/news/events-calendar/Pages/workshop-developing-precision-medicine-approaches-treatment-severe-obesity-adolescents.aspx)

2017 Panelist and Member, 2017 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults (faculty preparing guidelines for: Long-acting injectable antipsychotics in the treatment of schizophrenia)

2018 - present Working Goup member, content expert for psychositc disorders, International Consortium for Health Outcomes Measurement (ICHOM)

EX-US INTERNATIONAL COMMITTEE ACTIVITIES

2007 - 2011 Member, German Bipolar Disorder Treatment Guideline (“S-3”) Project (Chair: Prof. Dr. Dr. Michael Bauer)

2011 – 2015 Member, Task Force on Pediatric Bipolar Disorder (co-chairs: B. Findling and E. Youngstrom), International Society for Bipolar Disorders (ISBD)

2011 – 2018 Co-chair, Task Force on Bipolar Disorder Prodromes (co-chairs: C. Correll and G. Faedda,) International Society for Bipolar Disorders (ISBD)

2011 - present Member, Work Group on Prevention of Psychiatric Disorders, German Association of Psychiatry, Psychotherapy and Neurology (DGPPN) (Co-chairs: Prof. Dr. Dr. Michael Bauer; Prof. Dr. Joachim Klosterkotter)

2011 - present Member, Scientific Program Committee, bi-annual International Congress on Schizophrenia Research (ICOSR)

2012 – 2015 Member, Collegium Internationale Neuro-Psychopharmacologicum (CINP) algorithm of the pharmacological treatment of schizophrenia (senior author) http://www.cinp.org/cinp-schizophrenia-guidelines/

2012 - present Member, Education Committee, Schizophrenia International Research Society (SIRS)

2012 - present Member, Research Committee (chair: M. Leboyer), International Society for Bipolar Disorders (ISBD)

2012 - present Member Child and Adolescent Psychiatry Expert Group (since 09/2017: chair), German Schizophrenia Treatment Guideline (“S-3”) Project (Chair: Prof. Dr. Peter Falkei)

2015 – 2018 External expert, Advisory Committee for the European Network Child & Adolescent Psychopharmacology Network (ECAPN)

2016 - present Member, European College of Neuropsychopharmacology (ECNP) Taskforce on pediatric Neuroscience-based Nomenclature (pNbN) for psychotropic medications

Curriculum Vitae Christoph U. Correll, M.D. Page 14

2017 - present Member, Scientific Program Committee, bi-annual Schizophrenia International Research Society (SIRS) Meeting

2017 - present Senior Scientific Advisor, International advisory group for the Latin American Network in Early Psychosis (LATAM), led by Nicolas Crossley (Chile) and Rodrigo Bressan (Brazil)

2017 - present Member, European College of Neuropsychopharmacology (ECNP) Taskforce on Neuroscience-based Nomenclature (NbN) for psychotropic medications

2017 - present Member, German Association of Psychiatry, Psychotherapy and Neurology (DGPPN) Task-Force „Early Recognition and Prevention of Severe Psychiatric Disoders ["Früherkennung und Frühbehandlung von schweren psychischen Erkrankungen]

2018 - present Member, European Network Child & Adolescent Psychopharmacology Network (ECAPN)

2018 - present Member, European College of Neuropsychopharmacology Prevention of Mental Disorders and Promotion of Mental Health - Thematic Working Group (PMD-TWG) (Co-chairs: P. Fusar-Poli, C Arango)

2018 - present Executive Committee member, Work Group on Prevention of Psychiatric Disorders, German Association of Psychiatry, Psychotherapy and Neurology (DGPPN) (Chair: Prof. Dr. Andrea Pfennig)

DATA SAFETY MONITORING BOARD (DSMB) AND GLOBAL SAFETY ADVISORY BOARD ACTIVITIES

2003 - 2006 Member, Data Safety Monitoring Board for four Otsuka Pharmaceuticals

registration trials of aripiprazole (APEX) in children and adolescents with schizophrenia and bipolar disorder (2 Phase 3, acute phase placebo controlled FDA registration trials, one long-term placebo controlled trial and long-term one open label extension study)

2005 - 2008 Chair, Data Safety Monitoring Board for three Bristol-Meyers Squibb registration trials of aripiprazole in children and adolescents with autistic disorder (2 Phase 3, acute phase placebo controlled FDA registration trials, one long-term open label extension study)

2008 - 2009 Chair, Data Safety Monitoring Board for the Supernus Pharmaceuticals registration trials of molindone in children and adolescents with disruptive behavior disorders (1 Phase 2b, acute phase dose finding FDA registration study)

2008 - 2010 Co-Chair, Data Safety Monitoring Board for three Otsuka Pharmaceuticals registration trials of aripiprazole long-acting injectable in adults with schizophrenia (2 Phase 3 FDA relapse prevention registration trial programs)

2009 - 2010 Member, Data Safety Monitoring Board for the Cephalon registration trial of Armodafinil in adults with schizophrenia (2 Phase 3, acute phase placebo controlled FDA registration trials, one long-term open label extension study)

2010 - 2013 Chair, Data Safety Monitoring Board for the Cephalon registration trial of Armodafinil in adults with bipolar depression (3 Phase 3, acute phase placebo controlled FDA registration trials, one long-term open label extension study)

Curriculum Vitae Christoph U. Correll, M.D. Page 15

2011 - 2015 Chair, Data Safety Monitoring Board for the Lundbeck and Takeda registration trial of Lu AA21004 (vortioxetine) in children and adolescents with major depressive disorder (EMA and FDA registrational trial program, starting with two Phase 2b open dose escalation studies)

2012 Ad hoc Member, Futility Data Monitoring Committee (DMC) for Study HBBN, a Phase 3, multicenter, acute, double-blind, fixed-dose, placebo-controlled, parallel-arm study comparing 3 doses of pomaglumetad methionil with placebo in adult patients with schizophrenia, Eli Lilly and Company

2012 - 2013 Member, Global Safety Advisory Board for cross-specialty marketed products and compounds in clinical development, Takeda Pharmaceuticals, Inc.

2012 - 2014 Chair, Data Safety Monitoring Board for the Janssen Pharmaceuticals Phase 3 registration trial of 3-monthly paliperidone palmitate injections in adults with schizophrenia (one placebo controlled discontinuation Phase 3 FDA registration trial and one active controlled Phase 3 FDA registration trial compared to once monthly paliperidone palmitate)

2013 Expert consultant, FDA and EMA registrational study program of Edivoxetine by Eli Lilly for major depressive disorder

2013 - 2016 Chair, Data Safety Monitoring Board for the Pfizer Phase 3 registration trial of ziprasidone for manic or mixed episodes associated with bipolar I disorder in children and adolescents aged 10-17 years old

2015 - present Member, Otsuka Pharmaceuticals Global Pharmacovigilance Advisory Committee

2016 - present Chair, Data Safety Monitoring Board for the Lundbeck and Takeda registration trial program of vortioxetine in children (aged 6-12) and adolescents (aged 13-17) with major depressive disorder (EMA and FDA registrational trial program), including 2 randomized, double blind Phase 3 trials and one large and long-term open label extension study.

2017 - present Chair, Data Monitoring Committee for the Laboratorios Pharmaceuticos Rovi, S.A. PRISMA-3 FDA registration trial program of Risperidone ISM in adults with schizophrenia.

2018 - present Chair, Data Monitoring Committee for the Teva Pharmaceuticals subcutaneous long-acting injectable antipsychotic regulatory approval phase 3 RISE (RIsperidone Subcutaneous Extended release) study program (TV46000-CNS-30072) in adults with schizophrenia.

2018 - present Chair, Data Monitoring Committee for the Supernus Pharmaceuticals phase 3 study program of molindoine extended release for impulsive aggression in children and adolescents with attention-deficit/hyperactivity disorder

CNS REGULATORY EXPERIENCE

February 2009 Expert, Oral Hearing of the Scientific Advisory Group (SAG) of the European

Medicines Agency (EMA) regarding the European registration of aripiprazole for adolescents with schizophrenia (February 5, 2009)

June 2009 Expert, Oral Explanation in front of the Food and Drug Administration (FDA) regarding the US registration of quetiapine in children and adolescents with bipolar disorder (June 9/10, 2009)

Curriculum Vitae Christoph U. Correll, M.D. Page 16

July 2009 Expert, Oral Explanation in front of the 27-member state delegates of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the European registration of aripiprazole for adolescents with schizophrenia (July 20, 2009)

March 2010 Expert, Oral Explanation in front of the 27-member state delegates of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the European registration of quetiapine for adults with unipolar depression (March 16, 2010)

09/2010-2011 Expert consultant, Pediatric Investigational Plan (PIP) development for TC-5124 (mecamylamine hydrochloride) by Astra Zeneca for an EMA registrational study program for major depressive disorder

October 2010 Expert, Oral Explanation in front of the joint meeting of the Pediatric Committee (PDCO) and Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the schizophrenia indication of the Pediatric Investigational Plan (PIP) for aripiprazole in Europe (October 18, 2010)

March 2011 Expert, Oral Explanation in front of the meeting of the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) regarding the bipolar I disorder indication of the Pediatric Investigational Plan (PIP) for aripiprazole in Europe (March 17, 2011)

September 2011 Expert, Discussion Meeting of MedAvante with the Scientific Advice Work Party (SAWP) of the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA), regarding a request for the issuance of a Qualification Opinion on the regulatory use of videoconference based centralized ratings in schizophrenia trials in Europe (September 27, 2011)

October 2012 Expert, Debrief meeting with members of the Committee for Medicinal Products for Human Use (CHMP) in preparation for an Oral Explanation in front of the 27 member state delegates of the European Medicines Agency (EMA) regarding the European registration of aripiprazole for children and adolescents with bipolar I disorder (October 16, 2012)

December 2012 Expert, Oral Explanation in front of the 27-member state delegates of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the European registration of aripiprazole for children and adolescents with bipolar I disorder (December 11, 2012)

US MENTORSHIP PROGRAM PARTICIPATION October 2005 Mentor for the American Academy of Child and Adolescent Psychiatry (AACAP)

Travel Awardees at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2005.

October 2006 Mentor for the American Academy of Child and Adolescent Psychiatry (AACAP) Travel Awardees at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, CA, October 24-29, 2006.

October 2007 Mentor for the American Academy of Child and Adolescent Psychiatry (AACAP) Travel Awardees at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Boston, MA, October 23-28, 2007.

Curriculum Vitae Christoph U. Correll, M.D. Page 17

October 2008 Mentor for the American Academy of Child and Adolescent Psychiatry (AACAP) Travel Awardees at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28- November 2, 2008.

October 2010 Mentor for the American Academy of Child and Adolescent Psychiatry (AACAP) Travel Awardees at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), New York, NY, October 26-31, 2010.

EX-US INTERNATIONAL MENTORSHIP PROGRAM PARTICIPATION

August 2004 International Association in Child and Adolescent Psychiatry and Allied

Professions (IACAPAP) Donald J. Cohen Mentor of Donald J. Cohen Research Fellows attending the at 16th World Congress of the IACAPAP, Berlin, Germany, August 22 - 26, 2004

2006 - 2012 “Senior Advisor” for “Young Investigators in Biological Child and Adolescent Psychiatry (YIBcap)”, a national early investigator group of German child and adolescent psychiatrists (www.YIBcap.com).

DOCTORAL THESIS MENTOR /JURY MEMBER 2010-2013 Co-mentor, Primary investigator: Amber de Herdt, medical doctoral thesis

project at the Katholic University Leuven, Belgium, entitled “Associations between physical activity attitude, caloric expenditure, functional exercise capacity, metabolic functioning and brain plasticity in first episode psychotic patients and individuals at risk mental state for psychotic disorders”. Role: Co-mentor (other mentor: Prof. Marc De Hert)

2011-2012 Co-mentor, Primary investigator: Nella Lo Cascio, MD: medical doctoral thesis project at the Sapenzia University Rome, Italy, entitled “Early detection of schizophrenia: current findings and future tasks”. Role: Co-mentor (other mentors: Prof. Paolo Girardi, MD and Prof. Paolo Fiorinastro)

2012 External Judge, Davy Vancampfort: PhD thesis project at the Katholic University Leuven, Belgium, entitled “Metabolic Syndrome in Schizophrenia: Relationships with Physical Activity, Functional Exercise Capacity and Eurofit battery Test Performance”

2010-2015 Co-mentor, Primary investigator: Marie Stentebjerg-Olesen, MD: PhD thesis project at the Copenhagen University Hospital, Denmark entitled “Early Response to Antipsychotics as a Marker of Treatment Response in Early-Onset Schizophrenia”. Role: Co-mentor (other mentors: Prof. Pia Jeppesen, Prof. Anne Katrine Pagsberg, Prof. Anders Fink-Jensen)

2010-2017 Co-mentor (temporary), Primary investigator: Ditte Lammers: PhD psychology project at the Aalborg University, Denmark, entitled “Outcome of early onset schizophrenia compared to adult onset”. Role: Co-mentor (other mentors: Prof. Dr. Hans-Christoph Steinhausen, MD; M Lauritzsen, PhD)

2011-2016 Co-mentor, Primary investigator: Karsten Gjessing Jensen: PhD thesis project at the Copenhagen University Hospital, Denmark entitled “Cardiac and metabolic adverse events during treatment with aripiprazole or quetiapine in children or adolescents with psychosis”. Role: Co-mentor (other mentors: Prof. Anne Katrine Pagsberg, Prof. Anders Fink-Jensen)

Curriculum Vitae Christoph U. Correll, M.D. Page 18

2011-2017 Co-mentor, Primary investigator: Weiping Yu, MD: PhD thesis project at the Katholic University Leuven, Belgium, entitled “Antipsychotic Antipsychotic medications, genetic vulnerabilities and the risk of cardio-metabolic abnormalities in patients with severe mental illness”. Role: Co-mentor (other mentors: Prof. Marc De Hert, Dr. Ruud van Winkel)

2014-2017 Co-mentor, Primary investigator: Kathrine Hesselberg Nikolajsen, MD: PhD thesis project at the Aalborg University Hospital, Research Unit for Child and Adolescent Psychiatry, entitled “Psychopathology, autistic symptoms, obsessive-compulsive symptoms, cognitive deficits and their impact on quality of life and treatment response in first episode schizophrenia. A prospective study of adolescents and young adults”. Role: Co-mentor (other mentors: Dr. Marlene Lauritzsen; Dr. Rene Nielsen)

2014-2017 Co-mentor, Primary investigator: Sara Jimenez, MD: doctoral thesis project at the University of Granada, entitled “Identification of oxidative stess markers in major depressive disorder and bipolar disorder: metanalytic studies”. Role: Co-mentor (other mentor: Dr. Manuel Gurpegui Fernández de Legaria)

2015-2018 Co-mentor, Primary investigator: Mathilde Frahm Laursen, MD: PhD thesis project at the Aalborg University Hospital, Research Unit for Child and Adolescent Psychiatry, entitled “Characteristics and Correlates of Bipolar Disorder in Children and Adolescents”. Role: Co-mentor (other mentors: Prof. Rasmus Licht; Dr. Rene Nielsen)

2017-2018 Mentor, Primary investigator: Dr. phil. Lea Sarrar: Habilitation “Psychopathological aspects in the genesis a maintenance of adolescent eating disorders” “[“Psychopathologische Aspekte in der Genese und Aufrechterhaltung adoleszenter Esstoerungen”]. Role: Primary Mentor

2018-2020 Co-mentor, Primary investigator: Mikkel Højlund: PhD thesis project at the University of Southern Denmark, Odense, Denmark, entitled “Pharmacoepidemiological aspects of low-dose or off-label treatment with antipsychotics: Utilization and consequences”. Role: Co-mentor.

RESEARCH AWARD AND RESEARCH GRANT MENTORSHIP (47 AWARDS BY 25 MENTEES) May 2005 Mentor, Long Island Jewish Medical Center Academic Competition Paper

Award, granted to David Straker, DO, The Zucker Hillside Hospital, Glen Oaks, NY, for the manuscript “Cost Effective Screening Test for Metabolic Syndrome in Patients Treated with Second-Generation Antipsychotic Medications”

May 2005 Mentor for the Annual American Psychiatric Association (APA) Research Colloquium for Junior Investigators Award granted to Julie B. Penzner, BS, Albert Einstein College of Medicine, Bronx, NY

June 2005 Mentor, Einstein Research Fellowship Award, granted to Julie B. Penzner, BS, by Albert Einstein College of Medicine, Bronx, NY

2006-2008 Mentor, American Psychiatric Association (APA) Janssen Research Fellowship awardee Julie B. Penzner, MD, Weill-Cornell Medical College, New York, NY, for the research project “Identification of the Bipolar Prodrome”.

May 2008 Mentor, New Clinical Drug Evaluation Unit (NCDEU) New Investigator awardee Erin C. Soto, BS, Albert Einstein College of Medicine, NY, as part of the Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ, May 27-30, 2008.

Curriculum Vitae Christoph U. Correll, M.D. Page 19

June 2008 Mentor, Senior Research Fellowship Award, granted to Erin Callahan, BS, by Albert Einstein College of Medicine , Bronx, NY

April 2009 Mentor, Erin Callahan Soto, MD, 2009 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

April 2009 Mentor, Julie Penzner, MD, 2009 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

June 2009 Mentor, New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award, granted to Juan A Gallego, MD, The Zucker Hillside Hospital, Glen Oaks, NY, as part of the Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL, June 30-July 2, 2009.

July 2009 Mentor, John and Maxime Bendheim Child Psychiatry Foundation Award for Research, granted to Johnny Lops, DO, The Zucker Hillside Hospital, Glen Oaks, NY, for the project “Prospective Adolescent Mood Disorders Study (PAMDS)”

04/2010 Mentor, Taro Kishi, MD, PhD, Japan Research Foundation for Clinical Pharmacology funded award for two years for studies aborad for the project “Comparative Effectiveness of Interventions for Persistent Schizophrenia Symptoms”.

May 2010 Mentor, NIMH Division of Services and Intervention Research (DSIR) sponsored Child Intervention, Prevention and Services (CHIPS) Summer Research Institute awardee Lawrence Maayan, MD, Nathan Kline Institute, Orangeburg, NY, as part of the Summer Research Institute, Pittsburgh, PA, May 5.24-5.28, 2010.

June 2010 Mentor, New Clinical Drug Evaluation Unit (NCDEU) New Investigator awardee Lawrence Maayan, MD, Nathan Kline Institute, Orangeburg, NY, as part of the Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 14-17, 2010.

June 2010 Mentor, Senior Research Fellowship Award, granted to Agnieszka Janicka, BS, Albert Einstein College of Medicine , Bronx, NY

March 2011 Co-Mentor, van Ammeringen Foundation, granted to Michael Birnbaum, MD, St Luke’s Roosevelt Medical Center, New York, NY, for the program project “Early Identification and Intervention Program PEER (Prevention, Education, Evaluation, Rehabilitation)”.

April 2011 Mentor, Taishiro Kishimoto, MD, PhD, 2011 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

April 2011 Mentor, Taro Kishi, MD, PhD, 2011 Young Investigator Award ASCP Clinical Trials Workshop

May 2011 Mentor, Long Island Jewish Medical Center Academic Competition Paper Award, granted to Arusha Farahani, MD, The Zucker Hillside Hospital, Glen Oaks, NY, for the manuscript “Are Antipsychotics or Antidepressants Needed for Psychotic Depression? - A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy with Cotreatment”

May 2011 Mentor, Thrasher Foundation Early Career Award, granted to Marta Hauser, PhD, The Zucker Hillside Hospital, Glen Oaks, NY, for the project “Characterizing the Clinical Risk State for Bipolar Disorder in Adolescents“.

June 2011 Mentor, New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award, granted to Jimmi Nielsen, MD, Aalborg Psychiatric Hospital, Denmark, as part

Curriculum Vitae Christoph U. Correll, M.D. Page 20

of the Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 13-16, 2010.

June 2011 Mentor, New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award, granted to Marta Hauser, PhD, The Zucker Hillside Hospital, Glen Oaks, NY, as part of the Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 13-16, 2010.

April 2012 Mentor, Eva Schenk, MD, 2012 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

April 2012 Co-mentor, Jian-Ping Zhang, MD, PhD, NIMH K21 Grant “Pharmacogenetics of Antipsychotic-Induced Side Effects with a Focus of Weight Gain”

July 2012 Mentor, Nina Schweinfurth, 2012 Donald J Cohen Fellowship Award of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP)

July 2012 Mentor, Jatinder Chawla, MD, American Academy of Child and Adolescent Psychiatry (AACAP) 2012 Pilot Research Award: "Differential Effects of Risperidone and Aripiprazole on Prolactin-Mediated Alterations in Sex Hormones, Sexual Functioning and Bone Turnover in Antipsychotic-Naive Adolescents"

Jan-Apr 2013 Mentor, Sara Jimenez Fernandez, MD, Spanish Psychiatric Association funded International Research Exchange Grant for Psychiatry Residents for a 4-month Visiting Research Scientist period at The Zucker Hillside Hospital.

Mar-Jun 2013 Mentor, Miriam Gerstenberg, MD, Swiss National Fond funded Mobility Grant for a 4-month Visiting Research Scientist period at The Zucker Hillside Hospital.

March 2013 Mentor, Marta Hauser, PhD, Y-Mind Sao Paulo School of Advanced Science for Prevention of Mental Disorders Award, Sao Paolo, Brazil, March 25-29, 2013

March 2013 Mentor, Ditte Lammers, Y-Mind Sao Paulo School of Advanced Science for Prevention of Mental Disorders Award, Sao Paolo, Brazil, March 25-29, 2013

April 2013 Mentor, Marta Hauser, PhD, Career Development Institute for Bipolar Disorder. Pittsburgh, PA, April 6–9, 2013

April 2013 Mentor, Ditte Lammers, 2013 American Academy of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

April 2013 Mentor, Miriam Gerstenberg, 2013 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

April 2013 Mentor, Itaru Miura, 2013 American Academy of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

June 2013 Mentor, Michael Birnbaum, MD, American Academy of Child and Adolescent Psychiatry (AACAP) 2012 Pilot Research Award: "Exploring Barriers to Care in Early Psychosis"

October 2013 Mentor, Britta Galling, MD, German Research Association (Deutsche Forschungs Gemeinschaft (DFG)) funded award for two years for studies abroad for the project “Role of Antidepressants or Antipsychotics in Preventing Psychosis (RAAPP)”

June 2015 Mentor, Vishesh Agarwal, MD, 2015 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

June 2015 Mentor, Britta Galling, MD, European Society for Child and Adolescent Psychiatry (ESCAP) Research Academy award for junior researcher talents, Madrid, Spain, June 18-21, 2015.

Curriculum Vitae Christoph U. Correll, M.D. Page 21

May 2016 Mentor, Vishesh Agarwal, MD, 2016 Annual American Psychiatric Association (APA) Research Colloquium for Junior Investigators

June 2016 Mentor, Britta Galling, MD, 2016 American Association of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop Fellowship Award

September 2016 Mentor, Britta Galling, MD, European College of Neuropsychopharmacology (ECNP)Travel Award, Vienna, Austria, September 17-20, 2016.

01.2017-01.2019 Mentor, Britta Galling, MD, 2016 NARSAD Young Investigator Grant by the Brain and Behavior Resarch Foundation, entitled “Fluoxetine vs Aripiprazole Comparative Trial (FACT)

May 2017 Mentor, Jose Rubio, MD, 2017 American Psychiatric Association (APA) Research Colloquium Award

March 2018 Mentor, Britta Galling, MD, European Psychiatric Association (EPA) Travel Award, Nice, France, March 03-06, 2018.

April 2018 Mentor, Britta Galling, MD, European College of Neuropsychopharmacology (ECNP) School of Child and Adolescent Neuropsychopharmacology Award, Venice, Italy, 08-13, 2018.

August 2018 Mentor, Cagatay Ermis, MD, The Scientific and Technical Research Council of Turkey (TUBITAK), "2214a- researcher scholarship abroad" for the visiting scientist period at The Zucker Hillside Hospital, 8/25/18-2/15/19.

December 2018 Mentor, Olga Geisel, MD, Berlin Institute of Health (BIH) Gender Equality Funds Award (5,000 Euro)

July 2019 Mentor, Olga Geisel, MD, Berlin Institute of Health (BIH)-funded Digital Health Accelerator Program grant: “Online Psychiatric Evaluation Network - Internet Use (OPEN-IU)”

MEETING/PROGRAM ORGANIZER, SESSION CHAIR: US MEETINGS 1. Course Director, web-based CME Symposium by the University of Florida PeerView, entitled

“The Efficacy and Safety of Atypical Antipsychotics in Children and Adolescents With Psychosis, Mood, and Behavioral Disorders” (May 2006).

2. Chair, break out group “Prodrome” as part of the Research Forum by the Work Group on Research of the American Academy of Child and Adolescent Psychiatry (AACAP), entitled “Protective and Risk Factors in Pediatric Bipolar Disorder: Predicting Outcomes”, 32nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, CA, October 24-29, 2006.

3. Chair, Symposium entitled “Recognizing and Managing Atypical Antipsychotic Side Effects during Development”, 32nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, CA, October 24-29, 2006.

4. Chair, Symposium entitled “Improving Wellness and Functionality: The Role of Atypical Antipsychotics”, CME Symposium, Troy, MI, November 11, 2006.

5. Chair, Symposium entitled “Improving Wellness and Functionality: The Role of Atypical Antipsychotics”, CME Symposium, Chicago, IL, December 10, 2006.

6. Course Director, web-based CME Symposium by the University of Florida PeerView, entitled “Current Issues in the Use of Atypical Antipsychotics in Bipolar Disorder and Schizophrenia: Dosing, Switching, and Side Effect Management” (December 2006).

Curriculum Vitae Christoph U. Correll, M.D. Page 22

7. Co-Chair of the CME Live Satellite TV Broadcast program by i3 CME, entitled “First-Episode Schizophrenia: A Window of Opportunity for Best Practices" (Co-Chairs: P Buckley, CU Correll, A Miller), Atlanta April, 17, 2007.

8. Co-Chair of the CME Live Satellite Broadcast program by i3 CME, entitled “Strategies for Dosing and Switching Antipsychotics for Optimizing Clinical Outcomes” (Co-Chairs: P Buckley, CU Correll, P Masand), Atlanta April 24, 2007.

9. Chair, Symposium entitled “Improving Outcomes in Schizophrenia: Prodrome to Remission”, Annual Meeting of the American Psychiatric Association, San Diego, Ca, May 19-24, 2007

10. Chair and Program Development, Symposium entitled “Achieving Recovery With Atypical Antipsychotics: The Impact of Dosing, Switching and Side Effects To Optimize Outcomes” CME Symposium, Boston, MA, June 1, 2007.

11. Co-Chair of the CME symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” and Program Development of the presentation “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics"(Co-Chairs: CU Correll, S Prescorn, P Weiden), Cleveland, OH, June 2, 2007.

12. Co-Chair of the CME symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” and Program Development of the presentation “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics"(Co-Chairs: CU Correll, S Prescorn, P Weiden), Baltimore, MD, June 9, 2007.

13. Course Director and Chair of the CME Live Satellite TV Broadcast program, entitled “Promoting Metabolic and Endocrine Health in Children and Adolescents Treated with Antipsychotics", Boca Raton, FL, June 10, 2007.

14. Co-Chair of the CME symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” and Program Development of the presentation “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics"(Co-Chairs: CU Correll, S Prescorn, P Weiden), Garden City, NY, June 23, 2007.

15. Co-Chair of the CME symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” and Program Development of the presentation “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics"(Co-Chairs: CU Correll, S Prescorn, P Weiden), Philadelphia, PA, July 14, 2007.

16. Course Director, web-based CME Symposium by the Semel Institute for Neuroscience and Human Behavior at UCLA and PVI, PeerView Institute for Medical Education, entitled “Clinical Implications of Hyperprolactinemia Associated With Atypical Antipsychotic Agents” (August 2007).

17. Co-Chair of the CME Live Satellite TV Broadcast program by Neuroscience CME, entitled “Pharmacodynamics of Atypical Antipsychotics: Clinical Considerations and Practice Implications"(Co-Chairs: CU Correll, JM Kane, DD Miller), Washington DC, DC, August 22, 2007.

18. Course Director, web-based CME program by Medscape LLC, entitled “Case Series on Clinical Challenges in Diagnosing and Treating Schizophrenia and Bipolar Disorder in Children and Adolescents” (September 2007).

19. Project Chair and Director of the CME Institute activity “Use of Atypical Antipsychotics in Pediatric Disorders”, published as a Journal of Clinical Psychiatry Supplement (September 2007).

20. Co-Chair of the CME symposium entitled “Assessing the Role and Tolerability of Atypical Antipsychotics: Sedation, Metabolic/Endocrine Concerns and Functional Outcomes” (Co-Chairs: CU Correll, JM Kane), 20th U.S. Psychiatric & Mental Health Congress, Orlando, FL, October 11, 2007.

21. Chair of the CME symposium entitled “Integrating Physical and Mental Health During Antipsychotic Treatment”, Annual American Psychiatric Association Institute on Psychiatric Services meeting, New Orleans, LA, October 12, 2007.

Curriculum Vitae Christoph U. Correll, M.D. Page 23

22. Chair, Symposium entitled “Update on the Use of Antipsychotics in Children and Adolescents”, 33rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Boston, MA, October 23-28, 2007.

23. Chair, Special Interest Group entitled “Risks of Psychotropic Medications in Youth”, 33rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Boston, MA, October 23-28, 2007.

24. Co-Course Director and Co-Chair of the CME symposium “Advancing the Treatment of Childhood and Adolescent Schizophrenia and Bipolar Disorder: The Use of Atypical Antipsychotics” (Co-Chairs: CU Correll, Robert Findling, Karen Wagner), New York, NY, November 17, 2007

25. Co-Course Director and Co-Chair of the CME Live Satellite Broadcast program by i3 CME, entitled “Advances in the Identification and Management of Pediatric Psychotic and Mood Disorders: Childhood-Onset Schizophrenia, Childhood-Onset Bipolar Disorder, and the Schizophrenia Prodrome” (Co-Chairs: CU Correll, K Chang), New York, NY, November 27, 2007.

26. Co-Course Director and Co-Chair of the CME symposium, entitled “Advancing the Treatment of Childhood and Adolescent Schizophrenia and Bipolar Disorder: The Use of Atypical Antipsychotics” (Co-Chairs: CU Correll, Robert Findling, Karen Wagner), Boston, MA, December 8, 2007.

27. Chair, Symposium, entitled “Treatment of Children and Adolescents with Psychiatric Disorders: The Rising Use of Antipsychotics”, Annual Meeting of the American Psychiatric Association, Washington DC, May 3-8, 2008.

28. Co-Chair, Symposium, entitled “Is there a Link Between Antipsychotic Adverse Effects and Efficacy in Schizophrenia?” (Co-Chairs: CU Correll, JM Kane), Annual meeting of the New Drug Evaluation Unit (NCDEU), Phoenix, AZ, May 26-29, 2008.

29. Chair, Symposium, entitled “Applying the Pharmacology of Atypical Antipsychotics: Clinical Implications on Efficacy and Safety”, New York, NY, June 7, 2008.

30. Co-Chair, Symposium, entitled “Psychotropic Induced Weight Gain in Children and Adolescents: A Multidisciplinary Approach” (Co-Chairs: CU Correll, L Maayan), 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28-November 2, 2008.

31. Chair, Symposium, entitled “Risks and Benefits of Psychotropic Medications in Pediatric Patients”, 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28-November 2, 2008.

32. Chair, Symposium, entitled “Time Course of Antipsychotic Drug Response in Schizophrenia: A New Perspective”, International Congress on Schizophrenia Research (ICOSR), San Diego, California, March 28-April 01, 2009.

33. Chair, Symposium, entitled “Neurobiology, Prediction and Management of Antipsychotic Non-Response in Patients with Schizophrenia”, American Psychiatric Association Meeting, San Francisco, California, May 16-May 21, 2009.

34. Chair, Symposium, entitled “Update on the Risks and Benefits of Psychotropic Medications in Children and Adolescents: Evidence from Randomized Controlled Trials”, Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL, June 29-July 02, 2009.

35. Co-Chair, Symposium, entitled “Pharmacotherapeutic Combination Treatment Strategies in Schizophrenia: Methodology and Evidence” (Co-Chairs: CU Correll, G Petrides), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL, June 29-July 02, 2009.

36. Co-Chair, Symposium, entitled “Cardiometabolic Effects of Antipsychotics: Mechanisms, Interventions, Gaps and Directions” (Co-Chairs: CU Correll, L Maayan), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 14-June 17, 2010.

37. Co-Chair, Symposium, entitled “Etiologies and Treatment: Management of Cardiometabolic Risk Factors in Youth with Severe Mental Disorders” (Co-Chairs: CU Correll, L Maayan), 57th Annual

Curriculum Vitae Christoph U. Correll, M.D. Page 24

Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), New York, NY, October 26-31, 2010.

38. Co-Chair, Symposium, entitled “Evidence-Based Evaluation and Treatment of Youth with Maladaptive Aggression” (Co-Chairs: CU Correll, P Jensen), 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), New York, NY, October 26-31, 2010.

39. Co-Chair, Symposium, entitled “Underutilization of Evidence Based Treatment and Monitoring Strategies in Schizophrenia” (Co-Chairs: JM Kane, CU Correll), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 13-June 16, 2011.

40. Co-Chair, Symposium, entitled “Evidence-Based Evaluation and Treatment of Youth with Maladaptive Aggression” (Co-Chairs: CU Correll, P Jensen), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 13-June 16, 2011.

41. Chair, Symposium, entitled “Improving Treatments and Outcomes in Schizophrenia: How Far Have We Come?”, International Congress on Schizophrenia Research (ICOSR), April 2 – April 6, 2011.

42. Meeting Steering Committee Member, NIMH-funded 2-day conference entitled “Adipogenic and Metabolic Effects of Antipsychotic Drugs” (Meeting Organizers: D Allison, CU Correll, E Morrato, JW Newcomer, G Remington), Newark, NJ, July 1-11, 2011.

43. Co-Chair, Research Forum, entitled “Preventing Psychopathology in Childhood and Adolescence” (Co-Chairs: CU Correll, M Singh, MD), 59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Francisco, October 23, 2012.

44. Chair, Research Symposium, entitled “Balancing Benefits, Risks and Cost for New Treatments in Vulnerable Populations: Lessons from Child Psychiatry on the Need for a New Standard of Diverse Methodologies” (Chair: CU Correll, Co-Chair: JW Newcomer), 51st Annual meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 2-6, 2012.

45. Chair, Symposium, entitled “Effect of Trial Design, Population and Illness Phase on the Role of Long-Acting Injectable Antipsychotics for Signaling and Preventing Non-Adherence in Schizophrenia”, oral presentation as part of the symposium entitled “Novel and Underutilized Strategies to Improve Adherence and Reduce Relapse Risk in Schizophrenia” (Chair: CU Correll), Annual American Society of Clinical Psychopharmacology (ASCP) Meeting, Hollywood, FL, June 16-19, 2014.

46. Chair, Symposium, entitled “Emerging Biological Treatment Patterns and Paradigms in the Management of Schizophrenia”, (Chair: CU Correll), International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28 – April 1, 2015.

47. Co-Chair, Workshop entitled “Treatment Resistant Schizophrenia: Workshop on Consensus Criteria” (Co-Chairs: OD Howes; CU. Correll; JM. Kane), International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28 – April 1, 2015.

48. Chair, afternoon session of the 2016 the American Society of Clinical Psychopharmacology (ASCP) Fall meeting, entitled “Psychopharmacology: State-of-the-Art” (Chair: CU Correll), New York, NY, October 29, 2016.

49. Chair, afternoon session of the 2017 the American Society of Clinical Psychopharmacology (ASCP) Spring meeting, entitled “Psychopharmacology: State-of-the-Art” (Chair: CU Correll), Los Angeles, CA, March 25-26, 2017.

50. “Co-chair, American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop (Co-Chairs: CU. Correll; JM. Kane), New York, NY, April 27-28, 2017.

51. “Co-chair, American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop (Co-Chairs: CU. Correll; JM. Kane), New York, NY, April 23-24, 2018.

Curriculum Vitae Christoph U. Correll, M.D. Page 25

52. Co-chair, Workshop, entitled “Psychotropic Drug-Induced Weight Gain and/or Metabolic Syndrome: Recognition and Management” (Co-Chairs: CU. Correll; C Eap), American Psychiatric Association (APA) Meeting, New York, NY, May 4-9, 2018.

MEETING/PROGRAM ORGANIZER, SESSION CHAIR: EX-US INTERNATIONAL MEETINGS

1. Chair, Symposium entitled “What is the role of second-generation antipsychotics in the treatment of children and adolescents”, 16th World Congress of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Germany, August 22 - 26, 2004

2. Chair, Symposium entitled “Atypical Antipsychotic Use across Disease States in Children and Adolescents”, 31st Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2005.

3. Co-Chair of the symposium “Physical Health in Patients with Schizophrenia“ (Co-Chairs: CU Correll, E Ruether), Munich, May 04-05, 2007.

4. Co-Chair of the symposium “Physical Health in Patients with Schizophrenia“ (Co-Chairs: CU Correll, H Pollmaecher), Frankfurt, May 11-12, 2007.

5. Chair, independent oral session “Miscellaneous Treatments and Issues” 1st Annual Meeting of the Schizophrenia International Research Society (SIRS), Venice, Italy, June 21-25, 2008.

6. Chair, Symposium, entitled “Finding the Balance in Bipolar Disorder: From Theory to Practice” Collegium Internationale Neuro-Psychopharmacologicum (CINP), Munich, Germany, July 13-17, 2008.

7. Chair, Symposium, entitled “First Steps in Schizophrenia Management: The Importance of Early Intervention”, 21st European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, August 30-September 3, 2008.

8. Co-Chair, Symposium, entitled “Relevance of Early Recognition, Early Intervention and Prevention in Bipolar Disorder” (Co-chairs: M Bauer and CU Correll), Annual Meeting of the German Association of Bipolar Disorders (DGBS), Dresden, Germany, September 11-13, 2008.

9. Co-Chair, Symposium, entitled “Prodromal Presentations in Bipolar Disorder” (Co-chairs: A Bechdolf and CU Correll), 6th International Conference on Early Psychosis (IEPA), Melbourne, Australia, October 20-22, 2008.

10. Co-Chair, Symposium, entitled “Eating Disorders and Physical Changes” (Co-Chairs: K von Klitzing, CU Correll), XXXI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Hamburg, Germany, March 5 – March 7, 2009.

11. Co-Chair, Symposium, entitled “Early Identification and Intervention in Juvenile Psychoses: New Results and Clinical Perspectives” (Co-Chairs: BG Schimmelmann, CU Correll), XXXI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Hamburg, Germany, March 5 – March 7, 2009.

12. Co-Chair, Symposium, entitled “Early Recognition and Differential Diagnosis of Bipolar Disorder in Children and Adolescent” (Co-chairs: Bilke and CU Correll), Annual Meeting of the German Association of Bipolar Disorders (DGBS), Berlin, Germany, September 03-05, 2009.

13. Co-chair, Symposium, entitled “New Research in the Early Prediction of Antipsychotic Response in Schizophrenia” (Co-chairs: CU Correll and JM Kane), 2nd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 10-14, 2010.

14. Co-chair, Symposium, entitled “The Pharmacologic Treatment of Juvenile Onset Schizophrenia” (Co-Chairs: C Correll, B Schimmelmann), XXXIII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Essen, Germany, March 2 – March 5, 2011.

15. Co-chair, Symposium, entitled “Neurobiological and Neurodevelopmental Aspects of Early Identification in Schizophrenia” (Co-Chairs: C Correll, S Ehrlich), XXXIII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Essen, Germany, March 2 – March 5, 2011.

Curriculum Vitae Christoph U. Correll, M.D. Page 26

16. Chair, Symposium entitled “Treating Today for Tomorrow” (chair: CU Correll), annual German Society for Bipolar Disorder meeting, Mannheim, Germany, September 29-30, 2011.

17. Co-chair, Symposium, entitled “Early Recognition of Bipolar Disorders“ (Co-chairs: A Bechdolf, C Correll), 20th European Congress of Psychiatry, Prague, Czech Republic, March 3-6, 2012

18. Co-chair, Symposium, entitled “Recent Directions in the Treatment of Early-Onset Psychoses“ (Chair: C Arango, Co-chair: C Correll), 3rd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 14-18, 2012.

19. Co-chair, Symposium, entitled “Relapse Prevention in Schizophrenia: An Update on Preclinical Data, Pharmaceutical and Psychotherapeutic Options“ (Chair: S Leucht, Co-chair: C Correll), 3rd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 14-18, 2012.

20. Co-chair, “Prevention of psychotic and bipolar disorders in children and adolescents”. (Co-Chairs: C Correll, F Schultze-Lutter), XXXIV Annual Meeting der Deutschen Gesellschaft für Kinder- und Jugendpsychiatrie (DGKJP), Rostock, Germany, March 6 – March 9, 2013.

21. Co-Chair, English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei and C Correll). Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 27-30, 2013.

22. Chair, Symposium, entitled „Further Considerations in Psychiatry. What is Possible When the Aim and Strategy for Reaching Aims Coincide“ [„Weiter Denken in der Psychiatrie. Was alles möglich ist, wenn Therapieziel und Therapiestrategie zusammenpassen“], Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 27-30, 2013.

23. Chair, Symposium, entitled “Does a Prodrome Exist in Bipolar Disorder?”, (Co-chairs: C Correll, T Kishimoto), annual International Early Psychosis Association (IEPA) meeting, Tokyo, Japan, November 17-21, 2014.

24. Co-Chair, Symposium, entitled “The challenge of rational antipsychotic polypharmacy” [“Epidemiologie und Korrelate von Polypharmazie mit Antipsychotika in verschiedenen Altersgruppen”] (Chair: J Cordes, Co-Chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2014.

25. Co-Chair, English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei and C Correll). Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2014.

26. Co-Chair, "Early Onset Psychotic Disorders, clinical characteristics and antipsychotic treatment response", (Chairs: CU Correll), annual Nordic Psychiatric Conference (NPC), Copenhagen, Denmark, September 20-23, 2015.

27. Co-Chair, “Depressive episodes in the course of schizophrenia-spectrum disorders: clinical challenges, therapeutic strategies” (Co-chairs: S Englisch, C Correll), 5th European Conference on Schizophrenia Research (ECSR), Berlin, Germany, September 24-26, 2015.

28. Co-Chair, “Long Acting Psychiatry” (Co-chairs: C Correll, A Teitelbaum), 10th International Congress of the International Neuropsychiatric Association (INA), Jerusalem, Israel, October 14-16, 2015.

29. Co-Chair, English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei and C Correll). Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 25-28, 2015.

30. Co-Chair, Symposium, entitled “Measurement-based psychiatry: Toward rating scale-based assessments in the real world” (Co-Chairs: CU Correll, S Dinesen Østergaard), 13th World Congress of Biological Psychiatry (WFSBP), Copenhagen, Denmark, June 18–22, 2017.

31. Co-Chair, English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei and C Correll). Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 23-25, 2016.

Curriculum Vitae Christoph U. Correll, M.D. Page 27

32. Chair, Symposium, entitled “Controversies around antipsychotic treatment of psychosis”, 24th International Symposium about Current issues and Controversies in Psychiatry "Crisis in Psychiatry”, Barcelona, Spain, April 20-22, 2017.

33. Co-Chair, Symposium, entitled Measurement-based care versus standard care for major depression: Conducting a success randomized controlled trial with blind raters” (Chairs: C Correll, S Ostergaard), 13th World Congress of Biological Psychiatry, Copenhagen, Denmark, June 18-22, 2017.

34. Chair, Symposium, entitled “Transient positive symptoms, in transition to psychosis, or first episode psychosis - how to treat a moving target and improve outcome of affected youths?” (Chair: C Correll, Co-chair: M Franscini), 17th International European Society for Child and Adolescent Psychiatry (ESCAP) Congress, Geneva, Switzerland, July 9-11, 2017.

35. Co-Chair, Oral Presentations entitled “Integrated Care”, 4th European Assertive Outreach Foundation (EAOF) International Congress “European Congress on Integrated Care and Assertive Outreach” (Chair: I Kilian, Co-chair: C Correll), Hamburg, Germany, September 13-15, 2017.

36. Chair, Oral Presentations entitled “Models of Care”, 4th European Assertive Outreach Foundation (EAOF) International Congress “European Congress on Integrated Care and Assertive Outreach” (Chair: C Correll, Co-chair: T. Skuban-Eiseler), Hamburg, Germany, September 13-15, 2017.

37. Chair, Symposium, entitled “Oral Presentation Session: Psychotic disorders I” (Chair: C Correll, Co-chair: A Hassan), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

38. Co-Chair, Symposium, entitled “Antipsychotic treatment update: dissecting molecular mechanisms and enhancing the benefit-risk ratio” (Chair: D Mueller, Co-chair: C Correll), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

39. Chair, Satellite Symposium, entitled “Advances in schizophrenia: Why do we need new treatment options (Chair: C Correll), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

40. Co-Chair, Symposium, entitled “State-of-the-Art-Symposium: Psychotic Disorders” (Chair: P Falkei, Co-chair: C Correll), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

41. Chair, Roundtable, entitled “Models to Explain the Complexity”, 25th International Symposium about Current issues and Controversies in Psychiatry "Complexity in Psychiatry” (Presenters: J van Os, R Murray, T Insel), Barcelona, Spain, April 19-21, 2018.

42. Chair, Workshop 2: Treatment of youth with psychosis: Psychopharmacology, early intervention and personalized medicine”, part of the one-day symposium “Psychotic experices, symptoms and illness in children and adolescents: how do we translate knowledge into cliical practice?”, The 2nd biannial Øresund Conference in child and adolescent psychiatry, November 7th 2018 Bispebjerg Hospital, Copenhagen, Denmark, November 7, 2018.

43. Co-Chair, symposium, entitled “Early Psychoses: Data Regarding Clinical Course, Treatment and Outcome” [“Frühe Psychosen: Daten zu Klinik, Therapie und Verlauf], (Chair: A. Bechdolf, Co-chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

44. Chair, symposium, entitled “Keeping the Future in Sight – Schizophrenia Management with Perspective” [“Die Zukunft im Blick - Schizophreniebehandlung mit Perspektive”], Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

45. Co-chair, Symposium, entitled “Metabolic syndrome in psychiatry: recognition and management of psychotropic drug induced metabolic effects” (Co-chairs: C Eap, CU Correll), 27th European Congress of Psychiatry, organized by the European Psychiatric Association, Warsaw, Poland, April 6-9, 2019.

Curriculum Vitae Christoph U. Correll, M.D. Page 28

MEETING/PROGRAM REVIEWER OR PROGRAM COMMITTEE MEMBER

2007 - current Annual New Clinical Drug Evaluation Unit (NCDEU) / American Society for

Clinical Psychopharmacolgy (ASCP) Meeting Symposia Selection Committee

2007 - present Member, Subcommittee for the New Investigator Award meeting of the New Drug Evaluation Unit (NCDEU) / American Society for Clinical Psychopharmacolgy (ASCP) conference

2007 - present Member, Subcommittee for the Poster and Program Session Review, New Clinical Drug Evaluation Unit (NCDEU) / American Society for Clinical Psychopharmacolgy (ASCP) conference

2009 - 2015 Member, Subcommittee for the oral presentations and poster presentation selection, bi-annual International Congress on Schizophrenia Research (ICOSR) Committee

2010 - 2015 Member, Oral & Poster Abstract Committee, Program Committee, the International Congress for Schizophrenia Research (ICOSR)

2016 - 2017 Member, Program Committee, European Assertive Outreach Foundation (EAOF) 4th International Congress “European Congress on Integrated Care and Assertive Outreach”, held in Hamburg, Germany, September 13-15, 2017.

2016 - 2018 Member, Scientific Committee, 11th International Early Psychosis Association (IEPA) conference, held in Boston, Massachusetts October 7-10, 2018.

2017 - present Member, American College of Neuropsychopharmacology (ACNP) Program Committee

2018 - 2021 Member, Local Advisory Board, 13th European Congress on Mental Health in Intellectual Disability “Science meets Practice: Improving Mental Health in Persons with Intellectual Disability“, annual meeting of the European Association for Mental Health in Intellectual Disability (EAMHID), Berlin 2021 (May 6-8, 2021 or September 23-25, 2021)

JOURNAL REVIEWER

1. Academic Psychiatry

2. Acta Psychiatrica Scandinavica

3. American Journal of Psychiatry

4. Annals of General Psychiatry

5. Archives of General Psychiatry

6. Archives of Pediatric and Adolescent Medicine

7. Australian and New Zealand Journal of Psychiatry

8. Biological Psychiatry

9. Bipolar Disorders

10. BMC Clinical Pharmacology

11. BMC Psychiatry

12. BMJ

13. BMJ Open

Curriculum Vitae Christoph U. Correll, M.D. Page 29

14. Clinical Practice

15. Clinical Psychology Review

16. Clinical Schizophrenia and Related Psychoses

17. CNS Drugs

18. Contemporary Clinical Trials

19. Current Medical Research and Opinion

20. Current Opinion in Psychiatry

21. Diabetes/Metabolism Research and Reviews

22. Dove Press Journals

23. European Archives of Psychiatry and Clinical Neuroscience

24. European Child and Adolescent Psychiatry

25. European Journal of Neurology

26. European Neuropsychopharmacology

27. European Psychiatry

28. Expert Opinion on Drug Safety

29. Expert Opinion on Pharmacotherapy

30. General Hospital Psychiatry

31. Harvard Review of Psychiatry

32. Human Psychopharmacology: Clinical and Experimental

33. International Journal of Bipolar Disorders

34. International Journal of Neuropsychopharmacology

35. International Journal of Clinical Practice

36. International Journal of Developmental Neuroscience

37. International Journal of Pediatric Obesity

38. International Journal of Pediatric Endocrinology

39. JAMA

40. Journal of Adolescent Health

41. Journal of Affective Disorders

42. Journal of Child and Adolescent Psychopharmacology

43. Journal of Child Psychology and Psychiatry

44. Journal of Clinical and Experimental Neuropsychology

45. Journal of Clinical Pharmacy and Therapeutics

46. Journal of Clinical Psychiatry

47. Journal of Clinical Psychopharmacology

48. Journal of Comparative Effectiveness Research

49. Journal of Geriatric Psychiatry and Neurology

50. Journal of Pharmacy and Pharmacology

51. Journal of Pharmacogenomics

52. Journal of Psychiatric Research

53. Journal of the American Academy of Child and Adolescent Psychiatry

54. Lancet

55. Metabolism

56. McMaster PLUS/PIER Project and Evidence-Based Journals

57. Neuropsychiatric Diseases and Treatment

58. Neuropsychiatry

59. Neuropsychopharmacology

60. Neuroscience & Biobehavioral Reviews

Curriculum Vitae Christoph U. Correll, M.D. Page 30

61. New England Journal of Medicine

62. Nutrition and Metabolism

63. Obesity

64. Pediatrics

65. Pediatric Drugs

66. Pharmacogenetics and Genomics

67. Pharmacopsychiatry

68. Progress in Neuro-Psychopharmacology & Biological Psychiatry

69. Psychiatric Services

70. Psychiatric Times

71. Psychoneuroendocrinology

72. Schizophrenia Bulletin

73. Schizophrenia Research

74. The Medical Letter

75. The Primary Care Companion to the Journal of Clinical Psychiatry

76. Therapeutic Advances in Psychopharmacology

77. World Journal of Biological Psychiatry

78. International Journal of Bipolar Disorders

EDITORIAL BOARD ACTIVITIES 2006 - current Editorial Board member, Journal of Child and Adolescent Psychopharmacology

2007 - current Editorial Board member, The Open Psychiatry Journal

2009 - current Editorial Board member, European Neuropsychopharmacology

2009 - current Editorial Board member, Mind and Brain, The Psychiatric Journal

2009 - 2016 Editorial Board member, Schizophrenia Research and Treatment

2010 Guest editor, Special Issue, Bipolar Disorders (with M DelBello)

2010 Guest editor, Acta Psychiatrica Scandinavica (with J Nielsen)

2010 - current Editorial Board member, Medscape Psychiatry & Mental Health

2011 Guest section editor, Journal of the American Academy of Child and Adolescent Psychiatry, Psychopharmacology Section (with C Kratochvil, A Martin and J Walkup)

2011 - 2015 Associate Editor “Treatment Emergent Adverse Effects”, Journal of Child and Adolescent Psychopharmacology

2012 Guest section editor, Journal of the American Academy of Child and Adolescent Psychiatry, Clinical Reviews Section (with A Martin)

2012 Ad hoc Guest Field Editor, International Journal of Neuropsychopharmacology

2012 -2013 Guest editor, Special Issue, Bipolar Disorders (with R McIntyre)

2012 - current Advisory Board member, Pharmacopsychiatry

2012 - 2017 Editorial Board member, Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP)

2012 - 2018 Founding Editorial Board member, International Journal of Bipolar Disorders

2013 - 2019 Founding Editorial Board member, Mental Health & Prevention

2014 - current Editorial Board member, Clinical Psychopharmacology and Neuroscience

2016 - current Editorial Board member, Schizophrenia Research

Curriculum Vitae Christoph U. Correll, M.D. Page 31

2016 - current Associate Editor “Psychotic Disorders”, Journal of Child and Adolescent Psychopharmacology

2017 - current International Advisory Board member, Turkish Journal of Child and Adolescent Psychiatry

2017 - current Editorial Board member, CNS Spectrums

2017 - current Scientific Counsil member [Wissenschaftlicher Beirat], Deutsches Aerzteblatt

2019 - current International Advisory Board member, Canadian Journal of Psychiatry

GRANT REVIEWER STUDY SECTION AND AD HOC/SPECIAL EMPHASIS PANEL GRANT REVIEWER: US

2007 Member, Thrasher Research Fund, Salt Lake City, UT, USA

2009-2016 Member, American Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Award Selection Committee

2010-2016 Member, American Academy of Child and Adolescent Psychiatry (AACAP) Work Group on Research Junior Faculty Research Grant Selection Committee

2011 Member, National Institute of Mental Health (NIMH) Special Emphasis Panel for R01 grants submitted in response to PAR-08-160 “Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk”, October 27, 2011

2011-2015 Member, National Institute of Mental Health (NIMH) Initial Review Group for the Interventions Committee for Disorders Involving Children and Their Families (ITVC)

AD HOC GRANT REVIEWER: EX-US

Since 2006 Netherlands Organisation for Health Research and Development (ZonMw), Netherlands

Since 2007 Medical Research Council (MRC), London, UK Since 2007 Medizinische Forschungsförderung Innsbruck, Austria Since 2008 German Federal Ministry of Research and Education Since 2009 Catalan Agency for Health Technology Assessment and Research, Spain Since 2012 Swiss National Science Foundation Since 2014 Spanish National Agency for Scientific Evaluation (ANEP) Since 2015 Australian National Health and Medical Research Council (NHMRC)

INVITED LECTURES/ORAL PRESENTATIONS: US LOCAL/REGIONAL 1. “Risk-benefit ratio of pharmacological interventions in adolescents at clinical risk for

schizophrenia: the Recognition and Prevention (RAP) Program experience”, presented at Grand Rounds, Division of Child and Adolescent Psychiatry Schneider Children's Hospital & Zucker Hillside Hospital, Glen Oaks, NY (June 2001)

2. “Risks of second-generation antipsychotics in the treatment of children and adolescents”, Grand Rounds, Division of Child and Adolescent Psychiatry Schneider Children's Hospital & Zucker Hillside Hospital, Glen Oaks, NY (June 2003)

3. “Evaluation and Management of Pediatric Bipolar Disorder”, Grand Rounds presentation at Sagamore Children's Psychiatric Center, Dix Hills, NY (September 2003)

4. "Second-Generation Antipsychotic Use in Children and Adolescents", Grand Rounds presentation at Elmhurst Hospital Center, Elmhurst, NY (January 2004)

Curriculum Vitae Christoph U. Correll, M.D. Page 32

5. “Pediatric Bipolar Disorder: Controversies and Challenges”, Grand Rounds presentation at the Queens Children's Psychiatric Center, Bellerose, NY (March 2004)

6. “Treatment of Psychosis in Special Populations”, Grand Rounds presentation at the Queens Hospital Center, Mount Sinai Services, Jamaica, NY (April 2004)

7. “Challenges in the Diagnosis and Treatment of Bipolar Disorder in Youth”, Grand Rounds presentation at North Shore University Hospital, Manhasset, NY (April 2004)

8. “Weight Gain and Metabolic Abnormalities in Children and Adolescents Treated with Novel Antipsychotics”, Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY (May 2004)

9. “Drug-Induced Obesity”. Oral presentation at the interdisciplinary workshop “The Obesity Pandemic: 2004 and Beyond” at North Shore University Hospital, Manhasset, NY, July 22, 2004

10. “Can Schizophrenia be Prevented?”, Grand Rounds presentation at Nassau University Medical Center, Brookville, NY (January 2005)

11. “The Schizophrenia Prodrome: Identification and Treatment of At-risk Individuals”, Grand Rounds presentation at North Shore University Hospital, Manhasset, NY (February 2005)

12. “Atypical Antipsychotic-Induced Weight Gain and Metabolic Abnormalities in Children and Adolescents”, Grand Rounds presentation at Four Winds Hospital, Katonah, NY (February 2005)

13. “Management of Aggression in Patients with Severe Mental Disorders”, Grand Rounds presentation at Pederson-Krag Center, Huntington, NY (May 2005)

14. “The Metabolic Side Effects of Antipsychotics”, oral presentation at Bronx Psychiatric Center, NY, as part of the Spring Psychopharmacology Training Program on Efficacy and Adverse Effects of Atypical Antipsychotics, sponsored by the Bureau of Psychiatric Services and the New York State Office of Mental Health, Bronx, NY (May 2005)

15. “Weighing in on the Metabolic Side Effects of Novel Antipsychotics”, Grand Rounds presentation at Bassett Healthcare-Cooperstown, Cooperstown, NY (June 2005)

16. “Metabolic Syndrome and Associated Risks of Second-Generation Antipsychotics”, Grand Rounds presentation at Long Island College Hospital, Bronx, NY (June 2005)

17. “Management of Atypical Antipsychotic-Induced Metabolic Risk”, Grand Rounds presentation at Kingsboro Psychiatric Center, Bronx, NY (June 2005)

18. “When symptoms persist: evidence-based combination treatments for schizophrenia”, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY (August 2005)

19. “Metabolic Adverse Effects of Novel Antipsychotics”, Grand Rounds presentation at the Bronx Lebanon Medical Center, Bronx, NY (November 2005)

20. “Research Developments in the Field of Psychiatry - Why Consider a Career in Psychiatry” – Key Note at the American Medical Association Medical Student Charter Annual Fall Conference, Albert Einstein College of Medicine, Bronx, NY (November 2005)

21. “High Risk Studies in Individuals Considered Prodromal for Schizophrenia or Bipolar Disorder”, oral presentation as part of a workshop at the American Medical Association Medical Student Charter Annual Fall Conference, Albert Einstein College of Medicine, Bronx, NY (November 2005)

22. “The Treatment of Schizophrenia Across the Course of Illness”, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY (December 2005)

23. “Monitoring of Metabolic Side Effects of Second-Generation Antipsychotics during Development”, Grand Rounds presentation at Montefiore Medical Center, New York, NY (March 2006)

24. “Effect of Past Treatment History on Metabolic Risk of Atypical Antipsychotics”, Grand Rounds presentation at Stony Brook Medical Center, Stony Brook, NY (April 2006)

25. “Early Identification and Prevention of Schizophrenia-spectrum Disorders and Bipolar Disorder”, Grand Rounds presentation at Glen Cove Hospital, Glen Cove, NY (April 2006)

26. “Pediatric Bipolar Disorder: Challenges and Controversies”, Grand Rounds presentation at Four Winds Hospital, Katonah, NY (July 2006)

27. “Metabolic Risk of Atypical Antipsychotics” Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY (November 2006)

Curriculum Vitae Christoph U. Correll, M.D. Page 33

28. “Are Atypical Antipsychotics Mood Stabilizers and How Do They Compare in the Treatment of Bipolar Mania and Bipolar Depression?, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY, January 25, 2007

29. “Antipsychotic Switching and Dosing Paradigms: Individualized Treatment Approaches”, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY, January 31, 2007

30. “Is the Prevention of Schizophrenia an Obtainable Goal?”, Grand Rounds presentation at the Richmond University Medical Center, Staten Island, NY, February 9, 2007

31. “Diagnosing and Classifying Pediatric Bipolar Disorder Efficiently”, oral presentation as part of the “Neurobiology and Psychopharmacology” course for third and fourth year psychiatry residents, Richmond University Medical Center, Staten Island, NY, April 4, 2007

32. “Differentiating the Onset Phases of Bipolar Disorder and Schizophrenia”, oral presentation as part of the “Neurobiology and Psychopharmacology” course for third and fourth year psychiatry residents, Richmond University Medical Center, Staten Island, NY, April 4, 2007

33. “Evidence-based Treatment of Bipolar Mania”, oral presentation as part of the “Neurobiology and Psychopharmacology” course for third and fourth year psychiatry residents, Richmond University Medical Center, Staten Island, NY, April 4, 2007

34. “Recognition, Impact and Management of Weight Gain and Metabolic Abnormalities Associated with Antipsychotic Treatment in Youth”, oral presentation as part of a Half-day Consortium for Psychologists, New Hyde Park, NY, April 11, 2007.

35. “Evidence-based Treatment of Bipolar Depression”, oral presentation as part of the “Neurobiology and Psychopharmacology” teaching course for 3rd and 4th year psychiatry residents, Richmond University Medical Center, Staten Island, NY, May 2, 2007

36. “Effective Antipsychotic Dosing Strategies to Enhance Long-term Outcomes”, oral presentation as part of the “Neurobiology and Psychopharmacology” teaching course for 3rd and 4th year psychiatry residents, Richmond University Medical Center, Staten Island, NY, May 2, 2007

37. “Effective Antipsychotic Switching Strategies to Enhance Long-term Outcomes”, oral presentation as part of the “Neurobiology and Psychopharmacology” teaching course for 3rd and 4th year psychiatry residents, Richmond University Medical Center, Staten Island, NY, May 2, 2007

38. “Monitoring and Management of Antipsychotic-induced Metabolic Effects in Youth”, Grand Rounds at Rockland Children’s Psychiatric Center, Orangeburg, NY, June 5, 2007

39. “Managing Metabolic Syndrome in the Treatment of Schizophrenia”, oral presentation as part of the symposium “Psychopharmacology Update for Pharmacists”, Melville, NY, June 14, 2007

40. “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics", oral presentation as part of the symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” (Program Development and Co-Chairs: C Correll, S Prescorn, P Weiden), Garden City, NY, June 23, 2007

41. “Psychotropic Management of Children and Adolescents with Mental Illness”, oral presentation at Family and Children’s Association, Hempstead, NY, June 26, 2007

42. “Metabolic Considerations in the Antipsychotic Treatment of Children and Adolescents", Grand Rounds presentation at Sagamore Children’s Psychiatric Center, Dix Hills, NY, September 20, 2007

43. “Recognition and Prevention Strategies in Schizophrenia and Bipolar Disorder: How Far Have We Come?", Grand Rounds at the Westchester Campus of the Weill Cornell Department of Psychiatry at New York Presbyterian Hospital, Westchester, NY, October 30, 2007

44. “Can we Prevent Schizophrenia and Bipolar Disorder", Grand Rounds at the Manhattan Campus of the Weill Cornell Department of Psychiatry at New York Presbyterian Hospital, New York, NY, October 31, 2007

45. “Assessing the Safety and Tolerability of Agents used in the Treatment of Pediatric Bipolar Disorder and Schizophrenia”, oral presentation as part of the CME symposium “Advancing the Treatment of Childhood and Adolescent Schizophrenia and Bipolar Disorder: The Use of Atypical Antipsychotics” (Program Development and Co-Chairs: C Correll, R Findling, K Wagner), New York, NY, November 17, 2007

Curriculum Vitae Christoph U. Correll, M.D. Page 34

46. CME Live Satellite Broadcast program, entitled “Advances in the Identification and Management of Pediatric Psychotic and Mood Disorders: Childhood-Onset Schizophrenia, Childhood-Onset Bipolar Disorder, and the Schizophrenia Prodrome”, Co-Chairs: C Correll, K Chang) New York, NY, November 27, 2007

47. “Early Recognition and Prevention of Psychosis: How Far Have We Come?”, oral presentation as part of the Lieber Seminars series, Lieber Center, Department of Psychiatry Columbia University & New York State Psychiatric Institute, New York, NY, December 5, 2007

48. “Cardiovascular and Metabolic Risk in People with Severe Mental Illness”, Grand Rounds presentation at Holliswood Hospital, Holliswood, NY, December 19, 2007

49. “Effects of Antipsychotics on Body Composition and metabolic Status in Children and Adolescents with Bipolar Disorder Schizophrenia”, oral presentation to the New York Council on Child and Adolescent Psychiatry, Cornell University - New York Hospital and Medical Center, New York, NY, January 10, 2008

50. “Metabolic Dysregulations and Antipsychotic Treatment in Youth", Grand Rounds presentation at Queens Children’s Psychiatric Center, Bellerose, NY, March 20, 2008

51. “Early Identification and Intervention during the Prodromal Phase of Psychosis", Grand Rounds presentation at Richmond University Medical Center, Staten Island, NY, April 11, 2008

52. “Augmenting Treatment Response in Schizophrenia: What are the Options?", Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY, April 30, 2008

53. “Management of Schizophrenia and Bipolar Disorder in Children and Adolescents", Grand Rounds at the Westchester Medical Center, Valhalla, NY, May 13, 2008

54. “The Mechanism of Action of Atypical Antipsychotics: How Receptor-Binding Profiles Affect Safety Profiles“, oral presentation as part of the CME symposium “Applying the Pharmacology of Atypical Antipsychotics: Clinical Implications on Efficacy and Safety” (Chair: C Correll), New York, NY, June 7, 2008

55. ”Efficacy and Safety of Antipsychotics in Children and Adolescents”, Departmental Summer Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY, July 2, 2008

56. ”After CATIE, CUtLASS and EUFEST: Efficacy and Effectiveness of Antipsychotics in Schizophrenia”, Departmental Summer Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY, July 30, 2008

57. “Weight Gain an Metabolic Risk of Antipsychotics”, Grand Rounds presentation at St. Vincent’s Hospital, New York, NY, November 7, 2008

58. “Early Identification and Intervention Strategies in Subjects Considered At High Risk for Psychosis”, Grand Rounds Presentation at New York University Child Study Center, New York, NY, December 12, 2008

59. “Schizophrenia: Optimizing Patient Medication Adherence for Improved Outcomes”, Grand Rounds Presentation at Brookdale Medical Center, Brooklyn, NY, December 16, 2008

60. “Does a Prodrome Exist in Bipolar Disorder?”, Grand Rounds presentation, Westchester Medical Center, Westchester, NY, January 13, 2009.

61. “What is the Role of Endocrine Effects of Antipsychotics?”, Grand Rounds presentation, Coney Island Hospital, Brooklyn, NY, February 09, 2009.

62. “Balancing Efficacy and Tolerability in the Treatment with Antipsychotics?”, Grand Rounds presentation, Montefiore Hospital, Bronx, NY, February 12, 2009.

63. “Risks Versus Benefits of Antipsychotic Medications in Severe Mental Disorders”, Pilgrim State Hospital, Brentwood, NY, March 12, 2009.

64. “Combination Treatment and Augmentation Strategies in Schizophrenia”, oral presentation as part of the “Neurobiology and Psychopharmacology” course for third and fourth year psychiatry residents, Richmond University Medical Center, Staten Island, NY, April 7, 2009

65. “From the Prodrome to Relapse Prevention: Treatment of Schizophrenia Across the Stages of The Illness”, oral presentation as part of the “Neurobiology and Psychopharmacology” course for third and fourth year psychiatry residents, Richmond University Medical Center, Staten Island, NY, April 7, 2009

Curriculum Vitae Christoph U. Correll, M.D. Page 35

66. “Update on the State of The Art Treatment of Bipolar Depression”, oral presentation as part of the “Neurobiology and Psychopharmacology” course for third and fourth year psychiatry residents, Richmond University Medical Center, Staten Island, NY, April 7, 2009

67. “Beyond the Results of Effectiveness Trials: How should We Treat Schizophrenia?” Grand Rounds presentation at Richmond University Medical Center, Staten Island, NY, April 24, 2009.

68. ”Antipsychotic Drugs: Dosing, Switching and Combining”, Departmental Summer Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY, July 22, 2009

69. “After CATIE, CUtLASS, CAFÉ and EUFEST: How Should We Treat Schizophrenia?”, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY, October 14, 2009.

70. “Identification and Management of Cardiometabolic Risks of Antipsychotics in Children and Adolescents with Severe Psychiatric Disorders”, Grand Rounds presentation at Children’s Village Treatment Center, Dobbs Ferry, NY, December 17, 2009.

71. “Antipsychotic Use in Pediatric Patients with Severe Mental Disorders: Using Pharmacology to Maximize Outcomes”, Grand Rounds presentation at St Luke’s Roosevelt Medical Center, New York, NY, January 6, 2010.

72. “Cardiometabolic Risks of Antipsychotics”, Grand Rounds presentation at Maimonedes Medical Center, Brooklyn, NY, January 11, 2010

73. “Early Recognition and Prevention of Bipolar Disorder in Children and Adolescents”, Presentation at the Child and Adolescent Bipolar Foundation (CABF) Regional Parent Support Group meeting, Manhattan, NY, January 25, 2010

74. “Cardiometabolic Risks of Antipsychotics in Children and Adolescents with Severe Mental Disorders”, Journal Club Presentation, Sagamore Children’s State Hospital, Dix Hills, NY, January 28, 2010

75. “Does a Prodrome Exist in Bipolar Disorder?”, oral presentation as part of the Child Psychiatry Grand Rounds Program at the Zucker Hillside Hospital, Glen Oaks, NY, February 25, 2010

76. “Cardiometabolic Risks of Antipsychotics in Youth, oral presentation as part of the Pediatrics Grand Rounds Program, Brookdale Hospital, Brooklyn, NY, February 26, 2010

77. “When Symptoms Persist: Polypharmacy or Rational Augmentation Strategies in Schizophrenia?”, oral presentation as part of the Grand Rounds Program at the Zucker Hillside Hospital, Glen Oaks, NY, March 3, 2010

78. “Update on the Evidenced-Based Treatment of Bipolar Mania & Bipolar Depression”, oral presentation as part of the Grand Rounds Program at Nassau County University Medical Center, East Meadow, NY, March 24, 2010

79. “Polypharmacy and Combination Treatment Strategies in Schizophrenia”, Grand Rounds at the Westchester Medical Center, Valhalla, NY, March 30, 2010

80. “Update on the Evidence Based Treatment of Bipolar Depression”, Grand Rounds at Richmond University Medical Center, Staten Island, NY, September 10, 2010

81. “Update on the Risks and Benefits of Antipsychotics in Youth with Severe Psychiatric Disorders”, Grand Rounds at Rockland Children’s Psychiatric Center, Orangeburg, NY, November 2, 2010

82. “Early Identification and Treatment of Individuals at Risk for Psychosis”, oral presentation as part of Grand Rounds, St Luke’s Medical Center, New York, NY, November 3, 2010.

83. “Pharmacologic Treatments for Youth with Maladaptive Aggression: Best Practice Recommendations”, Presentation to the Office of Child and Family Health, NYC Administration for Children's Services, Psychotropic Advisory Committee, New York, NY, January 10, 2011

84. “Update on the Pharmacologic Treatment of Bipolar Disorder” Queens Hospital Center, Jamaica, NY, January 06, 2012

85. “Is Prevention of Schizophrenia and Attainable Goal?”, Grand Rounds at Sagamore Children’s State Hospital, Dix Hills, NY, February 16, 2012

86. “Polypharmacy in Schizophrenia: Reasons, Correlates and Evidence”, Grand Rounds at Richmond University Medical Center, Staten Island, NY, February 17, 2012

Curriculum Vitae Christoph U. Correll, M.D. Page 36

87. “Pharmacologic Treatment of Early-Onset Schizophrenia”, Grand Rounds at Queens Children’s Psychiatric Center, Queens, NY, March 22, 2012

88. “Antipsychotic Related Adverse Effects” oral presentation as part of the 1-day Centricity Series symposium entitled “Schizophrenia: Redefining Possibilities. The Feinstein Institute for Medical Research, Manhasset, NY, April 30, 2012

89. “Antidepressants for the psychotic prodrome: in search for the best research design”, Research Seminar at The Zucker Hillside Hospital, Glen Oaks, NY, July 18, 2012

90. “Applied Psychopharmacology to Enhance Outcomes in the Use of Antipsychotics”, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY, July 22, 2012

91. “Current Concepts of Metabolic Side Effects of Second-Generation Antipsychotic Medications”, Grand Rounds presentation at Harlem Hospital Center, New York, NY, August 23, 2012

92. “Efficacy and Tolerability of Antidepressants, Mood Stabilizers and Antipsychotics in Youth”, oral presentation as part of the Grand Rounds Program at Nassau County University Medical Center, East Meadow, NY, September 26, 2012

93. “Response in Schizophrenia: How Long Should We Wait Until Giving Up on An Antipsychotic”, Grand Rounds at Richmond University Medical Center, Staten Island, NY, October 19, 2012

94. “When Symptoms Persist: Augmentation and Combination Strategies in Schizophrenia”, Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY, May 1, 2013

95. “Does a Prodrome Exist in Bipolar Disorder?”, oral presentation as part of the Grand Rounds Program at Jersey Shore University Medical Center, Neptune, NJ, June 19, 2013

96. “Update on Pediatric Psychopharmacology: The Role of Antipsychotics in Youth”, oral presentation as part of the Grand Rounds Program at Nassau County University Medical Center, East Meadow, NY, June 19, 2013

97. “DSM-5 Changes and Implications: A Quick Clinical Guide”, Grand Rounds presentation at The Zucker Hillside Hospital, Glen Oaks, NY, August 21, 2013

98. “DSM-5: What Clinicians Need to Know”, Grand Rounds presentation at Four Winds Hospital, Katonah, NY, September 18, 2013

99. “When Symptoms Persist in Schizophrenia: Augmentation Strategies for Positive, Negative and Cognitive Symptoms”, Grand Rounds presentation at Pilgrim State Psychiatric Center, West Brentwood, NY, September 25, 2013

100. “Comparative Efficacy and Safety of Antipsychotics in Schizophrenia”, oral presentation as part of the Grand Rounds Program at the Zucker Hillside Hospital, Glen Oaks, NY, October 2, 2013

101. “DSM-5: Structure, Changes and Implications - A Clinical Guide”, Grand Rounds presentation at Queens Hospital Center, Jamaica, NY, December 20, 2013

102. “Managing Treatment Resistant Psychotic Disorders: Assessment, Switch and Augmentation Strategies", Grand Rounds at Queens Children’s Psychiatric Center, Queens, NY, January 16, 2014

103. “Identification and Treatment of Youth at High-Risk for and with Early-Onset Schizophrenia-Spectrum Disorders”, oral presentation as part of the CME Program of the Child Mind Institute, New York, NY, February 21, 2014

104. “Best Clinical Practices in Child and Adolescent Psychiatry” oral presentation as part of the Grand Rounds Program at Nassau County University Medical Center, East Meadow, NY, March 12, 2014

105. “Assessment and Management of Aggression in Youth”, Grand Rounds presentation at Four Winds Hospital, Katonah, NY, April 30, 2014

106. “DSM IV to DSM 5: what are the changes?”, Educational Series for non-medical mental health professionals, The Zucker Hillside Hospital, Glen Oaks, NY, May 28, 2014

107. “Pharmacologic Treatment of Children and Adolescents with Psychotic Disorders”, Grand Rounds presentation at Albert Einstein College of Medicine, Division of Child and Adolescent Psychiatry, NYCCC-Bronx campus, Bronx, NY, July 16, 2014

108. “Assessment and Treatment of Maladaptive Aggression in Youth” oral presentation as part of the Zucker Hillside Hospital Grand Rounds, Queens, NY, January 07, 2015

Curriculum Vitae Christoph U. Correll, M.D. Page 37

109. “Management of Maladaptive Aggression in Outpatient Children and Adolescents”, Grand Rounds presentation at Queens Hospital Center, Jamaica, NY, April 10, 2015.

110. “Risks and Benefits of Antipsychotic Polypharmacy in Schizophrenia”, Grand Rounds presentation at Essex County Hospital, Cedar Grove, NJ, June 18, 2015

111. "Early Identification and Prevention of Bipolar Disorder in Children and Adolescents", Grand Rounds presentation at Maimonides Hospital Center, New York, NY, November 11, 2015

112. "Applied Psychopharmacology to Enhance Outcomes in the Use of Antipsychotics", Grand Rounds presentation at Harlem Hospital Center, New York, NY, December 11, 2015

113. “Relapse Prevention in Schizophrenia and Related Psychiatric Disorders: Promoting Recovery through Improved Adherence”, Grand Rounds presentation at Mental Health Center, Neptun, NJ, December 16, 2015

114. “Prevention of Psychosis and Mania: Where do we Stand and Where Do We Go?”, Grand Rounds presentation at University Hospital Brooklyn, Brooklyn, NY, December 16, 2015

115. “Beyond Positive: Advances in the Management of Cognitive Symptoms in Schizophrenia”, oral presentation as part of the Grand Rounds Program at Nassau County University Medical Center, East Meadow, NY, January 13, 2016

116. “Structure and Relevance of Negative Symptoms in Schizophrenia”, oral presentation as part of the Grand Rounds Program at The Zucker Hillside Hospital, Glen Oaks, NY, February 10, 2016

117. “The Prodromes of Schizophrenia and Bipolar Disorder: Is Identification Possible, and Is Intervention Effective?”, Grand Rounds presentation at Lenox Hill Hospital, Manhattan, NY, March 10, 2016

118. “The Art and Science of Enhancing Effectiveness in Schizophrenia”, Grand Rounds presentation at Essex County Hospital, Cedar Grove, NJ, May 26, 2016

119. “Adolescent Mood Disorder and Psychosis Study: Progress and Next Steps”, research seminar, The Zucker Hillside Hospital, Glen Oaks, NY, June 22, 2016

120. “Duration of Untreated Illnesses Worldwide“, oral presentation at the “Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting”, New York, NY, October 13-14, 2016.

121. “Understanding Violence in Children and Adolescents: Epidemiology, Phenomenology, Assessment and Differential Diagnosis of Youth with Aggression and Violent Behaviors”, New York City Children’s Center Administration (NYCCC) and Advisory Council´s, 40th Lauretta Bender Honored Lecture Day, as part of the New York City Children’s Center Administration (NYCCC) and Advisory Council Lauretta Bender symposium, New York, NY, November 8, 2016

122. “Understanding Violence in Children and Adolescents: Environmental, Psychosocial and Pharmacological Management Strategies for Youth with Aggression and Violent Behaviors”, New York City Children’s Center Administration (NYCCC) and Advisory Council´s, 40th Lauretta Bender Honored Lecture Day, as part of the New York City Children’s Center Administration (NYCCC) and Advisory Council Lauretta Bender symposium, New York, NY, November 8, 2016

123. “Understanding Violence in Children and Adolescents: Interactive Case-Based Learning”, New York City Children’s Center Administration (NYCCC) and Advisory Council´s, 40th Lauretta Bender Honored Lecture Day, as part of the New York City Children’s Center Administration (NYCCC) and Advisory Council Lauretta Bender symposium, New York, NY, November 8, 2016

124. “Comparative Efficacy and Safety of Antipsychotics in Schizophrenia”, Grand Rounds Presentation at Bronx Lebanon Hospital Center, Bronx, NY, February 14, 2017.

125. “Assessment and Management of Aggression in Youth”, Grand Rounds Presentation at Brookdale Medical Center, Brooklyn, NY, February 15, 2017.

126. “Update on the Management of Cardiovascular Risk in Youth Receiving Antipsychotic Treatment and on the MOBILITY Trial”, oral presentation as part of the Grand Rounds Program at the Child and Adolescent Psychiatry Division of The Zucker Hillside Hospital, Glen Oaks, NY, March 9, 2017

Curriculum Vitae Christoph U. Correll, M.D. Page 38

127. “Assessment and Management of Youth at Risk for Psychosis”, oral presentation as part of the Grand Rounds Program at the Child and Adolescent Psychiatry Division of New York University, Langone Medical Center, New York, NY, March 10, 2017

128. “The Future of Psychiatric Diagnoses and Treatment: Where Are We Heading?”, oral presentation as part of the Grand Rounds Program at The Zucker Hillside Hospital, Glen Oaks, NY, May 3, 2017

129. “Metabolic Wellness Consideration in Schizophrenia”, oral presentation as part of the Grand Rounds Program at Manhattan Psychiatric Center, New York, NY, USA, July 20, 2017.

130. “Prevention of Psychosis and Mania: Where do we Stand and Where Do We Go?” Grand Rounds presentation at Icahn School of Medicine at Mount Sinai, Department of Psychiatry, March 20, 2018

131. “Optimizing the Management of Patients with Schizophrenia: The Oral Antipsychotic Paradigm”, oral presentation as part of the 1.5-day meeting, entitled “The Treatment of Schizophrenia, New York, NY, USA, March 8-9, 2019.

132. “Relapse Prevention and the Utility of Long-Acting Injectable Antipsychotics”, oral presentation as part of the 1.5-day meeting, entitled “The Treatment of Schizophrenia, New York, NY, USA, March 8-9, 2019.

133. “Management of the Treatment-Resistant Patient”, oral presentation as part of the 1.5-day meeting, entitled “The Treatment of Schizophrenia, New York, NY, USA, March 8-9, 2019.

INVITED LECTURES/ORAL PRESENTATIONS: US NATIONAL/INTERNATIONAL 1. “Strategies to reduce the risk of prodromal interventions and research”, presented at the First

Annual International Prodromal Schizophrenia Research Workshop, New York, NY, April 6-9, 2002

2. “Novel Antipsychotics: Their Role in Preventing Psychosis in High-Risk Individuals”, presented at the 29th Annual Meeting of the American Academy of Clinical Psychiatrists, Chicago, IL, October 10-12, 2003.

3. “Biological Markers of Antipsychotic-Adherence in Children and Adolescents”, presented at the 4th Annual Adherence Workshop by the Adherence and Behavior Change Program, Health and Behavioral Science Research Branch, Division of Mental Disorders, Behavioral Research, and AIDS, National Institute of Mental Health, Alexandria, October 14, 2003

4. “Second-Generation Antipsychotic-Induced Weight Gain and Metabolic Abnormalities", as part of the symposium entitled "Long-term Outcomes For Adolescents with Schizophrenia”, presentation at the 50th American Academy of Child and Adolescent Psychiatry Anniversary Meeting in Miami Beach, FL, October 14-19, 2003

5. “Is there a Rationale for Polypharmacy in the Treatment of Schizophrenia?” Oral presentation at the 9th Annual Central New York Psychopharmacology Update “Psychiatric Polypharmacy: What Does the Data Say on Combining Psychiatric Medications?”, Syracuse, NY, October 21, 2004

6. “Polypharmacy in Schizophrenia: What is the controlled Evidence?”, Grand Rounds presentation at Stamford Hospital, Stamford, CT, January 2005

7. “Prospective Study of Second-Generation Antipsychotic-Induced Insulin Resistance in Antipsychotic-Naïve Children and Adolescents”, oral presentation at the International Congress on Schizophrenia Research (ICOSR), Savannah, GA, April 02-06, 2005

8. “When Symptoms Persist: Evidence-based Augmentation Strategies for Schizophrenia”, Grand Rounds presentation at The University of Rochester Medical Center, Strong Ties Community Support Program, Rochester, NY (April 2005)

9. “Weight Gain and Metabolic Effects of Antipsychotics”, oral presentation at Hutchings Psychiatric Center, Syracuse, NY, as part of the Spring Psychopharmacology Training Program on Efficacy and Adverse Effects of Atypical Antipsychotics by the Bureau of Psychiatric Services and the New York State Office of Mental Health, Bronx, NY (May 2005)

Curriculum Vitae Christoph U. Correll, M.D. Page 39

10. “Does a Bipolar Prodrome Exist?”, oral presentation at the 4th Annual Meeting of the International Prodromal Research Network (IPRN), Yountville, CA, September 11-14, 2005.

11. “Risks and Benefits of Atypical Antipsychotics in Never-treated Prodromal and First Episode Psychotic Individuals”, oral presentation at the 4th Annual Meeting of the International Prodromal Research Network (IPRN), Yountville, CA, September 11-14, 2005

12. “Identification and Treatment of Mood and Anxiety Disorders in Clinical Settings”, presented at the 2005 Annual Slocum-Dickson Teaching Day, Slocum-Dickson Medical Group, New Hartford, NY, November 12, 2005

13. “Risk Benefit Evaluation of Atypical Antipsychotics Across Disease States”, Grand Rounds presentation at Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH (January 2006)

14. “Prospective Study of Anthropometric and Metabolic Effects of Atypical Antipsychotics in Youth with Bipolar Spectrum Disorders”, oral presentation as part of the Fourth Annual NIMH Collaborative Pediatric Bipolar Disorder Conference, Chicago, IL, March 31 – April 1, 2006.

15. “The Metabolic Issues and Antipsychotic Treatments” and “The Psychiatric Issues: Optimizing Antipsychotic Efficacy”, oral presentations as part of the national CME program “Balancing Psychiatric and Metabolic Perspectives”, sponsored by the Joslin Diabetes Center, Chicago, IL (June 2006)

16. “The Metabolic Issues and Antipsychotic Treatments” and “The Psychiatric Issues: Optimizing Antipsychotic Efficacy”, oral presentations as part of the national CME program “Balancing Psychiatric and Metabolic Perspectives”, sponsored by the Joslin Diabetes Center, Dearborn, MI (June 2006)

17. “The Metabolic Issues and Antipsychotic Treatments” and “The Psychiatric Issues: Optimizing Antipsychotic Efficacy”, oral presentations as part of the national CME program “Balancing Psychiatric and Metabolic Perspectives”, sponsored by the Joslin Diabetes Center, Boston, MA (June 2006)

18. “Weight Gain and Metabolic Abnormalities Associated with Second-Generation Antipsychotics During Development”, Grand Rounds presentation at the University of Medicine and Dentistry of New Jersey, Newark, NJ, October 2006

19. “Treatment options for the acute and long-term stabilization of the agitated and psychotic patient ” oral presentation, roundtable discussion and video conference program as part of the CME symposium, entitled “Risk and Benefits of Atypical Antipsychotics: Focus on Sedation”, New Jersey, October, 23, 2006

20. “Atypical Antipsychotic-Induced Body Composition and Metabolic Changes During Development”, oral presentation as part of the symposium “Recognizing and Managing Atypical Antipsychotic Side Effects during Development” (Chair: C Correll), 32nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, CA, October 24-29, 2006

21. “Improving Functional Outcomes in Mental Health Disorders”, oral presentation as part of the CME symposium series “Improving Wellness and Functionality: The Role of Atypical Antipsychotics”, Miami, FL, November 4, 2006

22. “The Roadmap From Pharmacology to Long-term Treatment”, oral presentation as part of the CME symposium series “A Roadmap: Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness”, Providence, RI, November 10, 2006

23. “Improving Functional Outcomes in Mental Health Disorders”, oral presentation as part of the CME symposium series “Improving Wellness and Functionality: The Role of Atypical Antipsychotics”, Troy, MI, November 11, 2006

24. “Improving Functional Outcomes in Mental Health Disorders”, oral presentation as part of the CME symposium series “Improving Wellness and Functionality: The Role of Atypical Antipsychotics”, Chicago, IL, December 9, 2006

25. “Pharmacotherapy of Children and Adolescents with Psychotic Disorders”, oral presentation as part of the Psychopharmacology Training Program, sponsored by the Bureau of Psychiatric Services and the New York State Office of Mental Health, Syracuse, NY, December 12-13, 2006

Curriculum Vitae Christoph U. Correll, M.D. Page 40

26. “Metabolic Profiles of Atypical Antipsychotics”, Grand Rounds presentation at the Cincinnati University Hospital, Cincinnati, OH, January 10, 2007

27. “Effects of Atypical Antipsychotics on Body Composition, Lipid and Glucose Status: Lessons from a Large Cohort Study of Children and Adolescents with Severe Mental Disorders”, Grand Rounds presentation at the Cincinnati Children’s Hospital, Cincinnati, OH, January 10, 2007

28. “Safety and Side Effect Management: Weight Gain, Prolactin, Metabolic Syndrome, & Diabetes", oral presentation as part of the “Consensus Meeting on Outpatient Prescribing of Antipsychotics in Youth: Treatment Recommendations and Research Priorities”, Dallas, TX, February 12-13, 2007.

29. “Achieving Recovery With Atypical Antipsychotics: The Impact of Dosing, Switching and Side Effects To Optimize Outcomes”, oral presentation as part of the 3-day CME Symposium “Practical Psychopharmacology Update 2007, Las Vegas, NV, March 1, 2007.

30. “Adverse Effect Profiles and Safety of Second-Generation Antipsychotics in Children and Adolescents”, oral presentation as part of a hearing in front of the Food and Drug Administration (FDA), Titusville, MD, March 14, 2007

31. “What are the Risks and Benefits of Atypical Antipsychotics?”, Grand Rounds at the State University of New York, Syracuse, New York, NY (March 2007)

32. “Design Issue in Pediatric Psychopharmacology: Bringing Evidence to Practice and Bringing Practice to Evidence", oral presentation as part of the Annual Clinical Trials Workshop, cosponsored by the American Association of Psychopharmacology (ASCP), and the National Institute of Mental Health (NIMH), New York, NY, April 26, 2007

33. “Atypical Antipsychotic-Induced Changes in Body Composition, Lipid Metabolism and Insulin Resistance in Antipsychotic Naïve Youth”, oral presentation as part of the symposium entitled ”Recent Advances in Understanding and Treating Adverse Effects of Antipsychotics”, International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2007.

34. “First-Episode Psychosis: A Window of Opportunity for Best Practices", CME Live Satellite TV Broadcast with Peter Buckley, MD, Alexander Miller, MD, and Christoph Correll, MD, Atlanta, GA, April 17, 2007

35. “Strategies for Dosing and Switching Antipsychotics for Optimal Clinical Management", CME Live Satellite TV Broadcast with P Masand, P Buckley and C Correll, Atlanta, GA, April 24, 2007

36. “Early Intervention in the Psychotic Prodrome: Has Its Time Come?” oral presentation as part of the symposium entitled “Improving Outcomes in Schizophrenia: Prodrome to Remission” (Chair: C Correll), Annual Meeting of the American Psychiatric Association, San Diego, Ca, May 19-24, 2007

37. “Are Antidepressants an Alternative For the Early Treatment of the Psychotic Prodrome?” oral presentation as part of the symposium entitled “Optimum Treatment in Early Psychosis”, Annual Meeting of the American Psychiatric Association, San Diego, Ca, May 19-24, 2007

38. “Achieving Recovery With Atypical Antipsychotics: The Impact of Dosing, Switching and Side Effects To Optimize Outcomes”, oral presentation as part of the 3-day CME Symposium “Practical Psychopharmacology Update 2007”, Cambridge, MA, June 1, 2007.

39. “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics", oral presentation as part of the symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” (Program Development and Co-Chairs: C Correll, S Prescorn, P Weiden), Cleveland, OH, June 2, 2007

40. “Promoting Metabolic and Endocrine Health in Children and Adolescents Treated with Antipsychotics", CME Live Satellite TV Broadcast program with R Findling and L Sikich, Boca Raton, FL, June 10, 2007

41. “Weight Gain and Metabolic Effects of Atypical Antipsychotics in Pediatric Patients”, oral presentation as part of the symposium “Atypical Antipsychotic Medications: Effectiveness and Safety Across the Life Cycle”, annual meeting of the New Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 11-13, 2007

Curriculum Vitae Christoph U. Correll, M.D. Page 41

42. “Recovery and General Health Maintenance”, oral presentation as part of the symposium entitled “National Forum on the Advances in Psychopharmacology and Recovery in Severe Mental Illness”, Miami, FL, June 16, 2007

43. “The Metabolic Syndrome and Cardiovascular Safety of Atypical Antipsychotics", oral presentation as part of the symposium entitled “Pharmacology of Atypical Antipsychotics: Impact on Efficacy and Safety” (Program Development and Co-Chairs: C Correll; S Prescorn, P Weiden), Philadelphia, PA, July 14, 2007

44. “Pharmacodynamics of Atypical Antipsychotics: Clinical Considerations and Practice Implications”, CME Live Satellite TV Broadcast program with S Pescorn and P Weiden, Washington, DC, August 22, 2007

45. “Identification and Management of Adverse Effects of Antipsychotics in Youth", oral presentation as part of the annual Clinical Pediatric Psychopharmacology Course, New York, NY, September 7, 2007

46. “The Metabolic and Endocrine Profiles of Atypical Antipsychotics: How and When to Switch Therapies”, oral presentation as part of the symposium, entitled “Assessing the Role and Tolerability of Atypical Antipsychotics: Sedation, Metabolic/Endocrine Concerns and Functional Outcomes” (Co-chairs: C Correll, J Kane) at the 20th U.S. Psychiatric & Mental Health Congress, Orlando, FL, October 11, 2007.

47. “Antipsychotics and the Insulin Resistance Syndrome: Where Do We Stand and Where Do We Go?”, oral presentation as part of the symposium, entitled “Integrating Physical and Mental Health During Antipsychotic Treatment” (Chair: C Correll) at the Annual American Psychiatric Association Institute on Psychiatric Services meeting, New Orleans, LA, October 12, 2007.

48. “Metabolics in 2007: What is the Practitioner’s Responsibility?”, oral presentation at the American Society of Psychopharmacology Annual Fall Meeting, New York, NY, October 21, 2007.

49. “Metabolic Effects of Atypical Antipsychotics in Pediatric Patients”, oral presentation as part of the symposium entitled “Current Research on Child Bipolar Disorder” (chair: B Geller), 33rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Boston, MA, October 23-28, 2007.

50. “Recognition and Management of Antipsychotic-Induced Adverse Effects” oral presentation as part of the symposium entitled “Update on the Use of Antipsychotics in Children and Adolescents” (chair: C Correll), 33rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Boston, MA, October 23-28, 2007.

51. “Assessing the Safety and Tolerability of Agents used in the Treatment of Pediatric Bipolar Disorder and Schizophrenia”, oral presentation as part of the CME symposium “Advancing the Treatment of Childhood and Adolescent Schizophrenia and Bipolar Disorder: The Use of Atypical Antipsychotics” (Program Development and Co-Chairs: C Correll, R Findling, K Wagner), Boston, MA, December 8, 2007

52. “Prodromal Presentations in Children and Adolescents at Clinical High Risk for Schizophrenia and Bipolar Disorder”, Grand Rounds presentation at Bradley Hospital, Rhode Island, RI, February 13, 2008

53. “Challenges in Pharmacologic Management of Major Psychiatric Disorders in Children and Adolescents: Optimizing Treatment By Minimizing Adverse Effects“, oral presentation as part of the symposium “Treatment of Children and Adolescents with Psychiatric Disorders: The Rising Use of Antipsychotics” (Chair: C Correll), Annual Meeting of the American Psychiatric Association, Washington, DC, May 3-8, 2008

54. “Can Schizophrenia Be Prevented? Interventions During The Psychotic Prodrome", Grand Rounds at the University of Pittsburgh and Western Psychiatric Center Pittsburgh, PA, May 12, 2008

55. “The Morbidity and Mortality of Patients With Mental Health Disorders: How Atypical Antipsychotics Have the Potential to Impact Clinical Outcomes“, oral presentation as part of the CME symposium “Applying the Pharmacology of Atypical Antipsychotics: Clinical Implications on Efficacy and Safety” (Chair: A Abi-Dargham), Teaneck, NJ, May 17, 2008

Curriculum Vitae Christoph U. Correll, M.D. Page 42

56. “How Are Weight Gain And Metabolic Dysfunction Related to Antipsychotic Efficacy in Schizophrenia?“, oral presentation as part of the symposium “Is there a Link Between Antipsychotic Adverse Effects and Efficacy in Schizophrenia? (Chair: CU Correll), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ, May 27-30, 2008

57. “Improving Outcomes through Adequate Monitoring and Management of Psychotropic Adverse Events in Children and Adolescents”, oral presentation as part of the American Academy of Child and Adolescent Psychiatry (AACAP) 2008 Advanced Psychopharmacology Institute (Co-Chairs: M DelBello, C Kratochvil), 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28-November 2, 2008

58. “Antipsychotic and Mood Stabilizer Effects on Metabolic Health in Pediatric Patients”, oral presentation as part of the symposium, entitled “Multidisciplinary Approach to Weight Gain and Metabolic Abnormalities Associated with Antipsychotics in Youth” (Co-Chairs: C Correll and L Maayan), 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28-November 2, 2008

59. “Risks and Benefits of Antipsychotics in Children and Adolescents with Psychosis, Mania and Autistic Disorder” oral presentation as part of the symposium, entitled “Risks and Benefits of Psychotropic Medications in Pediatric Patients” (Chair: C Correll), 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28-November 2, 2008

60. “Prevention of Emerging Schizophrenia and Bipolar Disorder: Is it an Attainable Goal (Yet)?”, Grand Rounds presentation at Yale University, New Haven, CT, November 18, 2008

61. “Practical Antipsychotic Pharmacology for the 21st Century: Polypharmacy and Augmentation Strategies in Schizophrenia“, oral presentation as part of the symposium, entitled “Update on Antipsychotics: Treatment of Patients with Schizophrenia Spectrum Disorders in 2008 and Beyond”, Dartmouth Medical Center, Hanover, NH, November 21, 2008

62. “Antipsychotic Medication Side Effects: Detection, Monitoring, and Intervention”, oral presentation as part of the symposium, entitled “Update on Antipsychotics: Treatment of Patients with Schizophrenia Spectrum Disorders in 2008 and Beyond”, Dartmouth Medical Center, Hanover, NH, November 21, 2008

63. “Use of Antipsychotics in the Treatment of Children with Psychiatric Disorders”, oral presentation as part of the symposium, entitled “Update on Antipsychotics: Treatment of Patients with Schizophrenia Spectrum Disorders in 2008 and Beyond”, Dartmouth Medical Center, Hanover, NH, November 21, 2008

64. “From the Brain to the Bed Side: Using Knowledge About Pharmacology to Improve Antipsychotic Treatment Outcomes in Youths”, oral presentation as part of the American Academy of Child and Adolescent Psychiatry (AACAP) 2009 Psychopharmacology Update Institute (Chair: G Carlson), New York, NY, January 23-24, 2009

65. “Importance of Monitoring Medications in Youth with Bipolar Disorder and Schizophrenia”, oral presentation as part of the CME symposium “Bipolar Disorder and Schizophrenia in Children & Adolescents: Diagnostic and Treatment Issues”, Miami, FL, January 24, 2009

66. “Polypharmacy And Children's Mental Health Care: “Dammed if You Do...Dammed if You Don't”, oral presentation as part of the Georgia Psychiatric Physicians Association Winter CME Meeting “A Practical Guide to Managing Clinical Challenges in the 21st Century: Swimming Upstream with the Sharks”, Atlanta, GA, February 13-14, 2009.

67. “Polypharmacy- Why Use One Drug, When 2, or 3 (or more) Might Work?”, oral presentation as part of the “Expert Debate“ of the Georgia Psychiatric Physicians Association Winter CME Meeting “A Practical Guide to Managing Clinical Challenges in the 21st Century: Swimming Upstream with the Sharks”, Atlanta, GA, February 13-14, 2009.

68. “Patterns and Predictive Value of Early Treatment Response in Adolescents With Schizophrenia-Spectrum Disorders”, oral presentation as part of the symposium entitled “Time Course of Antipsychotic Drug Response in Schizophrenia: A New Perspective” (Chair: C Correll), International Congress on Schizophrenia Research (ICOSR), San Diego, CA, March 28-April 01, 2009.

Curriculum Vitae Christoph U. Correll, M.D. Page 43

69. “Discordant Cardiometabolic Risk of Atypical Antipsychotics Despite Worsening of Body Composition During First-Time Use in Children and Adolescents”, oral presentation as part of the symposium entitled ”Side-effects of Antipsychotic Drugs: Epidemiology, Mechanisms of Action, Measurement, and Treatment” (Chair: S Leucht), International Congress on Schizophrenia Research (ICOSR), San Diego, CA, March 28-April 01, 2009.

70. “Efficacy and Safety of Antipsychotic Medications in Youth”, oral presentation as part of the 2009 Spring Psychiatric Update in Madison, Madison, WI, April 3-4, 2009.

71. “Safety and Tolerability of Second-Generation Antipsychotics: Differential Properties for Adverse Effects in Children and Adolescents”, oral presentation as part of the symposium entitled “Managing the Spectrum of Psychiatric Disorders in Children and Adolescents: Evidence-Based Use of Atypical Antipsychotics” as part of the 2009 College of Psychiatric and Neurologic Pharmacists Annual Meeting, Jacksonville, FL, April 21, 2009.

72. “Therapeutic Management of Antipsychotic Non-response in Patients with Schizophrenia” , oral presentation as part of the symposium entitled “Neurobiology, Prediction and Management of Antipsychotic Non-Response in Patients with Schizophrenia” (Chair: C Correll), American Psychiatric Association Meeting, San Francisco, CA, May 16-May 21, 2009.

73. “Atypical Antipsychotics in Children and Adolescents: Balancing Safety and Efficacy”, Recorded CME Roundtable Discussion (faculty: C Correll, M Rappley, A Robb, B Vitiello) sponsored by the Food and Drug Association, Washington, DC, June 11, 2009.

74. “Combination Treatments for Positive Symptoms, General Psychopathology, and Adverse Effects“, oral presentation as part of the symposium “Pharmacotherapeutic Combination Treatment Strategies in Schizophrenia: Methodology and Evidence” (Co-Chairs: C Correll, G Petrides), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL, June 29-July 02, 2009

75. “Risks and Benefits of Antipsychotics in Youth with Psychosis, Mania, Autistic Disorder and Disruptive Behavior Disorders“, oral presentation as part of the symposium “Update on the Risks and Benefits of Psychotropic Medications in Children and Adolescents: Evidence from Randomized Controlled Trials” (Chair: C Correll), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL, June 29-July 02, 2009

76. “Effects of Divalproex or Lithium Combination with Atypical Antipsychotics in Youth with Bipolar Disorder “, oral presentation as part of the symposium “Mood Stabilizers in Childhood Bipolar Disorders” (Chair: B Vitiello), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, FL, June 29-July 02, 2009

77. “Effectiveness of Antipsychotic in Children and Adolescents with Severe Mental Disorders”, oral presentation as part of the symposium “At the Crossroads of Medicine and Policy: Psychotherapeutic Medications for Children – What does the Evidence Tell us, Who Decides?” by the Florida Mental Health Institute, Destin, FL, October 17, 2009

78. “Applying Pharmacologic Knowledge to Improve Antipsychotic Outcomes in Youth”, oral presentation as part of the 2009 Advanced Psychopharmacology Update: Evidence-based Treatment and Beyond (chair: G Carlson), Honolulu, HI, October 27, 2009.

79. “Psychopharmacological Treatment of Psychotic Disorders, Including the Efficacy and Safety Data of Second Generation Antipsychotics”, oral presentation as part of the American Academy of Child and Adolescent Psychiatry (AACAP) 2010 Psychopharmacology Update Institute (Chair: L Greenhill), New York, NY, January 22-23, 2010

80. “Improving the Physical and Mental Health in the Seriously and Persistently Mentally Ill”, oral presentation as part of the state-wide Grand Rounds for the New York State Office of Mental Health Albany, NY, January 27, 2010

81. “Diagnosis and Treatment of Psychotic Disorders in Youth”, oral presentation as part of the 2010 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Review Course of Child and Adolescent Psychiatry and Training Session for the Oral Exam (chairs: M DelBello and R Kowatch), Cincinnati, OH, April 21-24, 2010

82. “Medication Side Effects in Children and Adolescents Treated with Antipsychotics”, oral presentation as part of the 35th AACAP Annual Review Course of Child and Adolescent

Curriculum Vitae Christoph U. Correll, M.D. Page 44

Psychiatry and Training Session for the Oral Exam Board Review Course (chairs: M DelBello and R Kowatch), Cincinnati, OH, April 21-24, 2010

83. “How Effective and Safe Are Antipsychotics in Youth?”, oral presentation at the Lakeside Behavioral Health Center, Orlando, FL, May 20, 2010

84. “Efficacy and Tolerability of Antipsychotics and Mood Stabilizers in Children and Adolescents with Serious and Complex Mental Health Diagnoses”, oral presentation as part of the Expert Panel Meeting on Psychotropic Medication Regimens for Children and Adolescents in Statewide Inpatient Psychiatric Programs sponsored by the Florida Medicaid Drug Therapy Management Program for Behavioral Health & the Department of Child & Family Studies, the Louis de la Parte Florida Mental Health Institute, College of Behavioral and Community Sciences at the University of South Florida, Tampa, FL, May 20, 2010

85. “Evidence-based Pharmacologic and Non-pharmacologic Treatments for Very Aggressive Children and Adolescents”, oral presentation as part of the Expert Panel Meeting on Psychotropic Medication Regimens for Children and Adolescents in Statewide Inpatient Psychiatric Programs sponsored by the Florida Medicaid Drug Therapy Management Program for Behavioral Health & the Department of Child & Family Studies, the Louis de la Parte Florida Mental Health Institute, College of Behavioral and Community Sciences at the University of South Florida, Tampa, FL, May 20, 2010

86. "Changing Practice: We Know What to Do; How Do We Get it Done?", oral presentation as part of the symposium “New Investigators Symposium: Translational Perspectives on Treatment Development.” (Co-Chairs: B Lebowitz, N Schooler), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 14-July 17, 2010

87. "Effectiveness of a Behavioral Weight Management Program in Obese Patients with Psychotic Disorders Vs. Obese Patients from the General Population", oral presentation as part of the symposium “Cardiometabolic Effects of Antipsychotics: Mechanisms, Interventions, Gaps and Directions” (Co-Chairs: C Correll, L Maayan), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 14-July 17, 2010

88. “From Brain to Bedside: Using Knowledge about Antipsychotic Pharmacology to Enhance Treatment Outcomes in Children and Adolescents”, oral presentation as part of the Colorado Psychiatric Association meeting, Denver, CO, 06.19.2010

89. “Efficacy of Antipsychotics and Mood Stabilizers in Children and Adolescents with Autistic and Aggressive Spectrum Disorders, Bipolar Disorder and Psychotic Disorders”, oral presentation as part of the Colorado Psychiatric Association meeting, Denver, CO, 06.19.2010

90. “Frequency, Monitoring and Management of Adverse Effects Associated with Antipsychotics and Mood Stabilizers in Children and Adolescents with Severe Psychiatric Disorders”, oral presentation as part of the Colorado Psychiatric Association meeting, Denver, CO, 06.19.2010

91. “Cardiometabolic Risk Modification in Youth With Severe Psychiatric Disorders”, oral presentation as part of the symposium, entitled “Etiologies and Treatment: Management of Cardiometabolic Risk Factors in Youth with Severe Mental Disorders” (Co-Chairs: C Correll, L Maayan), 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), New York, NY, October 26-31, 2010

92. “Systematic Review of Randomized Controlled Trials of Pharmacologic Treatments for Youth with Maladaptive Aggression and Related Best Practice Recommendations”, oral presentation as part of the symposium, entitled “Evidence-Based Evaluation and Treatment of Youth with Maladaptive Aggression” (Co-Chairs: C Correll, P Jensen), 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), New York, NY, October 26-31, 2010

93. “Diagnostic and Therapeutic Challenges in Early-Onset Bipolar Disorder”, oral presentation as part of Pediatrics Grand Rounds, Bassett Medical Center, Cooperstown, NY, November 11, 2010.

94. “Pharmacologic Treatment of Bipolar Spectrum Disorders Across the Lifespan”, oral presentation as part of Interdepartmental Grand Rounds, Bassett Medical Center, Cooperstown, NY, November 11, 2010.

95. "Antipsychotic Use in Children and Adolescents: How Can We Best Maximize Treatment Effectiveness?", oral presentation as part of the Oregon Children's Mental Health Conference by

Curriculum Vitae Christoph U. Correll, M.D. Page 45

the Oregon Council of Child and Adolescent Psychiatry, NAMI Multnomah-National Alliance on Mental Illness, Oregon Pediatric Society and Providence Health & Services, Portland, OR, February 12, 2011

96. "Doctors Worry too: How Do Doctors Monitor Safety and Effectiveness of Medications for Children", oral presentation as part of the Oregon Children's Mental Health Conference by the Oregon Council of Child and Adolescent Psychiatry, NAMI Multnomah-National Alliance on Mental Illness, Oregon Pediatric Society and Providence Health & Services, Portland, OR, February 12, 2011.

97. “Inadequate Adherence to Monitoring Guidelines for Cardiometabolic Monitoring of Antipsychotics”, oral presentation as part of the symposium, entitled “Underutilization of Evidence Based Treatment and Monitoring Strategies in Schizophrenia” (Co-Chairs: J Kane, C Correll), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 13-June 16, 2011.

98. “Systematic Review of Randomized Controlled Trials of Pharmacologic Treatments for Youth with Maladaptive Aggression”, oral presentation as part of the symposium, entitled “Evidence-Based Evaluation and Treatment of Youth with Maladaptive Aggression” (Co-Chairs: C Correll, P Jensen), Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 13-June 16, 2011.

99. “Antipsychotic Adverse Cardiovascular Effects in Children, Adolescents, and First-break Patients”, oral presentation as part of the NIMH-funded 2-day conference entitled “Adipogenic and Metabolic Effects of Antipsychotic Drugs”, Newark, NJ, July 1-11, 2011.

100. “Efficacy and Tolerability of Antipsychotics in Youth”, Grand Rounds presentation at the Walter Reed National Military Medical Center Bethesda, MD, October 14, 2011.

101. “Update on Child and Adolescent Psychiatry Plus Early Identification and Intervention in Individuals at Risk for Psychosis”, oral presentation as part of the American Society for Psychopharmacology (ASP) Annual Fall Meeting, New York, NY, October 15-16, 2011.

102. “Cardiometabolic Effects of Antipsychotic Switching in Youth: Results From the SATIETY Study”, oral presentation as part of the symposium entitled “Cardiometabolic Risk Quantification, Monitoring, and Management in Antipsychotic Treated Youth: Scientific Update” (Chair: G Nicol), 58th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2011.

103. Discussant for the symposium entitled “Obesity and the Course and Treatment of Pediatric Bipolar Disorder” (chair: B Goldstein), 58th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2011.

104. “Suicidality and Hospitalization As Cause and Outcome of Pediatric Psychiatric Emergency Room Visits”, oral presentation as part of the symposium entitled “Emergency Child Psychiatry: An Update on Policies, Services, and Practice” (Chair: L Baptista Neto), 58th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2011.

105. “Safety of Psychotropic Drugs Used in Youth with Autism Spectrum Disorders”, oral presentation as part of the Autism Speaks Autism Treatment Network and the Autism Intervention Research Network on Physical Health annual meeting, Boston, MA, Nov 17-18, 2011

106. “Gradual and Overlapping Antipsychotic Switch Strategies Are Associated with Less All-Cause Discontinuation in Schizophrenia: Results from a Meta-analysis of Different Switch Strategies”, oral presentation as part of the Hot Topics symposium (chair: A Abi-Dargham), annual meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, December 4-8, 2011.

107. “Efficacy and Safety of Psychopharmacological Treatments for Psychotic Disorders in Youth: Integrating Current Data into Clinical Practice”, oral presentation as part of the 2012 annual AACAP Psychopharmacology Update Institute, Child and Adolescent Psychopharmacology: Integrating Current Data into Clinical Practice, New York, NY, January 20-21, 2012.

108. “Prevention of Psychosis: Current Approaches and Future Directions”, oral presentation as part of the symposium entitled “Trajectory-Based Disease Modifying Treatments in Pediatric Psychiatry”

Curriculum Vitae Christoph U. Correll, M.D. Page 46

(chair: J March), 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) meeting, Phoenix, AZ, May 29-June 1, 2012.

109. “Update on the Evidence Based Treatment of Chronic Impulsive Aggression in Children and Adolescents Aged 6-17 year Old”, oral presentation as part of the Expert Panel Meeting on Psychotropic Medication Regimens for Children and Adolescents in Statewide Inpatient Psychiatric Programs sponsored by the Florida Medicaid Drug Therapy Management Program for Behavioral Health & the Department of Child & Family Studies, the Louis de la Parte Florida Mental Health Institute, College of Behavioral and Community Sciences at the University of South Florida, Tampa, FL, September 22-23, 2012

110. “Update on the Evidence Based Treatment of Major Depressive Disorder Under the Age of 6 and Aged 6-17 Years Old”, oral presentation as part of the Expert Panel Meeting on Psychotropic Medication Regimens for Children and Adolescents in Statewide Inpatient Psychiatric Programs sponsored by the Florida Medicaid Drug Therapy Management Program for Behavioral Health & the Department of Child & Family Studies, the Louis de la Parte Florida Mental Health Institute, College of Behavioral and Community Sciences at the University of South Florida, Tampa, FL, September 22-23, 2012.

111. “Update on the Evidence Based Treatment Manic or Mixed Episodes of Bipolar 1 Disorder in Children and Adolescents Aged 6-17 Years Old”, oral presentation as part of the Expert Panel Meeting on Psychotropic Medication Regimens for Children and Adolescents in Statewide Inpatient Psychiatric Programs sponsored by the Florida Medicaid Drug Therapy Management Program for Behavioral Health & the Department of Child & Family Studies, the Louis de la Parte Florida Mental Health Institute, College of Behavioral and Community Sciences at the University of South Florida, Tampa, FL, September 22-23, 2012.

112. “Prevention of Psychosis” oral presentation as part of the Research Forum, entitled “Preventing Psychopathology in Childhood and Adolescence” (Co-Chairs: C Correll, M Singh), 59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Francisco, October 23, 2012.

113. “Treatment of Children and Adolescents with Psychotic Disorders: From Prodrome to Refractoriness”, oral presentation as part of the all-day Institute “Advanced Psychopharmacology for Clinical Practice” (Chair: T Wilens), 59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Francisco, October 23, 2012.

114. “Update On Adverse Effects of Second Generation Antipsychotics In Youth”, oral presentation as part of the symposium entitled “Can We Make Antipsychotics Safer for Kids Who Need Them” (Chair: L Sikich), 59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Francisco, October 23-27, 2012.

115. “Current and Therapies in Schizophrenia”, oral presentation as part of a symposium entitled “Broadening Horizons: A Focus on Current and Emerging Therapies in Schizophrenia”, 25th Annual US Psychiatric & Mental Health Congress, San Diego, CA, November 8-11, 2012.

116. “Efficacy and Tolerability of Interventions for Impulsive Aggression in Autism Spectrum Disorder”, oral presentation as part of the Current Trends in Autism meeting, Burlington, MA, Nov 09-10, 2012

117. “After CATIE, CUtLASS, CAFÉ and EUFEST: How Should We Treat Schizophrenia?”, oral presentation as part of the 4th Annual Big Sky Psychiatry Conference, Big Skye, MT, January 25, 2013.

118. “Cardiometabolic Risks of Antipsychotics in Kids and Adults”, oral presentation as part of the 4th Annual Big Sky Psychiatry Conference, Big Skye, MT, January 25, 2013.

119. “Treating Aggression in Youth“, oral presentation as part of the 2013 Statewide Grand Rounds program of the Office of Mental Health New York, Albany, February 20, 2013.

120. “Psychosis”, oral presentation as part of the 38th Annual Review Course in Child and Adolescent Psychiatry and Training Session for the Oral Exams, held by the American Academy of Child and Adolescent Psychiatry (co-chairs. C Galanter, M Rynn). Jersey City, NJ, March 13-16, 2013.

121. “Selective Effects of Individual Antipsychotic Cotreatments on Cardiometabolic and Hormonal Risk Status: Results from a Systematic Review and Meta-analysis”, oral presentation, 14th

Curriculum Vitae Christoph U. Correll, M.D. Page 47

International Congress on Schizophrenia Research (ICOSR), 14th International Congress on Schizophrenia Research, Orlando FL, April 11-25, 2013.

122. “Assessment and Treatment of the Attenuated Psychosis Syndrome and Pediatric-Onset Schizophrenia“, oral presentation as part of the symposium, entitled “Cutting Edge Treatment of Schizophrenia Over the Life Cycle” (Chair: Ira Glick) annual meeting of the American Psychiatric Association (APA), San Francisco, CA, May 18-22, 2013.

123. “Efficacy and Tolerability of Antipsychotics in Children and Adolescents with Schizophrenia“, oral presentation as part of the symposium, entitled “Approaches to Schizophrenia Across the Lifespan” (Chair: S Schulz) annual meeting of the American Psychiatric Association (APA), San Francisco, CA, May 18-22, 2013.

124. “Risk factors for Medical Co-Morbidities Observed at Onset of Psychosis“, oral presentation as part of the symposium, entitled “Identifying and Managing Emerging Medical Comorbidities in Early Mental Illness” (Chair: R Heinssen) 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) meeting, Hollywood, AZ, May 26-29, 2013.

125. “Increasing Utilization of Clozapine Through Knowledge About Risk Factors for and Management of Serious and Non-Serious Adverse Effects”, oral presentation as part of the symposium, entitled “Clozapine: How Far Have We Come?” (Chair: J Kane) 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) meeting, Hollywood, AZ, May 26-29, 2013.

126. “Medication Adherence and Compliance in Schizophrenia: Raising the Bar”, oral presentation as part of a US-wide CME series, Baltimore, MD, June 10, 2013.

127. “Medication Adherence and Compliance in Schizophrenia: Raising the Bar”, oral presentation as part of a US-wide CME series, Cleveland, OH, June 11, 2013.

128. “Medication Adherence and Compliance in Schizophrenia: Raising the Bar”, oral presentation as part of a US-wide CME series, Boston, MA, June 18, 2013.

129. “Efficacy and Tolerability of Antipsychotics in Youth with Severe Psychiatric Disorders: Results from Randomized Controlled Trials“, oral presentation as part of the Clinical Perspectives session, entitled “Integrating Behavioral and Medical Findings From Studies Assessing Risk, Efficacy, Tolerability, and Safety for Children Receiving Antipsychotic Medications” (Chair: S Stock), annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

130. “Psychopharmacologic Treatment Options for Youth with Autism Spectrum Disorders“, oral presentation as part of the Workshop session, entitled “Individualizing Treatments for Children and Adolescents with Autism Spectrum Disorders” (Chair: S Ameis), annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

131. “Assessment and Interventions during the Psychosis Prodrome”, oral presentation as part of the Institute “Psychotic Disorders in Youth: Diagnostic and Treatment Considerations” (Co-chairs: Y Dvir, J Frazier), annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

132. “Assessing and Maximizing the Safety and Tolerability of Agents Used in the Treatment of Children and Adolescents with Psychotic Disorders”, oral presentation as part of the Clinical Perspectives session, entitled “Improving the Quality of Care for Patients with Early Onset Psychosis” (Chair: N Okereke), annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

133. “Dysglycemic Signals in Antipsychotic-Treated Children and Adolescents with Schizophrenia-Spectrum Disorders: Trajectories, and Moderating and Mediating Factors”, oral presentation as part of the symposium “Pathophysiology and Treatment of Obesity and Glucose Dysregulation in Schizophrenia” (chair: F Jarskog, co-chair S. Stroup), annual meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 8-12, 2013.

134. “Treating the Child and Adolescent with Refractory Psychotic Disorders”, oral presentation as part of the 2014 annual AACAP Psychopharmacology Update Institute, Child and Adolescent Psychopharmacology: “Treating the Refractory Patient: Adding Expertise to Evidence-Based Methods”, New York, NY, January 10-11, 2014.

Curriculum Vitae Christoph U. Correll, M.D. Page 48

135. “Effect of Trial Design, Population and Illness Phase on the Role of Long-Acting Injectable Antipsychotics for Signaling and Preventing Non-Adherence in Schizophrenia”, oral presentation as part of the symposium entitled “Novel and Underutilized Strategies to Improve Adherence and Reduce Relapse Risk in Schizophrenia” (Chair: CU Correll), Annual American Society of Clinical Psychopharmacology (ASCP) Meeting, Hollywood, FL, June 16-19, 2014.

136. “Duration of Untreated Psychosis and Its Correlates in Patients with Schizophrenia-Spectrum Disorders: Results from a Large Meta-analysis of First Episode Studies”, oral presentation as part of the symposium entitled “Leveraging the Internet and Social Media to Improve Pathways to Care and Shorten DUP in Schizophrenia” (Chair: JM. Kane), Annual American Society of Clinical Psychopharmacology (ASCP) Meeting, Hollywood, FL, June 16-19, 2014.

137. “Placebo Response Across Disease Categories”, oral presentation as part of the American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop, Hollywood, FL, June 19-20, 2014.

138. “Diagnostic and Assessment Issues in Pediatric Psychopharmacology”, oral presentation as part of the American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop, Hollywood, FL, June 19-20, 2014.

139. “Long-Acting Injectable Antipsychotics: Utilization, Evidence, Barriers and Target Groups”, oral presentation, Presidential Symposium, entitled “Missed Opportunities in Psychiatric Practice” (Chair: M. Olfson), annual American Psychiatric Association (APA) meeting, May 3-7, 2014, New York, NY.

140. "Prevention and Treatment of Early Phase Psychotic Disorders", Research Seminar, McLean Hospital, Boston, MA, July 18, 2014.

141. “Assessing and Managing Adverse Effects of Antipsychotics”, oral presentation as part of the symposium entitled “Overcoming Challenges in Schizophrenia: Strategies for Long-Term Management and Relapse Prevention”, 27th Annual U.S. Psychiatric & Mental Health Congress, Rosen Shingle Creek Resort, Orlando, Florida, September 21, 2014

142. “After CATIE, CUtLASS, CAFÉ and EUFEST: How Should We Treat Schizophrenia?”, Grand Rounds presentation, Vanderbilt University, Nashville, TN, January 09, 2015.

143. “Causes and Management of Metabolic Syndromes in Children and Adolescents with Mental Illness”, oral presentation as part of the 20th annual Psychopharmacology Update of the Nevada Psychiatric Association, Las Vegas, NV, February 11-15, 2015.

144. “Update on the Pharmacological Treatment and clinical Predictors of Therapeutic Response to Antipsychotics in First-Episode Schizophrenia”, oral presentation as part of the symposium entitled “Optimizing the Treatment of First Episode Psychosis” (chair: C Arango), 15th International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2015.

145. "Top 5 Challenges in the Treatment of Patients with Mental Illness and Metabolic Syndrome”, oral presentation as part of a Comprehensive Session, 2015 US Psychiatric Congress, San Diego, CA, September 10-13, 2015.

146. "The Neurobiology of Cognitive Impairment in Schizophrenia”, oral presentation as part of the symposium entitled “Enhancing Patient Functioning in Schizophrenia: The Importance of Addressing Cognitive Impairment”, 2015 US Psychiatric Congress, San Diego, CA, September 10-13, 2015.

147. The Clinical High-Risk Approach in Bipolar Disorder: Is Prevention an Attainable Goal?, International Society of Bipolar Disorder (ISBD) Webinar, October 28, 2015.

148. “Management of Youth with Early-Onset Schizophrenia: When First-line Treatments Fail”, oral presentation as part of the Clinical Perspectives session, entitled “The Next Best Treatment: When First-Line Treatment Fails. Overview of Standard Treatment and Alternative Treatment of Depression, Bipolar, Early-Onset Schizophrenia Spectrum Disorder, and ADHD”, Annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Antonio, TX, October 26-31, 2015.

149. “Efficacy and safety of antipsychotics in youth with severe psychiatric disorders: Update and best clinical practice proposal”, oral presentation as part of the Clinical Perspectives session, entitled

Curriculum Vitae Christoph U. Correll, M.D. Page 49

“Antipsychotic Medication Treatment in Clinical Practice: Beyond the Trends and Headlines”, Annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Antonio, TX, October 26-31, 2015.

150. “Assessing and Optimizing Tolerability of Antipsychotics in the Treatment of Children and Adolescents”, oral presentation as part of the Symposium, entitled “Risk and Benefit: Weighing in on Adverse Effects of Psychotropic Medication in Kids (Co-Chairs J Strawn, B Coffey), Annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Antonio, TX, October 26-31, 2015.

151. “Targeting Efficacy and Tolerability of Antipsychotics in Youth With Severe Psychiatric Disorders to Improve Outcomes”, Master Clinician - Clinical Consultation Breakfast session”, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Antonio, TX, October 26-31, 2015.

152. “Managing Patients with First Episode Psychosis”, oral presentation as part of the Workshop, entitled “Early Psychosis Services”, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Antonio, TX, October 26-31, 2015.

153. “Diagnosing and Managing Depressive Episodes in the DSM-5 Era”, oral presentation as part of the Grand Rounds Program at University of Florida Health Medical Center, Jacksonville, FL, November 10, 2015.

154. “Efficacy and Tolerability of Antipsychotics in Youth with Severe Psychiatric Disorders”, oral presentation as part of The Annual UC Davis Psychotic Disorder Conference, Sacramento, CA, November 13, 2015.

155. “Beyond Positive: Advances in the Management of Cognitive Symptoms in Schizophrenia”, oral presentation as part of the Grand Rounds Program at the University of California Los Angeles (UCLA) Olive View Mental Health Center, Sylmar, CA, January 7, 2016.

156. “Relapse Prevention in Schizophrenia and Related Psychiatric Disorders: Promoting Recovery through Improved Adherence”, oral presentation as part of the Grand Rounds Program at the Georgia Memorial University Medical Center, Savannah, GA, January 8, 2016.

157. “Diagnostic and Assessment Issues in Pediatric Psychopharmacology”, oral presentation together with Philipp Auby, as part of the American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop, New York, NY, April 20-21, 2016.

158. “Tardive Dyskinesia Revisited: What’s New?” oral presentation as part of a one-day CME symposium entitled General Medical Education (GME) Psychiatry Update 2016, Los Angeles, CA, May 21, 2016.

159. Detection and Management of Early Onset Psychosis”, Grand Rounds presentation at the University of Texas Medical Branch, Galveston, TX, May 24, 2016.

160. “Beyond Positive: Advances in the Management of Cognitive Symptoms in Schizophrenia”, oral presentation as part of the Grand Rounds Program at the John George Psychiatric Hospital, San Leandro, CA, July 7, 2016.

161. “Metabolic Dysregulation in Mood and Psychotic Disorders: What Clinicians Should Know”, oral presentation as part of the 2-day American Society of Clinical Psychopharmacology (ASCP) Fall Meeting, entitled “Psychopharmacology: State-of-the-Art”, New York, NY, October 29-30, 2016.

162. “Tardive Dyskinesia: New Treatments for an Old Ailment?”, oral presentation as part of a one-day CME symposium entitled General Medical Education (GME) Psychiatry Update 2017, Los Angeles, CA, March 25, 2017.

163. “Metabolic Dysregulation in Mood and Psychotic Disorders: What Clinicians Should Know”, oral presentation as part of the American Society of Clinical Psychopharmacology (ASCP) Spring Meeting, entitled “Psychopharmacology: State-of-the-Art”, Los Angeles, CA, March 25-26, 2017.

164. “What is New in the Treatment of Schizophrenia”, oral presentation as part of the Founders symposium, entitled “Optimizing the Treatment of Schizophrenia” (Co-chairs: C Schulz, C Tamminga), 16th International Congress on Schizophrenia Research (ICOSR), San Diego, CA, March 24-28, 2017.

Curriculum Vitae Christoph U. Correll, M.D. Page 50

165. “Meta-Analysis of Tardive Dyskinesia Rates in Randomized-Controlled Studies comparing First-to Second-Generation Antipsychotics”, oral presentation as part of the 16th International Congress on Schizophrenia Research (ICOSR), San Diego, CA, March 24-28, 2017.

166. “Applied Biostatistics”, oral presentation, as part of the American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop, New York, NY, April 27-28, 2017.

167. “Diagnostic, Assessment, and Methodology Issues in the Development of Antidepressants and Mood Stabilizers”, oral presentation, as part of the American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop, New York, NY, April 27-28, 2017.

168. “Diagnostic and Assessment Issues in Pediatric Psychopharmacology”, oral presentation as part of the American Society of Clinical Psychopharmacology (ASCP) Clinical Trials Workshop, New York, NY, April 27-28, 2017.

169. “Optimizing Treatment in Schizophrenia: An Update”, oral presentation as part of the 2017 US Psychiatric and Mental Health Congress, New Orleans, LA, September 17, 2017.

170. “Biopsychosocial and Behavioral Factors Associated with the Development of Severe Obesity”, discussant in the break out session and panelist in the final panel discussion as part of the “National Instute of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored workshop on “Developing Precision Medicine Approaches to the Treatment of Severe Obesity in Adolescents, Rockville, MD, September 18-19, 2017.

171. “Tardive Dyskinesia: New Treatments for an Old Ailment?”, oral presentation as part of a one-day CME symposium entitled General Medical Education (GME) Psychiatry Update 2017, Philadelphia, PA, October 7, 2017.

172. “Characteristics and Effects of the Duration of Untreated psychosis on Outcons in Patients with Schizophrenia: Results from a Large-Scale Meta-analysis”, oral presentation as part of the symposium, entitled “Duration of Untreated Psychosis: Evidence for Impact on Clinical Course and Biologic Mechanisms”, American College of Neuropsychopharmacology (ACNP) 56th Annual Meeting, Palm Springs, CA, December 3-7, 2017.

173. "Diagnostic and Therapeutic Challenges in Early-Onset Bipolar Disorder", Grand Rounds Presentation at Sheppard Pratt Health System, Baltimore, MD, January 24, 2018.

174. “Metabolic syndrome in psychiatry: an overview “, oral presentation as part of the Workshop (1268), entitled “Psychotropic drug induced weight gain and/or metabolic syndrome: recognition and management” (Co-Chairs: CU Correll; C Eap), American Psychiatric Association (APA) annual meeting, New York, NY, May 5-9, 2018.

175. “Psychosis, Cognition and the Metabolic Syndrome: At the Intersection between Illness an Treatment“, oral presentation as part of the Symposium, entitled “Body-Behavior-Brain interactions in Psychosis” (Chair: S Frangou), American Psychiatric Association (APA) annual meeting, New York, NY, May 5-9, 2018.

176. “The Schizophrenia Prodrome: Spotting Schizophrenia Early and Accurately”, oral presentation at the 2018 Montana Psychiatry Conference, Chico, MT, November 10, 2018.

177. “Schizophrenia: Best Practices for Acute and Maintenance Treatment”, oral presentation at the 2018 Montana Psychiatry Conference, Chico, MT, November 10, 2018.

178. “Evidence-based Identification and Intervention for People at Risk for and with Early Phase Psychosis”, oral presentation as par of the AACAP January Psychopharmacology Meeting, entitled “Early Treatment Intervention - When, What and For How Long”, New York, NY, USA, January 25-26, 2019.

179. “Early Identification of Youth at Risk: Psychosis”, oral presentation as part of the annual meeting of the American Association of Directors of Child and Adolescent psychiatry (AADCAP), Park City, UT, USA, April 25-27, 2019.

Curriculum Vitae Christoph U. Correll, M.D. Page 51

INVITED LECTURES/ORAL PRESENTATIONS: Ex-US INTERNATIONAL 1. “Tardive Tourette’s syndrome: Variant of tardive dyskinesia or discrete medication-induced

extrapyramidal side effect syndrome?”, presented at the International Symposium on Mental and Behavioral Dysfunction in Movement Disorders, Montreal, Canada, October 10-13, 2001

2. “Tardive Tourette’s syndrome: Nonexistent or underrecognized?”, presented at the XII World Congress of Psychiatry, Yokohama, Japan, August 24-29, 2002

3. “Research Opportunities Involving Antipsychotic-Treated Youth”, oral presentation at the 1st Scandinavian Child and Adolescent Psychiatry Research Network Meeting “Research on Atypical Antipsychotics in Scandinavian Child and Adolescent Psychiatry", Lund, Sweden, February 5-6, 2004

4. “Change in Body Composition and Metabolic State Induced by Atypical Antipsychotic Treatment in Children and Adolescents”, oral presentation at the 1st Scandinavian Child and Adolescent Psychiatry Research Network Meeting “Research on Atypical Antipsychotics in Scandinavian Child and Adolescent Psychiatry”, Lund, Sweden, February 5-6, 2004

5. “Can Psychosis Be Prevented in High-Risk Adolescents?”, oral presentation at the 1st Scandinavian Child and Adolescent Psychiatry Research Network Meeting “Research on Atypical Antipsychotics In Scandinavian Child and Adolescent Psychiatry”, Lund, Sweden, February 5-6, 2004

6. “Risk-benefit evaluation of early interventions with atypical antipsychotics for youths at high risk for psychosis”. Oral presentation as part of the symposium “What is the role of second-generation antipsychotics in the treatment of children and adolescents”, 16th World Congress of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Germany, August 22-26, 2004

7. “Safety of Aripiprazole in children and adolescents with psychotic, mood and disruptive behavior disorders: a 3-month prospective trial”. Oral presentation at the 16th World Congress of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Germany, August 22 - 26, 2004

8. “Prospective Study of second-generation antipsychotic-induced insulin resistance in antipsychotic-naïve children and adolescents”, oral presentation at the 16th World Congress of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Germany, August 22-26, 2004

9. “The Early Onset of Antipsychotic Effect – A Hypothesis Tested, Confirmed and Extended”, oral presentation at the 43rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, December 12-16, 2004

10. “Update on Adverse Anthropometric and Metabolic Effects of Atypical Antipsychotics in Children and Adolescents”, oral Presentations at the 2nd Scandinavian Child and Adolescent Psychiatry Research Network Meeting “Research on Atypical Antipsychotics In Scandinavian Child and Adolescent Psychiatry”, Lund, Sweden, April 14-15, 2005

11. “Novel Antipsychotic-Induced Weight Gain and Metabolic Abnormalities in Youth”, presented at part of the symposium “Early-onset Schizophrenia: Research Update” at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2005.

12. “Atypical Antipsychotics for Adolescents At Risk For Schizophrenia-Spectrum Disorders”, oral presentation as part of the symposium “Atypical Antipsychotic Use across Disease States in Children and Adolescents” (Chair: U Correll) presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2005.

13. “Pharmacologic Treatment of Schizophrenia Across the Course of Illness”, Grand Rounds presentation at Brampton Hospital, Brampton, Ontario, Canada (October 2005)

14. “Augmentation Strategies in the Treatment of Schizophrenia”, Grand Rounds presentation at Whitby Mental Health Centre, Ontario, Canada (October 2005)

Curriculum Vitae Christoph U. Correll, M.D. Page 52

15. “Diagnostic and Treatment Challenges in the Early Course of Psychotic Disorders”, Grand Rounds presentation at St Joseph’s Hospital, Hamilton, Ontario, Canada (October 2005)

16. “Challenges in the treatment of schizophrenia”, Grand Rounds presentation at Memorial University of Newfoundland, St Johns, NF, Canada (November 2005)

17. “The Prodrome of Psychotic Disorders and Bipolar Disorder”, Grand Rounds presentation at London Psychiatric Hospital, London, Ontario, Canada (May 2006)

18. “Prevalence Rates and Mechanisms of Metabolic Syndrome Associated with Atypical Antipsychotics”, oral presentation as part of the workshop entitled “When therapeutic lifestyle interventions fail: pharmacologic treatments for metabolic syndrome in psychiatry”, Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006

19. “Metabolic Risks of Second-Generation Antipsychotics”, oral presentation as part of the symposium entitled “New Developments in Schizophrenia: From Neurobiology to Public Health”, Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006

20. “Update on Evidence-Based Treatments of Bipolar Mania and Bipolar Depression”, Grand Rounds presentation at Nova Scotia Hospital, Halifax, Nova Scotia, Canada (June 2006)

21. “Diagnosis and Treatment of Pediatric Bipolar Disorder”, Grand Rounds presentation at British Columbia University Children’s Hospital, Vancouver, Canada (July 2006)

22. “Challenges in the Diagnosis and Treatment of Early-onset Bipolar Disorder”, Grand Rounds presentation at The Children’s Hospital, Vancouver, Canada (August 2006)

23. “Evidence-based Treatment of Bipolar Disorder”, Lunch Rounds presentation at the Homewood Mental Health & Addiction Centre, Guelph, Canada (September 2006)

24. “Metabolic Risks of Second-generation Antipsychotics”, Morning Rounds presentation at Grand River Hospital, Kitchener/Waterloo, Canada (September 2006)

25. “Body Composition Changes and Abnormalities in Glucose and Lipid Metabolism Associated with Atypical Antipsychotic Treatment”, Noon Rounds presentation at Brampton Peel Memorial Hospital, Toronto, Canada (September 2006)

26. “When Symptoms Don’t Remit With Antipsychotic Treatment: Dosing and Augmentation Strategies”, Grand Rounds presentation at Prince Albert Hospital, Saskatoon, Saskatchewan, Canada (November 2006)

27. “Risk Benefit Ratios of Atypical Antipsychotics: Focus on Metabolic Health”, Morning Rounds presentation at the Calgary University Hospital, Calgary, Alberta, Canada (November 2006)

28. “Recent Advances in the Evidence-based Treatment of Bipolar Mania and Bipolar Depression”, Grand Rounds presentation at Alberta Hospital, Ponoka, Alberta, Canada (November 2006)

29. “Antipsychotic Non-Adherence: A Major Mental Health Issue”, Morning Rounds presentation at Edmonton Hospital, Edmonton, Winnipeg, Canada (November 2006)

30. “Recognition and Interventions in Individuals at High Risk for Bipolar Illness”, workshop as part of the Symposium, entitled “Long-term Treatment of Psychiatric Disorders in the Ambulatory Care Setting Carl Gustav Carus University of Dresden, Dresden, Germany, March 23-24, 2007

31. “Early Identification of Bipolar Disorder and Schizophrenia”, oral presentation as part of the Symposium, entitled “Long-term Treatment of Psychiatric Disorders in the Ambulatory Care Setting”, Carl Gustav Carus University of Dresden, Dresden, Germany, March 23-24, 2007

32. “Understanding, Monitoring and Reducing Adverse Effects of Antipsychotics”, oral presentation as part of the Pan-European symposium entitled “Impact on Physical Health – A Roadmap for Psychiatrists”, Rome, Italy, April 20-21, 2007

33. “Antipsychotics in the Treatment of Juvenile Psychoses”, oral presentation as part of the symposium entitled “Early Recognition and Treatment of Schizophrenia-Spectrum Psychoses during Adolescence: Opportunities and Recognition of Patients Who Would Benefit“, Bern, Switzerland, May 03-04, 2007

34. “Physical Health in Psychiatry – From Practice Guidelines to Clinical Practice”, oral presentation as part of the symposium entitled “Physical Health in Patients with Schizophrenia“ (Co-chairs: C Correll, D Ruether), Munich, May 04-05, 2007

Curriculum Vitae Christoph U. Correll, M.D. Page 53

35. “Physical Health in Psychiatry – From Practice Guidelines to Clinical Practice”, oral presentation as part of the symposium entitled “Physical Health in Patients with Schizophrenia“ (Co-chairs: C Correll, T Pollmaecher), Frankfurt, May 11-12, 2007

36. “Non-Adherence: A Major Mental Health Problem”, Grand Rounds presentation at Lakeridge Health Centre Oshawa, Oshawa, Ontario, Canada, June 20, 2007.

37. “Non-Compliance in Psychiatry”, Grand Rounds presentation at Markham Stouffville Medical Centre, Marcum, Ontario, Canada, June 21, 2007.

38. “Prevalence and Correlates of Non-Compliance to Psychiatric Medications”, Grand Rounds presentation at North York General Hospital, North York, Ontario, Canada, June 22, 2007.

39. “Non-Adherence to Antipsychotic Medications”, Grand Rounds presentation at Whitby Mental Health Centre, Whitby, Ontario, Canada, June 22, 2007.

40. “Early Identification and Intervention in Schizophrenia: How far Have We Come?”, oral presentation at a Scandinavian Child and Adolescent Psychiatry Research Network Meeting, Lund, Sweden, August 29, 2007

41. “Early Identification and Intervention in Bipolar Disorder: Where Do We Need To Go?”, oral presentation at a Scandinavian Child and Adolescent Psychiatry Research Network Meeting, Lund, Sweden, August 29, 2007

42. “Update on the Metabolic Side Effects of Atypical Antipsychotics”, oral presentation at a Scandinavian Child and Adolescent Psychiatry Research Network Meeting, Lund, Sweden, August 29, 2007

43. “Does a Prodrome Exist in Bipolar Disorder?”, oral presentation as part of the symposium, entitled “Dresden Perspectives on Psychiatric Research”, Carl Gustav Carus University of Dresden, Dresden, Germany, September 28-29, 2007

44. “Challenges of Long-term Physical and Mental Health and Well-being in Schizophrenia”, oral presentation annual meeting of the Japanese Society of Clinical Neuropsychopharmacology, Osaka, Japan, October 5, 2007.

45. “Metabolic Health Issues in Patients with Schizophrenia”, oral presentation as part of the symposium, entitled ”Tolerability of Atypical Antipsychotics: Recent Controversies and Future Management” (chair: W Fleischhacker) at the Annual European Clinical Neurosychopharmacology meeting, Vienna, Austria, October 17, 2007.

46. “Safety and Tolerability of Antipsychotics in Children and Adolescents”, oral presentation at the Psychopharmacology Update in Child and Adolescent Psychiatry meeting, Aalborg, Denmark, November 22, 2007

47. “Early Consideration of Long-term Outcomes: Elements of Effective Antipsychotic Management”, oral presentation as part of the symposium “Thinking About Long-term Outcomes Early On: Prevention and Intervention in the Management of Schizophrenia” (chair: J Klosterkoetter), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Potsdam, Germany, November 21-24, 2007

48. “Combining Efficacy and Tolerability in the Management with Antipsychotics”, oral presentation at the Annual Holmenkollen Advent Symposium, Olso, Norway, November 29, 2007

49. “Management of Metabolic Adverse Effects of Antipsychotics”, oral presentation annual meeting of the Scandinavian Association of Psychiatry, Malmoe, Sweden, November 30, 2007

50. “The Psychiatrist and the Current Possibilities of Antipsychotic Treatments”, oral presentation as part of the symposium “Effective Treatment, Optimal Patient Management and Ethical Standards in Psychiatry”, Potsdam, Berlin, December 14-15, 2007

51. “Does a Prodrome Exist in Bipolar Disorder?”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Pharmacotherapy of Schizophrenia and Bipolar Disorder” by the Quebec Psychiatric Association, Montreal, Canada, January 26-27, 2008

52. “Update on the Evidence-based Treatment of Bipolar Mania and Bipolar Depression”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Pharmacotherapy of Schizophrenia and Bipolar Disorder” by the Quebec Psychiatric Association, Montreal, Canada, January 26-27, 2008

Curriculum Vitae Christoph U. Correll, M.D. Page 54

53. “Can Schizophrenia be Prevented?”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Pharmacotherapy of Schizophrenia and Bipolar Disorder” by the Quebec Psychiatric Association, Montreal, Canada, January 26-27, 2008

54. “Is there Evidence for the Efficacy and Safety of Polypharmacy in Schizophrenia?”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Pharmacotherapy of Schizophrenia and Bipolar Disorder” by the Quebec Psychiatric Association, Montreal, Canada, January 26-27, 2008

55. “Pharmacological Treatment of Psychotic Youth”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Pharmacotherapy of Schizophrenia and Bipolar Disorder” by the Quebec Psychiatric Association, Montreal, Canada, January 26-27, 2008

56. “Real-life Dosing and Switching of Atypical Antipsychotics”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Pharmacotherapy of Schizophrenia and Bipolar Disorder” by the Quebec Psychiatric Association, Montreal, Canada, January 26-27, 2008

57. “Addressing Challenges of Long-term Physical and Mental Well-Being in Schizophrenia” oral presentation as part of the symposium “Treatment of Schizophrenia Across the Lifespan of the Disease (Chair: M. Maj), XII Congress of the Italian Society of Psychopathology, Rome, Italy, February 19-23, 2008

58. “Assessing the Overall Effectiveness of Second-Generation (“Atypical”) Antipsychotics”, oral presentation as part of the symposium, entitled “Balancing Risks and Benefits and Treatment with Antipsychotics”, Collegium Internationale Neuro-Psychopharmacologicum (CINP), Pacific-Asia Regional Meeting, Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia, March 02-05, 2008

59. “Antipsychotic combinations versus monotherapy in schizophrenia: A meta-analysis of randomized controlled trials", oral presentation, 1st Annual Meeting of the Schizophrenia International Research Society, Venice, Italy, June 21-25, 2008

60. “Balancing Efficacy and Tolerability in the Treatment with Antipsychotics", oral presentation, International Seminar on Psychiatry, cosponsored by the Midlands Psychiatric Research Group in collaboration with the World Psychiatric Association (WPA)’s Section on Psychiatry in Developing Countries & World Association for Psychosocial Rehabilitation (WAPR), Birmingham, UK, June 27-28, 2008

61. ”Treatment of bipolar disorder: focus on mania – efficacy and safety", oral presentation as part of the symposium, entitled “Finding the Balance in Bipolar Disorder: From Theory to Practice” (Chair: C Correll), Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, July 13-17, 2008

62. ”Mechanisms and Consequences of Antipsychotic Weight Gain”, oral presentation at the Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie Eschenallee, Berlin, Germany, July 16, 2008

63. “The Use of Antipsychotics in Children and Adolescents: Liability and Pharmacovigilance” (Discussant), as part of the “Targeted Expert Meeting (TEM) on Child and Adolescent Disorders and Treatment”, 21st European College of Neuropsychopharmacology, Barcelona, Spain, August 29-30, 2008

64. “Early Intervention with Antidepressant Drugs in Schizophrenia”, oral presentation as part of the symposium entitled “Early Intervention in Schizophrenia: Rationale and Treatment Options”, 21st European College of Neuropsychopharmacology, Barcelona, Spain, August 30-September 3, 2008

65. “Earlier diagnosis and treatment is the key to advancing schizophrenia outcomes“, oral presentation as part of the symposium entitled “First Steps in Schizophrenia Management: The Importance of Early Intervention” (Chair: C Correll), 21st European College of Neuropsychopharmacology, Barcelona, Spain, August 30-September 3, 2008

66. “The Bipolar Prodrome: Has the Time Come for Early Recognition and Intervention?”, oral presentation as part of the symposium, entitled “Relevance of Early Recognition, Early Intervention and Prevention in Bipolar Disorder” (Co-chairs: M Bauer and C Correll), Annual Meeting of the German Association of Bipolar Disorders (DGBS), Dresden, Germany, September 11-13, 2008

Curriculum Vitae Christoph U. Correll, M.D. Page 55

67. “The Art and Science of Antipsychotic Treatment of Schizophrenia”, oral presentation as part of the Conference entitled “Schizophrenia Update 2008”, Centre for Addiction and Mental Health, Toronto, Ontario, Canada, October 3, 2008

68. “Optimizing Effectiveness of Antipsychotics in Schizophrenia – Relevance of Illness Phase and Pharmacology” oral presentation as part of the Conference entitled “Psychiatry into the 21st Century”, London, October 4, 2008

69. “Does a Prodrome Exist in Bipolar Disorder?” oral presentation as part of the symposium “Prodromal Presentations in Bipolar Disorder” (Co-chairs: A Bechdolf and C Correll), 6th International Conference on Early Psychosis (IEPA), Melbourne, Australia, October 20-22, 2008

70. “Is There A Role of Antidepressants for the Treatment of the Psychotic Prodrome?” oral presentation as part of the symposium “Prodromal Presentations in Bipolar Disorder and Schizophrenia” (Chair: A Yung), 6th International Conference on Early Psychosis (IEPA), Melbourne, Australia, October 20-22, 2008

71. “Identifying and Managing the Cardiometabolic Risks of Antipsychotics”, Grand Rounds presentation at the Department of Psychiatry, Centre de Recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Université de Montreal, Montreal, Quebec, Canada, November 3, 2008

72. “Optimizing the Treatment of Schizophrenia”, Grand Rounds presentation at the Department of Psychiatry, Hôpital St-Jerome, Montreal, Quebec, Canada, November 3, 2008

73. “Current Considerations in the Treatment of Schizophrenia”, Grand Rounds presentation at the Department of Psychiatry, Hôpital Sacre-Coeur, Montreal, Quebec, Canada, November 4, 2008

74. “Optimizing the Treatment of Schizophrenia”, Grand Rounds presentation at the Department of Psychiatry, Hôpital de Joliette, Joliette, Quebec, Canada, November 3, 2008

75. “Polypharmacy: Consequences for Interactions and Adverse Events”, oral presentation as part of the symposium, entitled “Elements of Psychopharmacologic Drug Safety with Special Consideration of Therapeutic Drug Monitoring” (chairs: J Cordes, G Juckel), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2008

76. “Systematic Retrospective and Prospective Evaluation of the Bipolar Prodrome”, oral presentation as part of the symposium, entitled “Bipolar Disorder – Prodrome and Prognosis” (chairs: M Bauer, G Juckel), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2008

77. “Changes in Body Weight and Metabolic Parameters in Children and Adolescents During Antipsychotic Therapy”, oral presentation as part of the symposium, entitled “Eating Disorders and Physical Changes” (Co-Chairs: K von Klitzing, C Correll), XXXI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Hamburg, Germany, March 5 – March 7, 2009

78. “The Bipolar and Schizophrenia Prodrome”, oral presentation as part of the symposium, entitled “Early Identification and Intervention in Juvenile Psychoses: New Results and Clinical Perspectives” (Co-Chairs: B Schimmelmann, C Correll), XXXI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Hamburg, Germany, March 5 – March 7, 2009

79. “Prolactin Changes in Children and Adolescent during Antipsychotic Therapy”, oral presentation as part of the symposium, entitled “Psychopharmacology” (Co-Chairs: G Lehmkuhl, F Haessler), XXXI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Hamburg, Germany, March 5 – March 7, 2009

80. “Individualized Treatment with Antipsychotics: From Theory to Practice”, oral presentation as part of the symposium entitled “Rapid Improvement or Long-term Stability? – Effective Strategies for In- and Outpatients”, Duesseldorf, Germany, March 13-14, 2009

81. “Long-term Management Goals for Patients with Bipolar Disorder and Schizophrenia”, oral presentation as part of the symposium, entitled “Long-Term Management Goals in Schizophrenia and Bipolar Disorder: Diagnosis and Treatment”, Rome, Italy, March 20, 2009

Curriculum Vitae Christoph U. Correll, M.D. Page 56

82. “Individualized Treatment with Antipsychotics: From Theory to Practice”, oral presentation as part of the symposium entitled “Rapid Improvement or Long-term Stability? – Effective Strategies for In- and Outpatients”, Munich, Germany, March 20-21, 2009

83. “Management of Bipolar Disorder: A Clinical Perspective”, Grand Rounds presentation, Peter Lougheed Hospital, Calgary, BC, Canada, April 1, 2009

84. “Optimizing the Management of Bipolar Disorder”, Grand Rounds presentation, Ridge Meadows Hospital, Maple Ridge, BC, Canada, April 2, 2009

85. “Maximizing Effectiveness Informed by Pharmacology”, Webcast presentation as part of the symposium entitled “Diversity in Antipsychotics: Efficacy versus Tolerability” as part of the NVVP Congress, Groningen, The Netherlands, April 2, 2009

86. “Management of Bipolar Disorder: A Clinical Perspective”, Grand Rounds presentation, West End Mental Health Clinic, Vancouver, BC, Canada, April 2, 2009

87. “Long-Term Effects of Psychopharmacologic Treatments in Childhood and Adolescence”, oral presentation as part of the 2009 CME Course “Prevention in Child and Adolescent Psychiatry” by the Community Madrid, Madrid, Spain, May 7-8, 2009

88. “Optimizing Efficacy and Effectiveness in Schizophrenia Treatment”, WebCast presentation as part of the First Great Partnership Conference for Trainees and SAS Psychiatrists, Birmingham, UK, May 30, 2009

89. “Strategies for Dosing and Switching for Optimal Clinical Management”, oral presentation as part of the 2009 Conference “Controversies in Psychiatry – Schizophrenia”, organized by the Biological Psychiatry Section of the Polish Psychiatric Association, Cracow, Poland, June 5-6, 2009

90. “Long-term Management Goals for Patients with Bipolar Disorder and Schizophrenia”, oral presentation as part of the symposium entitled “Symptoms and Psychopathological Dimensions of Mood and Psychotic Disorders: From the Neurobiology to the Clinic”, Pisa, Italy, June 6, 2009

91. “New Approaches for Treatment Resistant Depression. oral presentation as part of the symposium “Treatment Resistant Depression: Ways out of the Deep Valley” (Chair: G Bondolfi), Annual Meeting of the Swiss Association for Psychiatry and Psychotherapy, Geneva, Switzerland, September 3, 2009

92. “Early Recognition in Bipolar Disorder: Interface between Child and adolescent Psychiatry and Adult Psychiatry”, oral presentation as part of the symposium, entitled “Early Syndromes in Bipolar Disorder” (Co-chairs: G Juckel and P Braeunig), Annual Meeting of the German Association of Bipolar Disorders (DGBS), Berlin, Germany, September 03-05, 2009

93. “Depression ADHD und ODD: Comorbidity, Risk Marker or Prodrome of Bipolar Disorder?”, oral presentation as part of the symposium, entitled “Early Recognition and Differential Diagnosis of Bipolar Disorder in Children and Adolescent” (Co-chairs: Bilke and C Correll), Annual Meeting of the German Association of Bipolar Disorders (DGBS), Berlin, Germany, September 03-05, 2009

94. “Key Elements in the Relapse Prevention of Bipolar Disorder”, oral presentation as part of the symposium, entitled “Relapse Prevention of Bipolar Disorder in Ambulatory Care” (Co-chairs: Gratz and P Braeunig), Annual Meeting of the German Association of Bipolar Disorders (DGBS), Berlin, Germany, September 03-05, 2009.

95. “Cardiometabolic Considerations During Antipsychotic Use in Clinical Practice”, oral presentation as part of a meeting of the Icelandic Psychiatric Association, Reykjavik, Iceland, October 1, 2009

96. “The Art and Science of Treating Bipolar Affective Disorder”, oral presentation as part of a meeting of the Hong Kong College of Psychiatrists and the Society for the Advancement of Bipolar Disorder, Hong Kong, October 23, 2009.

97. “Risk-Benefit Evaluation in the Treatment with Antipsychotics”, Grand Rounds presentation at the University Hospital Bern, Bern, Switzerland, November 17, 2009.

98. “Update on the Antipsychotic Therapy of Affective and Psychotic Disorders”, Grand Rounds presentation at the University Hospital Basel, Basel, Switzerland, November 18, 2009.

99. “Physical Morbidity in Schizophrenia: An Overview”, oral presentation as part of the symposium, entitled “Schizophrenia and Affective Disorders” (chairs: E Seifritz, J Schoepf), Zuerich, Switzerland, November 19, 2009

Curriculum Vitae Christoph U. Correll, M.D. Page 57

100. “Physical Morbidity in Schizophrenia: Consequences for Clinical Practice”, oral presentation as part of the symposium, entitled “Schizophrenia and Affective Disorders” (chairs: E Seifritz, J Schoepf), Zuerich, Switzerland, November 19, 2009.

101. “The Metabolic Syndrome in Child and Adolescent Psychiatry”, oral presentation as part of the symposium “The Metabolic Syndrome in Psychiatry: Who, when and how to treat”, sponsored by the Research Committee of Danish Psychiatric Society (chair: H Lublin), Copenhagen, Denmark, November 21, 2009

102. “Cardiometabolic Effects of Antipsychotics in Never Treated Children and Adolescents with Severe Psychiatric Disorders ”, oral presentation as part of the symposium, entitled “Physical Health Effects of Psychiatric Medications” (chairs: K Kahl and H-J Moller), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 25-28, 2009

103. “Psychiatric Medication Safety in the US”, oral presentation as part of the symposium, entitled “International Medication Safety in Psychiatry” (chair: E Ruether), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 25-28, 2009

104. “Optimizing Effectiveness of Antipsychotics in the treatment of Children and Adolescents with Psychotic Disorders", oral presentation as part of the symposium entitled “Antipsychotic Treatment of Adolescents”, Copenhagen, Denmark, 21. January, 2010

105. “Clinical Experience from the Zucker Hillside Hospital in Treating Adolescent Schizophrenia", Grand Rounds presentation at the Department of Child and Adolescent Psychiatry, University of Gotenburg, Gotenburg, Denmark, 22. January, 2010

106. “Time Course and Relevance of Early Treatment Response in Adolescents with Schizophrenia-Spectrum Disorders", oral presentation as part of the symposium entitled “New Research in the Early Prediction of Antipsychotic Response in Schizophrenia” (co-chairs: C Correll and J Kane), 2nd Annual Meeting of the Schizophrenia International Research Society, Florence, Italy, April 10-14, 2010

107. “Efficacy and Safety of Antipsychotics in Adolescents with Early-Onset Schizophrenia", oral presentation as part of the symposium entitled “Research and Treatment in Children and Adolescents with Early-Onset Schizophrenia” (chair: S Kumra), 2nd Annual Meeting of the Schizophrenia International Research Society, Florence, Italy, April 10-14, 2010

108. “Pharmacologic Treatment of Bipolar Mania and Bipolar Depression”, oral presentation as part of the symposium by the Italian Academy of Psychiatry Science, entitled “Bipolar Disorder: Diagnosis and Treatment” (co-chairs: A Siracusano, E Sacchetti), Rome, Italy, April 23, 2010

109. “Pharmacologic Treatment of Bipolar Mania and Bipolar Depression”, oral presentation as part of the symposium by the Italian Academy of Psychiatry Science, entitled “Bipolar Disorder: Diagnosis and Treatment” (chair: F. Bogetto), Turin, Italy, May 14, 2010

110. “Novel Antipsychotics in the Treatment of Children and Adolescents”, oral presentation as part of the symposium, entitled “Therapeutic Interventions in Schizophrenia” (co-chairs: J Peuskens, F Mesotten) at the 3rd Meeting of Western Europe Society of Biological Psychiatry, Berlin, Germany, June 3-5, 2010

111. “The Treatment of Bipolar Disorder and Schizophrenia in Children and Adolescents”, oral presentation as part of the symposium entitled “Emerging treatment options for children and adolescents with psychiatric illness” at the XXVII meeting of the International College of Neuropsychopharmacology (CINP), Hong Kong, China, June 6-10, 2010

112. “Optimising Treatment Strategies in Schizophrenia – Effective Management for Long Term Benefits”, oral presentation as part of the symposium entitled “Maximizing Long Term Outcomes in Psychiatric Care : The Critical Importance of Physical Health” (chair: H Millar) at the XXVII meeting of the International College of Neuropsychopharmacology (CINP), Hong Kong, China, June 6-10, 2010

113. “Efficacy of Second-Generation Antipsychotic Medications in Disorders Starting in Childhood”, oral presentation at the “Course on Pharmacodynamics and Pharmacokinetics of Psychotropic Medications: Combining Efficacy and Tolerability”, San Sebastian, Spain, June 24-25, 2010

Curriculum Vitae Christoph U. Correll, M.D. Page 58

114. “Applied Antipsychotic Pharmacology: From Theory to Clinical Practice”, oral presentation at the “Course on Pharmacodynamics and Pharmacokinetics of Psychotropic Medications: Combining Efficacy and Tolerability”, San Sebastian, Spain, June 24-25, 2010

115. “Selecting Optimal Treatment Plans: Real-Life Dosing, Switching and Monitoring of Antipsychotic Agents”, oral presentation at the “Course on Pharmacodynamics and Pharmacokinetics of Psychotropic Medications: Combining Efficacy and Tolerability”, San Sebastian, Spain, June 24-25, 2010

116. “Antipsychotic Use: Ways to Optimize Outcomes”, oral presentation at the “Course on Pharmacodynamics and Pharmacokinetics of Psychotropic Medications: Combining Efficacy and Tolerability”, San Sebastian, Spain, June 24-25, 2010

117. “Antipsychotic-Related Metabolic and Endocrine Adverse Events in Pediatric Patients: Frequency, Monitoring and Management Strategies", oral presentation as part of the symposium entitled “Weight Gain and Psychotropic Drugs”, 23rd European Clinical Neuropsychopharmacology Congress, Amsterdam, The Netherlands, August 28 - September 1 2010

118. “Efficacy of Pharmacologic Treatments of Bipolar Disorders in Youth”, oral presentation as part of the Aalborg Psychopharmacology Summer School Course on Recent Advances in Assessment and Treatment of Adolescent Affective Disorders (course leader: HC Steinhausen), Aalborg, Denmark, September 1-2, 2010.

119. “Tolerability of Pharmacologic Treatments of Bipolar Disorders in Youth”, oral presentation as part of the Aalborg Psychopharmacology Summer School Course on Recent Advances in Assessment and Treatment of Adolescent Affective Disorders (course leader: HC Steinhausen), Aalborg, Denmark, September 1-2, 2010

120. “Management of Treatment Refractory Bipolar Disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, September 1-2, 2010

121. “Early Identification and Intervention in Adolescents and Young Adults with the Psychosis Risk Syndrome and First Episode Psychosis: Where do We Stand and Where Do We Go?”, oral presentation to the First Episode Team, Department of Psychiatry, University of Leuven, Kortenberg, Belgium, September 7, 2010

122. “From the Prodrome to First Episode Schizophrenia: Early Identification and Intervention in Adolescents and Young Adults with Psychosis Spectrum Disorders”, oral presentation as part of the Annual Master Class Program, University of Leuven, Kortenberg, Belgium, September 7, 2010

123. “Antipsychotic Use in Adolescents and Young Adults: Balancing Efficacy and Tolerability to Maximize Outcomes”, oral presentation as part of the Annual Master Class Program, University of Leuven, Kortenberg, Belgium, September 7, 2010

124. “Antipsychotic Use in Adolescents and Young Adults: Balancing Efficacy and Tolerability”, oral presentation, Antwerp, Netherlands, September 8, 2010

125. “Pharmacological Treatment of Major Depressive Disorder with Insufficient Response”, oral presentation as part of the Annual Conference of the Turkish Association of Psychiatry, Izmir, Turkey, October 8, 2010

126. “Optimizing the Management of Early Episode Bipolar Disorder”, oral presentation as part of the annual meeting of the Asociación Española de Psiquiatría Privada (ASEPP), Barcelona, Spain, October 17-20, 2010.

127. “Efficacy and Tolerability of Antipsychotics in Children and Adolescents”, oral presentation as part of the symposium entitled “Use of Medications in Child Psychiatry: How to make the Right Choice? (chair: E. Roman), Annual Conference of the XXII Congress of the Spanish Society for Clinical Pharmacology, Madrid, Spain, October 20-22, 2010

128. “Efficacy and Safety of Antipsychotic Combination Therapy”, oral presentation as part of the symposium, entitled “Polypharmacy in the Treatment of Schizophrenia: Complications and Opportunities of Rational Combination Therapy” (co-chairs: J Cordes, B Janssen), Annual Meeting

Curriculum Vitae Christoph U. Correll, M.D. Page 59

of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 24-27, 2010

129. “Medication Safety and Regulatory Approval Processes”, oral presentation as part of the symposium, entitled “Medications – Focus on Safety” (co-chairs: E Ruether, J Fritze), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 24-27, 2010

130. “Evidence-based Treatment of Non-Affective Psychoses in Children and Adolescents”, oral presentation as part of the Child and Adolescent Colloquia Berlin, Charite University and Medical School, Berlin, Germany, January 26, 2011

131. “Treatment of Bipolar Disorder”, oral presentation as part of the symposium “Controversies about the Treatment of Bipolar Disorder” (Chair: A. Siracusano), XIV Congress of the Italian Society of Psychopathology, Rome, Italy, February 15-19, 2011

132. “How Do Clinicians Decide Which Antipsychotic to Give to Which Patient?”, oral presentation as part of a satellite symposium, European Psychiatric Association Meeting, Vienna, Austria, March 12 – March 15, 2011

133. “Risk-Benefit Evaluation of Antipsychotic Therapy in Juvenile Onset Schizophrenia”, oral presentation as part of the symposium, entitled “The Pharmacologic Treatment of Juvenile Onset Schizophrenia” (Co-Chairs: C Correll, B Schimmelmann), XXXIII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Essen, Germany, March 2 – March 5, 2011

134. “Early Identification in Schizophrenia: Clinical Relevance of Neurobiological Aspects”, oral presentation as part of the symposium, entitled “Neurobiological and Neurodevelopmental Aspects of Early Identification in Schizophrenia” (Co-Chairs: C Correll, S Ehrlich), XXXIII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Essen, Germany, March 2 – March 5, 2011

135. “Correlates and Outcomes of Polypharmacy in Children and Adolescents with Psychotic Disorders”, oral presentation as part of a symposium, entitled “Polypharmacy: The Good, The Bad and The Ugly - Special Populations”, Europe Regional Collegium Internationale Neuro-Psychopharmacologicum (CINP) Meeting, Salzburg, Austria, April 1- April 2, 2011

136. “Antipsychotic-Induced Weight Gain and Metabolic Side Effects in Children and Adolescents”, oral presentation as part of Grand Rounds at the University of Ottawa Institute of Mental Health, Ottawa, Canada, April 07, 2011

137. “Schizophrenia: A Brief Review”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Update on the Treatment of Mental Illness: A Review of the Evidence and Experience” by the Quebec Psychiatric Association, Montreal (AMPQ), Canada, April 8-9, 2011

138. “Markers and Predictors of Response to Therapy”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Update on the Treatment of Mental Illness: A Review of the Evidence and Experience” by the Quebec Psychiatric Association, Montreal (AMPQ), Canada, April 8-9, 2011

139. “Cardiovascular and Metabolic Risk in People with Severe Mental Illness”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Update on the Treatment of Mental Illness: A Review of the Evidence and Experience” by the Quebec Psychiatric Association, Montreal (AMPQ), Canada, April 8-9, 2011

140. “A Focus on Bipolar Disorder”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Update on the Treatment of Mental Illness: A Review of the Evidence and Experience” by the Quebec Psychiatric Association, Montreal (AMPQ), Canada, April 8-9, 2011

141. “Improving the Management of Patients with Mental Illness”, oral presentation as part of the two-day Psychopharmacology Symposium entitled “Update on the Treatment of Mental Illness: A Review of the Evidence and Experience” by the Quebec Psychiatric Association, Montreal (AMPQ), Canada, April 8-9, 2011

Curriculum Vitae Christoph U. Correll, M.D. Page 60

142. “Update on the Antipsychotic Treatment of Adolescents with Psychosis: Trial Design and Outcomes” oral presentation at the Workshop” Tolerance and Effects of Antipsychotics in Children and Adolescents with Psychosis”, Copenhagen, Denmark, May 11, 2011

143. “Clinical Experience and Results from The Zucker Hillside Hospital Recognition and Prevention (RAP) Program: A Longitudinal Perspective”, oral presentation at the annual meeting “From Prodromal Symptoms to Psychosis in Children and Adolescents” of the Catalan Association of Child and Adolescent Psychiatry, Barcelona, Spain, May 20, 2011

144. “Clinical Update on Pharmacological Interventions in Prodromal Patients: Discussion and Practical Clinical Cases”, oral presentation at the annual meeting “From Prodromal Symptoms to Psychosis in Children and Adolescents” of the Catalan Association of Child and Adolescent Psychiatry, Barcelona, Spain, May 20, 2011

145. “The Art and Science of Treating Bipolar Affective Disorder”, oral presentation at the Society for the Advancement of Bipolar Affective Disorder, Hong Kong, China, May 28, 2011

146. “The Art and Science of Treating Bipolar Disorder”, oral presentation at the Hong Kong Society of Private Psychiatrists, Hong Kong, China, May 30, 2011

147. “Atypical Approaches to Schizophrenia and Bipolar Disorder - An Inter-Professional Collaborative Program”, oral presentation as part of the annual meeting of the Quebec Psychiatric Association (AMPQ), Tremblant, Canada, June 1-4, 2011

148. “Antipsychotics and the Metabolic Syndrome”, oral presentation as part of a symposium at the Spanish National Congress of the Society of Child and Adolescent Psychiatry (AEPNyA), Alicante, Spain, June 3, 2011

149. "Psychosis Risk Syndrome: clinical characteristics and definitions", oral presentation as part of the symposium entitled “Psychosis Risk Syndrome (PRS) - Identification, Neurobiology and Intervention”, 24th European Neuropsychopharmacology Congress, Paris, France, September 3-7, 2011

150. "Early Treatment of Acute Manic Episodes in Bipolar Disorder ", oral presentation as part of the symposium entitled “Clinical Controversies and Realities of Treating Bipolar Mania Patients”, 24th European Neuropsychopharmacology Congress, Paris, France, September 3-7, 2011

151. "Critical decision points in the management of schizophrenia patients not responding to treatment“, participation as an expert in the “Brainstorming Session” (chairs: M. Davidson, J Kane), 24th European Neuropsychopharmacology Congress, Paris, France, September 3-7, 2011

152. “Individualization vs. Guidelines, oral presentation as part of the symposium entitled “Treating Today for Tomorrow” (chair: C Correll), annual German Society for Bipolar Disorder meeting, Mannheim, Germany, September 29-30, 2011

153. “Schizophrenias and their Treatment in Adolescence: An International Perspective”, oral presentation as part of the annual “Curriculum Developmental Pharmacology in Childhood and Adolescence” of the Commission of Developmental Pharmacology (chairs: B Schimmelmann, F Haessler), jointly sponsored by the German Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJP), Federal Working Group of Hospital Chairs in Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (BAG), and the Professional Association for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy in Germany (BKJPP), Rostock, Germany, September 29-30, 2011

154. “Advancing the Treatment of Bipolar Affective Disorder”, oral presentation at the 1st Riyadh Military Hospital International Symposium in Psychiatry “Advances in Psychiatry and Addiction”, jointly sponsored by the Kingdom of Saudi Arabia, Ministry of Defense and Aviation and the Saudi Psychiatric Association, Riyadh, Saudi Arabia, October 25-26, 2011

155. “Design, Implementation and Conduct of Clinical Trials: Challenges and Opportunities”, oral presentation and workshop at the 1st Riyadh Military Hospital International Symposium in Psychiatry “Advances in Psychiatry and Addiction”, jointly sponsored by the Kingdom of Saudi Arabia, Ministry of Defense and Aviation and the Saudi Psychiatric Association, Riyadh, Saudi Arabia, October 25-26, 2011

Curriculum Vitae Christoph U. Correll, M.D. Page 61

156. “Latest Data on the Prospective Identification of the Bipolar Prodrome”, oral presentation as part of the symposium, entitled “Progress in the Early Identification of Bipolar Disorder – Symposium of the Network for Early Recognitions and Intervention in Bipolar Disorders (NERIBID)” (co-chairs: M Bauer, A Pfennig). Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 23-26, 2011

157. "Psychobiology of Schizoaffective Disorder", oral presentation as part of the meeting, entitled “International Pathways of Investigation in Psychiatry, Psychotherapies, and combined treatments”, Rome, Italy, November 26, 2011

158. “Early prediction of antipsychotic response in schizophrenia”, oral presentation at the Nordic Psychiatry Academy Meeting, Copenhagen, Denmark, January 20-21, 2012

159. “When Symptoms Persist: Combination and Augmentation Strategies in Schizophrenia”, oral presentation at the Department of Psychiatry, University Hospital Eppendorf, Hamburg, Germany, February 09, 2012

160. “Early Recognition from the Perspective of Child and Adolescent Psychiatry”, oral presentation as part of the first Early Recognition and Prevention workshop of the German Bipolar Disorder Early Recognition Network (NERIBID), Department of Psychiatry, University Hospital Eppendorf, Hamburg, Germany, February 10, 2012

161. “Clinical Correlates of the Bipolar Prodrome”, oral presentation as part of the symposium entitled “Early Recognition of Bipolar Disorders“ (co-chairs: A Bechdolf, C Correll), 20th European Congress of Psychiatry, Prague, Czech Republic, March 3-6, 2012

162. “Is switching antipsychotic medications in stable patients ever a good idea?”, oral presentation as part of the symposium entitled “Making the right decisions to prevent recurrence in bipolar disorder in the long-term“ (chair: H Grunze), 5th International Society of Bipolar Disorders (ISBD) Meeting, Istanbul, Turkey, March 14-17, 2012

163. “Interventions During the Attenuated Psychosis Syndrome: What is the Evidence?”, oral presentation as part of the 5th Journée Internationale des Pathologies Emergentes de l’Adolescent et du Jeune Adulte (JIPEJAAD) Conference, Paris, France, March 20, 2012.

164. “Psychosis”, oral presentation as part of the one day conference “Developmental Psychopharmacology in Childhood and Adolescence”, co-sponsored by the Universities of Basel, Bern and Zurich, Bern, Switzerland, March 30, 2012

165. “Efficacy and Safety of Antipsychotics in Early-Onset Schizophrenia: A Meta-analysis of Randomized Controlled Trials”, oral presentation as part of the symposium, entitled “Recent Directions in the Treatment of Early-Onset Psychoses“ (chair: C Arango, co-chair: C Correll), 3rd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 14-18, 2012

166. “Relapse Prevention in Schizophrenia: A Systematic Review and Meta-analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics”, oral presentation as part of the workshop, entitled “Relapse Prevention in Schizophrenia: An Update on Preclinical Data, Pharmaceutical and Psychotherapeutic Options“ (chair: S Leucht, co-chair: C Correll), 3rd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 14-18, 2012

167. "Raising the bar for outcomes – from the cradle to the grave”, oral presentation as part of the symposium, entitled “Life under the burden of a psychiatric disorder – Implications for function”, Stockholm, May 24, 2012

168. "Comparative Efficacy and Effectiveness of Antipsychotics in Schizophrenia: What have We Learned?”, oral presentation as part of the 1st International Symposium on Controversies in Psychiatry (Mexico division), entitled “Predictive Indicators of Response to Psychopharmacologic Medications”, Cancun, Mexico, May 31-June 1, 2012

169. “Treatment Resistant Bipolar Disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 29-30, 2012

Curriculum Vitae Christoph U. Correll, M.D. Page 62

170. “Cardiometabolic Side-effects of Antipsychotics in Children and Adolescents”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (course leader: R Nielsen), Aalborg, Denmark, August 29-30, 2012.

171. “Bipolar Disorder: An Individualized Treatment Approach” oral presentation as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Toronto, Canada, October 27, 2012

172. “Applied Pharmacology: Antipsychotic Dosing and Switching Strategies” oral presentation as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Toronto, Canada, October 27, 2012

173. “Complexities in Patient Management: Substance Abuse, Children and Adolescents, Cognition” oral presentation as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Toronto, Canada, October 27, 2012

174. “Improving Patient Management Through Applied Pharmacology”, Workshop as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Toronto, Canada, October 27, 2012

175. “Can Bipolar Disorder be Recognized Early and Prevented? Oral presentation as part of the symposium “Early Recognition of Bipolar Disorder”, Charite, Berlin, Germany, November 7, 2012

176. Using Knowledge about Antipsychotic Pharmacology to Enhance Treatment Outcomes in Children and Adolescents, Grand Rounds, Alberta Children’s Hospital, Calgary, Canada, November 16, 2012

177. “Bipolar Disorder: A Brief Update” oral presentation as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Saskatoon, Canada, November 17, 2012

178. “Applying Pharmacology to the Patient: Antipsychotic Dosing and Switching Strategies” oral presentation as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Saskatoon, Canada, November 17, 2012

179. “Complexities in the Management of Patients with Substance Abuse, Pediatric Populations and those with Cognitive Impairments” oral presentation as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Saskatoon, Canada, November 17, 2012

180. “Improving Patient Management Through Applied Pharmacology”, Workshop as part of the Canadian Psychiatric Association Annual CME Meeting entitled “Challenges and Insights in Schizophrenia and Bipolar Disorder: From Theory to Patient”, Saskatoon, Canada, November 17, 2012

181. “Prevention of psychiatric disorders – how do we find the balance between cost and benefit?” Discussion Forum (Discussants: A. Bechdolf, CU Correll, M Lambert, G Lehmkuhl, U Hegerl, JM Fegert, W Maier), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 21-24, 2012

182. “Prevention of Schizophrenia: Is this an Attainable Goal?”, plenary lecture as part of the Japanese Society for Prevention and Early Intervention in Psychiatry (JSEIP) annual meeting, Tokyo, Japan, December 15-16, 2012.

183. "Early Intervention in Youth with Psychosis: Benefits and Risks“ [Frühintervention in Kindern und Jugendlichen mit Psychotischen Erkrankungen: Nutzen und Risiken"], oral presentation at the Universität zu Köln, Germany, February 13, 2013.

184. “Phenomenological Characterization of Prodromal Stages in Bipolar Disorder”, oral presentation as part of the symposium, entitled “Prevention of psychotic and bipolar disorders in children and adolescents”. (Co-Chairs: C Correll, F Schultze-Lutter), XXXIV Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Rostock, Germany, March 6 – March 9, 2013.

Curriculum Vitae Christoph U. Correll, M.D. Page 63

185. “Guideline-Consistent Therapy of Schizophrenia in Childhood and Adolescence”, oral presentation as part of the symposium, entitled “Guideline-Consistent Therapy of Schizophrenia and Tourette’s Disorder in the Areas of Child and Adolescent Psychiatry and Adult Psychiatry“. (Co-Chairs: A Hasan, V Rößner), XXXIV Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Rostock, Germany, March 6 – March 9, 2013.

186. “How to assess and study treatment adherence in schizophrenia? The influence of clinical trial design on adherence outcome measures”, oral presentation as part of the symposium entitled “Schizophrenia: Protecting what is important for the patients” (chair: W Fleischhacker), 21st European Psychiatric Association (EPA) meeting, Nice, France, April 6-9, 2013.

187. “Maintaining symptom stability in the long-term treatment of bipolar I disorder”, oral presentation as part of the symposium entitled „Relapse prevention and long-term management in bipolar I disorder” (chair: E Vieta, co-chair: C Correll), 21st European Psychiatric Association (EPA) meeting, Nice, France, April 6-9, 2013.

188. “Antipsychotic use in adolescents and young adults with disruptive behavior disorders”, oral presentation at a CME meeting sponsored by the Hong Kong Association for Child and Adolescent Psychology and Psychiatry, Hong Kong, April 29, 2013.

189. “Pharmacology and clinical experience in patients with bipolar disorder and first episode psychosis”, oral presentation as part of the symposium, entitled “Dopaminergic and Serotonergic Partial Agonism. What we know and what we don’t know yet”, annual meeting of the Asociación Española de Psiquiatría Privada (ASEPP), Barcelona, Spain, May 9-11, 2013.

190. "The Role of Monotherapy and Add-on Treatment in the Maintenance Management of Bipolar Disorder”, oral presentation as part of the meeting, entitled “Individualized and personalized care in bipolar disorder and schizophrenia long-term treatment”, Rome, Italy, June 21, 2013.

191. “Validation of the New Bipolar Prodrome Symptom Scale - Prospective (BPSS-P) in 150 adolescents and young adults”, oral presentation as part of the symposium entitled „Clinical Predictors of the Bipolar Prodrome” (Chair: M Bauer, co-chair G Juckel), 11th World Congress of Biological Psychiatry of the World Federation of Societies for Biological Psychiatry (WFSBP), Kyoto, Japan, June 23-27, 2013.

192. “Management of treatment resistant acute unipolar depressive disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 28-29, 2013

193. “Management of treatment resistant acute bipolar depressive disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 28-29, 2013.

194. “Management of treatment resistant acute bipolar disorder: Case discussions”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 28-29, 2013.

195. “Update on the Acute and Maintenance Treatment of Bipolar Disorder”, plenary lecture as part of the annual Asian College of Neuropsychopharmacology (AsCNP) meeting, Beijing, China, September 11-14, 2013.

196. “The identification and treatment of the schizophrenia prodrome”, oral presentation as part of the symposium entitled “Phase Specific Treatment of Schizophrenia: Evidence and Clinical Practice” (Chair: J Kane, Co-chair: T Kishimoto), annual Asian College of Neuropsychopharmacology (AsCNP) meeting, Beijing, China, September 11-14, 2013.

197. “Controversies and Advances in the Management of Mood Disorders”, Grand Rounds presentation at Douglas Mental Institute, McGill University, Montreal, Canada, September 27, 2013.

198. “The Management of Mood Disorders: Controversies and Advances”, Grand Rounds presentation at Hospital du Sacre Coeur de Montreal, Montreal, Canada, September 27, 2013.

Curriculum Vitae Christoph U. Correll, M.D. Page 64

199. ”Broadening Options for the Management of Mood Disorders”, Congress Symposium (Co-Chairs: C Correll, R McIntyre), Annual Meeting of the Canadian Psychiatric Association (CPA), Ottawa, Canada, September 26-28, 2013.

200. “Relevance of study design for the effectiveness of long-acting injectable antipsychotics in schizophrenia”, oral presentation as part of the symposium entitled „Schizophrenia – Long-term treatment and protecting what’s important”, (Chair: J Kane), Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 05-09, 2013.

201. “Acute and Maintenance Management of Schizophrenia: From the Prodrome to Treatment Resistance”, oral presentation as part of the English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei, C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 27-30, 2013.

202. “Differentiation of Bipolar Disorder from Cluster B Personality Disorders and Traits” [“Differenzierung zu Persönlichkeitsstörungen vom Cluster B”], oral presentation as part of the symposium entitled “Early Stages of Bipolar Disorder - Differentiation of Illness Related Symptoms from Comorbiditeis (Network NERIBID)” [“Frühe Stadien bipolarer Störungen - Differenzierung krankheitsbedingter Symptomatik gegenüber Komorbidität (Netzwerk NERIBID)”] (Co-chairs: M Bauer, A Pfennig), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 27-30, 2013.

203. “Efficacy – How convincing are new options of the therapy?” [“Effizienz – Wie ueberzeugend sind die neuen Therapieoptionen?”], oral presentation as part of the symposim entitled “Options of the individualized therapy of schizophrenia “ [“Optionen in der individualisierten Therapie der Schizophrenie“] (Chair: D Naber), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 27-30, 2013.

204. “Long-acting Injectable Antipsychotics and Personalized Medicine?” [“Lang-anhaltende injizierbare Antipsychotika und Personalisierte Medizin?”], oral presentation as part of the symposim entitled “Further Considerations in Psychiatry. What is Possible When the Aim and Strategy for Reaching Aims Coincide“ [“Weiter Denken in der Psychiatrie. Was alles möglich ist, wenn Therapieziel und Therapiestrategie zusammenpassen“] (Chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 27-30, 2013.

205. “Controversies and Advances in the Management of Mood Disorders”, St-Mary’s Hospital, Montreal, Canada, February 12, 2014.

206. “Advances in Managing Unipolar and Bipolar Mood Disorders”, Hopital Pierre-Boucher, Montreal, Canada, February 12, 2014.

207. “Refractory Schizophrenia and Other Psychotic Disorders”, Hopital Maisonneuve-Rosemont, Montreal, Canada, February 13, 2014.

208. “Options for Treatment Resistant Schizophrenia”, Institut Philippe-Pinel de Montreal, Montreal, Canada, February 13, 2014.

209. “Controversies and Advances in the Management of Mood Disorders”, Saint Hyacinthe Hospital, Montreal, Canada, February 14, 2014.

210. “Update on the Management of Unipolar and Bipolar Mood Disorders”, CHUS Sherbrooke, Sherbrooke, Canada, February 14, 2014.

211. “Acute Treatment of Schizophrenia”, oral presentation as part of the Manchester Schizophrenia Masterclass 2014 (chair: P Haddad), Manchester, UK, February 27, 2014.

212. “From Clinical Research to Clinical Practice”, oral presentation as part of the Manchester Schizophrenia Masterclass 2014 (chair: P Haddad), Manchester, UK, February 27, 2014.

213. “Comparative Safety and Tolerability of Antipsychotics in Schizophrenia”, oral presentation as part of the Manchester Schizophrenia Masterclass 2014 (chair: P Haddad), Manchester, UK, February 27, 2014.

214. “Acute Treatment of Schizophrenia”, oral presentation as part of the London Schizophrenia Masterclass 2014 (chair: M Patel), London, UK, February 28, 2014.

Curriculum Vitae Christoph U. Correll, M.D. Page 65

215. “From Clinical Research to Clinical Practice”, oral presentation as part of the London Schizophrenia Masterclass 2014 (chair: M Patel), London, UK, February 28, 2014.

216. “Comparative Safety and Tolerability of Antipsychotics in Schizophrenia”, oral presentation as part of the London Schizophrenia Masterclass 2014 (chair: M Patel), London, UK, February 28, 2014.

217. “The Role of Long-Acting Antipsychotics in Schizophrenia”, Grand Rounds, Strathcona Mental Health Center, Vancouver, Alberta, Canada, March 26, 2014.

218. “Efficacy and Safety of Oral and Long-Acting Antipsychotics in Schizophrenia”, Grand Rounds, Kelowna General Hospital, Kelowna, Alberta, Canada, March 27, 2014.

219. “Update on the Acute and Maintenance Treatment of Schizophrenia”, oral presentation, annual Alberta Psychiatric Association (APA) meeting, Banff, Alberta, Canada, March 28, 2014.

220. “Maintenance Treatment in Schizophrenia”, oral presentation, Grand Rounds, Douglas Hospital, Montreal, Canada, March 31, 2014.

221. “Relapse Prevention in Patients with Schizophrenia”, oral presentation, Grand Rounds, Allan Memorial Institute, Montreal, Canada, March 31, 2014.

222. “Maintenance Treatment and Relapse Prevention in Schizophrenia: What Is the Evidence?”, oral presentation, Grand Rounds, Royal Ottawa Hospital, Ottawa, Canada, April 1, 2014.

223. “Cardiometabolic Risk in Youth with Severe Mental Disorders”, oral presentation as part of the 2-day symposium entitled “Healthy Actives Lives (HeAL) International Meeting, Padua, Italy, April 4-5, 2014.

224. “Obesity and Cardiovascular Disease in Schizophrenia”, oral presentation as part of the plenary session, entitled “The Clinical Challenges of Comorbidity with Addiction and Somatic Disease “ (chair: N Stefanis, co-chair: M Cannon), 3rd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 5-9, 2014.

225. “Dysglycemic Signals in Children and Adolescents Treated with Antipsychotics for the First Time”, oral presentation as part of the symposium, entitled “When does the trouble start? Obesity, diabetes risks and metabolic disturbances in young people with psychosis“ (chair: C Galletly), 3rd Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 5-9, 2014.

226. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Community Hospital Bonn, Bonn, Germany, April 10, 2014

227. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Community Hospital Dueren, Dueren, Germany, April 11, 2014.

228. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Vitos Hospital Rheingau, Eltville, Germany, April 28, 2014.

229. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Community Hospital Viersen, Viersen, Germany, May 12, 2014.

230. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Isar-Amper-Hospital Haar, Haar, Germany, May 13, 2014.

231. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Technical University Munich, Munich, Germany, May 15, 2014.

232. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the University Hospital Hamburg Eppendorf, Hamburg, Germany, May 16, 2014

233. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Pfalzklinikum for Psychiatry und Neurology, Klingenmünster, Germany, May 20, 2014.

234. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Hospital Augsburg, Augsburg, Germany, May 21, 2014.

235. “Anchoring emerging evidence to real world clinical practice”, oral presentation as part of the symposium entitled “New Horizons in Schizophrenia: Navigating the Evidence at the Frontier of

Curriculum Vitae Christoph U. Correll, M.D. Page 66

Patient Care”, (Co-Chairs: W Honer, S Kapur), Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Vancouver, Canada, June 22-26, 2014.

236. “Comparative efficacy of LAIs versus oral antipsychotics in schizophrenia”, oral presentation as part of the symposium entitled “Impact of maintenance treatment on the natural illness progression in schizophrenia”, (Chair: A Malla), Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Vancouver, Canada, June 22-26, 2014.

237. “The Role of Long-acting Antipsychotics in the Management of Schizophrenia”, Grand Rounds presentation at the Community Hospital Cologne, Cologne, Germany, July 1, 2014.

238. “Trends and Complications in the Identification of the Bipolar Prodrome”, research seminar at the department of psychiatry, Federal University of Sao Paolo, Sao Paolo, Brazil, August 22, 2014.

239. “Unmet Needs in the Treatment of Schizophrenia”, oral presentation as part of the 2-day conference “Open Minds – Expanding the Frontiers of Schizophrenia” (chair: R Bressan), Sao Paolo, Brazil, August 22-23, 2014.

240. “Current Best Practices for the Treatment of Schizophrenia”, oral presentation as part of the 2-day conference “Open Minds – Expanding the Frontiers of Schizophrenia” (chair: R Bressan), Sao Paolo, Brazil, August 22-23, 2014.

241. “Management of treatment resistant acute unipolar depressive disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 28, 2014.

242. “Management of treatment resistant acute bipolar depressive disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 28, 2014.

243. “Management of treatment resistant acute bipolar disorder: Case discussions”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (bipolar disorders) (course leader: R Nielsen), Aalborg, Denmark, August 28, 2014.

244. “Pharmacologic Treatment of Children and Adolescents with Autistic and Aggressive Spectrum Disorders”, oral presentation as part of the annual meeting of the Chilean Association for Child and Adolescent Psychiatry, Vina del Mar, Chile, September 2, 2014.

245. “Early Identification and Interventions in Individuals at High Risk for Psychosis”, oral presentation as part of the annual meeting of the Chilean Association for Child and Adolescent Psychiatry, Vina del Mar, Chile, September 2, 2014.

246. “Pharmacologic Treatment of Children and Adolescents with Psychotic Disorders”, oral presentation as part of the annual meeting of the Chilean Association for Child and Adolescent Psychiatry, Vina del Mar, Chile, September 2, 2014.

247. “When Symptoms Persist: What Can Child Psychiatrist Learn From Adult Data for The Treatment of Resistant Psychotic and Mood Disorders?”, oral presentation as part of the annual meeting of the Chilean Association for Child and Adolescent Psychiatry, Vina del Mar, Chile, September 2, 2014.

248. “Evidence Based Management of Adverse Events: Principles, Prevention and Treatment“, oral presentation as part of the all-day Northern German Psychiatry Symposium 4, Hamburg, Germany, September 27, 2014.

249. “Evidence Based Pharmacologic Therapy in The Face of Insufficient Effectiveness and Treatment Resistance”, workshop as part of the all-day Northern German Psychiatry Symposium 4, Hamburg, Germany, September 27, 2014.

250. “Pediatric clinical trials: methodological issues and problems”, oral presentation as part of the symposium, entitled “Unmet needs in paediatric psychopharmacology” (Co-Chairs: J Buitelaar, A Zuddas), annual meeting of the European College of Neuropsychopharmacology, Berlin, Germany, October 18-21, 2014.

251. “The Role of Long-Acting Injectables in Schizophrenia”, oral presentation as part of the symposium, entitled “Impact of Maintenance Treatment on the Natural Illness Progression in

Curriculum Vitae Christoph U. Correll, M.D. Page 67

Schizophrenia” (Chair: W Fleischhacker), annual meeting of the European College of Neuropsychopharmacology, Berlin, Germany, October 18-21, 2014.

252. “Cardiometabolic Risk in First Episode Schizophrenia-Spectrum Disorder Patients: Baseline Results from the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) Study”, oral presentation at the symposium entitled “It`s About Time: Improving Physical Health in First Episode Psychosis: Rationale for the HeAL Approach” (Chair: J Curtis, Co-chair: F Gaughran), annual International Early Psychosis Association (IEPA) meeting, Tokyo, Japan, November 17-19, 2014.

253. “Does a Prodrome Exist in Bipolar Disorder?”, oral presentation at the symposium entitled “New Developments in the Early Recognition of Individuals At Risk for or with Emerging Schizophrenia and Bipolar Spectrum Disorders” (Chair: C Correll, Co-chair: T Kishimoto), annual International Early Psychosis Association (IEPA) meeting, Tokyo, Japan, November 17-19, 2014.

254. “Age-dependent risk for weight gain and metabolic abnormalities associated with antipsychotics”, oral presentation at the iphYs Special Interest Group Session, entitled “Improving Physical Health in Young People with First Episode Psychosis”, 9th IGAKUKEN International Symposium on Promoting Recovery of Young People with Psychosis: The iFEVR and ipYs Joint Meeting, Tokyo, Japan, November 20, 2014.

255. “Epidemiology and Correlates of Antipsychotic Polypharmacy Across Different Age Groups”, oral presentation as part of the symposium, entitled “The challenge of rational antipsychotic polypharmacy” (Chair: J Cordes, Co-Chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2014.

256. “Acute and Maintenance Management of Schizophrenia: From the Prodrome to Treatment Resistance”, oral presentation as part of the English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei, C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2014.

257. “Leading the Way: Depot Antipsychotics in the Maintenance Therapy of Schizophrenia”, oral presentation as part of the Symposium entitled “Early Intervention in Schizophrenia: Depot Antipsychotics from the Start – the New Approach?” (Chair: HJ Moeller), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 26-29, 2014.

258. “Real Life Dosing, Switching, and Augmenting of Second Generation Antipsychotics in Schizophrenia”, oral presentation as part of the symposium entitled “Comprehensive Approaches to the Treatment of Patients with Schizophrenia”, Regional World Psychiatric Association Meeting, Hong Kong, December 12, 2014.

259. “Psychopharmacotherapy of Psychoses [Psychopharmakotherapie von Psychosen]”, oral presentation as part of the symposium, entitled “S3 Guidelines Schizophrenia: Status of the Discussion for Children and Adolescents [S3 Leitlinien Schizophrenie - Stand der Diskussion für Kinder und Jugendliche]”, XXXVI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Munich, Germany, March 4 – March 7, 2015.

260. “Diagnostic and Symptomatic Trajectories in Youth with a Clinical High Risk Syndrome for Psychosis [Diagnostische und Symptomatische Verläufe in Jugendlichen mit einem Risikosyndrom für eine Psychose]”, oral presentation as part of the symposium, entitled “Early Recognition of Psychoses [Früherkennung von Psychosen - neueste Daten]”, XXXVI Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Munich, Germany, March 4 – March 7, 2015.

261. “Negative symptoms in schizophrenia: pharmacological aspects”, oral presentation as part of the session “Debate 1: Negative symptoms in schizophrenia” (chair: V Perez), 22nd International Symposium on Current Issues and Controversies in Psychiatry: Targets in clinical practice: symptoms or disorders?”, Barcelona, Spain, March 6-7, 2015.

262. “Challenges and Opportunities in the Long-term Management of Schizophrenia” [“Herausforderungen und Optionen in der Langzeitbehandlung der Schizophrenie“], oral presentation as part of a symposium at the Carl Gustav Carus University Dresden, March 25, 2015.

Curriculum Vitae Christoph U. Correll, M.D. Page 68

263. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the LVR Hospital Bedburg-Hau, Bedburg-Hau, Germany, April 13, 2015.

264. “Detection and Differential Diagnosis of Clinical High Risk and First Episode Psychosis in the Age of DSM-5”, oral presentation as part of the 3- day conference, entitled “Evidence-Based Medicine in Schizophrenia”, Lundbeck Foundation, Copenhagen, April 15-17, 2015.

265. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Vitos Klinikum, Heppenheim, Germany, April 17, 2015.

266. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the St. Augustinus-Kliniken, Neuss, Germany, April 20, 2015.

267. “Efficacy and safety of long-acting injectable antipsychotics”. Oral presentation as part of a symposium, entitled “Management of schizophrenia today: the way forward” (chair: S De Giorgi, S Sacchetti), Naples, Italy, April 21-22, 2015.

268. “Antipsychotics in Schizophrenia: When and How to Treat?”, plenary lecture (Chair: J. Mari), World Congress on Brain, Behavior and Emotions 2015, Porto Alegre, Brazil, April 29-May 2, 2015.

269. “Pre-Clinical Stages of Bipolar Disorder”, oral presentation as part of the symposium, entitled “Prevention of Bipolar Disorder: Is this an Attainable Goal?” (Chair: R Grassi de Oliveira), World Congress on Brain, Behavior and Emotions 2015, Porto Alegre, Brazil, April 29-May 2, 2015.

270. “Long-Term Treatment in Schizophrenia“ [“Langzeittherapie in der Schizophrenie“], Grand Rounds presentation at the Community Hospital Huyseinstift, Essen, Germany, May 7, 2015.

271. “Long-Term Treatment in Schizophrenia“ [“Langzeittherapie in der Schizophrenie“], Grand Rounds presentation at the Community Hospital Aue, Aue, Germany, May 13, 2015.

272. “Risk Factors for Medical Comorbidities at the Onset of Psychosis: Relevance for Improved Care Delivery in Patients Diagnosed with Schizophrenia” oral presentation as part of the symposium entitled “Implementation of Coordinated Specialty Care for First-Episode Psychosis in U.S. Community Mental Health Clinics” (Chair: M Brunette), Annual Meeting of the American Association of Psychiatry (APA), Toronto, Canada, May 16-20, 2015.

273. “Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development” oral presentation as part of the symposium entitled “It's About Time! Improving Physical Health Outcomes in Young People Prescribed Antipsychotic Medications” (Co-chairs: D Shiers, P Ward), Annual Meeting of the American Association of Psychiatry (APA), Toronto, Canada, May 16-20, 2015.

274. “Pharmacological Treatment in the RAISE-ETP Study” oral presentation as part of the symposium entitled “Findings from the Recovery After an Initial Episode of Schizophrenia Study” (Co-chairs: J Kane, A. Goldstein), Annual Meeting of the American Association of Psychiatry (APA), Toronto, Canada, May 16-20, 2015.

275. “Antipsychotic-Related Effects on Cardiometabolic Risk Factors and Illness Development in Youth and Adults” oral presentation as part of the Canadian iphYs Meeting entitled “Keeping the Body in Mind” (Chair: S Robertson), Annual Meeting of the American Association of Psychiatry (APA), Toronto, Canada, May 21, 2015.

276. “Adverse Effect Risk, Monitoring and Management of Psychotropic Medications in Children and Adolescents”, oral presentation as part of the 1-day symposium entitled ”Child & Adolescent Psychopharmacology Update”, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, May 28, 2015.

277. “Patient and Carer Self Assessment: Gaps and Opportunities”, oral presentation as part of the symposium entitled ”From Trials to the Real World: Meaningful Outcome Measures in Psychiatry” (chair: S Leucht), Lundbeck Institute, Copenhagen, Denmark, May 27, 2015.

278. The role of long-acting antipsychotics in schizophrenia”, oral presentation as part of the regional medical education symposium, Salamanca, Spain, May 30, 2015.

Curriculum Vitae Christoph U. Correll, M.D. Page 69

279. “Update on Research in Schizophrenia”, plenary lecture, Third Chinese Schizophrenia Research Forum, organized by the Chinese Schizophrenia Research Cooperation of the Chinese Psychiatry Association, Beijing, China, June 6, 2015

280. “Making Use of Existing Data”, oral presentation, Third Chinese Schizophrenia Research Forum, organized by the Chinese Schizophrenia Research Cooperation of the Chinese Psychiatry Association, Beijing, China, June 6, 2015

281. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Isar-Amper-Klinikum, Haar, München, Germany, June 11, 2015.

282. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life” [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the ZPE Emmendingen, Emmendingen, Germany, June 12, 2015.

283. “How to Write a Successful Grant?”, oral presentation, European Society for Child and Adolescent Psychiatry (ESCAP) Research Academy 3-Day Workshop, Madrid, Spain, June 18-21, 2015.

284. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Klinikum Ludwigsburg, Ludwigsburg, Germany, June 29, 2015.

285. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Vivantes Wenckebach-Klinikum, Berlin, Germany, June 30, 2015.

286. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Vitos Haina Klinik, Haina, Germany, July 1, 2015.

287. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Ökumenisches Hainich Klinikum, Mühlhausen, Germany, July 2, 2015.

288. „Long-term depot antipsychotic treatment of schizophrenia: Focus on quality of life“ [„Langzeit-Depot-Therapie der Schizophrenie unter dem Aspekt der Lebensqualität“], Grand Rounds presentation at the Privat-Nerven-Klinik Dr. Fontheim, Liebenburg, Germany, July 3, 2015.

289. “Ultra-high Risk Research in Bipolar Disorder” oral presentation as part of the Summer University in Psychiatry, Sousse, Tunisia, July 20-24, 2015

290. “The Development, Validation and Practical Use of the Bipolar Prodrome Symptom Scale (BPSS) Retrospective and Prospective Versions” oral presentation as part of the Summer University in Psychiatry, Sousse, Tunisia, July 20-24, 2015

291. “How to Design and Study and Write a Successful Grant” oral presentation as part of the Summer University in Psychiatry, Sousse, Tunisia, July 20-24, 2015

292. “How to Write and Publish Research Reports” oral presentation as part of the Summer University in Psychiatry, Sousse, Tunisia, July 20-24, 2015

293. Long-Term Treatment in Schizophrenia“ [“Langzeittherapie in der Schizophrenie“], Grand Rounds presentation at the University Hospital Dortmund, Germany, August 28, 2015.

294. “Evidence Based Management of Adverse Events: Principles, Prevention and Treatment“, oral presentation as part of the all-day Northern German Psychiatry Symposium, Braunschweig, Germany, September 19, 2015.

295. “Evidence Based Pharmacologic Therapy in The Face of Insufficient Effectiveness and Treatment Resistance”, workshop as part of the all-day Northern German Psychiatry Symposium, Braunschweig, Germany, September 19, 2015.

296. “Cardiovascular risk in patients with severe mental illness: causes, status and solutions”, oral presentation as part of the symposium entitled “Pharmacological and non-pharmacological interventions to reduce cardiovascular disease in patients with schizophrenia”, annual Nordic Psychiatric Conference (NPC), Copenhagen, Denmark, September 20-23, 2015.

Curriculum Vitae Christoph U. Correll, M.D. Page 70

297. ‘Efficacy of antidepressants for positive, negative and cognitive symptoms in schizophrenia: critical analysis derived from randomized clinical trials”, oral presentation as part of the symposium entitled “Depressive episodes in the course of schizophrenia-spectrum disorders: clinical challenges, therapeutic strategies” (Co-chairs: S Englisch, C Correll), 5th European Conference on Schizophrenia Research (ECSR), Berlin, Germany, September 24-26, 2015.

298. “Management of Early-Phase Schizophrenia: Impacting Illness Trajectories and Creating Opportunities”, Grand Rounds presentation, Foothills Medical Center, Calgary, Canada, September 29, 2015.

299. Management of Early-Phase Schizophrenia: Impacting Illness Trajectories and Creating Opportunities”, Grand Rounds presentation, University of Alberta Hospital. Edmonton, Canada, September 30, 2015.

300. “Efficacy and safety of pharmacologic treatments for resistant depression”, oral presentation as part of the symposium entitled “Treatment Resistant Depression: From Neurobiology to Clinical Practice”, Canadian Psychiatric Association (CPA) annual meeting, Vancouver, Canada, October 1 - 3, 2015.

301. “Long-Acting Injectable Antipsychotics: Utilization, Evidence, Barriers and Target Groups”, Grand Rounds presentation at the Abarbanel Mental Health Clinic, Tel Aviv, Israel, October 13, 2015.

302. “The Role of Long-Acting Antipsychotics in the Long-term Management of Schizophrenia”, oral presentation as part of the satellite symposium entitled“, Long-Acting Psychiatry” (Co-Chair: CU. Correll, A Teiltelbaum), 10th International Congress of the International Neuropsychiatric Association (INA), Jerusalem, Israel, October 14-16, 2015.

303. “Long-Acting Injectable Antipsychotics: Utilization, Evidence, Barriers and Target Groups”, Grand Rounds presentation at the Sheba Mental Health Clinic, Tel Aviv, Israel, October 15, 2015

304. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Centre intégré de santé et de services sociaux de Joilette, Saint-Charles-Borromée, Canada, November 2, 2015.

305. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Institut Universitaire en santé mentale de Québec, Québec City, Canada, November 3, 2015.

306. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Jean Talon Hospital, Montreal, Canada, November 4, 2015.

307. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, St. Mary's Hospital Center, Montreal, Canada, November 5, 2015.

308. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Jewish General Hospital, Montreal, Canada, November 5, 2015.

309. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Centre intégré de santé et de services sociaux de Joilette, Montreal, Canada, November 6, 2015.

310. “Efficacy and Safety of Antipsychotics in Children and Adolescents -The Old, the New and the Future”, oral presentation at the regional meeting of the Quebec Psychiatric Association, Montreal, Canada, November 6, 2015.

311. “Efficacy and Safety of Antipsychotics in Adults -The Old, the New and the Future”, oral presentation at the regional meeting of the Quebec Psychiatric Association, Montreal, Canada, November 6, 2015.

312. “From the Brain to the Bed Side: Applied Pharmacology in the Treatment with Antipsychotics”, oral presentation as part of the half-day symposium, entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: R. Whale), London, UK, November 17, 2015.

Curriculum Vitae Christoph U. Correll, M.D. Page 71

313. Pharmacological Treatment of Schizophrenia: An Update”, oral presentation as part of the half-day symposium, entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: R. Whale), London, UK, November 17, 2015.

314. “From the Brain to the Bed Side: Applied Pharmacology in the Treatment with Antipsychotics”, oral presentation as part of the half-day symposium, entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: R. Chithiramohan), Birmingham, UK, November 18, 2015.

315. “Pharmacological Treatment of Schizophrenia: An Update”, oral presentation as part of the half-day symposium, entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: R. Chithiramohan), Birmingham, UK, November 18, 2015.

316. “Consideration and Management of Antipsychotic Adverse Effects”, oral presentation as part of the half-day entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: R. Chithiramohan), Birmingham, UK, November 18, 2015.

317. “From the Brain to the Bed Side: Applied Pharmacology in the Treatment with Antipsychotics”, oral presentation as part of the half-day symposium, entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: A. Ramakrishnan), Nottingham, UK, November 18, 2015.

318. “Pharmacological Treatment of Schizophrenia: An Update”, oral presentation as part of the half-day symposium, entitled "Update on the treatment of schizophrenia: keeping the brain and body in mind" (Chair: A. Ramakrishnan), Nottingham, UK, November 18, 2015.

319. “Challenges in the Long-term Management of Schizophrenia”, Grand Rounds presentation at the University Hospital Hamburg Eppendorf, Hamburg, Germany, November 19, 2015.

320. “Better Perspectives: Retaining Functionality and Improving Quality of Life” [“Bessere Perspektive: Erhalt der Funktion und mehr Lebensqualitaet”], oral presentation as part of the Symposium entitled “Schizophrenia Management Today: Early, Better, to Achieve More” [“Schizophrenie-Behandlung heute: frueher, besser, mehr erreichen”] (Chair: V Arolt), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 25-28, 2015.

321. “Pharmacotherapy for People with Schizophrenia: Weighing the Options”, oral presentation as part of the English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei, C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 25-28, 2015.

322. “Combination Treatments for Schizophrenia” [“Kombinationstherapie der Schizophrenie”], oral presentation as part of the symposium entitled “Psychopharmacologic Combination Treatments of Severe mental Illness: New Results Regarding Efficacy and Safety” [“Psychopharmakologische Kombinationstherapien bei schweren psychischen Erkrankungen; Neue Daten zu Effektivität und Sicherheit"] (Co-chairs: J Cordes, C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 25-28, 2015.

323. “From Clinical Studies to Real-World Practice: New Long Acting Injectable Antipsychotics”, oral presentation as part of the half-day symposium entitled “Schizophrenia: Improving Outcomes and management Strategies for Patients“ (Chair: P. Thomas), Lille, France, December 2, 2015.

324. “From Clinical Studies to Real-World Practice: New Long Acting Injectable Antipsychotics”, oral presentation as part of the half-day symposium entitled “Schizophrenia: Improving Outcomes and management Strategies for Patients“ (Chair: T d’Amato), Lyon, France, December 3, 2015.

325. “From Clinical Studies to Real-World Practice: New Long Acting Injectable Antipsychotics”, oral presentation as part of the half-day symposium entitled “Schizophrenia: Improving Outcomes and management Strategies for Patients“ (Chair: D. Misdrahi), Bordeaux, France, December 4, 2015.

326. “From Here to another Dimension - Maintenance Treatment and Relapse Prevention in Schizophrenia”, oral presentation as part of the symposium entitled “The Schizophrenias - A Bleulerian Disease” (Co-chairs: MO. Krebs, JA Lesturgeon), Congrès de l'Encéphale 2016, Paris, France, January 20-22, 2016.

Curriculum Vitae Christoph U. Correll, M.D. Page 72

327. “Diagnosis and Management of Schizophrenia and Schizoaffective Disorder“ [„Diagnose und Therapie der schizoaffektiven Stoerung und der Schizophrenie”], Grand Rounds presentation at the Vivantes Wenckebach-Klinikum, Berlin, Germany, January 28, 2016.

328. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, Ipswich Hospital, Ipswich, Queensland, Australia, February 15, 2016

329. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, The Prince Charles Hospital, Brisbane, Queensland, Australia, February 15, 2016

330. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, The Prince Charles Hospital, Woolloongabba, Queensland, Australia, February 15, 2016

331. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, The Latrobe Hospital, Traralgon, Victoria, Australia, February 16, 2016

332. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, The Private St. Vincent Hospital, Melbourne, Victoria, Australia, February 16, 2016

333. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, Black Dog Institute, Prince of Wales Hospital, Sydney, Australia, February 17, 2016

334. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, Cumberland Hospital, Sydney, New South Wales, Australia, February 18, 2016

335. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, Liverpool Hospital, Sydney, New South Wales, Australia, February 18, 2016

336. “Too Little Too Late: When Should Relapse Prevention Start in Schizophrenia?”, Grand Rounds Presentation, Glenside Health Services Center, Adelaide, South Australia, Australia, February 19, 2016

337. “After CATIE, CuTLASS and CAFÉ: How Should We Treat Schizophrenia?, Grand Rounds Presentation, Royal Ottawa Hospital, Ottawa, Ontario, Canada, February 22, 2016.

338. “Management of Schizophrenia Throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds Presentation, Halton Regional Hospital, Oakville, Ontario, Canada, February 23, 2016.

339. “Management of Schizophrenia Throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds Presentation, Trillium Health Partners, Mississauga Ontario, Canada, February 23, 2016.

340. “Management of Schizophrenia Throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds Presentation, Lakeridge Regional Hospital, Oshawa, Ontario, Canada, February 24, 2016.

341. “Effectiveness of Early Intervention Services for Patients with Early Psychosis: Systematic Review and Meta-Analysis of Specialized Care versus Usual or Modular Care”, oral presentation as part of the symposium entitled “Improving Identification and Treatment of Early Phase Psychosis” (Chair: JM Kane), 5th Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 2-6, 2016.

342. “Differentiation between the Prodrome to Schizophrenia-Spectrum and Bipolar-Spectrum disorders: Can We Separate Clinical High-Risk States?”, oral presentation as part of the symposium entitled “Psychosis in Children and Adolescents: From the Prodrome to Schizophrenia” (Chair: AK Pagsberg), 5th Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 2-6, 2016.

343. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Parkwood Institute, London, Ontario, Canada, April 11, 2016.

344. “Applying Measurement Based Approaches to Psychiatric Care”, Grand Rounds presentation, London Prevention and Early Intervention in Psychosis Program (PEPP) , London, Ontario, Canada, April 11, 2016.

Curriculum Vitae Christoph U. Correll, M.D. Page 73

345. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Newfoundland (WebEx), Canada, April 12, 2016.

346. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Chatham-Kent Health Alliance, Chatham, Ontario, Canada, April 12, 2016.

347. “Antipsychotic Polypharmacy: Correlates, Evidence and Outcomes”, Grand Rounds presentation, Nova Scotia (WebEx), Canada, April 13, 2016.

348. “Management of Schizophrenia throughout the Illness Course: Impacting Disease Trajectories and Creating Opportunities”, Grand Rounds presentation, Homewood Health Centre, Guelph, Ontario, Canada, April 13, 2016.

349. “Delusions: Nature Approach”, oral presentation as part of the Debate “Delusions: Nature vs Nurture” (Chair: J Marques Teixeira; Opponent: J van Os), 23rd International Symposium about Current Issues and Controversies in Psychiatry, Barcelona, Spain, April 28-30, 2016.

350. “Move Against the Use of Long-Acting Injectable Antipsychotics in Early Stage Schizophrenia”, oral presentation as part of the debate as part of the session “The Pros and Cons of Giving Use of Long-Acting Injectable Antipsychotics to Early Stage Patients”, (Chair: D Castle; Opponent: T Kishimoto), 5th PsyAcademy Faculty Update Meeting, entitled “Getting There Together: Achieving Real Functional Recovery at the Early Stage”, Tokyo, Japan, May 28, 2016.

351. “Early Intervention in Schizophrenia: Results From the Recovery After an Initial Schizophrenia Episode (RAISE) Study” oral presentation as part of the 5th PsyAcademy Faculty Update Meeting, entitled “Getting There Together: Achieving Real Functional Recovery at the Early Stage” (Chair: K Watanabe), Tokyo, Japan, May 28, 2016.

352. “Functional Recovery in Schizophrenia”, oral presentation as part of the 5th PsyAcademy Faculty Update Meeting, entitled “Getting There Together: Achieving Real Functional Recovery at the Early Stage” (Chair: M Tomita), Tokyo, Japan, May 29, 2016.

353. “Psychiatry and Mental Health: The Past, the Present and the Future”, oral presentation as part of the 5th PsyAcademy Faculty Update Meeting, entitled “Getting There Together: Achieving Real Functional Recovery at the Early Stage” (Chair: M Tomita), Tokyo, Japan, May 29, 2016.

354. “Early Intervention For Psychosis In The USA: The Recognition and Prevention Program (RAP)”, oral presentation as part of the annual meeting of the Early Psychosis Foundation (EPISO) (Chair EH Chen), Hong Kong, China, May 30, 2016.

355. “Optimizing the Management and Outcomes of People with Early-Phase Schizophrenia”, oral presentation as part of the PsyAcademy Korea symposium entitled “Early stage of schizophrenia and its recovery” (Chair: JS Kwon), Seoul, Korea, May 31, 2016.

356. “Optimizing the Management and Outcomes of People with Early-Phase Schizophrenia”, Grand Rounds presentation, Asan University Medical Center, Seoul, Korea, June 1, 2016.

357. “Optimizing the Management and Outcomes of People with Early-Phase Schizophrenia”, Grand Rounds presentation, National Center for Mental Health, Seoul, Korea, June 1, 2016.

358. “Optimizing the Management and Outcomes of People with Early-Phase Schizophrenia”, Grand Rounds presentation, Severance Hospital, Yonsei University, Korea, June 1, 2016.

359. “From pilot study to Full-fledged RCT - Lessons learned and impact”, oral presentation as part of the one-day Mind My Mind Summer Seminar 2016, Copenhagen, Denmark, June 6, 2016.

360. “Evidence-based treatment of youth with schizophrenia: Where are we now and where do we need to go?”, Key Note Lecture as part of the one-day Tolerability and Efficacy of Antipsychotics (TEA) Study Group symposium, Copenhagen, Denmark, June 14, 2016.

361. “Characteristics and Management of Youth with Mood Disorders”, oral presentation as part of grand rounds, The Hospital for Sick Children and Centre for Addiction and Mental Health, Centre for Addiction and Mental Health (CAMH), Toronto, June 27, 2016.

362. “Brexpiprazole as a treatment for schizophrenia”, oral presentation as part of the symposium, entitled “Is it time to step up our expectations around MDD and schizophrenia treatment?” (Chair: C Han), Seoul, Korea, July 4, 2016.

Curriculum Vitae Christoph U. Correll, M.D. Page 74

363. “Update on the Treatment of Schizophrenia: Keeping the Brain and Body in Mind”, oral presentation as part of the symposium, entitled “Treat the Mind, Respect the Body“ (Chair: T Barnes), British Association for Psychopharmacology (BAP), Brighton, UK, July 18, 2016.

364. “Update on the Treatment of Schizophrenia: Keeping the Brain and Body in Mind”, oral presentation as part of the grand rounds program, Hallam Street Hospital, West Bromwich, UK, July 20, 2016.

365. “Update on the Treatment of Schizophrenia: Keeping the Brain and Body in Mind”, oral presentation as part of the grand rounds program, Rampton Hospital, Nottinghamshire, UK, July 21, 2016.

366. “Update on the Treatment of Schizophrenia: Keeping the Brain and Body in Mind”, oral presentation as part of the grand rounds program, Penn Hospital, Wolverhampton, UK, July 22, 2016.

367. “Efficacy and Safety of Atypical Antipsychotics: An Update”, oral presentation at the 2016 Conference on Transgenerational Mental Health”, Basel, Switzerland, August 17-19 2016.

368. “Controversies Around the Diagnosis of Bipolar Disorder in Children and Adolescents", oral presentation as part of the Annual Meeting of the Chilean Society for Bipolar Disorders (SOCHITAB), Chilean Chapter of the International Society for Bipolar Disorders (ISBD), Santiago de Chile, Chile, September 8-9, 2016.

369. “Early detection and management of people considered at high-risk for bipolar disorder”, Key Note Lecture at the Annual Meeting of the Chilean Society for Bipolar Disorders (SOCHITAB), Chilean Chapter of the International Society for Bipolar Disorders (ISBD), Santiago de Chile, Chile, September 8-9, 2016.

370. “Phenomenology, illness trajectory and management of first episode bipolar disorder”, Key Note Lecture at the Annual Meeting of the Chilean Society for Bipolar Disorders (SOCHITAB), Chilean Chapter of the International Society for Bipolar Disorders (ISBD), Santiago de Chile, Chile, September 8-9, 2016.

371. “Efficacy and tolerability of atypical antipsychotics: research trials and clinical reality”, oral presentation as part of the symposium, entitled “Atypical antipsychotics: recent research findings and applications to clinical practice” (Chair: R. Murray), Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Vienna, Austria, September 17-20, 2016.

372. “Affective disorders: childhood precursors, prognosis, and treatment implications”, oral presentation as part of the symposium entitled “Children and adolescents are not little adults: precursors, prognosis and treatment”, Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Vienna, Austria, September 17-20, 2016.

373. “Management of schizophrenia throughout the illness course" key note lecture, Annual Pacific Psychopharmacology Conference, Vancouver, Canada, September 23, 2016.

374. "Managing clozapine resistance: every patient is a case study” introductory lecture as part of a workshop and case studies Co-chairs: R White, C Correll), Annual Pacific Psychopharmacology Conference, Vancouver, Canada, September 23, 2016.

375. “Maximizing Efficacy and Safety during the Maintenance Treatment of Schizophrenia: Thinking Long-term from the Beginning”, Grand Rounds presentation, Foothills Medical Center, Calgary, Canada, September 26, 2016.

376. “Maximizing Efficacy and Safety during the Maintenance Treatment of Schizophrenia: Thinking Long-term from the Beginning”, Grand Rounds presentation, Sheldon Chumir Medical Center, Calgary, Canada, September 26, 2016.

377. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation, Vancouver General Hospital, Vancouver, Canada, September 27, 2016.

378. “Scientific evidence of the effect of pharmacological treatments for agitation in children and adults”, oral presentation as part of the one-day meeting entitled “Pharmacological treatment of Agitation in Psychiatry”, Roskilde, Denmark, October 6, 2016.

Curriculum Vitae Christoph U. Correll, M.D. Page 75

379. “Optimizing Outcomes in the Treatment of Schizophrenia - Weighing Treatment Options”, oral presentation as part of Grand Rounds, Kowloon Hospital, Hong Kong, November 3, 2016.

380. “Improving Outcomes in the Treatment of Schizophrenia Throughout the Illness Course: A Stitch in Time”, oral presentation at a regional meeting of the Hong Kong Association of Pharmacists held jointly with the Hong Kong Pharmaceutical Care Foundation, Hong Kong, November 3, 2016.

381. “Early Intervention for Psychosis in The USA - The RAP Program”, oral presentation to the Castle Peak Hospital EASY Team, Castle Peak Hospital, Hong Kong, November 4, 2016.

382. “Optimizing, the Management and Outcomes of People with Early-Phase Schizophrenia”, oral presentation as part of the symposium, entitled “Early Stage of Schizophrenia and its Functional Recovery” (Chair: YK Yang), 17th Pacific Rim College of Psychiatrist (PRCP) Scientific Meeting, Taiwan Society of Psychiatry (TSOP), Kaohsiung, Taiwan, November 3-5, 2016.

383. “Optimizing Outcomes in Schizophrenia Throughout the Illness Course: The Value of Early Intervention and Maintenance Treatment”, oral presentation as part of the 9th Psychiatry Day, Lund, Sweden, November 17, 2016.

384. “Optimizing Outcomes in Schizophrenia Throughout the Illness Course: The Value of Early Intervention and Maintenance Treatment”, oral presentation at the Forensic Psychiatric Centre, Trelleborg, Sweden, November 18, 2016.

385. “Pharmacotherapy for People with Schizophrenia: Weighing the Options”, oral presentation as part of the English Track State-of-the-Art Symposium entitled “Psychotic Disorders” (Co-chairs: P Falkei, C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 23-26, 2016.

386. “Pro: Olanzapine is not a first-line agent in people with schizophrenia“ [“Olanzapin ist aufgrund seiner kardiometabolischen Risiken kein Erstlinienmedikament bei der Behandlung von Menschen mit Schizophrenie“], oral presentation as part of the Pro-Con-Debate: “Olanzapine is not a first-line agent in people with schizophrenia“ [“Olanzapin ist aufgrund seiner kardiometabolischen Risiken kein Erstlinienmedikament bei der Behandlung von Menschen mit Schizophrenie“]” (Chair: G. Gründer), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 23-26, 2016.

387. “Assessment of the cardiometabolic risk in the mentally ill: which parameters and tools are useful?” [Bestimmung des kardiometabolischen Risikos psychisch Kranker: Welche Parameter und Tools sind zweckmäßig?], oral presentation as part of the symposium entitled „Increased cardiometabolic risk in the mentally ill – causes and treatment“ [„Das erhöhte kardiometabolische Risiko psychisch Kranker - Ursachen und Behandlung]“ (Co-chairs: F Lederbogen, A Ströhle), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 23-26, 2016.

388. „Early Recognition of Psychotic Disorders: Characteristics and Prediction“ [“Frueherkennung psychotischer Erkrankungen: Charakteristika und klinische Praediktion“], oral presentation as part of the symposium entitled „Early Recognition and Intervention for Psychotic Disorders“ [„Frueherkennung und Fruehbehandlung von Psychosen“], (Co-chairs: H. Walter, A Bechdolf), Charite, Berlin, Germany, January 25, 2017.

389. „State of the Art: Diagnosis, Outcome and Management of Schizophrenia“ [„Diagnose, Verlauf und Therapie schizophrener Erkrankungen“], oral presentation as part of the Annual Psychiatry Symposium, Osnabrueck, Germany, April 1, 2017.

390. „New Developments in the Drug Treatment of Schizophrenia“, oral presentation as part a Lunch Symposium, 45th Spring Congress Dutch Association Psychiatry (NVVP 2017), Maastricht, Netherlands, April 6, 2017.

391. “Oral versus Long-acting Injectable Antipsychotics in the Maintenance Treatment of Schizophrenia”, Grand Rounds presentation at the Pamela Youde Nethersole Eastern Hospital, Hong Kong, April 12, 2017.

392. “Functional Recovery, the Ultimate Treatment Goal in Schizophrenia”, Grand Rounds presentation at the Kwai Chung Hospital, Hong Kong, April 13, 2017.

Curriculum Vitae Christoph U. Correll, M.D. Page 76

393. “Enhancing Efficacy and Effectiveness in the Acute Illness Phase of Schizophrenia, oral presentation at the Chinese Psychiatric Association Meeting, Wuhan, China, April 15, 2017.

394. “Ultimate treatment goal as Functional Recovery: The Ultimate Treatment Goal in Schizophrenia”, Grand Rounds presentation at the National Center for Mental Health (NCMH), Seoul, Korea, April 18, 2017.

395. “Comparative Efficacy and Safety of Antipsychotics in the Acute and Maintenance Treatment of Schizophrenia” [„Nutzen und Risiken von Antipsychotika bei der Akut- und Langzeitbehandlung

der Schizophrenie“], oral presentation at the Department of Psychiatry, Charite Campus Benjamin Franklin, Berlin, Germany, May 10, 2017.

396. “Assessment and Management of the Psychosis and Mania Prodrome”, oral presentation at the

27th Turkish Child and Adolescent Psychiatry Congress, Izmir, Turkey, May 10-14, 2017.

397. “How to Conduct and Publish Clinical Research”, oral presentation at the 27th Turkish Child and Adolescent Psychiatry Congress, Izmir, Turkey, May 10-14, 2017.

398. “Risks and Benefits of Antipsychotics in Youth with Severe Mental Disorders”, oral presentation at the 27th Turkish Child and Adolescent Psychiatry Congress, Izmir, Turkey, May 10-14, 2017.

399. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation at the Royal Victoria Hospital, Barrie, ON, Canada, May 24, 2017

400. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation at Lakeridge Health Hospital, Oshawa, ON, Canada, May 24, 2017

401. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation at St Joseph's Hospital, Hamilton, ON, Canada, May 25, 2017

402. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation at Brampton Civic Hospital, Brampton, ON, Canada, May 25, 2017

403. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation at Freeport Hospital, Kitchener, ON, Canada, May 26, 2017

404. “Opportunities to Optimize Outcomes Throughout the Illness Course of Schizophrenia: A Stitch In Time”, Grand Rounds presentation at Humber River Hospital, York, ON, Canada, May 26, 2017

405. “Measurement-based care versus standard care for major depression: Conducting a successful randomized controlled trial with blind raters”, oral presentation as part of the symposium entitled “Measurement-based psychiatry: Toward rating scale-based assessments in the real world” (Co-Chairs: CU Correll, S Dinesen Østergaard), 13th World Congress of Biological Psychiatry (WFSBP), Copenhagen, Denmark, June 18–22, 2017.

406. “Pharmacological treatment of children and adolescents with severe mental disorders”, oral presentation as part of the WFSBP young researchers Session 2 on pharmacological treatment and non-invasive brain stimulation (CO-chairs: F Garcia, F Thibaut), 13th World Congress of Biological Psychiatry (WFSBP), Copenhagen, Denmark, June 18–22, 2017.

407. “Pharmacological treatment of bipolar disorder in children and adolescents”, oral presentation as part of the symposium entitled “Pharmacological treatment of bipolar disorder in children, adolescents and adults" (Co-Chairs: CU Correll, A Nierenberg), 13th World Congress of Biological Psychiatry (WFSBP), Copenhagen, Denmark, June 18–22, 2017.

408. “Definitions and epidemiology of treatment resistance”, oral presentation as part of the symposium entitled “Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment” (Co-Chairs: JM Kane, O Agid), 13th World Congress of Biological Psychiatry (WFSBP), Copenhagen, Denmark, June 18–22, 2017.

409. “Thinking long-term from the beginning to optimize outcomes in schizophrenia”, oral presentation as part of Grand Rounds at the Mental Health Clinic Enschede, Enschede, Netherlands, June 28, 2017.

Curriculum Vitae Christoph U. Correll, M.D. Page 77

410. “Switching and dosing of antipsychotics: getting it right”, oral presentation as part of Grand Rounds at the Mental Health Clinic Enschede, Enschede, Netherlands, June 28, 2017.

411. “Thinking long-term from the beginning to optimize outcomes in schizophrenia”, oral presentation as part of Grand Rounds at the Mental Health Clinic Etten-Leur, Etten-Leur, Netherlands, June 28, 2017.

412. “Switching and dosing of antipsychotics: getting it right”, oral presentation as part of Grand Rounds at the Mental Health Clinic Etten-Leur, Etten-Leur, Netherlands, June 28, 2017.

413. “Early detection and management of people considered at high-risk for bipolar disorder”, oral presentation as part of the annual meeting of the the International Society for Bipolar Disorders (ISBD) Colombian chapter and the Asociación Colombiana de Trastornos del Ánimo (ACTA), Medellin, Colombia, August 25-26, 2017.

414. “Phenomenology, illness trajectory and management of first episode bipolar disorder”, oral presentation as part of the annual meeting of the the International Society for Bipolar Disorders (ISBD) Colombian chapter and the Asociación Colombiana de Trastornos del Ánimo (ACTA), Medellin, Colombia, August 25-26, 2017.

415. “Can D2 partial agonists improve functioning in clinical practice?”, oral presentation as part of the satellite symposium entitled “Can we improve functioning in our patients with schizophrenia? The potential role of D2 partial agonists”, European College of Neuropsychopharmacology (ECNP) Meeting, Paris, September 2-5, 2017

416. “Appropriate treatment choice in recent-onset schizophrenia: applicability and usefulness of a novel e-health tool”, oral presentation as part of the Expert Science Exchange Session (C Correll, R Emsley, J Kane), European College of Neuropsychopharmacology (ECNP) Meeting, Paris, September 2-5, 2017

417. “Early Intervention for First Episode Schizophrenia: What is the Effectiveness of Coordinated Specialty Care versus Usual Care?”, oral presentation as part of the Early Psychosis Foundation Hong Kong (EPISO AGM) Meeting, September 9, 2017

418. “Assertive early detection and early intervention in (severe) mental disorders: The US Experience and Results from a Comprehensive Meta-analysis”, oral presentation as part of the Keynote Lecture Symposium on “Early detection and early intervention”, 4th European Assertive Outreach Foundation (EAOF) International Congress “European Congress on Integrated Care and Assertive Outreach” (Chair: M Lambert, Co-chair: A Bechdolf), Hamburg, Germany, September 13-15, 2017.

419. “Update on the Bipolar Prodrome: From Conceptualization to Implementation”, oral presentation as part of the symposium on “Early Phases of Bipolar Disorder”, 4th European Assertive Outreach Foundation (EAOF) International Congress “European Congress on Integrated Care and Assertive Outreach” (Chair: I Melle, Co-chair: A Bechdolf), Hamburg, Germany, September 13-15, 2017.

420. “Management of Schizophrenia Across Different Illness Stages”, oral presentation at Sapienza University, Rome, September 27, 2017.

421. “Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with severe mental illness”, oral presentation as part of the symposium entitled “Increased morbidity and mortality among patients with severe mental illness”, (Chair: F Schneider, Co-chair: R Heun), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

422. “New Antipsychotic Treatments for Patients with Schizophrenia” oral presentation as part of the symposium entitled “Antipsychotic Treatment Update: Dissecting Molecular Mechanisms and Enhancing The Benefit-Risk Ratio” (Chair: D Mueller, Co-chair: C Correll), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

423. “Brexpiprazole for relapse prevention in schizophrenia - The long-term view”, oral presentation as part of the Satellite Symposium, entitled “Advances in schizophrenia: Why do we need new treatment options (Chair: C Correll), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

424. “Pharmacotherapy for people with schizophrenia: Weighing the options“, oral presentation as part of the State-of-the-Art-Symposium, entitled “Psychotic Disorders” (Chair: P Falkei, Co-chair: C Correll), XVII World Psychiatric Association (WPA) Meeting, Berlin, Germany, October 8-12, 2017.

Curriculum Vitae Christoph U. Correll, M.D. Page 78

425. “Identification and Treatment of Bipolar Disorder in Youth”, oral presentation at Sapienza University, Rome, October 13, 2017.

426. “Treatment-resistant schizophrenia: strategies and treatment paths“ [„Therapieresistente Schizophrenie: Strategien und Behandlungswege"], grand rounds presentation, Klinik für Psychiatrie, Psychotherapie und Psychosomatik Bezirksklinikum Ansbach, Ansbach, Germany, October 18, 2017.

427. „Psychopharmacotherapy of Schizophrenia during Adolescence“ [„Psychopharmakotherapie bei Schizophrenie im Jugendalter“], oral presentation as part of the Child and Adolecent Afternoon [Kinder- und jugendpsychiatrischer Nachmittag], University of Marburg, Marburg, Germany, November 8, 2017

428. „How can we best achieve the long-term goals in schizophrenia?“ [“Wie können wir Langzeitziele in der Schizophrenie-Therapie am besten erreichen?"], oral presentation (Chair: S Kasper), annual meeting of the Österreichische Gesellschaft für Neuropsychopharmakologie (ÖGPB), Vienna, Austria, November 10, 2017.

429. „Long-Acting Antipsychotics in the Maintenance Therapy of Schizophrenia: The Role of Physician and Patient“ [„Langwirksame Antipsychotika bei der Erhaltungstherapie der Schizophrenie: Die Rolle von Arzt und Patient"], oral presentation as part of a symposium, annual meeting of the Österreichische Gesellschaft für Neuropsychopharmakologie (ÖGPB), Vienna, Austria, November 10, 2017.

430. „Progress in the evidence and practice of the pharmacological treatment of schizophrenia in 2017“ [„Fortschritte in der Evidenz und Praxis der medikamentoesen Behandlung der Schizophrenie: Stand 2017„], oral presentation as part of the half-day program “Goettingen Psychiatry Symposium” (Co-Chair: J Wiltfang, K Schnell), University of Goettingen, Goettingen,Germany, November 18, 2017

431. “Early Interventions for First Episode Psychosis: The US Experience and Meta-analysis of Coordinated Specialty Care versus Treatment as Usual”, oral presentation as part of a half-day Symposium on Schizophrenia, Aalborg, Denmark, November 21, 2017.

432. “Depot Antipsychotic Therapy in Schizophrenia: Already State of the Art?” [„Depottherapie bei Schizophrenie: Schon State of the Art?”], oral presentation as part of Grand Rounds at the Landeskrankenhaus Graz, Graz, Austria, November 23, 2017

433. “Non-dopaminergic Therapies in Schizophrenia“, oral presentation as part of the symposium, entitled “Novel therapies for Schizophrenia” (Chair: E. Vieta). Cibersam Meeting, Ateneo de Madrid, Madrid, Spain, November 23-24, 2017.

434. “How to design, conduct and get a clinical study published”, Masterclass as part of the 7th International Psychiatric Conference, organized by the Sudan Medical Specialization Board Council of Psychiatry and the Sudanese Psychiatric Association, Khartoum, Sudan, January 6, 2018.

435. “Antipsychotic efficacy and safety in children and adolescents with psychosis, bipolar disorder, aggression, autism and tic disorders”, Masterclass as part of the 7th International Psychiatric Conference, organized by the Sudan Medical Specialization Board Council of Psychiatry and the Sudanese Psychiatric Association, Khartoum, Sudan, January 6, 2018.

436. “Foundations and Effects of Modern Psychopharmacotherapy” [„Grundlagen und Effekte moderner Psychopharmakatherapie“], oral presentation as part of the 13th Berliner Psychiatrietage, Berlin, Germany, January 18-20, 2018.

437. „The Schizophrenia and Bipolar Prodrome: Commonalities and Differences“ [„Das schizophrene und das bipolare Prodrome: Gemeinsamkeiten und Unterschiede”], oral presentation as part of the symposium, enttitled „Psychotic Symptoms in Bipolar Disorder“ [„Psychotische Symptome in der bipolaren Stoerung“], Charite Berlin, January 17, 2018.

438. Early Recognition of Psychosis and Bipolar Disorder: Similarities and Differences“ [„Früherkennung bei Psychose und bipolarer Störung: Unterschiede und Gemeinsamkeiten”], oral presentation as part of the Colloquium at the Goethe University, Department of Child and Adolescent Psychiatry, Frankfurt, Germany, February 14, 2018

Curriculum Vitae Christoph U. Correll, M.D. Page 79

439. “Thinking Long-term From the Beginning to Optimize Outcomes in Schizophrenia: A Stitch in Time”, oral presentation as part of Grand Rounds (Chair: M Kelbrick), Berrywood Hospital, Northampton, UK, February 19, 2018

440. “Thinking Long-term From the Beginning to Optimize Outcomes in Schizophrenia: A Stitch in Time”, oral presentation as part of a one-day symposium on the management of schizophrenia (Chair: M George), Birmingham, UK, February 20, 2018

441. “Thinking Long-term From the Beginning to Optimize Outcomes in Schizophrenia: A Stitch in Time”, oral presentation as part of a one-day symposium on the management of schizophrenia (Chair: K Suresh), Essex, UK, February 20, 2018

442. “Thinking Long-term From the Beginning to Optimize Outcomes in Schizophrenia: A Stitch in Time”, oral presentation as part of a one-day symposium on the management of schizophrenia (Chair: D Walsh), Brighton, UK, February 21, 2018

443. “Long-term Management Issues in the Treatment of Attention-Deficit/Hyperactivity Disorder”, oral presentation as part of an evening symposium on Update on Best Practices in Attention-Deficit/Hyperactivity Disorder, Bangalore, India, February 24, 2018.

444. “Older or Newer Long-acting Injectable Antipsychotics: What is the state of the art?”, oral presentation at the National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India, February 24, 2018.

445. “Management of schizophrenia across the illness stages”, oral presentation as part of a meeting organized by the Hyderabad Psychiatric Society, Hyderabad, India, February 24, 2018.

446. “Management of schizophrenia across the illness stages” “Management of schizophrenia across the illness stages – What is the state of the art?”, oral presentation as part of a one-day symposium organized by the Bombay Psychiatric Society, Bombay, India, February 25, 2018.

447. “Efficacy and tolerability of antipsychotics in youth with psychotic, mood and aggressive spectrum disorders”, oral presentation as part of a one-day symposium organized by the Bombay Psychiatric Society, Bombay, India, February 25, 2018.

448. “Diagnosis and treatment of children and adolescents with bipolar disorder”, oral presentation as part of a one-day symposium organized by the Bombay Psychiatric Society, Bombay, India, February 25, 2018.

449. “Antipsychotic Polypharmacy Is Better than Monotherapy: Pro”, oral presentation as part of the “Debate: Antipsychotic Treatment: Polypharmacy Is Better than Monotherapy” (Chair: I. Bitter), European Psychiatric Association (EPA) Meeting, Nice, March 3-6, 2018.

450. “Polypharmacy in Antipsychotic Treatments”, Ask the Experts Session, European Psychiatric Association (EPA) Meeting, Nice, March 3-6, 2018.

451. “Cognitive symptoms in the recovery of psychosis”, oral presentation as part of the Roundtable, entitled “Complexities in Psychiatry: psychosis and bipolar disorders” (Chair: J Marques Teixeira), 25th International Symposium about Current Issues and Controversies in Psychiatry "Complexity in Psychiatry”, Barcelona, Spain, April 19-21, 2018.

452. “Comorbidities and mortality in affective disorders – can we change the trajectories?, oral presentation as part of the sympositum, entitled “The increased mortality in affective disorders – an overview and new results”, Copenhagen, Denmark, May 25, 2018.

453. „Psychopharmacology in Child and Adolescent Psychiatry: State of the Art“ [„Psychopharmakologie für Kinder- und Jugendpsychiatrie. State of the art“. Engadiner Sommerakademie, Zouz, Switzerland, June 21-23, 2018.

454. “Principles and Content of the New Neuroscience-based Nomenclature (NbN) for Psychotropic Drugs in Children and Adolescents”, oral presentation as part of the symposium, entitled “Progress of the neuroscience-based nomenclature (NbN) for Psychotropic Drugs”, Collegium Neuropsychopharmacologicum (CINP) World Congress, Vienna, June 16-19, 2018.

455. “Strategies for the Optimized Long-term Management of Schizophrenia” [“Strategien für eine optimierte Langzeitbehandlung der Schizophrenie”], oral presentation as part of the Psychiatry Psychotherapy Refresher - Berlin 2018“ ["Psychiatrie und Psychotherapie Refresher - Berlin 2018], Berlin, Germany, June 21-23, 2018.

Curriculum Vitae Christoph U. Correll, M.D. Page 80

456. “Management of Schizophrenia: What is the Role of Long-acting Injectable Antipsychotics?” [Therapie der Schizophrenie: Stellenwert der Depotmedikation”], oral presentation as part of the symposium “Modern Individualized Pharmacotherapy of Schizophrenia [“Moderne, individualisierte Pharmakotherapie der Schizophrenie”] (chair E. Seifriz, University of Zurich, Switzerland, June 22, 2018.

457. “RAND/UCLA Appropriateness Method (RUAM): What can the eHealth Too Contribute?” [RAND/UCLA Appropriateness Method (RUAM): “Was kann das e-Health-Tool leisten?”], oral presentation a spart of the symposium “Modern Individualized Pharmacotherapy of Schizophrenia [“Moderne, individualisierte Pharmakotherapie der Schizophrenie”] (Chair E. Seifriz, University of Zurich, Switzerland, June 22, 2018.

458. “Overview of Schizophrenia Treatment”, oral presentation as part of Grand Rounds, Portsmouth Hospital, St. Mary’s Community Halth Campus, Portsmouth, UK, July 10, 2018.

459. “Overview of Schizophrenia Treatment”, oral presentation as part of Grand Rounds, Royal South Hants Hospital, Southamptom, UK, July 10, 2018.

460. “Overview of Schizophrenia Treatment”, oral presentation as part of Grand Rounds, Basingstoke Parklands Hospital, Basingstoke, UK, July 11, 2018.

461. “Prodromal phase and early recognition of schizophrenia”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (Schizophrenia) (course leader: R Nielsen), Aalborg, Denmark, August 28, 2018.

462. “Early intervention in schizophrenia”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (Schizophrenia) (course leader: R Nielsen), Aalborg, Denmark, August 28, 2018.

463. “Evidence for Early Intervention Services, a Metaanalysis”, oral presentation at the Third Global Excellence in Health Prize Conference on Early Intervention in Psychosis, entitled “20 years anniversary for OPUS: Status and new initiatives?”, August 29-30, 2018, (Chair: M Nordentoft), Bispebjerg Hospital, Copenhagen, Denmark, August 29, 2018.

464. “Prodromal phase and early recognition of bipolar disorder”, oral presentation as part of the Aalborg Psychopharmacology Summer School course on Advanced Psychopharmacology (Bipolar Disorders) (course leader: R Nielsen), Aalborg, Denmark, August 30, 2018.

465. “Identification and management of first episode psychosis: Is there a “critical period?”, oral presentation as part of the two-day symposium, entitled “17th Charite Conference on Psychiatric Research: Emotional Neuroscience”, Berlin, Germany, August 31-September 1, 2018.

466. “Optimizing the Acute and Maintenance Treatment of Schizophrenia,” oral presentation as part of the “Symposium on Suicidology and Public Health”, Sapienza University, Rome, Italy, September 13, 2018.

467. “Keeping th Body in Mind and Thinking long-term from the Beginning: Strategies for Optimizing Care in People with Schizophrenia”, oral presentation as part of Grand Rounds at Lovisenberg Hospital, Oslo, Norway, September 21, 2018.

468. “Thinking long-term from the Beginning to Improve Outcomes in Schizophrenia: A Stitch in Time” oral presentation as part of Grand Rounds at Erfan Hospital, Jeddah, Saudi Arabia, September 24, 2018.

469. “Thinking long-term from the Beginning to Improve Outcomes in Schizophrenia: A Stitch in Time” oral presentation as part of Grand Rounds at Fakeeh Hospital, Jeddah, Saudi Arabia, September 24, 2018.

470. “Thinking long-term from the Beginning to Improve Outcomes in Schizophrenia: A Stitch in Time” oral presentation as part of Grand Rounds at Amal Mental Health Hospital, Riyadh, Saudi Arabia, September 24, 2018

471. “Thinking long-term from the Beginning to Improve Outcomes in Schizophrenia: A Stitch in Time” oral presentation as part of Grand Rounds at the Ministry of Mental Health Governmental Hospital, Riyadh, Saudi Arabia, September 24, 2018.

472. “Optimizing Outcomes in Schizophrenia: The Role of Long-Acting Injectable Antipsychotics”, oral presentation as part of the Pan-Arabic Psychiatric Association Meeting in Conjuction with the Egyptian Associan of Psychiatry, Cairo, Egypt, September 27, 2018.

Curriculum Vitae Christoph U. Correll, M.D. Page 81

473. “D2 partial agonists for relapse prevention in schizophrenia – the long-term view”, oral presenation as part of the symposium, entitled “Dopamine D2 partial agonists in the treatment of schizophrenia – finding the right balance” (Chair: CU. Correll), annual meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 6-9, 2018.

474. “Current challenges in schizophrenia management: The need to look beyond symptom control”, oral presenation, annual meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 6-9, 2018.

475. “Strategies for the Optimized Long-term Management of Schizophrenia” [“Strategien für eine optimierte Langzeitbehandlung der Schizophrenie”], oral presentation as part of the Psychiatry Symposium, Duesseldorf, Germany, October 13, 2018.

476. “Clinical Recovery in Schizophrenia”, oral presentation as part of a 2-day Symposium, entitled “Schizophrenia: Targeting clinical, functional and personal recovery”, University of Turin, Turin, Italy, November 5-6, 2018.

477. “Treatment of first episode and early phase psychosis”, oral presentation as part of the one-day symposium “Psychotic experices, symptoms and illness in children and adolescents: how do we translate knowledge into cliical practice?”, The 2nd biannial Øresund Conference in child and adolescent psychiatry, November 7th 2018 Bispebjerg Hospital, Copenhagen, Denmark, November 7, 2018.

478. “Treatment Options for the management of negative symptoms”, oral presentation as par of the two-day symposium, entitled “Addressing Schizophrenia: the challenge of the new Millennium”, Berlin, Germany, November 12-13, 2018.

479. “Cognitive Symptoms of Schizophrenia: a couple still to be explored”, oral presentation as par of the two-day symposium, entitled “Addressing Schizophrenia: the challenge of the new Millennium”, Berlin, Germany, November 12-13, 2018.

480. “Course and Management of Schizophrenia in Youth” [“Therapie und Verlauf der Schizophrenie im Jugendalter”], Grand Rounds Presentation, University of Heidelberg, Department of Child and Adolescent Psychiatry, Heidelberg, Germany, November 21, 2018.

481. “Can Schizophrenia be Prevented?”, oral presentation as part of the workshop, entitled “Prevention and Management of Schizophrenia” University of Odense, Odense, Denmark, November 22, 2018.

482. “Management of Schizophrenia”, oral presentation as part of the workshop, entitled “Prevention and Management of Schizophrenia” University of Odense, Odense, Denmark, November 22, 2018.

483. “Recovery in Schizophrenia: The Role of Psychopharmacological Treatment”, oral presentation as part of a half-day Symposium, entitled “Clinical Recovery in Schizophrenia”, University of Brescia, Brescia, Italy, November 23, 2018.

484. “Prevention of Relapse, Tolerabilty and Mortality Gap”, oral presentation as part of a half-day Symposium, entitled “Clinical Recovery in Schizophrenia”, University of Brescia, Brescia, Italy, November 23, 2018

485. “Recovery in Schizophrenia: The Role of Psychopharmacological Treatment”, oral presentation as part of a half-day Symposium, entitled “Clinical Recovery in Schizophrenia”, University of Milan, Milan, Italy, November 23, 2018.

486. “Prevention of Relapse, Tolerabilty and Mortality Gap”, oral presentation as part of a half-day Symposium, entitled “Clinical Recovery in Schizophrenia”, University of Milan, Milan, Italy, November 27, 2018

487. “Relevance and specificity of the Clinical Risk Syndrome for Psychosis and Bipolar Disorder During Adolescence” [“Relevanz und Spezifität von Risikosyndromen für Psychose und bipolare Störung im Adoleszentenalter”], oral presentation as part of the symposium entitled “Research Areas in Transitional Age Psychiatry” [“Forschungfelder der Transitionspsychiatrie”], (Chair: T Banaschwewski, Co-chair: M Driessen), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

488. “Antipsychotics and Suicidality” [“Antipsychotika und Suizidalität”], oral presentation as part of the symposium entitled “Psychotropic Medications and Suicidality” [“Psychopharmaka und Suizidalität”], (Chair: T Banaschwewski, Co-chair: M Driessen), Annual Meeting of the German

Curriculum Vitae Christoph U. Correll, M.D. Page 82

Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

489. Comparison of early intervention services vs usual care for early psychosis: Results of a meta-analysis” [“Vergleich von Frueherkennungszentren vs. Regelversorgung bei frueher Psychose: Ergebnisse einer Meta-Analyse”], oral presentation as part of the symposium, entitled “Early Psychoses: Data Regarding Clinical Course, Treatment and Outcome” [“Frühe Psychosen: Daten zu Klinik, Therapie und Verlauf], (Chair: A. Bechdolf, Co-chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

490. “Treatment with a Vision” [“Behandlung mit Weitblick”], oral presentation as part of the symposium, entitled “Keeping the Future in Sight – Schizophrenia Management with Perspective” [“Die Zukunft im Blick - Schizophreniebehandlung mit Perspektive”] (Chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

491. “Pharmacological Interventions for People with Schizophrenia: Current Evidence and New Developments“, oral presentation as part of the State-of-the-Art-Symposium, entitled “Psychotic Disorders” (Chair: P Falkei, Co-chair: C Correll), Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28-December 1, 2018.

492. “Treatment of Schizophrenia: An Update”, oral presentation as part of Grand Rounds at North Warwickshire Primary Care Centre, Nuneaton, UK, December 4, 2018.

493. “Treatment of Schizophrenia: An Update”, oral presentation as part of Grand Rounds at Woodbourne Priory Hospital, Birmingham, UK, December 5, 2018.

494. “Treatment of Schizophrenia: An Update”, oral presentation as part of Grand Rounds at Uffculme Centre, Birmingham, UK, December 5, 2018.

495. “Management of Schizophrenia: What is the Role of Long-acting Injectable Antipsychotics?” [Therapie der Schizophrenie: Stellenwert der Depotmedikation”], oral presentation as part of the symposium “Modern Individualized Pharmacotherapy of Schizophrenia [“Moderne, individualisierte Pharmakotherapie der Schizophrenie”] (Chair: B. Kraemer), Psychiatriezentrum Breitenau, Spitaeler Schaffhausen, Schaffhausen, Switzerland, December 7, 2018.

496. “RAND/UCLA Appropriateness Method (RUAM): What can the eHealth Too Contribute?” [RAND/UCLA Appropriateness Method (RUAM): “Was kann das e-Health-Tool leisten?”], oral presentation a spart of the symposium “Modern Individualized Pharmacotherapy of Schizophrenia [“Moderne, individualisierte Pharmakotherapie der Schizophrenie”] (Chair: B. Kraemer), Psychiatriezentrum Breitenau, Spitaeler Schaffhausen, Schaffhausen, Switzerland, December 7, 2018.

497. “Applied Biostatistics”, oral presentation as part of the 2-day workshop, entitled “2018 CNS International Clinical Trials Workshop: Clinical Trials by Design for Evidence Based Clinical Practice”, Tokyo, Japan, December 14-15, 2018.

498. “Diagnostic, Assessment and Methodology Issues in the Development of Treatments for Everyday Functioning and Cognition in Schizophrenia”, oral presentation as part of the 2-day workshop, entitled “2018 CNS International Clinical Trials Workshop: Clinical Trials by Design for Evidence Based Clinical Practice”, Tokyo, Japan, December 14-15, 2018.

499. “Behandlungsoptionen für das Management der Negativ-Symptomatik ” oral presentation as part of the 1-day symposium, entitled”„New therapeutic Options for Schizophrenia“ [“Neue Therapiemöglichkeiten für die Schizophrenie“] (chair: E Seifritz), Zürich, Switzerland, January 10, 2019.

500. “Is Rational Antipsychotic Polypharmacy possible in the Treatment of Schizophrenia?, oral presentation as part of a half-day Symposium on Schizophrenia, Aalborg, Denmark, January 15, 2019.

501. “Optimized Pharmacotherapy of Schizophrenia: Status 2019“ [“Optimierte Pharmakotherapie der Schizophrenie: Stand 2019“], oral presentation as part of the 1-day symposium, entitled”„Psychiatric Academy– Focus on Schizophrenia“ [“Psychiatrische Akademie: Fokus

Curriculum Vitae Christoph U. Correll, M.D. Page 83

Schizophrenie“] (chair: E Seifritz), Psychiatrische Klinik Königsfelden, Switzerland, January 17, 2019.

502. “Treatment of Schizophrenia with Antipsychotics 2019“ [“Antipsychotikatherapie der Schizophrenia 2019”], grand rounds presentation, Schlosspark-Klinik, Berlin, Germany, February 18, 2019.

503. „Management of Schizophrenia across the age Span“ [„Behandlung der Schizophrenie in der Lebensspanne“], grand rounds presentation, Martin Gropius Hospital, Eberswalde, Germany, February 20, 2019.

504. „Efficacy and Safety of Antipsychotics in Children and Adolescents with Severe Mental Illness” [„Wirkung und Nebenwirkung von Antipsychotika bei Kindern und Jugendlichen mit schweren psychiatrischen Erkrankungen“], oral presentation as part of the Colloquium 2019, Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany, February 20, 2019.

505. “Prevention and Early Recognition of Psychotic Disorders“ [“Praevention und Frueherkennung von Psychosen“], Nordostdeutsche Gesellschaft für Psychiatrie, Psychotherapie und Psychosomatik des Kindes- und Jugendalters (NKJPP), oral presentation as part of the Curriculum 2018/2019 zur Weiterbildung im Fachgebiet Kinder- und Jugendpsychiatrie und -psychotherapie, Berlin, Germany, February 21, 2019.

506. „Efficacy and Safety of Antipsychotics in Children and Adolescents with Severe Mental Illness” [„Wirkung und Nebenwirkung von Antipsychotika bei Kindern und Jugendlichen mit schweren psychiatrischen Erkrankungen“], Nordostdeutsche Gesellschaft für Psychiatrie, Psychotherapie und Psychosomatik des Kindes- und Jugendalters (NKJPP), oral presentation as part of the Curriculum 2018/2019 zur Weiterbildung im Fachgebiet Kinder- und Jugendpsychiatrie und -psychotherapie, Berlin, Germany, February 21, 2019.

507. „Brexpiprazole in Clinical Practice“ [„Brexpiprazol in der Klinik“], oral presentation, (chair: P. Rose), Psychiatrische Klinik Königsfelden, Königsfelden, Switzerland, February 26, 2019.

508. „Brexpiprazole in Clinical Practice“ [„Brexpiprazol in der Klinik“], oral presentation, (chair: M. Hatzinger), Soluthurner Spitaeler, Soluthurn, Switzerland, February 26, 2019.

509. “Brexpiprazole in Clinical Practice“ [„Brexpiprazol in der Klinik“], oral presentation, (chair: G. Damman), Klinik Muensterlingen, Muensterlingen, Switzerland, February 27, 2019.

510. “Brexpiprazole in Clinical Practice“ [„Brexpiprazol in der Klinik“], oral presentation, (chair: S. Walther), University Hospital Bern, Bern, Switzerland, February 27, 2019.

511. "Brexpiprazole in Clinical Practice“ [„Brexpiprazol in der Klinik“], oral presentation, (chair: B. Kraemer), Psychiatriezentrum Breitenau, Schaffhausen, Switzerland, February 28, 2019.

512. "Brexpiprazole in Clinical Practice“ [„Brexpiprazol in der Klinik“], oral presentation, (chair: M. Baumgartner), Klinik Schloessli, Oetwil am See, Switzerland, February 28, 2019.

513. “Early Intervention and Maintenance Treatment in the Management of Schizophrenia”, oral presentation as part of the two-day “1st FORUM of Advanced Training in Psychiatry”, Brescia, Italy, March 21, 2019.

514. „Pro & Contra Debate: Antipsychotics in the Long-term Management – What is needed for an Individualized Treatment?”, [Pro & Contra Debatte: Antipsychotika in der Langzeittherapie – was braucht es fuer eine individuelle Therapie?“]“, oral presentation as part of the one-day “9th Bamberger CNS-Summit 2019, Bamberg, Germany, March 23, 2019

515. “Metabolic syndrome in psychiatry: an overview”, oral presentation as part of the symposium, entitled “Metabolic syndrome in psychiatry: recognition and management of psychotropic drug induced metabolic effects”, 27th European Congress of Psychiatry, organized by the European Psychiatric Association, Warsaw, Poland, April 6-9, 2019.

516. “Long-acting Treatments in Schizophrenia: A Call to Action“, oral presentation as part of the symposium, entitled “How to optimize the daily care of patients with schizophrenia: from data to practice”, 27th European Congress of Psychiatry, organized by the European Psychiatric Association, Warsaw, Poland, April 6-9, 2019.

Curriculum Vitae Christoph U. Correll, M.D. Page 84

517. “State of the Art-Lecture: Antipsychotics in Child and Adolescent Psychiatry: What, How, For Whom, and For How Long?” [“State of the Art-Symposium: Antipsychotika in der Kinder- und Jugendpsychiatrie: Was, wie, fuer wen und fuer wie lange?"] (chair: M Koelch), XXXVII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Mannheim, Germany, April 10-13, 2019.

518. “Can Psychosis be Prevented? Therapeutic Options for People at Clinical High-Risk for Psychosis” [“Kann Psychose verhindert werden: Behandlungsstrategien für Menschen mit einem klinischen Risikosyndrom für eine Psychose“], oral presentation as part of the State-of-the-Art Symposium, entitled “Psychosis/Early Recognition” [“Psychose/Früherkennung” (chair: F Resch), XXXVII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Mannheim, Germany, April 10-13, 2019.

519. “Early Identification and Intervention as Necessary Treatment Options in Youth Psychiatry“ [“Früherkennung und Frühintervention als notwendige Angebote der Adoleszenzpsychiatrie”], oral presentation as part of the State-of-the-Art Symposium, entitled “Psychosis/Early Recognition” [“Psychose/Früherkennung” (chair: F Resch), XXXVII Annual Meeting of the German Association of Child and Adolescent Psychiatry (DGKJP), Mannheim, Germany, April 10-13, 2019.

520. “Preventing Treatment Resistance from the Beginning”, oral presentation as part of the Roundatable, entitled “Lack of Treatment Response in Psychotic Disorders” (Chair: PM Sanchez Gomez), 26th International Symposium about Current Issues and Controversies in Psychiatry "Treatment Resistance”, Barcelona, Spain, April 25-27, 2019.

521. “Clozapine and Beyond”, oral presentation as part of the Roundatable, entitled “Lack of Treatment Response in Psychotic Disorders” (Chair: PM Sanchez Gomez), 26th International Symposium about Current Issues and Controversies in Psychiatry "Treatment Resistance”, Barcelona, Spain, April 25-27, 2019.

522. “Optimizing Outcomes in Schizophrenia: What s the Role of LAIs?”, oral presentation as part of the 2-day Symposium, entitled “Schizophrenia Acadeny International Conference”, Budapest, Hungary, April 26-27, 2019.

523. “The Treatment of Schizophrenia 2019: Where do we Stand?, oral presentation as part of Grand Rounds, Victoria Mental Health Centre, Victoria, BC, Canada, April 29, 2019.

524. “The Treatment of Schizophrenia 2019: Where do we Stand?, oral presentation as part of Grand Rounds, St. Paul’s Hospital, Vacouver, BC, Canada, April 30, 2019.

525. “The Treatment of Schizophrenia 2019: Where do we Stand?, oral presentation as part of Grand Rounds, Regina General Hospital, Regina, SK, Canada, Mai 1, 2019.

526. “The Treatment of Schizophrenia 2019: Where do we Stand?, oral presentation as part of Grand Rounds, Victory Medical Clinic, Saskatoon, SK, Canada, Mai 2, 2019.

527. “The Treatment of Schizophrenia 2019: Where do we Stand?, oral presentation as part of Grand Rounds, Grey Nun’s Hospital, Edmonton, AB, Canada, Mai 2, 2019.

528. “Adverse effects of psychotropic medications in children and adolescents: practical considerations.”, state of the art lecture as part of the European Society for Child and Adolescent Psychiatry (ESCAP) meeting 2019, Vienna, June 30-July 2, 2019.

CME Radio, TV, Audio and PodCast Program Presentations 1. Correll CU, Findling RL, Scahill L, 2006. Audio Podcast Program 04.25.2006: The Efficacy and

Safety of Atypical Antipsychotics in Children and Adolescents With Psychosis, Mood, and Behavioral Disorder (www.peerviewpress.com/h/inR179)

2. Kane JM, Correll CU, Miller DD, 2006. Audio and TV Podcast Program 12.01.2006: Benefits and Risks of Antipsychotic Medication: A Focus on Sedation (http://www.arcmesa.org/7146/)

3. Correll CU, 2007. Audio Podcast Program 05.04.2007: Current Issues in the Use of Atypical Antipsychotics in Bipolar Disorder and Schizophrenia: Dosing, Switching, and Side Effect Management Episode (http://www.trumix.com/podshows/1467529)

Curriculum Vitae Christoph U. Correll, M.D. Page 85

4. Weiden PJ, Correll CU, Prescorn SH, 2007. Audio and TV Podcast Program 08.22.2007: Pharmacodynamics of Atypical Antipsychotics: Clinical Correlations and Practice Implications (http://www.cmeoutfitters.com/cmea.asp?ID=241)

5. Correll CU, 2007. ReachMD Radio Program 10.22.2007: Antipsychotic Treatment for Children: What's New? (http://www.reachmd.com/xmsegment.aspx?sid=1651)

6. Correll CU, Doraiswami PM, Carlson H, 2007. Audio Podcast Program 10.23.2007: Clinical Implications of Hyperprolactinemia Associated With Atypical Antipsychotic Agents Episode (http://www.trumix.com/podshows/2007782; http://www.peerviewpress.com/pc2/e005)

7. Findling RL, Scahill L, Frazier J, Correll CU, 2007. Audio Podcast Program 10.24.2007: T Recognizing and Managing Early-Onset Schizophrenia (www.peerviewpress.com/pc2/r337)

8. Correll CU, Findling RL; Sikich L, 2007. Audio Podcast Program 10.31.2007: Promoting Metabolic and Endocrine Health in Children and Adolescents Treated with Antipsychotics (http://www.arcmesa.org/7146/)

9. Correll CU, 2007. ReachMD Radio Program 11.26.2007: Adolescents at High Risk for Psychosis (http://www.reachmd.com/xmsegment.aspx?sid=1648)

10. Correll CU, 2007. ReachMD Radio Program 12.31.2007: Does a Prodrome exist in Bipolar Disorder? (http://www.reachmd.com/xmsegment.aspx?sid=1649)

11. Correll CU, 2008. ReachMD Radio Program 03.17.2008: Effects of Atypical Antipsychotics in Children

(http://www.reachmd.com/xmsegment.aspx?sid=2516)

12. Kane JM, Correll CU, 2008. Audio Podcast Program 09.05.2008: Predicting Response to Antipsychotic Therapy: The Impact of Early Onset of Action. (http://www.pvupdate.com/schiz71/e/001)

13. Correll CU, 2008. ReachMD Radio Program 11.17.2008: Applying the Pharmacology of Atypical Antipsychotics: Clinical Implications (http://www.reachmd.com/xmsegment.aspx?sid=2516)

14. Sederer L, Findling RL, Correll CU, 2009. Reducing Cardiometabolic Risk in Youth. (https://psyckesmedicaid.omh.state.ny.us/Common/CardiometabolicYouth.aspx)

15. Kohlstadt I, Vitiello B, Robb A, Correll C, Rappley, 2009. Audio-Digest Pediatrics; 55(16), August 21, 2009: Atypical Antipsychotics in Children and Adolescents: Balancing Safety and Efficacy. (www.audio-digest.org/antipsychotics)

16. Correll CU, 2009. Antipsychotics in children associated with significant weight gain and elevated lipids. (http://www.currentmedicine.tv/2010/psychiatry/christoph-correll-md-antipsychotics-in-children/)

17. Leucht S, Kahn R, Correll CU, 2011. Research Directions in Schizophrenia Treatment: Mechanisms of Action for Next-Generation Agents. (http://www.medscape.org/viewarticle/750960?src=0_mp_cmenl_0)

18. Correll CU. 2012. Early-Onset Schizophrenia: Do Adult Approaches Fit Young Patients?, part of: Correll CU, Findling RL, Arango C. 2012. Paediatric and Adolescent Psychiatrists in Europe Tackling Diagnostic and Treatment Uncertainties in Paediatric Schizophrenis and Bipolar Disorders. (www.peervoice.com/pvr36)

19. Correll CU. 2018. Antipsychotic Polypharmacy in Schizophrenia- Report from the European Psychiatric Association (EPA) Meeting, Nice, France, March 3-6, 3018. (http://filmek.olo.hu/EPA_2018/EPA_2018_Christopher_Corell_int_x264.mp4)

20. Correll CU. 2018. Schizophrenia Treatments With New Mechanisms of Action Are Emerging: Will It Matter?, part of “Clinical Advances in Schizophrenia: Toward a New Wave of Treatments“ (https://www.medscape.org/viewarticle/893800)

Curriculum Vitae Christoph U. Correll, M.D. Page 86

GRANT SUPPORT ACTIVE GRANTS

09/15-12/22 PCS-1406-19276 – 40-site, Patient Centered Outcomes Research Institute (PCORI)-funded grant “MOBILITY: Metformin for Overweight and Obese Children and Adolescents with Bipolar Spectrum Disorders Treated with Second-Generation Antipsychotics” ($13,493,176 total - $3,557,857 for the subcontracted Zucker Hillside Hospital New York Network Coordinating Center). Role: Greater New York Network Coordination Center PI, overall study Co-PI (PI: Melissa DelBello, MD)

http://www.mobilitystudy.org 01/16-12/20 Takeda-funded, 3-site, investigator-initiated grant: “Augmentation with

Vortioxetine in Schizophrenia (AVIS)” ($1,000,297). Role: PI

12/12-12/20 John and Maxime Bendheim Child Psychiatry Foundation Award for Research grant: “Personalized Diagnosis and Care for Mentally Ill Youth” ($75,061). Role: PI

09/08-06/20 R01 2U01MH081857 – 8-site linked NIMH RO-1 grant. Predictors and Mechanisms of Conversion to Psychosis (NAPLS). ($21,000,000 total and $2,900,000 for the Zucker Hillside Hospital site). Role: Co-I; Medical Director (PI: Barbara Cornblatt, PhD) http://www.clinicaltrials.gov/ct2/show/NCT01429454?term=napls&rank=1

09/15-12/19 Danish Mental Health Foundation funded grant: “Coronary artery disease as a cause of morbidity and mortality in patients suffering from schizophrenia: Epidemiology and status in order to provide prevention interventions and treatment. A clinical multidisciplinary large-scale academic investigator initiated clinical trial”. Role: Global Scientific Steering Committee Member (Co-PIs: Jørgen Aagaard, MD; Svend Eggert Jensen, MD)

01/15-12/19 Danish TrygFoundation and Danish Mental Health Foundation funded grant: “Mind My Mind”, a RCT of a new, transdiagnostic CBT-manual for indicated prevention and treatment of anxiety, depression and/or disruptive behaviour in school-aged children in Denmark). Role: International Advisory Board Member (PI: Pia Jeppesen, MD)

07/19-12/19 Berlin Institute of Health (BIH)-funded Digital Health Accelerator Program grant: “Online Psychiatric Evaluation Network - Internet Use (OPEN-IU)” (€287,700). Role: Mentor (PI: Olga Geisel, MD)

12/18-12/19 Berlin Institute of Health (BIH) Gender Equality Funds Award. (€5,000). Role: Mentor (PI: Olga Geisel, MD)

07/09-12/19 HHSN-271-2009-00019C - 34-site NIMH Contract: “Recovery After an Initial Schizophrenia Episode (RAISE)” ($24,000,000). Role: Co-I; Steering Committee Member; Publications Committee Member (PI: John Kane, MD)

https://raiseetp.org/ 12/14-08/19 Otsuka-funded investigator-initiated grant: “A Cluster Randomized, Multi-center,

Parallel-group, Rater-blind Study Comparing Treatment with Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia (PRELAPSE)” ($28,800,000). Role: Co-I (PI: John Kane, MD)

Curriculum Vitae Christoph U. Correll, M.D. Page 87

PAST GRANTS

12/10-05/19 Spanish Government grant “Safe Neuroleptic Treatment in Children and

Adolescents (SENTIA)” (€800,000). Role: Consultant (PI: Immaculada Palanca Maresca, MD)

04/12-09/18 NIMH K23MH097108 Grant “Pharmacogenetics of Antipsychotic-Induced Side Effects with a Focus of Weight Gain” ($839,500). Role: Co-Mentor (PI: Jian-Ping Zhang, MD, PhD)

08/14-06/18 NIMH-funded R34MH103835 grant “Developing Strategies to Reduce DUP in the Age of Social Media and the Internet” ($418,537). Role: Co-PI (PI: John M Kane, MD)

06/12-06/18 Bundesministerium für Bildung und Forschung (BmBF) (€1.907.735): A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients (COMBINE)” Role: Consultant (PI: Joachim Cordes, MD)

(http://www.clinicaltrials.gov/ct2/show/NCT01609153?term=combine&rank=1)

12/09-06/18 German Federation for Research (DFG) grant: “Early cognitive behavioural psychotherapy in subjects at high risk for bipolar affective disorders (EarlyCBT)” (€1,250,000). Role: Consultant (PI: Michael Bauer, MD)

08/13-05/18 NIMH-funded R01MH101506 grant “Multimodal Imaging of Executive and Reward Networks Across the Psychosis Spectrum (BRAINS)” ($646,165). Role: Co-Investigator (PI: Katherine Karlsgodt, PhD)

07/10-12/17 NIMH-funded Advanced Center for Intervention and Services Research (ACISR) grant P30MH090590: "Early Phase Psychosis: Informing Treatment Decisions” ($8,700,000). Role: Co-I; Director, Adverse Events Assessment and Prevention Unit; Co-Director, Knowledge Transfer Unit; Co-Director, Clinical Assessment Strategies Unit (PI: John Kane, MD)

07/14-06/17 NIMH-funded R21-MH102724-02 “Safety of Second Generation Antipsychotics for Adult Depression” ($475,500). Role: Co-I (PI: Tobias Gerhard, DPharm)

06/09-12/16 Danish Government grant: “Tolerability and Efficacy of Antipsychotics in Children and Adolescents with Psychosis (TEA Trial)” (€1,850,000). Role: Steering Committee Member (PI: Anne Katrine Pagsberg, MD)

(http://www.clinicaltrials.gov/ct2/show/NCT01119014?term=TEA&rank=8)

07/12-12/16 Novo Nordisk A/S-funded, investigator-initiated grant: “Does a GLP-1 receptor agonist decrease overweight and improve metabolic disturbances in antipsychotic-treated patients?” (€460,000) Role: Consultant (PI: Anders Fink-Jensen, MD)

09/11-08/16 Agency for Healthcare Research and Quality (AHRQ) center grant: “Centers for Education Research and Therapeutics” ($8,100,000). Role: Co-I; Director, Child and Adolescent Psychiatry Core (PI: Steven Crystal, MD)

07/11-10/15 Thrasher Research Fund funded Early Career study: “Characterizing the Clinical Risk State for Bipolar Disorder in Adolescents” ($26,750). Role: Co-PI; Mentor, (PI: Marta Hauser, PhD)

07/12-06/15 1C1CMS331052-01-00 CMMI Centers for Medicare and Medicaid Services (CMMI) grant “Improving Quality and Reducing Cost in Schizophrenia Care with New Technologies and New Personnel (ICRC)” ($9,200,000). Role: Co-I; Executive Committee Member (PI: John M Kane, MD)

Curriculum Vitae Christoph U. Correll, M.D. Page 88

10/13-10/14 American Academy of Child and Adolescent Psychiatry (AACAP) 2012 Pilot Research Award: "Exploring Barriers to Care in Early Psychosis" ($15,000). Role: Co-PI; Mentor (PI: Michael Birnbaum, MD)

10/12-10/14 American Academy of Child and Adolescent Psychiatry (AACAP) 2012 Pilot Research Award: "Differential Effects of Risperidone and Aripiprazole on Prolactin-Mediated Alterations in Sex Hormones, Sexual Functioning and Bone Turnover in Antipsychotic-Naive Adolescents" ($15,000). Role: Co-PI; Mentor (PI: Jatinder Chawla, MD)

07/08-06/14 1R01MH080274-01A2, NIMH-funded, 4-site, linked RO-1 grant in collaboration with the Johns Hopkins Medical School (PI: Mark Riddle, MD), and the University of North Carolina (PI: Linmarie Sikich, M.D.): “Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)” ($6,250,000 total and $1,788,930 for the Zucker Hillside Hospital site): Role: PI

07/12-06/14 NIMH-funded Supplement (NOT-MH-12-014) to the Advanced Center for Intervention and Services Research (ACISR) grant P30MH090590: "MC4R Genotype and Pediatric Antipsychotic Drug-Induced Weight Gain” ($125,000). Role: Co-I (PI: Anil Malhotra, MD)

09/08-08/13 NIMH-funded RO-1 MH080050 grant “Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)” ($2,200,000). Role: Consultant (PI: Joseph Blader, PhD)

05/10- 4/13 European Foundation for the Study of Diabetes/Lilly Mental Health in Diabetes Program grant: “Ten-Year Risk Estimates and Actual Rates of Diabetes and Coronary Heart Disease Events in Patients with Schizophrenia” (€50,000). Role: International Co-PI (European PI: Marc De Hert, MD)

04/10 - 04/12 Japan Research Foundation for Clinical Pharmacology funded grant “Comparative Effectiveness of Interventions for Persistent Schizophrenia Symptoms“ ($74,220). Role: Mentor (PI: Taro Kishi, MD, PhD)

05/07 - 04/12 Robert Wood Johnson Foundation funded grant: “Early Detection and Intervention for the Prevention of Psychosis” ($2,000,000). Role: Study Psychiatrist (PI: Barbara Cornblatt, PhD)

05/05 - 04/12 NIMH-funded RO-1 grant R01 MH61523: "Characterization of Prodromal Schizophrenia” ($1,250,000). Role: Co-PI; Medical Director (PI: Barbara Cornblatt, PhD)

07/07 - 12/11 NARSAD Young Investigator grant: “Molecular Mechanisms of Antipsychotic Induced Weight Gain” ($60,000). Role: PI

09/09 - 09/11 John and Maxime Bendheim Child Psychiatry Foundation Award for Research grant: “Prospective Adolescent Mood Disorders Study” ($37,000). Role: Co-PI; Mentor (PI: J Lops, DO)

07/08 - 06/11 NIMH-funded R21 MH079326 grant: “Early Detection of Risk Factors for Bipolar Mania” ($285,000). Role: Co-I (PI: Barbara Cornblatt, PhD)

09/05 - 08/10 NIMH-funded CONTI Center grant U01 MH074356 (PI: Daniel Javitt) - D-Serine in the Treatment of Schizophrenia – Cognitive Substudy ($1,270,000). Role: Consultant (Site PI: Barbara Cornblatt, PhD)

09/98 - 06/11 NIMH-funded RO-1 grant R01MH060004: “Preventing Morbidity in First Episode Schizophrenia” ($2,500,000). Role: Co-I (PI: Delbert Robinson, MD)

Curriculum Vitae Christoph U. Correll, M.D. Page 89

11/06 - 3/11 Feinstein Institute of Medical Research and North Shore – LIJ GCRC “Strategies to Reverse Antipsychotic Treatment Effects in Youth ($70,000). Role: PI

5/04 - 3/11 Research Award from the NIMH-funded North Shore - Long Island Jewish Health System General Clinical Research Center (GCRC)): "Anthropometric and Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents” ($100,000). Role: PI

7/05 - 6/10 NIMH-funded P30 MH074543 Advanced Center for Intervention and Services Research (ACISR) grant: "Early Phase Schizophrenia: Optimizing Outcomes” ($5,200,000). Role: Co-I; Director, Adverse Events Assessment and Prevention Unit; Co-Director, Knowledge Transfer Unit; Co-Director, Clinical Assessment Strategies Unit (PI: John Kane, MD)

7/06 - 6/07 NIMH-funded 5R01MH060229-05 grant “Treatment of Refractory Childhood Schizophrenia” ($329,722). Role: PI

04/03 - 03/07 Stanley Foundation-funded study "Double-blind, parallel-group comparison of risperidone and sertraline in adolescents at high risk for schizophrenia" ($150,000): Role: Co-PI; Medical Director (PI: Barbara Cornblatt, PhD)

10/03 - 9/06 Bristol-Myers Squibb/Otsuka Pharmaceuticals funded study "Open-Label Study of Aripiprazole in Individuals At-Risk for Chronic Mental Illness" ($75,000): Role: Co-PI; Medical Director (PI: Barbara Cornblatt, PhD)

7/04 - 6/05 North Shore - Long Island Jewish Research Institute Faculty Research Award: "Second-Generation Antipsychotic-Induced Effect on Central Appetite Regulation in Antipsychotic-Naïve Children and Adolescents" ($40,000). Role: PI

7/04 - 6/05 American Academy of Child and Adolescent Psychiatry (AACAP) 2004 Pilot Research Award: "Effect of Olanzapine and Risperidone on Hypothalamic Regulation of Food Intake in Antipsychotic-Naïve Youths with Schizophrenia-Spectrum Disorders" ($9,000). Role: PI

7/01 - 6/02 Long Island Jewish Medical Center Small Grant: "Effect of novel antipsychotics and antidepressants on BMI and glucose metabolism in adolescents at risk for schizophrenia during the first three months of treatment: an open-label naturalistic pilot study ($5,000)". Role: PI

Curriculum Vitae Christoph U. Correll, M.D. Page 90

BIBLIOGRAPHY GOOGLE SCHOLAR: H-INDEX = 92 [I100-INDEX = 82, I10-INDEX = 321] WEB OF SCIENCE CITATION REPORT: H-INDEX = 71 [I100-INDEX = 51; I10-INDEX = 275]

PEER REVIEWED ARTICLES (* indicates shared first or last authorship; name in italics indicates

mentee) https://www.ncbi.nlm.nih.gov/pubmed/?term=((Correll%2C+Christoph+U%5BAuthor%5D)+OR+Correll%2C+Christoph%5BAuthor%5D)+OR+Correll+CU%5BAuthor%5D+OR+(Correll+AND+Lambert)+OR+(Correll+AND+Leucht)+OR+(Correll+and+Linden)+OR+(Correll+and+Steube)+OR+(Correll+and+Walter)+OR+(Correll+AND+Carlson)+OR+(Correll+AND+Vitiello)+OR+(T-MAY+Steering+Group)+OR+(NP-C+Guidelines+Working+Group)+OR+(Correll+AND+Kahl)+OR+(Correll+CU+AND+Zhang)+OR+(Correll+AND+Crespo-Facorro)+OR+(Correll+AND+Kane) 1. Jankowski J, Tragaskis B, Coghill G, Correll C, Grant A, Hopwood K, Wormsley K. Nucleolar

organiser regions in oesophageal cytology and histology. Gullet 1992; 2:85-90.

2. Steube D, Wiethölter S, Correll C. Prognostic value of lower limb motor evoked potentials for motor impairment and disability after 8 weeks of stroke rehabilitation - a prospective investigation of 100 patients. Electromyogr Clin Neurophysiol 2001, 41(8):463-9.

Curriculum Vitae Christoph U. Correll, M.D. Page 91

3. Correll CU, Mendelowitz AJ. First psychotic episode - window of opportunity. Current Psychiatry 2003;2(4):50-67.

4. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003 Jul;160(7):1209-22.

5. Kane JM, Krystal J, Correll CU. Treatment models and designs for intervention research during the psychotic prodrome. Schizophr Bull 2003;29(4):747-756.

6. Correll CU, Malhotra AK, Saurabh K, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160(11):2063-5.

7. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther A, Nakayama E. The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophr Bull 2003;29(4):633-651.

8. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt, B. The assessment of “prodromal schizophrenia”. Schizophr Bull 2003;29(4):717-728.

9. Suckow RF, Fein M, Correll CU, Cooper TB. Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 25;799(2):201-8.

10. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry 2004;161(3):414-425.

11. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt, B. Non-specific and attenuated negative symptoms in patients at clinical risk for schizophrenia. Schizophr Res 2004;68:37-48.

12. Correll CU, Kane JM: The psychotic prodrome: How effective are early interventions? Adv Schiz Clin Psych 2004;1(1):2-10.

13. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004 Aug;174(4):477-89.

14. Kane, JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, Newcomer JW: Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004; Nov;65(11):1447-55

15. Saito E, Correll CU, Gallelli K, Parikh U, McMeniman M, Malhotra AK, Kafantaris V. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004;14(3):350-8.

16. Straker D, Correll CU, Kramer-Ginsberg E, Saint-Vil R, Abdulhamid N, Koshy F, Rubens E, Kane JM, Manu P. Cost-effective screening for metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005;162:1217-21.

17. Correll CU, Lencz T, Smith CW, Auther A, Nakayama E, Hovey L, McLaughlin D, Olsen R, Shah M, Foley C, Cornblatt BA. Prospective study of adolescents with subsyndromal psychosis: characteristics and outcome. J Child Adolesc Psychopharmacol 2005;15(3):418-33

18. Faries DE, Ascher-Svanum H, Zhu B, Correll CU, Kane JM. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics BMC Psychiatry. 2005 May 27;5(1):26.

19. Correll C, Linden M. Psychotropic drug presentation in medical and lay press journals. Pharmacopsychiatry. 2005 Jul;38(4):161-5.

20. Correll, CU. Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story? J Clin Psychiatry. 2005 Oct;66(10):1331-1332.

21. Correll, CU. Real life dosing with second-generation antipsychotics. J Clin Psychiatry 2005 Dec;66(12): 1610-1611.

22. Correll CU, Penzner JB, Parikh UH, Mughal TB, Javed T, Carbon M, Malhotra AK. Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):177-206.

23. Correll, CU. Real life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006 Jan;67(1):160-161.

Curriculum Vitae Christoph U. Correll, M.D. Page 92

24. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. J Clin Psychiatry 2006;67(4):575-583

25. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45(7):771-791.

26. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007 Jan;89(1-3):91-100.

27. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007 Apr;68(4):546-57.

28. Correll CU, Harris JL, Pantaleon Moya RA, Frederickson AM, Kane JM, Manu P. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. Schizophr Res. 2007 April;92:103-7.

29. Correll CU, Penzner JB, Frederickson AM, Richter JJ, Auther AM, Smith CW, Kane JM, Cornblatt BA. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull. 2007 May;33(3):703-14.

30. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):687-700.

31. Correll CU, Penzner JB, Lencz T, Auther A, Smith C, Kane JM, Malhotra AK, Cornblatt BA. Early identification and high risk strategies for bipolar disorder. Bipolar Disord. 2007 Jun;9(4):324-38.

32. Correll CU. Time to rethink the use of antipsychotic polypharmacy in schizophrenia? Canadian Journal of Diagnosis 2007 (Aug):3-9.

33. Correll CU. Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 1: challenges and developments. J Clin Psychiatry. 2007 Aug;68(8):1301-2.

34. Buckley PF, Correll CU, Miller AL. First-episode psychosis: a window of opportunity for best practices. CNS Spectr. 2007 Sep;12(9 Suppl 15):1-12.

35. Correll CU. First-episode psychosis: Diagnosis and management. Canadian Journal of Diagnosis 2007 (Sep):3-11.

36. Correll CU. Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 2: Methodological considerations. J Clin Psychiatry. 2007;68(9):1441-2.

37. Correll CU. Balancing efficacy and safety in the treatment with antipsychotics. CNS Spectr. 2007;12(10) (Suppl 17):12-20,35.

38. Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry. 2007 Oct;19(5):523-30.

39. DelBello MP, Correll CU, Carlson GA, Carlson HE, Kratochvil CJ. Pharmacological Management of Bipolar Disorder in a Youth With Diabetes. J Am Acad Child Adolesc Psychiatry. 2007 Oct;46(10):1375-1379.

40. Correll CU, Kane JM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: A systematic review. J Child Adolesc Psychopharmacol 2007;17(5): 647-655.

41. Correll CU. Acute and long-term adverse effects of antipsychotics. CNS Spectr. 2007;12(12) (Suppl 21):10-14.

42. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47:9-20.

43. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69 Suppl 1:4-17.

44. Carlson HE, Correll CU. Adverse effects of antipsychotics and mood stabilizers. Consequences of long-term metabolic and endocrine dysfunction. Psychiatric Times, January 2008;25(1): 25-28.

Curriculum Vitae Christoph U. Correll, M.D. Page 93

45. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;51:151-156.

46. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008 Mar 1;63(5):524-9.

47. Correll CU. Monitoring and Management of Antipsychotic-related Metabolic and Endocrine Adverse Effects in Children and Adolescents. Int Rev Psychiatry 2008;20(4):195-201.

48. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69 (suppl 4):26-36.

49. Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry. 2008 Apr 4;8:19.

50. Correll CU, Kane JM, Manu P. The Intervention Threshold for Low-Density Lipoprotein Cholesterol in Patients Receiving Second-Generation Antipsychotics: Expert Recommendation or National Standard? J Clin Psychiatry 2008 Apr;69(4):578-583.

51. Correll CU. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? J Clin Psychiatry 2008;69(4):674-675

52. Heald A, Correll CU. Diabetes management in schizophrenia: a comparison of UK and US guidance. MIMS Advances 2008;2(4):8-11.

53. Correll CU. Antipsychotic polypharmacy, part 2: Why use 2 antipsychotics when 1 is not good enough? J Clin Psychiatry 2008;69(5):860-861.

54. Walter G, Delaroche A, Soh N, Hunt G, Cleary M, Malhi G, Lambert T, Correll C, Rey J. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry 2008 Aug;16(4):253-62.

55. Lee KJ, Lee JS, Kim SJ, Correll CU, Wee H, Yoo SY, Jeong JM, Lee DS, Lee SI, Kwon JS. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr Scand. 2008 Sep;118(3):200-8.

56. Correll CU, Lencz T, Smith CW, Auther AM, McLaughlin D, Olsen R, Shah M, Foley C, Kane JM, Cornblatt BA. Predictors of remission or conversion to schizophrenia or bipolar disorder in adolescents with subsyndromal psychosis considered at high risk for schizophrenia. J Child Adolesc Psychopharmacol. 2008 Oct;18(5):475-90.

57. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008 Nov;10(7):788-97.

58. Bauer M, Juckel G, Correll CU, Leopold K, Pfennig A. Diagnosis and Treatment in the Early Phase of Bipolar Disorders. Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:50-4.

59. Carlson GA, Findling RL, Post RM, Birmaher B, Blumberg HP, Correll C, DelBello MP, Fristad M, Frazier J, Hammen C, Hinshaw SP, Kowatch R, Leibenluft E, Meyer SE, Pavuluri MN, Wagner KD, Tohen M. AACAP 2006 Research Forum--Advancing research in early-onset bipolar disorder: barriers and suggestions. J Child Adolesc Psychopharmacol. 2009 Feb;19(1):3-12.

60. Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and data from the Schizophrenia summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry. 2009;70 Suppl 1:4-46.

61. Correll CU, Frederickson AM, Figen V, Ginn-Scott EJ, Pantaleon Moya RA, Kane JM, Manu P. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):23-7.

62. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull. 2009 Mar;35(2):443-57.

63. Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors and screening need. J Clin Psychiatry. 2009;70(5):765-66.

Curriculum Vitae Christoph U. Correll, M.D. Page 94

64. Soto EC, Frederickson AM, Trivedi H, Lee A, Eugene MC, Shekher M, Weiskopf M, Allen-Dicker K, Dicker R, Fornari V, Correll CU. Frequency and Correlates of Inappropriate Pediatric Psychiatric Emergency Room Visits. J Clin Psychiatry 2009;70(8):1164-77.

65. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009 Sep;19(9):629-35.

66. Correll CU: Examining the profiles of atypical antipsychotics. Canadian Journal of Diagnosis 2009 (September): 3-15.

67. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of atypical antipsychotics during first-time use in children and adolescents. JAMA 2009, Oct 28;302(16): 1763-1771.

68. Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):563-73.

69. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348–1357.

70. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res. 2010 Mar;117(1):68-74.

71. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116-141.

72. Correll CU. Switching and combining antipsychotics. CNS Spectr. 2010 Apr;15(4 Suppl 6):8-11.

73. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010 Apr;51(4):390-431.

74. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of Medications Used to Reduce Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-analysis. Neuropsychopharmacology. 2010 Jun;35(7):1520-30.

75. Correll CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010 Jun;25 Suppl 2:S12-21.

76. Heald A, Montejo AL, Millar H, De Hert M, McCrae J, Correll CU. Management of physical health in patients with schizophrenia: practical recommendations. Eur Psychiatry. 2010 Jun;25 Suppl 2:S41-5.

77. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Van Tran Q, Pikalov A 3rd, Assunção-Talbott S. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010 Jul;24(7):1019-29.

78. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010 Jul;10(7):1175-200.

79. Nielsen J, Skadhede S, Correll CU. Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. Neuropsychopharmacology. 2010 Aug;35(9):1997-2004.

80. Correll CU, Druss BG, Lombardo I, O’Gorman C, Harnett JP, Sanders KN, Alvir JM, Cuffel BJ. Findings of a U.S. National Cardiometabolic Screening Program in 10,084 Psychiatric Outpatients. Psychiatr Serv. 2010 Sep;61(9):892-8.

81. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010 Sept 79(9):1115-24.

Curriculum Vitae Christoph U. Correll, M.D. Page 95

82. Manu P, Tsang J, Napolitano BA, Lesser ML, Correll CU. Predictors of insulin resistance in the obese with metabolic syndrome. Eur J Intern Med. 2010 Oct;21(5):409-13.

83. Olvet DM, Stearns WH, McLaughlin D, Auther AM, Correll CU, Cornblatt BA. Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome. Schizophr Res. 2010 Oct;123(1):59-63.

84. Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU. 10-Year trends in the treatment and outcomes of patients with first episode schizophrenia. Acta Psychiatr Scand. 2010 Nov;122(5):356-366.

85. Kane JM, Correll CU. Pharmacologic Treatment of Schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345-57.

86. Kahl KG, Greggersen W, Schweiger U, Cordes J, Correll CU, Ristow J, Burow J, Findel C, Stoll A, Balijepalli C, Göres L, Lösch C, Hillemacher T, Bleich S, Moebus S. Prevalence of the metabolic syndrome in men and women with alcohol dependence: results from a cross-sectional study during behavioural treatment in a controlled environment. Addiction. 2010 Nov;105(11):1921-7

87. Nasrallah HA, Goldberg JF, Correll CU. Differential diagnosis and therapeutic management of schizoaffective disorder. Ann Clin Psychiatry. 2010 Nov;22(4 Suppl 1):S1-12.

88. Correll CU. Understanding schizoaffective disorder: from psychobiology to psychosocial functioning. J Clin Psychiatry. 2010; 71 Suppl 2:8-13.

89. Rossi A, Cañas F, Fagiolini A, Larmo I, Levy P, Montes JM, Papageorgiou G, Sturlason R, Zink M, Correll CU. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Postgrad Med. 2011 Jan;123(1):135-59.

90. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011 Feb;17(2):97-107.

91. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JM, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011 Feb; 10(1)52-77.

92. Nielsen J, Munk-Jørgensen P, Skadhede S. Correll CU. Determinants of poor dental care in patients with schizophrenia. J Clin Psychiatry. 2011 Feb;72(2):140-3.

93. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011 Apr;26(3):144-58.

94. Correll CU, Cañas F, Larmo I, Levy P, Montes JM, Fagiolini A, Papageorgiou G, Rossi A, Sturlason R, Zink M. Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry 2011 March;26 (Special Issue 1):3-16.

95. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica. Psiquiatr Biol. 2011;18(3):89-104.

96. De Hert M, Dirix N, Demunter H, Correll CU. Prevalence and correlates of seclusion and restraint use in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2011 May;20(5):221-30.

97. Correll CU, Kratochvil CJ, March J. Developments in Pediatric Psychopharmacology: Focus on Stimulants, Antidepressants and Antipsychotics. J Clin Psychiatry. 2011 May;72(5):655-670.

98. De Hert M, Bobes J, Cetkovich-Bakmas M, Cohen D, Leucht S, Maj M, Ndetei DM, Newcomer JM, Uwakwe R, Asai I, Möller HJ, Gautam S, Detraux J, Correll CU. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual level. World Psychiatry. 2011 Jun;10(2):138-51.

Curriculum Vitae Christoph U. Correll, M.D. Page 96

99. Correll CU, Lops J, Figen V, Malhotra AK, Kane JM, Manu P. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry. 2011 Jun;72(6):854-60.

100. Woerner MG, Correll CU, Alvir JJ, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology. 2011 Jul;36(8):1738-46.

101. Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. J Clin Psychiatry 2011. July;72(7):936-41.

102. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: Opportunities, limitations and novel trial designs. Dialogues Clin Neurosci. 2011;13(2):155-72.

103. Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011 Aug;21(8):621-45.

104. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ. A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. Br J Psychiatry 2011 Aug;199:99-105.

105. Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA. Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis. Am J Psychiatry. 2011 Aug;168(8):806-13.

106. Kishi T, Okochi T, Kitajima T, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Correll CU, Iwata N. Lack of association between translin-associated factor X gene (TSNAX) and methamphetamine dependence in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1618-22.

107. Correll CU, Harris J, Figen V, Kane JM, Manu P. Frequency of Prolonged QTc in Children and Adolescents Hospitalized For Psychiatric Disorders: A Nested Case-Control Study. J Child Adolesc Psychopharmacol. 2011 Aug;21(4):365-8.

108. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: Prescriber attitudes, knowledge and behavior. Schizophr Res. 2011 Sep;131(1-3):58-62.

109. Correll CU, Kane JM, Manu P. Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2011;261:417-23.

110. Uggerby P, Nielsen RE, Correll CU, Nielsen J. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res. 2011 Sep;131(1-3):120-6.

111. Cañas F, Correll CU, Fagiolini A, Larmo I, Levy P, Papageorgiou G, Rossi A, Zink M, Montes JM. Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. Expert Opin Pharmacother. 2011 Oct;12(14):2245-63.

112. Kishi T, Fukuo Y, Okochi T, Kitajima T, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Correll CU, Iwata N. No significant association between SIRT1 gene and methamphetamine-induced psychosis in the Japanese population. Hum Psychopharmacol. 2011 Oct;26(7):445-50.

113. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26.

114. Correll CU. Individualizing Treatment for Patients With Bipolar Disorder: Optimizing Efficacy, Safety, and Tolerability. Current Psychiatry; 2011(Suppl):49-81.

115. Kishi T, Yoshimura R, Fukuo Y, Kitajima T, Okochi T, Matsunaga S, Inada T, Kunugi H, Kato T, Yoshikawa T, Ujike H, Umene-Nakano W, Nakamura J, Ozaki N, Serretti A, Correll CU, Iwata N. The CLOCK Gene and Mood Disorders: A Case-Control Study and Meta-analysis. Chronobiol Int. 2011 Nov;28(9):825-33.

116. Correll CU. Antipsychotics in the Treatment of Bipolar Disorder. Giorn Ital Psicopat. 2011;17:341-351.

Curriculum Vitae Christoph U. Correll, M.D. Page 97

117. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011 Dec;33(12):B16-39.

118. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011. Dec;21(6):517-35.

119. Correll CU. What are we looking for in new antipsychotics? J Clin Psychiatry. 2011;72(suppl 1):9-13.

120. Glick ID, Correll CU, Altamura CA, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized, clinical approach. J Clin Psychiatry. 2011;72(12):1616-1627.

121. Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, Jensen PS. Experts' recommendations for treating maladaptive aggression in youth. J Child Adolesc Psychopharmacol. 2011 Dec;21(6):505-15.

122. Kishi T, Fukuo Y, Okochi T, Kawashima K, Kitajima T, Inada T, Ozaki N, Musso GM, Kane JM, Correll CU, Iwata N. Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis. Hum Psychopharmacol. 2012 Jan;27(1):63-9.

123. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline Concordant Monitoring of Metabolic Risk in People with Mental Ill Health: Systematic Review and Meta-Analysis of Screening Practices. Psychol Med. 2012 Jan;42(1):125-47.

124. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012 Feb;134(2-3):180-6.

125. Leopold K, Ritter P, Correll CU, Marx C, Özgürdal S, Juckel G, Bauer M, Pfennig A. Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. J Affect Disord. 2012 Feb;136(3):1000-10.

126. Manu P, Ionescu-Tirgoviste C, Tsang J, Napolitano BA, Lesser ML, Correll CU. Dysmetabolic signals in "metabolically healthy" obesity. Obesity Research & Clinical Practice. 2012;6(1):e9-e20.

127. de Hoogd S, Overbeek WA, Heerdink ER, Correll CU, de Graeff ER, Staal WG. Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2012 Apr;22(2):166-73.

128. Manu P*, Correll CU*, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012 Apr;73(4):460-466.

129. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012 Apr;73(4):486-96.

130. Kishi T, Fukuo Y, Okochi T, Kawashima K, Moriwaki M, Furukawa O, Fujita K,Musso GM, Correll CU, Kane JM, Iwata N. The Relationship Between Acoustic Startle Response Measures and Cognitive Functions in Japanese Patients with Schizophrenia. Neuromolecular Med. 2012 Jun;14(2):131-8.

131. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012 Jun;138(1):18-28.

132. Knapp P, Chait A, Pappadopulos E, Crystal S, Jensen PS; on behalf of the T-MAY Steering Group. Treatment of Maladaptive Aggression in Youth: CERT Guidelines I. Engagement, Assessment, and Management. Pediatrics. 2012 Jun;129(6):e1562-e1576.

133. Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, Crystal S, Jensen PS; on behalf of the Treatment of Maladaptive Aggressive in Youth Steering Committee. Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. Pediatrics. 2012 Jun;129(6):e1577-e1586.

Curriculum Vitae Christoph U. Correll, M.D. Page 98

134. Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 2012 June;73(6):e757-e766.

135. Manu P, Ray K, Rein JL, De Hert M, Kane JM, Correll CU. Medical outcome of psychiatric inpatients with hyponatremia at the time of admission. Psychiatry Res. 2012 Jun 30;198(1):24-7.

136. Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G; Adipogenic and Metabolic Effects of APDs Conference Speakers, Allison DB. Recent Advances in Understanding and Mitigating Adipogenic and Metabolic Effects of Antipsychotic Drugs. Front Psychiatry. 2012;3:62.

137. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012 Jul;11(4):527-42.

138. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F; NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012 Jul;106(3):330-44.

139. Pfennig A, Correll CU, Leopold K, Juckel G, Bauer M. [Early recognition and intervention for bipolar disorders: State of research and perspectives.] Nervenarzt. 2012 Jul;83(7):897-902.

140. Zhang JP, Weiss J, McCardle M, Kofman M, Rosendahl E, Maayan L, Convit A, Manu P, Kane JM, Correll CU. Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients with Psychotic Disorders Compared to Patients with Non-Psychotic Disorders or No Psychiatric Disorders: Results from a 12-month, Real-World Study. J Clin Psychopharmacol. 2012 Aug;32(4):458-464.

141. Correll CU, Lauriello J, Malla A, Meyer JM. How to interpret findings concerning newly approved antipsychotic agents: clinical implications of the lurasidone PEARL 2 study. J Clin Psychiatry. 2012;73(8):e27.

142. De Hert M, Yu WP, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012 Sep 1;26(9):733-59.

143. Caemmerer J, Correll CU*, Maayan L*. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012 Sep;140(1-3):159-68.

144. Røge R, Møller BK, Andersen CR, Correll CU. Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far? Schizophr Res. 2012 Sep;140(1-3):204-13.

145. Kishimoto T, De Hert M, Carlson H, Manu P, Correll CU. Osteoporosis and Fracture Risk in People with Schizophrenia. Curr Opin Psychiatry. 2012 Sep;25(5):415-429.

146. Correll CU, Gallego J. Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin N Am. 2012 Sep;35(3):661-681.

147. Malhotra AK, Correll CU, Chowdhury NI, Müller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS, Ophoff RA, Lieberman JA, Meltzer HY, Lencz T, Kennedy JL. Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. Arch Gen Psychiatry. 2012;69(9):904-912.

148. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish register study. J Clin Psychopharmacol. 2012 Oct;32(5):678-83.

149. Manu P, Asif M, Khan S, Ashraf H, Mani A, Guvenek-Cokol P, Lee H, Kane JM, Correll CU. Risk factors for medical deterioration of psychiatric inpatients: opportunities for early recognition and prevention. Compr Psychiatry. 2012 Oct;53(7):968-74.

150. Auther AM, McLaughlin D, Nagachandran P, Akerman MB, Correll CU, Cornblatt BA. Prospective Study of Cannabis Use in Adolescents at Clinical High Risk for Psychosis: Impact on Conversion to Psychosis and Functional Outcome. Psychol Med. 2012 Dec;42(12):2485-97.

Curriculum Vitae Christoph U. Correll, M.D. Page 99

151. Nielsen J, Kane JM, Correll CU. Real-World Effectiveness of clozapine in patients with bipolar disorder: Results from a two-year mirror-image study. Bipolar Disorders. 2012 Dec;14(8):863-9.

152. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children and adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012 Dec 1;69(12):1247-56.

153. Correll CU, Citrome L. Individualizing treatment of positive and negative symptoms of schizophrenia. Psychiatric Annals 2012 Dec(Suppl):6-12.

154. Correll CU. Switching agents: why, when and how. Psychiatric Annals 2012 Dec(Suppl):16-18.

155. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Maintenance Treatment and Relapse Prevention in Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials of First-Generation and Second-Generation Antipsychotics. Mol Psychiatry. 2013 Jan;18(1):53-66.

156. Hauser M, Correll CU. Significance of prodromal symptoms of bipolar disorder in childhood and adolescence. Can J Psychiatry. 2013 Jan;58(1):22-31.

157. Pan PM, de Jesus DR, Gadelha A, Bressan RA, Correll CU, Mansur RB, Noto C, de Asevedo EM, Brietzke E. Translation and Adaption of the Scale of Prodromal Symptoms for Bipolar Disorder – Patient Version to Brazilian Portuguese. Trends Psychiatry Psychother. 2013;35(1):62-75.

158. Manu P*, Correll CU*, Wampers M, van Winkel R, Yu W, Shiffeldrim D, Kane JM, De Hert M. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res. 2013 Feb;143(2-3):358-62.

159. Uggerby P, Ostergaard SD, Røge R, Correll CU, Nielsen J. The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J. 2013 Feb;60(2):A4578.

160. Correll CU. The prevalence of negative symptoms in schizophrenia and their impact on patient functioning and course of illness. J Clin Psychiatry. 2013 Feb;74(2):e04.

161. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. A Rational, Evidence Informed Approach to Psychopharmacology for Adolescents with Early Onset, First Episode Psychoses. Curr Opin Psychiatry. 2013 Mar;26(2):219-30.

162. Vancampfort D, Correll CU, Probst M, Sienaert P, Wyckaert S, De Herdt A, Knapen J, De Wachter D, De Hert M. A review of physical activity correlates in patients with bipolar disorder. J Affect Disord. 2013 Mar 5;145(3):285-91.

163. Findling RL, Correll CU, Nyilas M, Forbes RA, McQuade RD, Jin N, Ivanova S, Mankoski R, Carson WH, Carlson GA. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. 2013 Mar;15(2):138-149.

164. Manu P*, Correll CU*, Wampers M, van Winkel R, Yu W, Mitchell A, De Hert M. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. Eur Neuropsychopharmacol. 2013 Mar;23(3):205-11.

165. Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, Umene-Nakano W, Nakamura J, Serretti A, Correll CU, Kane JM, Iwata N. The serotonin 1A receptor gene confers susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2013 Mar;263(2):105-18.

166. Vancampfort D, Vansteelandt C, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, De Hert M. Metabolic syndrome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013 Mar 1;170(3):265-74.

167. Manu P, Grudnikoff E, Khan S, Kremen NJ, Greenwald BS, Kane JM, Correll CU. Medical outcome of patients with dementia in a free-standing psychiatric hospital. J Geriatr Psychiatry Neurol. 2013 Mar;26(1):29-33.

168. Yu WP, De Hert M, Moons T, Claes SJ, Correll CU, van Winkel R. Body CNR1 and risk of the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2013 Apr;33(2): 186-92.

Curriculum Vitae Christoph U. Correll, M.D. Page 100

169. Vancampfort D, Correll CU, Scheewe TW, Probst M, De Herdt A, Knapen J, De Hert M. Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials. Clin Rehabil. 2013 Apr;27(4):291-8.

170. Kahl K, Greggersen W, Schweiger U, Cordes, J, Correll CU, Frieling H, Balijepalli C, Lösch C, Moebus S. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013 Apr;263(3):205-13.

171. Kishi T, Fukuo Y, Okochi T, Kawashima K, Moriwaki M, Furukawa O, Musso GM, Fujita K, Correll CU, Iwata N. Relationship between nicotine dependence and the endophenotype-related trait of cognitive function but not acoustic startle responses in Japanese patients with schizophrenia. Hum Psychopharmacol. 2013 May;28(3):220-9.

172. Carbon M, Correll CU. Rational use of generic psychotropic drugs. CNS Drugs. 2013 May;27(5):353-65.

173. Baeza I, Correll CU, Saito E, Amanbekova D, Ramani M, Kapoor S, Chekuri R, De Hert M, Carbon M. Frequency, Characteristics and Management of Adolescent Inpatient Aggression. J Child Adolesc Psychopharmacol. 2013 May;23(4):271-81.

174. Kishi T, Fujita K, Furukawa O, Suzuki T, Moriwaki M, Nitta M, Hattori M, Tsunoka T, Chekuri R, Kane JM, Correll CU, Iwata N. Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: Results from a 12-week, flexible dose study using raters masked to antipsychotic choice. Asian J Psychiatr. 2013 Jun;6(3):200-7.

175. Gerlinger G, Hauser M, De Hert M, Lacluyse K, Wampers M, Correll CU. Personal Stigma in Schizophrenia-Spectrum Disorders: A Systematic Review of Prevalence Rates, Correlates, Impact and Interventions. World Psychiatry. 2013 June;12(2):155-64.

176. Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013 Jun;74(6):603–613.

177. Correll CU, Zhao Q, Carson WH, Marcus R, McQuade R, Forbes A, Mankoski R. Validity of Early Antipsychotic Response to Aripiprazole in Adolescents with Schizophrenia and Its Predictive Value for Clinical Outcomes. J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):689-698.

178. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll CU, Kishimoto T. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. Schizophr Res. 2013 Jul;147(2-3):383-6.

179. Leopold K, Pfeiffer S, Correll CU, Bauer M, Pfennig A. [Early Recognition Centers for Mental Disorders - a Complementary Supply in the German Health System ] Früherkennungszentren für psychische Erkrankungen - ein Komplementärangebot der psychiatrischen Regelversorgung in Deutschland. Psychiatr Prax. 2013 Jul;40(5):264-70.

180. Zhang JP, Gallego J, Robinson D, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs first-generation antipsychotics in first episode schizophrenia: A systematic review and meta-analysis. Int J Neuropsychopharm. 2013 Jul;16(6):1205-18.

181. Noto MN, de Souza Noto C, de Jesus DR, Zugman A, Mansur RB, Berberian AA, Leclerc E, McIntyre RS, Correll CU, Brietzke E. Recognition of bipolar disorder type I before the first manic episode: challenges and developments. Expert Rev Neurother. 2013 Jul;13(7):795-807.

182. Kishi T, Sevy S, Chekuri R, Correll CU. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo controlled trials. J Clin Psychiatry. 2013 Jul;74(7):e642-e654.

183. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S37-41.

184. Birnbaum ML, Saito E, Gerhard T, Winterstein A, Olfson M, Kane JM, Correll CU. Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. Curr Psychiatry Rep. 2013 Aug;15(8):382-95.

185. Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC,

Curriculum Vitae Christoph U. Correll, M.D. Page 101

Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health. 2013 Aug 15;7(1):31.

186. Correll CU. Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Effects. J Clin Psychiatry. 2013 Aug;74(8):e16.

187. Hauser M, Galling B, Correll CU. Suicidal Ideation and Suicide Attempts in Children and Adolescents with Bipolar Disorder: A Systematic Review of Prevalence and Incidence Rates, Risk Factors and Controlled Interventions. Bipolar Disord. 2013 Aug;15(5):507-23.

188. Kane JM, Kishimoto T, Correll CU. Factors contributing to non-adherence in patients with psychotic disorders. World Psychiatry. 2013 Oct;12(3):216-26.

189. Vancampfort D, Wampers M, Correll CU, Mitchell AJ, De Herdt A, Probst M, De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug-naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013 Oct;12(3):240-50.

190. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales. Psychiatry Res. 2013 Oct 30;209(3):406-11.

191. Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K. Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30.

192. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs. oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013 Oct;74(10):957-65.

193. Ameis SH, Corbett-Dick P, Cole L, Correll CU. Decision Making and Antipsychotic Medication Treatment for Youth with Autism Spectrum Disorders: Applying Guidelines in the Real World. J Clin Psychiatry. 2013 Oct;74(10):1022-24.

194. Zeschel E, Correll CU, Haussleiter IS, Krüger-Özgürdal S, Leopold K, Pfennig A, Bechdolf A, Bauer M, Juckel G. The bipolar disorder prodrome revisited: Is there a symptomatic pattern? J Affect Disord. 2013 Nov;151(2):551-60.

195. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of non-steroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013 Nov;39(6):1230-41.

196. Lambert M, Bock T, Naber D, Löwe B, Schulte-Markwort M, Schäfer I, Gumz A, Degkwitz P, Schulte B, König HH, Konnopka A, Bauer M, Bechdolf A, Correll C, Juckel G, Klosterkötter J, Leopold K, Pfennig A, Karow A. [Mental Health of Children, Adolescents and Young Adults - Part 1: Prevalence, Illness Persistence, Adversities, Service use, Treatment Delay and Consequences]. Fortschr Neurol Psychiatr. 2013 Nov;81(11):614-27.

197. Karow A, Bock T, Naber D, Löwe B, Schulte-Markwort M, Schäfer I, Gumz A, Degkwitz P, Schulte B, König HH, Konnopka A, Bauer M, Bechdolf A, Correll C, Juckel G, Klosterkötter J, Leopold K, Pfennig A, Lambert M. [Mental health of children, adolescents and young adults - part 2: burden of illness, deficits of the german health care system and efficacy and effectiveness of early intervention services]. Fortschr Neurol Psychiatr. 2013 Nov;81(11):628-38.

198. Carrión RE, McLaughlin D, Goldberg TE, Auther AM, Olvet D, Correll CU, Cornblatt BA. Prediction of functional outcome in individuals at clinical high-risk for psychosis. JAMA Psychiatry. 2013 Nov 1;70(11):1133-42.

199. Kristensen D, Hageman I, Bauer J, Jørgensen MB, Correll CU. Antipsychotic Polypharmacy in a Treatment-Refractory Schizophrenia Population Receiving Adjunctive Treatment With Electroconvulsive Therapy. J ECT. 2013 Dec;29(4):267-72.

200. Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S, Chekuri R, Carbon M, Al-Jadiri A, Kishimoto T, Kane JM, Correll CU. Early-Non-Response Determined By the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia-Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2013 Dec;23(10):665-75.

Curriculum Vitae Christoph U. Correll, M.D. Page 102

201. Kishi T, Matsuda Y, Iwata N, Correll CU. Antipsychotics for Cocaine or Psychostimulant Dependence: Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials. J Clin Psychiatry. 2013 Dec; 74(10):e1169-1190.

202. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophr Bull. 2014 Jan;40(1):192-213.

203. Leopold K, Ratzer S, Correll CU, Rottmann-Wolf M, Pfeiffer S, Ritter P, Bauer M, Pfennig A. Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: Baseline results in the first 180 help-seeking individuals assessed at the Dresden high-risk project. J Affect Disord. 2014 Jan;152-154:427-33.

204. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National Trends in the Mental Health Care of Children and Adolescents by Office-Based Physicians. JAMA Psychiatry. 2014 Jan 1;71(1):81-90.

205. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014 Feb;53(2):153-73.

206. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014 Feb;53(2):174-87.

207. Pfennig A, Correll CU, Marx C, Rottmann-Wolf M, Meyer TD, Bauer M, Leopold K. Psychotherapeutic interventions in individuals at risk of developing bipolar disorder: A systematic review. Early Interv Psychiatry. 2014 Feb;8(1):3-11.

208. Miura I, Zhang JP, Nitta M, Lencz T, Kane JM, Malhotra AK, Yabe H, Correll CU. BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. Schizophr Res. 2014 Feb;152(2-3):365-72.

209. Manu P, Al-Dhaher Z, Khan S, Kane JM, Correll CU. Elevated Blood Urea Nitrogen and Medical Outcome of Psychiatric Inpatients. Psychiatr Q. 2014 Mar;85(1):111-20

210. Larsen JR, Vedtofte L, Holst JJ, Oturai P, Kjær A, Correll CU, Vilsbøll T, Fink-Jensen A. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open. 2014 Mar 25;4(3):e004227.

211. Manu P*, Correll CU*, Wampers M, van Winkel R, Yu W, Shiffeldrim D, De Hert M. Dysmetabolic features of the overweight patients receiving antipsychotic drugs. Eur Psychiatry. 2014 Mar;29(3):179-82.

212. Gupta S, Cahill JD, Ranganathan M, Correll CU. The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches. J Clin Psychiatry. 2014 Mar;75(3):285-7.

213. Rodday AM, Parsons SK, Correll CU, Robb AS, Zima BT, Saunders TS, Leslie LK. Child and adolescent psychiatrists' attitudes and practices prescribing second generation antipsychotics. J Child Adolesc Psychopharmacol. 2014 Mar;24(2):90-3.

214. Xiang YT, Li Y, Correll CU, Ungvari GS, Chiu HF, Lai KY, Tang QS, Hao W, Si TM, Wang CY, M Lee EH, He YL, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, Shinfuku N. Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). Int J Geriatr Psychiatry. 2014 Apr;29(4):359-66.

215. Cordes J, Thünker J, Regenbrecht G, Zielasek J, Correll CU, Schmidt-Kraepelin C, Agelink MW, Kahl KG, Gaebel W, Klimke A, Hauner H. Can an Early Weight Management Program Prevent Olanzapine- Induced Disturbances in Body Weight and Glucose and Lipid Metabolism? - One-Year Results from a 26-Week Randomized Trial. World J Biol Psychiatry. 2014 Apr;15(3):229-41.

216. Xiang YT, Yu X, Ungvari GS, Correll CU, Chiu HF. Outcomes of SARS Survivors in China: Not Only Physical and Psychiatric Co-morbidities. East Asian Arch Psychiatry. 2014 Mar;24(1):37-8.

217. An FR, Xiang YT, Yu L, Ding YM, Ungvari GS, Chan SW, Yu DS, Lai KY, Qi YK, Zeng JY, Wu PP, Hou ZJ, Correll CU, Newhouse R, Chiu HF. Prevalence of nurses' smoking habits in psychiatric and general hospitals in China. Arch Psychiatr Nurs. 2014 Apr;28(2):119-22.

Curriculum Vitae Christoph U. Correll, M.D. Page 103

218. Crowley MJ, McCrory DC, Chatterjee R, Gierisch JM, Myers ER, Schmit KM, Coeytaux RR, Correll CU, Kendrick AS, Sanders GD. Prioritization of Research Addressing Antipsychotics for Adolescents and Young Adults with Bipolar Disorder. Ann Intern Med. 2014 Apr 1;160(7):492-8.

219. Palanca-Maresca I, Ruiz-Antorán B, Centeno-Soto G, Jiménez-Fernandez S, García-Murillo L, Siles A, Villagrá S, Blasco-Fontecilla H, Iruela-Cuadrado L, Roman-Riechman E, Avendaño-Solá C, Correll CU. SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. Springerplus. 2014 Apr 14;3:187.

220. Correll CU, Kane JM. Schizophrenia: mechanism of action of current and novel treatments. J Clin Psychiatry. 2014 Apr;75(4):347-8.

221. Manu P, Al-Dhaher Z, Dargani N, Correll CU. Acanthosis Nigricans During Treatment With Aripiprazole. Am J Ther. 2014;21:e90-93.

222. Ifteni P*, Correll CU*, Burtea V, Kane JM, Manu P. Sudden Unexpected Death in Schizophrenia: Autopsy Findings in Psychiatric Inpatients. Schizophr Res. 2014 May;155(1-3):72-6.

223. Gerhard T, Akincigil A, Correll CU, Foglio NJ, Crystal S, Olfson M. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry. 2014 May;75(5):490-5.

224. Pfennig A, Leopold K, Bechdolf A, Correll CU, Holtmann M, Lambert M, Marx C, Meyer TD, Pfeiffer S, Reif A, Rottmann-Wolf M, Schmitt NM, Stamm T, Juckel G, Bauer M. Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial. Trials. 2014 May 8;15(1):161.

225. Xiang YT, Wong TS, Tsoh J, Ungvari GS, Correll CU, Ko FW, Hui DS, Chiu HF. Insomnia in Older Adults with Chronic Obstructive Pulmonary Disease (COPD) in Hong Kong: A Case-Control Study. COPD. 2014 Jun;11(3):319-24.

226. Manu P*, Correll CU*, Wampers M, Mitchell AJ, Probst M, Vancampfort D, De Hert M. Markers of Inflammation in Schizophrenia: Association vs. Causation. World Psychiatry. 2014 Jun;13(2):189-92.

227. Manu P, Khan S, Radhakrishnan R, Russ MJ, Kane JM, Correll CU. Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry. 2014 Jun;75(6):e573-7.

228. Toteja N, Gallego JA, Saito E, Gerhard T, Winterstein A, Olfson M, Correll CU. Prevalence and predictors of antipsychotic polypharmacy in children and adolescents. Int J Neuropsychopharmacol. 2014 Jul;17(7):1095-105.

229. Lee TY, Kim SN, Correll CU, Byun MS, Kim E, Jang JH, Kang DH, Yun JY, Kwon JS. Symptomatic and functional remission of subjects at clinical high risk for psychosis: A 2-year naturalistic observational study. Schizophr Res. 2014 Jul;156(2-3):266-71.

230. Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P. Effectiveness and Safety of Rapid Clozapine Titration in Schizophrenia. Acta Psychiatr Scand. 2014 Jul;130(1):25-9.

231. Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MB, Bilenberg N, Stenstrøm AD, Pedersen J, Nyvang L, Madsen S, Lauritsen MB, Vernal DL, Thomsen PH, Paludan J, Werge TM, Winge K, Juul K, Gluud C, Skoog M, Wetterslev J, Jepsen JR, Correll CU, Fink-Jensen A, Fagerlund B. Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. BMC Psychiatry. 2014 Jul 11;14(1):199.

232. Gou L, Zhou JS, Xiang YT, Zhu XM, Correll CU, Ungvari GS, Chiu HF, Lai KY, Wang XP. Frequency of involuntary admissions and its associations with demographic and clinical characteristics in china. Arch Psychiatr Nurs. 2014 Aug;28(4):272-6.

233. Correll CU, Hauser M, Penzner JB, Auther AM, Kafantaris V, Saito E, Olvet D, Carrión RE, Birmaher B, Chang KD, Delbello MP, Singh MK, Pavuluri M, Cornblatt BA. Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. Bipolar Disord. 2014 Aug;16(5):478-92.

234. Correll CU, Olvet D, Auther A, Hauser M, Kishimoto T, Synder S, Carrión RE, Cornblatt BA. The Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P): Description and

Curriculum Vitae Christoph U. Correll, M.D. Page 104

Validation in a Clinical High Risk Psychiatric Sample and Healthy Controls. Bipolar Disord. 2014 Aug;16(5):505-22.

235. Kane JM, Correll CU, Harvey PD, Olfson M. Clinical and cost implications of treating schizophrenia: safety, efficacy, relapse prevention, and patient outcomes. J Clin Psychiatry. 2014 Aug;75(8):e20.

236. Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014 Aug;19(4):330-9.

237. Ifteni P*, Correll CU*, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014 Sep;166:168-72.

238. Nielsen RE, Laursen MF, Lammers Vernal D, Bisgaard C, Jakobsen H, Steinhausen HC, Correll CU. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry. 2014 Sep;53(9):971-979.

239. Correll CU. Mechanism of action of antipsychotic medications. J Clin Psychiatry. 2014 Sep;75(9):e23.

240. Correll CU. The role of the extended health care team in successful LAI therapy: education to overcome barriers. J Clin Psychiatry. 2014 Sep;75(9):e25.

241. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A, Probst M, Scheewe TW, De Hert M. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables. Psychol Med. 2014 Oct;44(10):2017-2028.

242. Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R. Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. BMJ Open. 2014 Oct 10;4(10):e005708.

243. Wang ZM, Xiang YT, An FR, Correll CU, Ungvari GS, Wang CY, Lai KY, Bo QJ, Li Y, Zhong BL, Chiu HF. Frequency of Hyperprolactinemia and Its Associations With Demographic and Clinical Characteristics and Antipsychotic Medications in Psychiatric Inpatients in China. Perspect Psychiatr. 2014 Oct;50(4):257-63.

244. Ma XR, Hou CL, Zang Y, Jia FJ, Lin YQ, Li Y, Chiu HF, Ungvari GS, Correll CU, Lai KY, Zhong BL, Cao XL, Cai MY, Yun J, Xiang YT. Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients? J Affect Disord. 2014 Oct 13;172C:191-194.

245. Ifteni P, Moga MA, Burtea V, Correll CU. Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. Ther Clin Risk Manag. 2014 Oct 23;10:901-4.

246. Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA, Martínez-Cantarero C, Moreno C, de Andrés P, Cuerda C, de la Serna E, Correll CU, Fraguas D, Parellada M. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry. 2014 Nov;53(11):1179-1190.

247. Raebel MA, Penfold R, McMahon AW, Reichman M, Shetterly S, Goodrich G, Andrade S, Correll CU, Gerhard T. Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics. Pediatrics. 2014 Nov;134(5):e1308-14.

248. Zhou FC, Hou WM, Wang CY, Ungvari GS, Chiu HF, Correll CU, Shum DH, Man D, Liu DT, Xiang YT. Prospective memory performance in non-psychotic first-degree relatives of patients with schizophrenia: a controlled study. PLoS One. 2014 Nov 3;9(11):e111562.

249. Vernon JA, Grudnikoff E, Seidman AJ, Frazier TW, Vemulapalli MS, Pareek P, Goldberg TE, Kane JM, Correll CU. Antidepressants for cognitive impairment in schizophrenia - A systematic review and meta-analysis. Schizophr Res. 2014 Nov;159(2-3):385-94.

250. Correll CU. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. J Clin Psychiatry. 2014 Nov;75(11):e29.

251. Yildiz A, Vieta E, Correll CU, Nikodem M, Baldessarini RJ. Critical Issues on the Use of Network Meta-analysis in Psychiatry. Harv Rev Psychiatry. 2014 Nov-Dec;22(6):367-72.

Curriculum Vitae Christoph U. Correll, M.D. Page 105

252. Köster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014 Dec;19(4):511-31.

253. Stubbs B, Mitchell AJ, De Hert M, Correll CU, Soundy A, Stroobants M, Vancampfort D. The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis. Schizophr Res. 2014 Dec;160(1-3):1-8.

254. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM. Cardiometabolic Risk in First Episode Schizophrenia-Spectrum Disorder Patients: Baseline Results from the RAISE-ETP Study. JAMA Psychiatry 2014 Dec 1;71(12):1350-63.

255. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014 Dec;19 Suppl 1:35-53.

256. Stubbs B, De Hert M, Sepehry AA, Correll CU, Mitchell AJ, Soundy A, Detraux J, Vancampfort D. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014 Dec;130(6):470-86.

257. Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014 Dec;16(4):505-24.

258. Solmi M, Veronese N, Favaro A, Santonastaso P, Manzato E, Sergi G, Correll CU. Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology. 2015 Jan;51:237-52.

259. Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015 Jan;45(2):299-317.

260. Jensen KG, Juul K, Fink-Jensen A, Correll CU*, Pagsberg AK*. QTc changes during antipsychotic treatment of children and adolescents: A systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry. 2015 Jan;54(1):25-36.

261. Li Q, Xiang YT, Su YA, Shu L, Yu X, Chiu HF, Correll CU, Ungvari GS, Lai KY, Ma C, Wang GH, Bai PS, Li T, Sun LZ, Shi JG, Chen XS, Mei QY, Li KQ, Si TM. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. Aust N Z J Psychiatry. 2015 Feb;49(2):129-36.

262. Stubbs B, Eggermont L, Mitchell AJ, De Hert M, Correll CU, Soundy A, Rosenbaum S, Vancampfort D. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand. 2015 Feb;131(2):75-88.

263. Galling B, Correll CU. Do antipsychotics increase diabetes risk in children and adolescents? Expert Opin Drug Saf. 2015 Feb;14(2):219-41.

264. Brand S, Kirov R, Kalak N, Gerber M, Pühse U, Lemola S, Correll CU, Cortese S, Meyer T, Holsboer-Trachsler E. Perfectionism related to self-reported insomnia severity, but not when controlled for stress and emotion regulation. Neuropsychiatr Dis Treat. 2015 Feb 3;11:263-271.

265. Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry. 2015 Feb;14(1):56-63.

266. Zeschel E, Bingmann T, Bechdolf A, Krüger-Oezguerdal S, Correll CU, Leopold K, Pfennig A, Bauer M, Juckel G. Temperament and prodromal symptoms prior to first manic/hypomanic episodes: Results from a pilot study. J Affect Disord. 2015 Mar 1;173C:39-44.

267. Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck RA, Severe J, Goldstein A, Azrin S, Heinssen R, Kane JM. Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. Am J Psychiatry. 2015 Mar 1;172(3):237-48.

Curriculum Vitae Christoph U. Correll, M.D. Page 106

268. Kahl KG, Schweiger U, Correll C, Müller C, Busch ML, Bauer M, Schwarz P. Depression, anxiety disorders, and metabolic syndrome in a population at risk for type 2 diabetes mellitus. Brain Behav. 2015 Mar;5(3):e00306.

269. Xiang YT, Chiu HF, Ungvari GS, Correll CU, Lai KY, Wang CY, Si TM, Lee EH, He YL, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, Shinfuku N. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009. Hum Psychopharmacol. 2015 Mar;30(2):94-9.

270. Leopold K, Nikolaides A, Bauer M, Bechdolf A, Correll CU, Jessen F, Juckel G, Karow A, Lambert M, Klosterkötter J, Ruhrmann S, Pfeiffer S, Pfennig A. [Services on early recognition of psychoses and bipolar disorders in Germany: Inventory survey study]. Nervenarzt. 2015 Mar;86(3):352-8.

271. Kane JM, Schooler NR, Marcy P, Correll CU, Brunette MF, Mueser KT, Rosenheck RA, Addington J, Estroff SE, Robinson J, Penn DL, Robinson DG. The RAISE Early Treatment Program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry. 2015 Mar;76(3):240-246.

272. Sühs KW, Correll C, Eberlein CK, Pul R, Frieling H, Bleich S, Kahl KG. Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group. Brain Behav. 2015 Apr;5(4):e00318.

273. Xiang YT, Wong TS, Tsoh J, Ungvari GS, Correll CU, Sareen J, Penner-Goeke K, Ko FW, Hui DS, Chiu HF. Quality of Life in Older Patients With Chronic Obstructive Pulmonary Disease (COPD) in Hong Kong: A Case-Control Study. Perspect Psychiatr Care. 2015 Apr;51(2):121-7.

274. Haddad PM, Kishimoto T, Correll CU, Kane JM. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015 May;28(3):216-21.

275. Zhang XY, Chen DC, Tan YL, Tan SP, Luo X, Zuo L, Rao W, Yu Q, Kou C, Allen M, Correll CU, Wu J, Soares JC. A functional polymorphism in the interleukin-1beta and severity of nicotine dependence in male schizophrenia: A case-control study. J Psychiatr Res. 2015 May;64:51-8.

276. Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. Schizophr Bull. 2015 May;41(3):627-36.

277. Zink M, Correll CU. Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Rev Clin Pharmacol. 2015 May;8(3):335-52.

278. Rodday AM, Parsons SK, Mankiw C, Correll CU, Robb AS, Zima BT, Saunders TS, Leslie LK. Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2015 May;25(4):351-361.

279. Wang ZM, Zhu H, Pan YL, Chiu HF, Correll CU, Ungvari GS, Lai KY, Cao XL, Li Y, Zhong BL, Zhang XY, Xiang YT. Electroconvulsive Therapy and Its Association With Demographic and Clinical Characteristics in Chinese Psychiatric Patients. J ECT. 2015 Jun;31(2):114-8.

280. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015 Jun;14(2):119-136.

281. Kane JM, Correll CU. Making the link between science and symptoms in schizophrenia. J Clin Psychiatry. 2015 Jun;76(6):e15.

282. Addington J, Heinssen RK, Robinson DG, Schooler NR, Marcy P, Brunette MF, Correll CU, Estroff S, Mueser KT, Penn D, Robinson JA, Rosenheck RA, Azrin ST, Goldstein AB, Severe J, Kane JM. Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatr Serv. 2015 Jul 1;66(7):753-6.

283. Grudnikoff E, Taneli T, Correll CU. Characteristics and disposition of youth referred from schools for emergency psychiatric evaluation. Eur Child Adolesc Psychiatry. 2015 Jul;24(7):731-43.

Curriculum Vitae Christoph U. Correll, M.D. Page 107

284. Grudnikoff E, Soto EC, Frederickson A, Birnbaum ML, Saito E, Dicker R, Kane JM, Correll CU. Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. Eur Child Adolesc Psychiatry. 2015 Jul;24(7):797-814.

285. Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. Am J Psychiatry. 2015 Jul 1;172(7):617-29.

286. Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, Correll C, Soares JC, Yang F, Wang SL, Zhang XY. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015 Aug;58:130-40.

287. Galling B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015 Aug;14(8):1181-1199.

288. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015 Aug;132(2):97-108.

289. Xiang YT, Ungvari GS, Correll CU, Chiu HF, Lai KY, Wang CY, Si TM, Lee EH, He YL, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, Shinfuku N. Use of electroconvulsive therapy for Asian patients with schizophrenia (2001-2009): trends and correlates. Psychiatry Clin Neurosci. 2015 Aug;69(8):489-96.

290. Pascu AM, Ifteni P, Teodorescu A, Burtea V, Correll CU. Delayed identification and diagnosis of Huntington's disease due to psychiatric symptoms. Int J Ment Health Syst. 2015 Aug 23;9:33.

291. Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, Kane JM, Saito E, Correll CU. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. J Am Acad Child Adolesc Psychiatry. 2015 Sep;54(9):718-727.

292. Risgaard B, Waagstein K, Winkel BG, Jabbari R, Lynge TH, Glinge C, Albert C, Correll CU, Haunsø S, Fink-Jensen A, Tfelt-Hansen J. Sudden cardiac death in young adults with previous hospital-based psychiatric inpatient and outpatient treatment: a nationwide cohort study from Denmark. J Clin Psychiatry. 2015 Sep;76(9):e1122-9.

293. Bossie CA, Alphs LD, Correll CU. Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. Int Clin Psychopharmacol. 2015 Sep;30(5):272-281.

294. Song Y, Xiang YT, Huang Y, Wang X, Wang X, Zhang F, Kwan JS, Chan OC, Wang Z, Ungvari GS, Correll CU, Zaroff C. Impairments in Negative Facial Emotion Recognition in Chinese Schizophrenia Patients Detected With a Newly Designed Task. J Nerv Ment Dis. 2015 Sep;203(9):718-724.

295. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry. 2015 Sep 1;172(9):870-880.

296. Veronese N, Bano G, Bertozzo G, Granziera S, Solmi M, Manzato E, Sergi G, Cohen AT, Correll CU. Vitamin k antagonists’ use and fracture risk: results from a systematic review and meta-analysis. J Thromb Haemost. 2015 Sep;13(9):1665-1675.

297. Vernal DL, Kapoor S, Al-Jadiri A, Sheridan EM, Borenstein Y, Mormando C, David L, Singh S, Seidman AJ, Carbon M, Gerstenberg M, Saito E, Kane JM, Steinhausen HC, Correll CU. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a

Curriculum Vitae Christoph U. Correll, M.D. Page 108

Prospective, Naturalistic Cohort Study. J Child Adolesc Psychopharmacol. 2015 Sep;25(7):535-547.

298. Zheng W, Tang LR, Correll CU, Ungvari GS, Chiu HF, Xiang YQ, Xiang YT. Frequency and Correlates of Distant Visual Impairment in Patients with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. East Asian Arch Psychiatry. 2015 Sep;25(3):115-21.

299. Galling B, Calsina Ferrer A, Abi Zeid Daou M, Sangroula D, Hagi K, Correll CU. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015 Oct;14(10):1587-608.

300. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015 Oct;14(3):339-47.

301. Li Q, Xiang YT, Su YA, Shu L, Yu X, Correll CU, Ungvari GS, Chiu HF, Ma C, Wang GH, Bai PS, Li T, Sun LZ, Shi JG, Chen XS, Mei QY, Li KQ, Si TM, Kane JM. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). Schizophr Res. 2015 Oct;168(1-2):523-9.

302. Cornblatt BA, Carrión RE, Auther A, McLaughlin D, Olsen RH, John M, Correll CU. Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. Am J Psychiatry. 2015 Oct 1;172(10):986-4.

303. Guo T, Xiang YT, Xiao L, Hu CQ, Chiu HF, Ungvari GS, Correll CU, Lai KY, Feng L, Geng Y, Feng Y, Wang G. Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. Am J Psychiatry. Oct 1;172(10):1004-13.

304. Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A; European Child and Adolescent Clinical Psychopharmacology Network. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. Eur Neuropsychopharmacol. 2015;25(10):1513-31.

305. Sneider B, Pristed SG, Correll CU, Nielsen J. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. Eur Neuropsychopharmacol. 2015;25(10):1669-76.

306. Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015 Oct 31;15(1):271.

307. Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr Bull. 2015 Nov;41(6):1227-36.

308. Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll CU. Decreased Pain Sensitivity Among People with Schizophrenia: A Meta-analysis of Experimental Pain Induction Studies. Pain. 2015 Nov;156(11):2121-31.

309. Veronese N, Solmi M, Rizza W, Manzato E, Sergi G, Santonastaso P, Caregaro L, Favaro A, Correll CU. Vitamin D status in anorexia nervosa: A meta-analysis. Int J Eat Disord. 2015 Nov;48(7):803-13.

310. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O’Donovan M, Correll CU, Kane JM, van Os J, Insel TR. Schizophrenia. Nature Reviews Disease Primers. 2015 Nov 12;1:15067.

311. Solmi M, Veronese N, Manzato E, Sergi G, Favaro A, Santonastaso P, Correll CU. Oxidative stress and antioxidant levels in patients with anorexia nervosa: A systematic review and exploratory meta-analysis. Int J Eat Disord. 2015 Nov;48(7):826-41.

Curriculum Vitae Christoph U. Correll, M.D. Page 109

312. Veronese N, Cereda E, Solmi M, Fowler SA, Manzato E, Maggi S, Manu P, Abe E, Hayashi K, Allard JP, Arendt BM, Beck A, Chan M, Audrey YJ, Lin WY, Hsu HS, Lin CC, Diekmann R, Kimyagarov S, Miller M, Cameron ID, Pitkälä KH, Lee J, Woo J, Nakamura K, Smiley D, Umpierrez G, Rondanelli M, Sund-Levander M, Valentini L, Schindler K, Törmä J, Volpato S, Zuliani G, Wong M, Lok K, Kane JM, Sergi G, Correll CU. Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. Obes Rev. 2015 Nov;16(11):1001-15.

313. Correll CU. Advances in Dopamine Partial Agonism. Psych Evidence-Based Consults. 2015 Nov; 1(1):11-14.

314. Lambert M, Correll C. [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro]. Nervenarzt. 2015 Nov;86(11):1420-3.

315. Gerstenberg M, Hauser M, Al-Jadiri A, Sheridan EM, Kishimoto T, Borenstein Y, Vernal DL, David L, Saito E, Landers SE, Carella M, Singh S, Carbon M, Jiménez-Fernández S, Birnbaum ML, Auther A, Carrión RE, Cornblatt BA, Kane JM, Walitza S, Correll CU. Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. J Clin Psychiatry. 2015 Nov;76(11):e1449-58.

316. Carrión RE, McLaughlin D, Auther AM, Olsen R, Correll CU, Cornblatt BA. The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis. Psychol Med. 2015 Nov;45(15):3341-54.

317. Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget. 2015 Nov 17;6(36):39088-97.

318. So R, Hirota T, Yamamoto Y, Hishimoto A, Correll CU. Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. Gen Hosp Psychiatry. 2015 Nov-Dec;37(6):621.e3-4.

319. Ifteni P, Grudnikoff E, Koppel J, Kremen N, Correll CU, Kane JM, Manu P. Haloperidol and sudden cardiac death in dementia: autopsy findings in psychiatric inpatients. Int J Geriatr Psychiatry. 2015 Dec;30(12):1224-9.

320. Stentebjerg-Olesen M, Ganocy SJ, Findling RL, Chang K, DelBello MP, Kane JM, Tohen M, Jeppesen P, Correll CU. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry. 2015 Dec; 24(12):1485-96.

321. Jiménez-Fernández S, Gurpegui M, Díaz-Atienza F, Pérez-Costillas L, Gerstenberg M, Correll CU. Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. J Clin Psychiatry. 2015;76(12):1658–1667.

322. Rios AC, Noto MN, Rizzo LB, Mansur R, Martins FE Jr, Grassi-Oliveira R, Correll CU, Brietzke E. Early stages of bipolar disorder: characterization and strategies for early intervention. Rev Bras Psiquiatr. 2015 Dec;37(4):343-9.

323. Noto MN, Noto C, Caribé AC, Miranda-Scippa Â, Nunes SO, Chaves AC, Amino D, Grassi-Oliveira R, Correll CU, Brietzke E. Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. Rev Bras Psiquiatr. 2015 Dec;37(4):280-8.

324. De Hert M, Van Bos L, Sweers K, Wampers M, De Lepeleire J, Correll CU. Attitudes of Psychiatric Nurses about the Request for Euthanasia on the Basis of Unbearable Mental Suffering(UMS). PLoS One. 2015 Dec 23;10(12):e0144749.

325. Tang LR, Zheng W, Zhu H, Ma X, Chiu HF, Correll CU, Ungvari GS, Xiang YQ, Lai KY, Cao XL, Li Y, Zhong BL, Lok KI, Xiang YT. Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. Perspect Psychiatr Care. 2016 Jan;52(1):4-11.

Curriculum Vitae Christoph U. Correll, M.D. Page 110

326. Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, Ungvari GS, Correll CU, Chiu HF, Xue Y, Tian TF, Wu AS, Ma X, Wang G. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016 Feb;46(3):623-35.

327. Xiang YT, Ungvari GS, Correll CU, Chiu HF, Shinfuku N. Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. Epidemiol Psychiatr Sci. 2016 Feb;25(1):9-17.

328. Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, Correll CU, Taylor D. Worldwide Differences in Regulations of Clozapine Use. CNS Drugs. 2016 Feb;30(2):149-61.

329. Tveito M, Correll CU, Bramness JG, Engedal K, Lorentzen B, Refsum H, HøisethG. Correlates of major medication side effects interfering with daily performance: results from a cross-sectional cohort study of older psychiatric patients. Int Psychogeriatr. 2016 Feb;28(2):331-40.

330. De Hert M, De Beugher A, Sweers K, Wampers M, Correll CU, Cohen D. Knowledge of Psychiatric Nurses About the Potentially Lethal Side-Effects of Clozapine. Arch Psychiatr Nurs. 2016 Feb;30(1):79-83.

331. Solmi M, Veronese N, Luchini C, Manzato E, Sergi G, Favaro A, Santonastaso P, Correll CU. Oxidative Stress and Antioxidant Levels in Patients with Anorexia Nervosa after Oral Re-alimentation: A Systematic Review and Exploratory Meta-analysis. Eur Eat Disord Rev. 2016 Mar;24(2):101-5.

332. Zhou JS, Zhong BL, Xiang YT, Chen Q, Cao XL, Correll CU, Ungvari GS, Chiu HF, Lai KY, Wang XP. Prevalence of aggression in hospitalized patients with schizophrenia in China: A meta-analysis. Asia Pac Psychiatry. 2016 Mar;8(1):60-69.

333. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo JJ, Lane HY, Sung FC, Liao CH, Arango C, Correll CU. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016 Mar 1;73(3):247-59.

334. Zaninotto L, Solmi M, Toffanin T, Veronese N, Cloninger CR, Correll CU. A meta-analysis of temperament and character dimensions in patients with mood disorders: Comparison to healthy controls and unaffected siblings. J Affect Disord. 2016 Apr;194:84-97.

335. Gerstenberg M, Theodoridou A, Traber-Walker N, Franscini M, Wotruba D, Metzler S, Müller M, Dvorsky D, Correll CU, Walitza S, Rössler W, Heekeren K. Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. Psychol Med. 2016 Apr;46(5):1069-78.

336. Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, Addington J, Brunette MF, Correll CU, Estroff SE, Marcy P, Robinson J, Meyer-Kalos PS, Gottlieb JD, Glynn SM, Lynde DW, Pipes R, Kurian BT, Miller AL, Azrin ST, Goldstein AB, Severe JB, Lin H, Sint KJ, John M, Heinssen RK. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2016 Apr 1;173(4):362-72.

337. Solmi M, Zaninotto L, Toffanin T, Veronese N, Lin K, Stubbs B, Fornaro M, Correll CU. A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. J Affect Disord. 2016 May 15;196:32-46.

338. Baumel A, Correll CU, Birnbaum M. Adaptation of a peer based online emotional support program as an adjunct to treatment for people with schizophrenia-spectrum disorders. Internet Interv. 2016 Mar 29;4:35-42.

339. Galling B, Roldán A, Rietschel L, Hagi K, Walyzada F, Zheng W, Cao XL, Xiang YT, Kane JM, Correll CU. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016 May;15(5):591-612.

Curriculum Vitae Christoph U. Correll, M.D. Page 111

340. Li Y, Cao XL, Zhong BL, Ungvari GS, Chiu HF, Kelly YC, Zheng W, Correll CU, Xiang YT. Smoking in male patients with schizophrenia in China: A meta-analysis. Drug Alcohol Depend. 2016 May 1;162:146-53.

341. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016 May;46(7):1459-72.

342. Solmi M, Veronese N, Correll CU, Favaro A, Santonastaso P, Caregaro L, Vancampfort D, Luchini C, De Hert M, Stubbs B. Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2016 May;133(5):341-51.

343. Veronese N, Solmi M, Luchini C, Lu RB, Stubbs B, Zaninotto L, Correll CU. Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. J Affect Disord. 2016 Jun;197:268-80.

344. Park SY, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis SH, Gerhard T, Olfson M, Correll CU. Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):456-468.

345. Østergaard SD, Lemming OM, Mors O, Correll CU, Bech P. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016 Jun;133(6):436-44.

346. Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biol Psychiatry. 2016 Jun 15;79(12):952-61.

347. Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU*, Jeppesen P*. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol. 2016 Jun;26(5):410-27.

348. Solmi M, Gallicchio D, Collantoni E, Correll CU, Clementi M, Pinato C, Forzan M, Cassina M, Fontana F, Giannunzio V, Piva I, Siani R, Salvo P, Santonastaso P, Tenconi E, Veronese N, Favaro A. Serotonin transporter gene polymorphism in eating disorders: Data from a new biobank and META-analysis of previous studies. World J Biol Psychiatry. 2016 Jun;17(4):244-57.

349. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016 Jun;15:166–174.

350. Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016 Jun;16(6):601-14.

351. Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. J Child Adolesc Psychopharmacol. 2016 Jun;26(5):458-70.

352. Correll CU, Maayan L, Kane JM, De Hert M, Cohen D. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients with Schizophrenia-Spectrum Disorders: Results from a Meta-analysis of Randomized Controlled Trials. J Clin Psychiatry. 2016 Jun;77(6):e746-56.

353. Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016 Jul;174(1-3):82-92.

354. Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016 Jul;174(1-3):93-98.

355. Garay RP, Citrome L, Samalin L, Liu CC, Thomsen MS, Correll CU, Hameg A, Llorca PM. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921-36.

Curriculum Vitae Christoph U. Correll, M.D. Page 112

356. Hou CL, Xiang YT, Wang ZL, Everall I, Tang Y, Yang C, Xu MZ, Correll CU, Jia FJ. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. Schizophr Res. 2016 Jul;174(1-3):71-6.

357. Rosenheck R, Leslie D, Sint K, Lin H, Robinson DG, Schooler NR, Mueser KT, Penn DL, Addington J, Brunette MF, Correll CU, Estroff SE, Marcy P, Robinson J, Severe J, Rupp A, Schoenbaum M, Kane JM. Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program. Schizophr Bull. 2016 Jul;42(4):896-906.

358. Manu P, Sarvaiya N, Rogozea LM, Kane JM, Correll CU. Benign Ethnic Neutropenia and Clozapine Use: A Systematic Review of the Evidence and Treatment Recommendations. J Clin Psychiatry. 2016 Jul;77(7):e909-e916.

359. Van Meter AR, Burke C, Youngstrom EA, Faedda GL, Correll CU. The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes. J Am Acad Child Adolesc Psychiatry. 2016 Jul;55(7):543-55.

360. Baumel A, Correll CU, Hauser M, Brunette M, Rotondi A, Ben-Zeev D, Gottlieb JD, Mueser KT, Achtyes ED, Schooler NR, Robinson DG, Gingerich S, Marcy P, Meyer-Kalos P, Kane JM. Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. Psychiatr Serv. 2016 Sep 1;67(9):1035-8.

361. Miura I, Zhang JP, Hagi K, Lencz T, Kane JM, Yabe H, Malhotra AK, Correll CU. Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. Psychoneuroendocrinology. 2016 Oct;72:1-10.

362. Lo Cascio N, Saba R, Hauser M, Vernal DL, Al-Jadiri A, Borenstein Y, Sheridan EM, Kishimoto T, Armando M, Vicari S, Fiori Nastro P, Girardi P, Gebhardt E, Kane JM, Auther A, Carrión RE, Cornblatt BA, Schimmelmann BG, Schultze-Lutter F, Correll CU. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. Eur Child Adolesc Psychiatry. 2016 Oct;25(10):1091-102.

363. Üçok A, Çıkrıkçılı U, Ergül C, Tabak Ö, Salaj A, Karabulut S, Correll CU. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS Drugs. 2016 Oct;30(10):997-1006

364. Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016 Oct;176(2-3):220-30.

365. Carrión RE, Demmin D, Auther AM, McLaughlin D, Olsen R, Lencz T, Correll CU, Cornblatt BA. Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res. 2016 Oct;81:95-101.

366. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016 Oct;21(5):393-402.

367. Yu X, Correll CU, Xiang YT, Xu Y, Huang J, Yang F, Wang G, Si T, Kane JM, Masand P. Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. Shanghai Arch Psychiatry. 2016 Oct 25;28(5):241-252.

368. Baumel A, Pawar A, Kane JM, Correll CU. Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. J Child Adolesc Psychopharmacol. 2016 Oct;26(8):740-749.

369. Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Anghelescu IG, Correll CU. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr. 2016 Oct;21(5):403-418.

Curriculum Vitae Christoph U. Correll, M.D. Page 113

370. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry. 2016;77(suppl 3):1-24.

371. Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff RA, Kane JM, Malhotra AK, Correll CU. Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophr Bull. 2016 Nov;42(6):1418-1437.

372. Solmi M, Veronese N, Sergi G, Luchini C, Favaro A, Santonastaso P, Vancampfort D, Correll CU, Ussher M, Thapa-Chhetri N, Fornaro M, Stubbs B. The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. Addiction. 2016 Nov;111(11):1914-1922.

373. Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, Correll CU. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2016 Nov;134(5):385-398.

374. Stubbs B, Koyanagi A, Veronese N, Vancampfort D, Solmi M, Gaughran F, CarvalhoAF, Lally J, Mitchell AJ, Mugisha J, Correll CU. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. BMC Med. 2016 Nov 22;14(1):189.

375. Lambert M, Niehaus V, Correll C. Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder. Pharmacopsychiatry. 2016 Nov;49(6):229-244.

376. Brand S, Kirov R, Kalak N, Gerber M, Schmidt NB, Lemola S, Correll CU, Holsboer-Trachsler E. Poor sleep is related to lower emotional competence among adolescents. Behavioral Sleep Medicine. 2016 Nov-Dec;14(6):602-14.

377. Thompson T, Correll CU, Gallop K, Vancampfort D, Stubbs B. Is pain perception altered in people with depression? A systematic review and meta-analysis of experimental pain research. J Pain. 2016 Dec;17(12):1257-1272.

378. Kim E, Correll CU, Mao L, Starr HL, Alphs L. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS Spectr. 2016 Dec;21(6):466-477.

379. Trevisan C, Veronese N, Bolzetta F, De Rui M, Correll CU, Zambon S, Musacchio E, Sartori L, Peressinotto E, Crepaldi G, Solmi M, Manzato E, Sergi G, Low Hemoglobin Levels or Anemia and Risk of Developing Deprssion in the Elderly: Results from the Prospective PRO.V.A Study. J Clin Psychiatry. 2016 Dec;77(12):e1549-e1556.

380. Carrión RE, Correll CU, Auther AM, Cornblatt BA. A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. Schizophr Bull. 2017 Jan;43(1):64-74.

381. Guo HM, Liu M, Xiang YT, Zhao J, Ungvari GS, Correll CU, Ng CH, Chiu HF, Duan ZP. Insomnia in Adults With Chronic Hepatitis B, Liver Failure, and Cirrhosis: A Case-Control Study. Perspect Psychiatr Care. 2017 Jan;53(1):67-72.

382. Hauser M, Zhang JP, Sheridan EM, Burdick KE, Mogil R, Kane JM, Auther A, Carrión RE, Cornblatt BA, Correll CU. Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and to Be Most Promising for Predictive Algorithms for Conversion to Psychosis: A Meta-Analysis. J Clin Psychiatry. 2017 Jan;78(1):e28-e40.

383. James BO, Omoaregba JO, Raji SO, Imishue OE, Okonoda KM, Nyamali YI, Famuyiwa PA, Correll CU. Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. Psychiatry Res. 2017 Feb;248:134-139.

384. Correll CU, Ng-Mak DS, Stafkey-Mailey D, Farrelly E, Rajagopalan K, Loebel A. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry. 2017 Feb 10;16:9.

385. Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in

Curriculum Vitae Christoph U. Correll, M.D. Page 114

schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017 Feb;16(1):77-89.

386. Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017 Mar;56(3):191-202.

387. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-229.

388. Murray R, Correll CU, Reynolds GP, Taylor D. Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. Ther Adv Psychopharmacol. 2017 Mar;7(1 Suppl):1-14.

389. Cervesi C, Park SY, Galling B, Molteni S, Masi G, Gerhard T, Olfson M, Correll CU. Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders: Results of a Meta-Analysis and Meta-Regression Analyses. J Clin Psychiatry. 2017 Mar;78(3):347-357.

390. Rubio JM, Correll CU. Duration and relevance of untreated psychiatric disorders, 1: psychotic disorders. J Clin Psychiatry. 2017 Mar;78(3):358-359.

391. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017 Mar;78(3):e264-e278.

392. Rubio JM, Correll CU. Duration and Relevance of Untreated Psychiatric Disorders, 2: Nonpsychotic Psychiatric Disorders and Substance Use Disorders. J Clin Psychiatry. 2017 Apr;78(4):464-465.

393. Veronese N, Cereda E, Stubbs B, Solmi M, Luchini C, Manzato E, Sergi G, Manu P, Harris T, Fontana L, Strandberg T, Amieva H, Dumurgier J, Elbaz A, Tzourio C, Eicholzer M, Rohrmann S, Moretti C, D'Ascenzo F, Quadri G, Polidoro A, Lourenço RA, Moreira VG, Sanchis J, Scotti V, Maggi S, Correll CU. Risk of Cardiovascular Disease Morbidity and Mortality in Frail and Pre-Frail Older Adults: Results from a Meta-Analysis and Exploratory Meta-Regression Analysis. Ageing Res Rev. Ageing Res Rev. 2017 May;35:63-73.

394. Thompson T, Gallop K, Correll CU, Carvalho AF, Veronese N, Wright E, Stubbs B. Pain perception in Parkinson's disease: A systematic review and meta-analysis of experimental studies. Ageing Res Rev. 2017 May;35:74-86.

395. Correll CU, Yu X, Xiang Y, Kane JM, Masand P. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017 May;29(2):92-107.

396. Thompson T, Oram C, Correll CU, Tsermentseli S, Stubbs B. Analgesic effects of alcohol: A systematic review and meta-analysis of controlled experimental studies in healthy participants. J Pain. 2017;18(5):499-510.

397. Pristed SG, Correll CU, Nielsen J. Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. Psychiatry Res. 2017 May 23;255:198-203.

398. Garay RP, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017 Jun;17(6):593-609.

Curriculum Vitae Christoph U. Correll, M.D. Page 115

399. Correll CU*, Solmi M*, Veronese M*, Bortolato B, Rosson S, Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, Collantoni E, Pigato G, Favaro A, Monaco F, Kohler C, Vancampfort D, Ward PB, Gaughran F, Carvalho AF, Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017 Jun;16(2):163-180.

400. Molteni S, Carbon M, Lops J, Soto EC, Cervesi C, Sheridan EM, Galling B, Saito E, Krakower S, Dicker R, Foley C, Fornari V, Balottin U, Correll CU. Correlates of Subjective Caregiver Strain in Caregivers of Youth Evaluated in a Pediatric Psychiatric Emergency Room. J Child Adolesc Psychopharmacol. 2017 Jun;27(5):451-461.

401. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017 Jun 29;13:757-777.

402. Lo Cascio N, Curto M, Pasqualetti P, Lindau JF, Girardi N, Saba R, Brandizzi M, Monducci E, Masillo A, Colafrancesco G, Solfanelli A, De Crescenzo F, Kotzalidis GD, Dario C, Ferrara M, Vicari S, Girardi P, Auther AM, Cornblatt BA, Correll CU*, Fiori Nastro P*. Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. Psychiatry Res. 2017 Jul;253:296-302.

403. Browne J, Penn DL, Meyer-Kalos PS, Mueser KT, Estroff SE, Brunette MF, Correll CU, Robinson J, Rosenheck RA, Schooler N, Robinson DG, Addington J, Marcy P, Kane JM. Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. Schizophr Res. 2017 Jul;185:167-172.

404. Correll CU*, Rubio JM*, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675-684.

405. Winterstein AG, Soria-Saucedo R, Gerhard T, Correll CU, Olfson M. Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers. J Clin Psychiatry. 2017 Jul;78(7):e744-e781.

406. Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Jul 1;74(7):719-728.

407. Mhalla A, Ben Mohamed B, Correll CU, Amamou B, Mechri A, Gaha L. Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use. Ann Gen Psychiatry. 2017 Jul 12;16:30.

408. Lambert M, Schöttle D, Ruppelt F, Rohenkohl A, Sengutta M, Luedecke D, Nawara LA, Galling B, Falk AL, Wittmann L, Niehaus V, Sarikaya G, Rietschel L, Gagern C, Schulte-Markwort M, Unger HP, Ott S, Romer G, Daubmann A, Wegscheider K, Correll CU, Schimmelmann BG, Wiedemann K, Bock T, Gallinat J, Karow A. Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study. Acta Psychiatr Scand. 2017 Aug;136(2):188-200.

409. Birnbaum ML, Rizvi AF, Correll CU, Kane JM, Confino J. Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders. Early Interv Psychiatry. 2017 Aug;11(4):290-295.

410. Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MG, Bilenberg N, Stenstrøm AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Correll CU, Fink-Jensen A. Quetiapine extended release versus aripiprazole in children and adolescents with first-

Curriculum Vitae Christoph U. Correll, M.D. Page 116

episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry. 2017 Aug;4(8):605-618.

411. Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):53-60.

412. Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):69-76.

413. Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, Sanchez R, Nyilas M, Carson W. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2017 Sep;56(9):784-792.

414. Wang L, Kong QM, Li K, Li XN, Zeng YW, Chen C, Qian Y, Feng SJ, Li JT, Su Y, Correll CU, Mitchell PB, Yan CG, Zhang DR, Si TM. Altered intrinsic functional brain architecture in female patients with bulimia nervosa. J Psychiatry Neurosci. 2017 Sep 26;42(6):160183.

415. Sultan RS, Olfson M, Correll CU, Duncan EJ. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. J Clin Psychiatry. 2017 Sep/Oct;78(8):e933-e939.

416. Baumel A, Pawar A, Mathur N, Kane JM, Correll CU. Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors: A Systematic Review. J Clin Psychiatry. 2017 Sep/Oct;78(8):e957-e969.

417. Jensen KG, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Pagsberg AK. Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial. J Clin Psychiatry. 2017 Sep/Oct;78(8):e1035-e1046.

418. Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017 Sep/Oct;78(8):1136-1147.

419. Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M, Carvalho AF, Correll CU. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 2017 Oct;22(5):415-426.

420. Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll CU, De Hert M, Gaughran F, Schneider F, Kinnafick F, Falkai P, Möller HJ, Kahl KG. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018 Oct;54:124-144.

421. Collantoni E, Solmi M, Gallicchio D, Santonastaso P, Meneguzzo P, Carvalho AF, Stubbs B, Clementi M, Pinato C, Forzan M, Cassina M, Fontana F, Piva I, Siani R, Salvo P, Tenconi E, Veronese N, Correll CU, Favaro A. Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism and Eating Disorders: Data From a New Biobank and Meta-Analysis of Previously Published Studies. Eur Eat Disord Rev. 2017 Nov;25(6):524-532.

422. Stengel A, Haas V, Elbelt U, Correll CU, Rose M, Hofmann T. Leptin and Physical Activity in Adult Patients with Anorexia Nervosa: Failure to Demonstrate a Simple Linear Association. Nutrients. 2017 Nov 3;9(11).

423. Rohde C, Polcwiartek C, Correll CU, Nielsen J. Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. J Pers Disord. 2017 Nov 9:1-15.

424. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Teresa Garcia-Unzueta M, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study. Schizophr Res. 2017 Nov;189:134-141.

Curriculum Vitae Christoph U. Correll, M.D. Page 117

425. Goldstein BI, Birmaher B, Carlson GA, DelBello MP, Findling RL, Fristad M, Kowatch RA, Miklowitz DJ, Nery FG, Perez-Algorta G, Van Meter A, Zeni CP, Correll CU, Kim HW, Wozniak J, Chang KD, Hillegers M, Youngstrom EA. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disord. 2017 Nov;19(7):524-543.

426. Correll CU. Epidemiology and Prevention of Tardive Dyskinesia. J Clin Psychiatry. 2017 Nov/Dec;78(9):e1426.

427. Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec;78(9):1344-1350.

428. Xiao L, Ganocy SJ, Findling RL, Chang K, DelBello MP, Kane JM, Tohen M, Xiang YT, Correll CU. Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial. J Clin Psychiatry. 2017 Nov/Dec;78(9):e1158-e1166.

429. Østergaard SD, Opler MGA, Correll CU. Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). Innov Clin Neurosci. 2017 Dec 1;14(11-12):68-72.

430. Jagannath V, Theodoridou A, Gerstenberg M, Franscini M, Heekeren K, Correll CU, Rössler W, Grünblatt E, Walitza S. Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. Front Psychiatry. 2017 Dec 20;8:292.

431. Jagannath V, Gerstenberg M, Correll CU, Walitza S, Grünblatt E. A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. J Neural Transm (Vienna). 2018 Jan;125(1):89-102.

432. Correll CU, Lauriello J. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan? J Clin Psychiatry. 2018 Jan/Feb;79(1).

433. Robinson DG, Schooler NR, Correll CU, John M, Kurian BT, Marcy P, Miller AL, Pipes R, Trivedi MH, Kane JM. Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. Am J Psychiatry. 2018 Feb 1;175(2):169-179.

434. Lambert M, Schöttle D, Sengutta M, Ruppelt F, Rohenkohl A, Luedecke D, Nawara LA, Galling B, Falk AL, Wittmann L, Niehaus V, Sarikaya G, Handwerk U, Rothländer W, Rietschel L, Gagern C, Lange B, Meigel-Schleiff C, Naber D, Schulte-Markwort M, Krüger H, Unger HP, Sippel S, Ott S, Romer G, Daubmann A, Wegscheider K, Correll CU, Schimmelmann BG, Bock T, Gallinat J, Karow A. Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III). Early Interv Psychiatry. 2018 Feb;12(1):96-106.

435. Østergaard SD, Foldager L, Mors O, Bech P, Correll CU. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. Schizophr Bull. 2018 Feb 15;44(2):453-462.

436. Xiao L, Correll CU, Feng L, Xiang YT, Feng Y, Hu CQ, Li R, Wang G. Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor. CNS Spectr. 2018 Feb 20:1-9.

437. Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018 Mar;137(3):187-205.

438. Jensen KG, Gärtner S, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Juul K, Pagsberg AK. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with

Curriculum Vitae Christoph U. Correll, M.D. Page 118

first-episode psychosis: results from the TEA trial. Psychopharmacology (Berl). 2018 Mar;235(3):681-693.

439. Lambert M, Ruppelt F, Siem AK, Rohenkohl AC, Kraft V, Luedecke D, Sengutta M, Schröter R, Daubmann A, Correll CU, Gallinat J, Karow A, Wiedemann K, Schöttle D. Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). Schizophr Res. 2018 Mar;193:377-383.

440. Jain R, Correll CU. Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. J Clin Psychiatry. 2018 Mar 20;(2).

441. Gerhard T, Stroup TS, Correll CU, Huang C, Tan Z, Crystal S, Olfson M. Antipsychotic Medication Treatment Patterns in Adult Depression. J Clin Psychiatry. 2018 Mar/Apr;79(2). pii: 16m10971

442. Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, Correll CU. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr Bull. 2018 Apr 6;44(3):603-619.

443. Rask Larsen J, Dima L, Correll CU, Manu P. The Pharmacological Management of Metabolic Syndrome. Expert Rev Clin Pharmacol. 2018 Apr;11(4):397-410.

444. Brunette MF, Mueser KT, Babbin S, Meyer-Kalos P, Rosenheck R, Correll CU, Cather C, Robinson DG, Schooler NR, Penn DL, Addington J, Estroff SE, Gottlieb J, Glynn SM, Marcy P, Robinson J, Kane JM. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res. 2018 Apr;194:4-12.

445. Sultan RS, Correll CU, Schoenbaum M, King M, Walkup JT, Olfson M. National Patterns of Commonly Prescribed Psychotropic Medications to Young People. J Child Adolesc Psychopharmacol. 2018 Apr;28(3):158-165.

446. Silverman BL, Martin W, Memisoglu A, DiPetrillo L, Correll CU, Kane JM. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018 May;195:245-251.

447. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018 May 14;12:1215-1238.

448. Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M; Tardive Dyskinesia Assessment Working Group. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018 May 8;79(3). pii: 17cs11959.

449. John M, Lencz T, Malhotra AK, Correll CU, Zhang JP. A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene. 2018 Jun;16:143-164.

450. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018 Jun 15;389:21-27.

451. Correll CU*, Rubio JM*, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018 June;17(2):149-160.

452. Hebebrand J, Peters T, Schijven D, Hebebrand M, Grasemann C, Winkler TW, Heid IM, Antel J, Föcker M, Tegeler L, Brauner L, Adan RAH, Luykx JJ, Correll CU, König IR, Hinney A, Libuda L. The role of genetic variation of human metabolism for BMI, mental traits and mental disorders. Mol Metab. 2018 Jun;12:1-11.

453. Correll CU*, Galling B*, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig TJ, Nordentoft M, Srihari VH, Guloksuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Severe JB, Kane JM. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry. 2018;75(6):555-565.

454. Si T, Li N, Lu H, Cai S, Zhuo J, Correll CU, Zhang L, Feng Y. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. J Psychopharmacol. 2018 Jun;32(6):691-701.

Curriculum Vitae Christoph U. Correll, M.D. Page 119

455. Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018 Jun 8;14:1463-1474.

456. Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, Fitzgerald H, Correll CU. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018 Jun 8;14:1475-1492.

457. Vernal DL, Stenstrøm AD, Staal N, Christensen AMR, Ebbesen C, Pagsberg AK, Correll CU, Nielsen RE, Lauritsen MB. Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. Eur Child Adolesc Psychiatry. 2018 Aug; 27(8):965–975.

458. Wang G, Zheng W, Li XB, Wang SB, Cai DB, Yang XH, Ungvari GS, Xiang YT, Correll CU. ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. J Psychiatr Res. 2018 Aug 2;105:23-32.

459. Kølbæk P, Blicher AB, Buus CW, Feller SG, Holm T, Dines D, O'Leary KM, Sørensen RS, Opler M, Correll CU, Mors O, Bech P, Østergaard SD. Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI). Nord J Psychiatry. 2018 Aug;72(6):431-436.

460. Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, Monaco F, Carvalho AF, Stubbs B, Veronese N, Correll CU. Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophr Bull. 2018 Aug 20;44(5):1133-1150.]

461. Lehmann CS, Hofmann T, Elbelt U, Rose M, Correll CU, Stengel A, Haas V. The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. J Clin Med. 2018 Sep 18;7(9).

462. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018 Oct;17(3):330-340.

463. Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll CU, De Hert M, Gaughran F, Schneider F, Kinnafick F, Falkai P, Möller HJ, Kahl KG. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018 Oct;54:124-144.

464. Cather C, Brunette MF, Mueser KT, Babbin SF, Rosenheck R, Correll CU, Kalos-Meyer P. Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial. Psychiatry Res. 2018 Oct;268:303-311.

465. Sultan RS, Correll CU, Zohar J, Zalsman G, Veenstra-VanderWeele J. What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2018 Oct;57(10):719-721.

466. Higdon C, Correll CU, Crystal S, Patel N, DelBello MP; MOBILITY team. Mobility for All? J Am Acad Child Adolesc Psychiatry. 2018 Oct;57(10):792-793.

467. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018 Oct 8;8(11):303-318.

468. Ameis SH, Kassee C, Corbett-Dick P, Cole L, Dadhwal S, Lai MC, Veenstra-VanderWeele J, Correll CU. Systematic review and guide to management of core and psychiatric symptoms in youth with autism. Acta Psychiatr Scand. 2018 Nov;138(5):379-400.

469. Solmi M, Fornaro M, Toyoshima K, Carvalho AF, Köhler CA, Veronese N, Stubbs B, de Bartolomeis A, Correll CU. Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2018 Nov 21:1-17.

Curriculum Vitae Christoph U. Correll, M.D. Page 120

470. Østergaard SD, Foldager L, Mors O, Bech P, Correll CU. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand. 2018 Nov;138(5):420-431.

471. Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Gründer G, Paulzen M. Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol. 2018 Nov;33(6):322-329.

472. Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC Psychiatry. 2018 Nov 14;18(1):365.

473. Correll CU, Shi L, Weiss C, Hobart M, Eramo A, Duffy RA, Weiller E, Baker RA. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2018 Oct 11:1-11.

474. Solmi M, Correll CU, Carvalho AF, Ioannidis JPA. The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. Epidemiol Psychiatr Sci. 2018 Dec;27(6):537-542.

475. Tveito M, Smith RL, Molden E, Haslemo T, Refsum H, Hartberg C, Correll CU, Høiseth G. Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients. J Clin Psychopharmacol. 2018 Dec;38(6):570-576.

476. Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O'Brien CF. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. J Clin Psychiatry. 2018 Dec 18;80(1).

477. Correll CU, Sliwa JK, Najarian DM, Saklad SR. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectr. 2018 Dec 27:1-17.

478. Rohde C, Polcwiartek C, Correll CU, Nielsen J. Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. J Pers Disord. 2018 Dec;32(6):823-837.

479. Birnbaum ML, Rizvi AF, Faber K, Addington J, Correll CU, Gerber C, Lahti AC, Loewy RL, Mathalon DH, Nelson LA, Voineskos AN, Walker EF, Ward E, Kane JM. Digital Trajectories to Care in First-Episode Psychosis. Psychiatr Serv. 2018 Dec 1;69(12):1259-1263.

480. Larsen JR, Svensson CK, Vedtofte L, Jakobsen ML, Jespersen HS, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Holst JJ, Correll CU, Vilsbøll T, Fink-Jensen A. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectr. 2018 Dec 31:1-12.

481. Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial. J Clin Psychiatry. 2019 Jan 8;80(2). pii: 18m12495.

482. Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. One-Year Follow-up on Liraglutide Treatment for Prediabetes and Overweight/Obesity in Clozapine- or Olanzapine-Treated Patients. Acta Psychiatr Scand. 2019 Jan;139(1):26-36.

483. Cheng Z, Yuan Y, Han X, Yang L, Zeng X, Yang F, Lu Z, Wang C, Deng H, Zhao J, Xiang YT, Correll CU, Yu X. Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world" clinical trial. Psychiatry Res. 2019 Jan 24;273:631-640.

484. Solmi M, Konayagi A, Thompson T, Fornaro M, Correll CU, Veronese N. Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. Epidemiol Psychiatr Sci. 2019 Jan 30:1-9.

Curriculum Vitae Christoph U. Correll, M.D. Page 121

485. Vancampfort D, Firth J, Correll CU, Solmi M, Siskind D, De Hert M, Carney R, Koyanagi A, Carvalho AF, Gaughran F, Stubbs B. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019 Feb;18(1):53-66.

486. Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor-agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019 Feb;21(2):293-302.

487. Correll CU, Chatterjee P, Gitzinger SH, Lubarda J, Morgan M. Assessment of Current Clinical Practices in Recognizing and Treating Bipolar Disorder. CNS Spectr. 2019 Feb;24(1):217-218.

488. McIntyre RS, Remington G, Correll CU, Weber R, Farahmand K, Lundt L, Burke J, Siegert S. Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder. CNS Spectr. 2019 Feb;24(1):210-211.

489. Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019 Mar 5;80(2). pii: 18com12123.

490. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and Long-Term Mortality Risk in Patients with Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. Schizophr Bull. 2019 Mar 7;45(2):315-329.

491. Kane JM, Correll CU, Delva N, Gopal S, Savitz A, Mathews M. Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study. J Clin Psychopharmacol. 2019 Mar/Apr;39(2):180-182.

492. Van Meter A, Guinart D, Bashir A, Sareen A, Cornblatt BA, Auther A, Carrión RE, Carbon M, Jiménez-Fernández S, Vernal DL, Walitza S, Gerstenberg M, Saba R, Cascio NL, Correll CU. Bipolar Prodrome Symptom Scale - Abbreviated Screen for Patients: Description and validation. J Affect Disord. 2019 Apr 15;249:357-365.

493. Correll CU, Stanford AD, Claxton A, Du Y, Weiden PJ. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry Res. 2019 Apr;274:176-181.

494. Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. J Clin Psychiatry. 2019 Apr 23;80(3). pii: 18m12546.

495. Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019;76(5):499-507.

496. Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019 Jun;18(2):208-224.

497. Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, Silverman BL, Ehrich EW. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. Am J Psychiatry. 2019 Jun 1;176(6):457-467.

498. Burkhardt E, Pfennig A, Breitling G, Pfeiffer S, Sauer C, Bechdolf A, Correll CU, Bauer M, Leopold K. Creativity in persons at-risk for bipolar disorder-A pilot study. Early Interv Psychiatry. 2018 Oct 10. [Epub ahead of print]

499. Jensen KG, Correll CU, Rudå D, Klauber DG, Decara MS, Fagerlund B, Jepsen JRM, Eriksson F, Fink-Jensen A, Pagsberg AK. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in

Curriculum Vitae Christoph U. Correll, M.D. Page 122

Children and Adolescents With Psychosis (TEA) Trial. J Am Acad Child Adolesc Psychiatry. 2019 Mar 8. [Epub ahead of print]

500. Højlund M, Pottegård A, Johnsen E, Kroken RA, Reutfors J, Munk-Jørgensen P, Correll CU. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016. Br J Clin Pharmacol. 2019 Mar 29. [Epub ahead of print]

501. Schoretsanitis G, Haen E, Gründer G, Hiemke C, Endres K, Ridders F, Correll CU, Paulzen M. Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. Eur J Clin Pharmacol. 2019 Apr 9. [Epub ahead of print]

502. Frahm Laursen M, Valentin JB, Licht RW, Correll CU, Nielsen RE. Longitudinal outcomes in pediatric- and adult-onset bipolar patients compared to healthy and schizophrenia controls. Bipolar Disord. 2019 May 9. [Epub ahead of print]

503. Krogmann A, Peters L, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU. Keeping Up with the Therapeutic Advances in Schizophrenia: A Review of Novel and Emerging Pharmacological Entities. CNS Spectrums. 2019 - in press.

504. Højlund M, Correll CU. Dosing and Switching of Long-acting Antipsychotics in the Treatment of Schizophrenia. Expert Opin Pharmacother. 2019 – in press

505. Rubio JM, Kane JM, Correll CU. Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review of Evidence-based Management Options. CNS Drugs. 2019 – in press

506. Peters L, Krogmann A, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU. Long-Acting Injections in Schizophrenia: A 3-Year Update on Randomized Controlled Trials Published 01/2016-03/2019. Curr Psychiatry Rep. 2019 - in press.

507. Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Comparison of clozapine vs other oral second-generation antipsychotics with hospitalization and all-cause discontinuation as co-primary outcomes among patients with schizophrenia: A systematic review and meta-analysis of cohort studies. JAMA Psychiatry – in press

EDITORIALS, COMMENTARIES

1. Correll CU. Early intervention in psychosis: where science meets community psychiatry. Resident and Staff Physician. 2004 (Suppl.):41-46.

2. Correll CU, Kane JM. Highlights from the 157th annual meeting of the American Psychiatric Association (APA). Adv Schiz Clin Psych. 2004;1(2):71-3.

3. Correll CU. Elevated cardiovascular risk in patients with bipolar disorder: When does it start and where does it lead? J Clin Psychiatry. 2008;69(12):1948-52.

4. Correll CU. Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health. 2009 Aug;12(3):93. [commentary]

5. Correll CU. Expert Commentary: Antipsychotics and Kids: Data Mostly Reassuring. Clinical Psychiatry News. 2010 March; 38(3):4.

6. DelBello MP, Correll CU. Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. Bipolar Disord. 2010 Mar;12(2):113-5.

7. Correll C, Kishimoto T, Carlson H. Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. Evid Based Ment Health. 2010 May;13(2):54.

8. Correll CU, Nielsen J. Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand 2010 Nov;122(5):341-4.

9. Correll CU. Antipsychotic dosing: How often is too much and how infrequent is too little? http://www.schizophreniaforum.org/for/live/detail.asp?liveID=79

10. Correll CU. Antipsychotic use in children. Physician’s Weekly 2011 Jan 24;28(4):1.

Curriculum Vitae Christoph U. Correll, M.D. Page 123

11. Carbon M, Correll CU. Review: quetiapine monotherapy improves response and remission compared with placebo in generalised anxiety disorder. Evid Based Ment Health. 2011 Nov;14(4):109.

12. Kane JM, Cornblatt B, Correll CU, Goldberg T, Lencz T, Malhotra AK, Robinson D, Szeszko P. The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. Schizophr Bull. 2012 Jan;38(1):1-4.

13. Correll CU. How would you handle the risk of metabolic syndrome in a young person with schizophrenia? Focus 2012 Spring;X(2):154-156.

14. Correll CU, Gerhard T, Olfson M. Prescribing of psychotropic medications to children and adolescents: Quo vadis? World Psychiatry. 2013 June;12(2):127-8.

15. Correll CU, Sikich L, Reeves G, Riddle M. Metformin for antipsychotic related weight gain and metabolic abnormalities: When, how long and for whom? Am J Psychiatr. 2013 Sep;170(9):947-52.

16. Correll CU, De Hert M. Antipsychotics for acute schizophrenia: making choices. Lancet. 2013 Sep 14;382(9896):919-20.

17. Correll CU, Carbon M. Efficacy of Pharmacologic and Psychotherapeutic Interventions in

Psychiatry: To Talk or To Prescribe: Is that the Question? JAMA Psychiatry. 2014;71(6):624-26.

18. McIntyre RS, Correll C. Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. Bipolar Disord. 2014 Aug;16(5):451-4.

19. Correll CU, Kishimoto T, Kane JM. Do Long-Acting Injectable Antipsychotics Improve Adherence and Related Outcomes? http://www.cmeinstitute.com/psychs-talk/default.aspx

20. Correll CU, Blader JC. Antipsychotic Use in Youth Without Psychosis: A Double-edged Sword. JAMA Psychiatry. 2015;72(9):859.

21. Kane JM, Correll CU. What is the Role of Clozapine in Schizophrenia? JAMA Psychiatry. 2016 Mar 1;73(3):187-8.

22. Kane JM, Correll CU. ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis: The Importance of Replication Studies. JAMA Psychiatry. 2017;74(1):11-12.

23. Rubio JM, Correll CU. Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. Evid Based Ment Health. 2017 Feb;20(1):e6.

24. Correll CU, Galling B. Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants

or Stimulants Add to the Risk for Type 2 Diabetes? J Am Acad Child Adolesc Psychiatry. 2017 Aug;56(8):634-635.

25. Correll CU, Carbon M. A new class of VMAT-2 inhibitors for tardive dyskinesia. Lancet Psychiatry. 2017 Aug;4(8):574-575.

26. Rubio JM, Correll CU. Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. Evid Based Ment Health. 2018 Aug;21(3):e11.

27. Solmi M, Correll CU. Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can't). Evid Based Ment Health. 2019 Feb;22(1):e3.

LETTERS 1. Correll CU, Pleak RR: Efficacy of paroxetine in adolescent major depression. J Am Acad Child

Adolesc Psychiatry. 2002; 41(11):1269.

2. Correll CU, Kane JM, Malhotra AK. Risks From Antipsychotic Medications in Children and Adolescents—Reply. JAMA. 2010;303(8):730.

3. Correll CU. Evidence-based flying taking off: maximising the effectiveness of a novel airline user decision-making tool. Int J Clin Pract. 2010 Dec;64(13):1836-7.

Curriculum Vitae Christoph U. Correll, M.D. Page 124

4. De Hert M, Vancampfort D, Correll CU, Peuskens J, van Winkel R, Mitchell AJ. Monitoring cardiometabolic risk in schizophrenia - authors’ reply. Br J Psychiatry. 2012;201:76-77. [letter]

5. Vancampfort D, Mitchell AJ, Correll CU, Sienaert P, De Hert M. Response to Bartoli et al. Am J Psychiatry. 2013 Aug 1;170(8):928-9.

6. Samaras K, Correll CU, Mitchell AJ, De Hert M; HeAL Collaborators (Healthy Active Lives for people with severe mental illness). Diabetes risk potentially underestimated in youth and children receiving antipsychotics. JAMA Psychiatry. 2014 Feb 1;71(2):209-10.

7. Nielsen J, Ifteni P, Manu P, Kane JM, Correll CU. Reply: To PMID 24354448. Acta Psychiatr Scand. 2014 Jul;130(1):70-1.

8. Nielsen J, Manu P, Kane JM, Correll CU. Dr Nielsen and colleagues reply. J Clin Psychiatry. 2015 Dec;76(12):1694-1695.

9. Veronese N, Bano G, Granziera S, Solmi M, Cohen AT, Correll CU. Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis: reply. J Thromb Haemost. 2016 Jan;14(1):221-223.

10. Samaras K, Curtis J, Correll CU for the HeAL Collaborators (Healthy Active Lives for people with severe mental illness). Premature mortality and schizophrenia: the need to HeAL right from the start. JAMA Psychiatry. 2016 May 1;73(5):535-6.

11. Curran RL, Badran IA, Peppers V, Pedapati EV, Correll CU, DelBello MP. Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy. J Child Adolesc Psychopharmacol. 2016 Jun;26(5):490-1.

12. Kane JM, Robinson DG, Schooler NR, Lin H, Rosenheck RA, Heinssen RK; RAISE-ETP Study Group. Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP Results. Am J Psychiatry. 2016 May 1;173(5):535-6.

13. Østergaard SD, Mors O, Correll CU, Bech P. Association of Positive and Negative Syndrome Scale (PANSS) short forms with global functioning and quality of life. Acta Psychiatr Scand. 2016 Dec;134(6):565-566.

14. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Kane JM. Dr Correll and Colleagues Reply. J Clin Psychiatry. 2017 Sep/Oct;78(8):e1062.

15. Fink-Jensen A, Correll CU, Vilsbøll T. Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply. JAMA Psychiatry. 2017 Nov 1;74(11):1173-1174.

16. Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM. Corrigendum to "Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies" [Schizophr. Res. 174 (2016) 82-92]. Schizophr Res. 2017 Dec;190:191-194.

17. Correll CU, Galling B, Kane JM. Disturbing Lack of Early Intervention Studies in Bipolar Disorder. JAMA Psychiatry. 2018 Nov 1;75(11):1202-1203.

18. Solmi M, Koyanagi A, Thompson T, Fornaro M, Correll CU, Veronese N. Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. Epidemiol Psychiatr Sci. 2019 Mar 8:1.

Curriculum Vitae Christoph U. Correll, M.D. Page 125

BOOK CHAPTERS

1. Correll CU, Kane JM: Is there a rationale for antipsychotic polypharmacy in schizophrenia? In: Fleischhacker WW, Hummer M (eds): Schizophrene Stoerungen - State of the Art III. Verlag Integrative Psychiatrie, Innsbruck, 2004, pp. 95-112.

2. Correll CU. Weight gain and metabolic abnormalities in pediatric bipolar patients. In: Treatment of Bipolar Disorder in Children and Adolescents. B Geller & M DelBello (eds.), Guilford Publications, Inc. New York. 2008, pp. 361-391.

3. Correll CU, Auther A, Cornblatt BA. Won’t leave his room: clinical high risk for developing psychosis. In: DSM-IV-TR® Casebook and Treatment Guide for Child Mental Health. Galanter CA, Jensen PS (eds.), American Psychiatric Publishing, Inc., Arlington, VA. 2009, pp.392-395.

4. Correll CU. Managing the Health Outcomes of Schizophrenia Treatment in Children and Adolescents. In: Medical Illness and Schizophrenia. Meyer J & Narsrallah HA (eds.), American Psychiatric Publishing, Inc., Arlington, VA. 2009, pp 343-376.

5. Correll CU. Antipsychotic Medications. In: Textbook of Child and Adolescent Psychiatry. Dulcan M (ed.), American Psychiatric Publishing, Inc. New York. 2010, pp 743-774.

6. Correll CU. Pediatric Schizophrenia. In: Encyclopedia of Psychopharmacology, Stolerman, IP (Ed.), Springer, Heidelberg. 2010, pp 977-981.

7. Correll CU. Antipsychotic Medications: Typical and Atypical. In: Pediatric Psychopharmacology: Principles and Practice, Second Edition. Martin A, Scahill L and Kratochvil CJ (eds.), Oxford University Press, Inc. New York. 2011, pp 312-337.

8. Leucht S, Correll CU, Kane JM. Approaches to treatment resistant patients. In: Schizophrenia. 3rd Edition. Hirsch SR, Weinberger DR (eds). Blackwell Publishing Ltd. West Sussex, UK. 2011, pp 540-560.

9. Correll CU. Tardive Dyskinesia. In: Encyclopedia of Autism Spectrum Disorders, Stolerman, IP (Ed.), Springer, Heidelberg. 2011

10. Carbon M, Correll CU. Pharmacotherapie. In: Juvenile Psychosen – Entwicklungspsychopathologie, Früherkennung und Therapie Schizophrenia. Schimmelmann, B; Resch (eds). Kohlhammer, Suttgart, Germany. 2014, pp249-270.

11. Correll CU. Safety of Oral Drug Treatments for Schiophrenia: Recognizing and Managing Adverse Effects; In: Schizophrenia Handbook. Pharmacy Europe, Cogora Ltd, London. 2014, pp19-22.(http://www.hospitalpharmacyeurope.com/handbooks)

12. Kane J, Kishimoto K, Correll CU. Treatment-resistant schizophrenia. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (http://www.uptodate.com/contents/treatment-resistant-schizophrenia; Accessed on January 29, 2015)

13. Correll CU. Antipsychotic Medications. In: Textbook of Child and Adolescent Psychiatry. 2nd edition. Dulcan M (ed.), American Psychiatric Publishing, Inc. New York. 2016, pp795-846.

14. Correll CU, Haddad P, Abbott C, Keith S. Antipsychotic treatment and adherence in schizophrenia; In: Antipsychotic Long-acting Injections, Haddad P, Lambert T, Lauriello J (eds), Oxford University Press 2016, pp1-29.

15. Kishimoto T, Correll CU, Kane JM. Comparative Effectiveness of Oral antipsychotics and Long-acting Injections; In: Antipsychotic Long-acting Injections, Haddad P, Lambert T, Lauriello J (eds), Oxford University Press 2016, pp87-98.

16. Correll CU, Auther A, Cornblatt BA. Won’t leave his room: clinical high risk for developing psychosis. In: DSM-5® Casebook and Treatment Guide for Child Mental Health. Galanter CA, Jensen PS (eds.), American Psychiatric Publishing, Inc., Arlington, VA. 2016.

17. Kane JM, Correll CU. Schizophrenia: Pharmacological Treatment; In: Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, 11th Edition, Benjamin J. Sadock, Virginia A. Sadock, and Pedro Ruiz (eds). Lippincott Williams & Wilkins, Philadelphia, PA, 2017, pp1519-1531.

18. McCutcheon R, Correll CU, Howes O, Kane JM. Treatment Response and Resistance in Schizophrenia: Principles and Definitions; In: Treatment Response and Resistance in Schizophrenia, Oliver Hower (ed), Oxford University Press, New York, NY, 2018, pp4-15.

Curriculum Vitae Christoph U. Correll, M.D. Page 126

19. McCutcheon R, Correll CU, Howes O, Kane JM. A Case of Pseudo-Treatment Resistance; In: Treatment Response and Resistance in Schizophrenia, Oliver Hower (ed), Oxford University Press, New York, NY, 2018, pp165-166.

20. McCutcheon R, Correll CU, Howes O, Kane JM. A Case of Early-Onset Treatment Resistance; In: Treatment Response and Resistance in Schizophrenia, Oliver Hower (ed), Oxford University Press, New York, NY, 2018, pp166-167.

21. Kane J, Rubio J, Kishimoto K, Correll CU. Treatment-resistant schizophrenia. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (http://www.uptodate.com/contents/treatment-resistant-schizophrenia; Accessed on June 7, 2019)

ONLINE CME ARTICLES AND PROGRAMS 1. Correll CU, 2007. Development and Treatment of Schizophrenia in a Pediatric Patient

2. (http://www.medscape.com/viewprogram/7845)

3. Correll CU, 2007. Current Understanding in the Development of Bipolar Disorder in Pediatric Patients (http://www.medscape.com/viewprogram/8269)

4. Newcomer JW, Buckley PF, Correll CU, 2007. Metabolic Considerations in the Treatment of Schizophrenia (http://www.medscape.com/viewarticle/558812)

5. Correll CU, Ketter TA, Perlis RH, Thase, ME, 2008. New Data in the Recognition and Management of Bipolar Disorder (http://www.medscape.com/viewarticle/575233)

6. Correll CU, 2008. Diagnosing and Treating Bipolar Disorder in the Child and Adolescent

(http://www.medscape.com/viewprogram/9063)

7. Correll CU, 2008. Implementing New Evidence in the Management of Pediatric Schizophrenia and Bipolar Disorder (http://www.medscape.com/viewprogram/14625)

8. Correll CU, 2008. The Expanding Role of Antipsychotic Augmentation in Major Depression

(http://www.medscape.com/viewprogram/15798)

9. Correll CU, 2008. Moving Toward the Goal of Recovery: Maximizing Maintenance Therapy and Relapse Prevention in Schizophrenia (http://www.medscape.com/viewprogram/17170)

10. Lieberman JA, Cook JA, Correll CU, 2008. Major Depression and Psychoses: Screening, Accurately Diagnosing, and Properly Managing in Primary Care (http://www.peerviewpress.com/r415)

11. Correll CU. Effect of hyperprolactinemia during development in children and adolescents. J Clin Psychiatry. 2008 Aug;69(8):e24.

12. Correll CU, 2009. Uncovering the Complexities of Comorbid Attention Deficit/Hyperactivity Disorder in Pediatric Patients (www.peerviewpress.com/q118)

13. Correll CU, 2009. Antipsychotics in Children and Adolescents: Balancing Safety and Efficacy (http://cme.medscape.com/viewarticle/712816)

14. Correll CU, 2009. Psychiatry and Mental Health/Antipsychotic Treatment in Major Mental Illness -- Volume 3 (http://cme.medscape.com/viewprogram/30469)

15. Kohlstadt I, Vitiello B, Robb A, Correll C, Rappley, M. 2009. Atypical Antipsychotics in Children and Adolescents: Balancing Safety and Efficacy. Au Audio Digest Pediatrics, Volume 55, Issue 16, August 21, 2009 (htp://www.cme-ce-summaries.com/pediatrics/pd5516.html)

16. Correll CU, 2010. Antipsychotic Use in Youth (http://www.medscape.com/viewarticle/718519)

17. Correll CU, 2010. Practical Dosing Strategies in the Treatment of Schizophrenia: Part 2 - Switching and Combining Antipsychotics (http://www.psychweekly.com/aspx/article/articledetail.aspx?articleid=1107 and http://www.primarypsychiatry.com/aspx/articledetail.aspx?articleid=2609)

18. Correll CU, 2010. Symptomatic Presentation and Initial Treatment for Schizophrenia in Children and Adolescents. (http://www.cmeinstitute.com/newcme/launcher.asp?test=1356)

Curriculum Vitae Christoph U. Correll, M.D. Page 127

19. Correll CU, 2010. Safety and Tolerability of Antipsychotic Treatment in Young People with Schizophrenia. (http://www.cmeinstitute.com/newcme/launcher.asp?test=1336)

20. Correll CU, 2010. Addressing Adverse Effects of Antipsychotic Treatment in Young Patients With Schizophrenia. (http://www.cmeinstitute.com/newcme/launcher.asp?test=1360)

21. Correll CU, 2010. Managing Schizophrenia. (http://www.cmeinstitute.com/newcme/launcher.asp?test=1285)

22. Cornblatt BA, Correll CU, 2010. Psychosis Risk Syndrome or Attenuated Psychotic Symptoms Syndrome and DSM-5. (http://www.medscape.com/viewarticle/727682)

23. Correll CU. Symptomatic presentation and initial treatment for schizophrenia in children and adolescents. J Clin Psychiatry. 2010 Nov;71(11):e29.

24. Correll CU, Hauser M, 2011. Pediatric Bipolar Disorder: A Valid Condition? (http://www.medscape.com/viewarticle/735114)

25. Correll CU, Hauser M, 2011. The Year In Psychosis and Bipolar Disorder: The Most Important Studies of 2010. (http://www.medscape.com/viewarticle/735211)

26. Correll CU, 2011. Adjunctive Therapy for Schizophrenia: Current and Emerging Directions. (http://www.medscape.com/viewarticle/738924)

27. Correll CU, 2011. Rare and Unusual Psychiatric Syndromes. (http://www.medscape.com/features/slideshow/rare-psych)

28. Correll CU. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011 Jan;72(1):e01.

29. Correll CU. Psychobiology and psychosocial functioning of schizoaffective disorder. J Clin Psychiatry. 2011 Feb;72(2):e05.

30. Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011 Aug;72(8):e26.

31. Kane JM, Correll CU. Performance improvement CME: managing schizophrenia. J Clin Psychiatry. 2011 Oct;72(10):e31.

32. Correll CU, Carbon M, 2011. The year in psychiatry: Studies not to miss from 2011. (http://www.medscape.com/viewarticle/753970?src=mp&spon=12)

33. Kane JM, Correll CU, Kelly DL, Velligan DI, 2011. Patient-Tailored Strategies to Improve Medication Adherence in Schizophrenia. (http://www.schizophreniacme.com/Login.aspx?ReturnUrl=%2feNewsletter%2fDetails.aspx%3fActivity%3d00407520001&Activity=00407520001)

34. Correll CU, Stetka B, 2012. Rare and Unusual Psychiatric Syndromes Part 2: Culture Bound Syndromes. http://www.medscape.com/features/slideshow/culture-synd

35. Correll CU, Carbon M, 2012. Branded versus generic psychotropic medication: Is one better than the other? (http://www.medscape.com/viewarticle/761370)

36. Stetka BS, Correll CU. 2012. Psychiatry Game Changers. (http://www.medscape.com/features/slideshow/gcpsych2012)

37. Stetka BS, Correll CU. 2013. A Guide to DSM-5. (http://www.medscape.com/viewarticle/803884?src=wnl_edit_specol)

38. Carbon M, Correll CU. 2013. Neurotransmitter Modulation Pathways in Schizophrenia: The Match Game. 2013. (http://www.medscape.org/viewarticle/804659)

39. Correll CU. 2013. Vortioxetine: A New Antidepressant Choice in the United States (http://www.medscape.com/viewarticle/811959?nlid=35168_421&src=wnl_edit_medp_psyc&spon=12)

40. Stetka BS, Correll CU. 2013. Psychiatry Practice Changers: 2013. (http://www.medscape.com/viewarticle/817954)

41. Stetka BS, Correll CU. 2014. 7 Advances in Schizophrenia. (http://www.medscape.com/viewarticle/819068?src=wnl_edit_specol&uac=76431FG)

42. Stetka BS, Correll CU. 2014. Rare and Unusual Psychiatric Syndromes (http://www.medscape.com/features/slideshow/rare-psych#20)

Curriculum Vitae Christoph U. Correll, M.D. Page 128

43. Correll CU, Stetka BS. 2014. 20 More Rare and Unusual Psychiatric Syndromes (http://www.medscape.com/features/slideshow/culture-synd)

44. Kane JM, Correll CU. 2014. Making the Link Between Science and Symptoms in Schizophrenia. http://www.cmeinstitute.com/Activities/Pages/video/kane.aspx.

45. Correll CU. 2017. Optimizing Strategies for Switching Antipsychotics in Schizophrenia. http://ime.peervoice.com/v/index.html?collection=240200382&presentation=240200382-p1&MemberID=999&Language=en#screen4

46. Correll CU. 2018. Risk factors for TD and Effiacy of VMAT2 inhibiitors. https://www.medscape.org/viewarticle/896534

47. Citrome L, Correll CU, Kane JM, Meyer JM, Nasrallah HA. 2018. Why New Treatments for Schizophrenia Should Be on Your Radar. https://www.medscape.org/viewarticle/896535

PUBLISHED ABSTRACTS (SELECTION) 1. Correll CU, Kane, JM. Tardive Tourette syndrome: Variant of tardive dyskinesia or discrete

medication-induced extrapyramidal side effect syndrome? Movement Disorders 2001;16(Suppl 1):48 [abstract].

2. Correll CU, Lencz T, Obuchowski M, Shah M, Smith C, Auther A, Olsen R, Kane JM, Cornblatt BA: Risks of pharmacological interventions in adolescents considered prodromal for schizophrenia. Schizophr Res 2002;53(Suppl):41 [abstract].

3. Cornblatt B, Lencz T, Correll C, Author A, Smith C. Treating the prodrome: Naturalistic findings from the RAP Program. Acta Psychiatr Scand 2002;106 (S413):44 [abstract].

4. Correll CU, Parikh UH, Kane JM, Malhotra AK. Novel antipsychotic-induced weight gain and metabolic effects in children and adolescents with psychotic and aggressive disorders. J Invest Medicine 2003;51 (Suppl 2):373 [abstract].

5. Correll CU, Kane JM, O’Shea D, Razi K, Malhotra AK. Antipsychotic polypharmacy in the treatment of schizophrenia. Schizophr Res 2003;60(Suppl.):37 [abstract].

6. Correll CU, Parikh UH, John M. Kane, Malhotra AK. Changes in body composition in children and adolescents treated with second generation antipsychotics. Biol Psychiatry 2004 (suppl);55:16 [abstract].

7. Saito E, Correll CU, Kafantaris V, Gallelli K, McMeniman M, Parikh U, Malhotra AK. Hyperprolactinemia and sexual side effects in children and adolescents treated with atypical antipsychotic agents. Biol Psychiatry 2004 (suppl);55:42 [abstract].

8. Correll CU, Parikh UH, John M. Kane, Malhotra AK. Second generation antipsychotic-induced insulin resistance in antipsychotic-naive children and adolescents. Biol Psychiatry 2004 (suppl);55:147 [abstract].

9. Olshanskiy V, Parikh UH, Mughal T, Moroff M, Kane JM, Malhotra AK, Correll CU: Changes in Composition in Children and Adolescents Treated with Second-Generation Antipsychotics. Schizophr Bull 2005; 31(5):567 [abstract].

10. Parikh UH, Mughal T, Olshanskiy V, Kane JM, Malhotra AK, Correll CU. New-onset Dyslipidemia in Children and Adolescents Treated with Second-Generation Antipsychotics. Schizophr Bull 2005; 31(5):567-8 [abstract].

11. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Malhotra AK, Kane JM, Cornblatt BA. The Prodrome in Early-onset Bipolar Disorder: Onset Pattern and Symptom Constellation. Biol Psychiatry 2005 (suppl 8);57:35 [abstract].

12. Correll CU, Parikh UH, Mughal T, Shah M, Pleak RR, Gutkovich Z, Olshanskiy V, Moroff M, Kane JM, Malhotra AK. Development of Insulin Resistance in Antipsychotic-naïve Youngsters Treated with Novel Antipsychotics. Biol Psychiatry 2005 (suppl 8);57:35-36 [abstract].

Curriculum Vitae Christoph U. Correll, M.D. Page 129

13. Correll CU, Parikh UH, Mughal T, Kane JM, Malhotra AK. New-onset Dyslipidemia in Antipsychotic-naïve Youngsters Treated with Atypical Antipsychotics. Biol Psychiatry 2005 (suppl 8);57:36 [abstract].

14. Correll CU, Parikh UH, Mughal T, Olshanskiy V, Moroff M, Pleak RR, Foley C, Shah M, Gutkovich Z, Kane JM, Malhotra AK. Body Composition Changes Associated with Second-Generation Antipsychotics. Biol Psychiatry 2005 (suppl 8);57:36 [abstract].

15. Cornblatt BA, Lencz T, Smith C, Correll C, Auther A, Nakayama E. Social isolation: a critical intervention target in prodromal research. Schizophr Bull 2005; 31(5):219 [abstract].

16. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Malhotra AK, Kane JM, Cornblatt BA. Onset pattern and time course of prodromal symptoms in early-onset bipolar disorder. Bipolar Disorders 2005;7 (Suppl 2):44 [abstract].

17. Lencz T, Kingsley R, Szesko P, Correll CU, Malhotra AK, Cornblatt BA. A simple fMRI probe of fronto-striatal function based on stimulus response incompatibility. Neuroimage 2005;26 (suppl 1):33 [abstract].

18. Correll CU, Parikh UH, Mughal T, Olshanskiy V, Kane JM, Malhotra AK. Second-Generation Antipsychotic-Induced Weight Gain, Insulin Resistance and Dyslipidemia in Treatment-Naive Children and Adolescents. Biol Psychiatry 2006 (suppl 1);59(8):79 [abstract].

19. Correll CU, Parikh UH, Mughal T, Goodwin L, Kane JM, Malhotra AK. Effect of Atypical Antipsychotics on Hypothalamic Key Regulatory Peptides for Appetite and Energy Balance in Treatment-Naïve Youth. Biol Psychiatry 2006 (suppl 1);59(8):165 [abstract].

20. Cornblatt BA, Smith CW, Auther A, Shah MR, Foley C, Lencz T, Correll CU, Kane JM. Treatment of the schizophrenia prodrome: Do antidepressants work? Neuropsychopharmacology 2006;31(12):114 [abstract].

21. Correll CU, Mughal T, Dudas M, Kane JM, Malhotra AK. Effect of Atypical Antipsychotics on Prolactin Levels and Reproductive Functioning in Children and Adolescents. Neuropsychopharmacology 2006;31(12):132 [abstract].

22. Correll CU, Mughal T, Parikh U, Kane JM, Malhotra AK. Atypical Antipsychotic-Induced Changes in Body Composition, Lipid Metabolism and Insulin Resistance in Antipsychotic Naïve Youth. Schizophrenia Bulletin 2007;33(2):496-7 [abstract].

23. Mughal T, Dudas M, Kane JM, Malhotra AK, Correll CU. Long-term Effects of Atypical Antipsychotics on Prolactin Levels and Reproductive Functioning in Children and Adolescents. Schizophrenia Bulletin 2007;33(2):503 [abstract].

24. Correll CU, Penzner JB, Richter JJ, Auther A, Smith CW, Kane JM, Cornblatt BA. The prodrome to psychotic and non-psychotic mania in early-onset bipolar disorder. Bipolar Disord 2007;9 (Suppl 1): 30 [abstract]

25. Cornblatt BA, Smith CW, Auther A, Nagachandran P, McLaughlin D, Rifkin A, Correll CU. Differentiating Between Prodromal Mania and Prodromal Schizophrenia. Neuropsychopharmacology 2007;32(12): [abstract].

26. Correll CU, Nyilas M, Aurang C, van Beek A, Jin N, Marcus R, Forbes RA, McQuade RD, Iwamoto T, Carson W. Long-Term Safety And Tolerability Of Aripiprazole In Children (10-17 y/o) with Bipolar I Disorder. Neuropsychopharmacology 2007;32(12): [abstract]

27. Cornblatt BA, Smith CW, Auther A, Baskir L, Correll CU. Antidepressants: An effective treatment for the prodromal phase of schizophrenia? Schizophr Res 2008;102(1-3) (suppl 2): 32-33 [abstract].

28. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S: Antipsychotic combinations versus monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Res 2008;102(1-3) (suppl 2): 35 [abstract].

Curriculum Vitae Christoph U. Correll, M.D. Page 130

29. Forbes RA, Nyilas M, Jin N, Owen R, Todorov S, Carson W, Correll CU. A 6-week study of the efficacy and tolerability of aripiprazole in pediatric patients with schizophrenia. Schizophr Res 2008;102(1-3) (suppl 2): 236 [abstract].

30. Nyilas M, Forbes RA, Jin N, Aurang C, Johnson B, Owen R, Iwamoto T, Carson W, Correll CU. Long-term tolerability and safety of aripiprazole in the treatment of pediatric patients with schizophrenia or bipolar disorder. Schizophr Res 2008;102(1-3) (suppl 2): 243 [abstract].

31. Correll CU, Kane JM, Goff D, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Pikalov A, Assunção-Talbott S. Aripiprazole in Combination with Risperidone or Quetiapine: Results from a 16-Week, Randomized, Double-Blind Study in Patients with Schizophrenia. Schizophr Res 2008;102(1-3) (suppl 2): 254 [abstract].

32. Correll CU. How Are Weight Gain And Metabolic Dysfunction Related to Antipsychotic Efficacy in Schizophrenia? Schizophr Res 2008;102(1-3) (suppl 2): 236-7 [abstract].

33. Correll CU, Kane JM, Olshanskiy V, Napolitano B, Malhotra AK. Discordant Cardiometabolic Risk of Atypical Antipsychotics Despite Worsening of Body Composition During First-Time Use in Children and Adolescents. Schizophrenia Bulletin 2009;35(Suppl 1):40-1 [abstract].

34. Smith CW, Baskir L, Auther A, McLaughlin D, Correll C, Cornblatt BA. Differential Impact of Neurocognition on the Prediction of Social and Role Functional Outcome in the Schizophrenia Prodrome. Schizophrenia Bulletin 2009;35(Suppl 1):325 [abstract].

35. Forbes RA, Nyilas M, Johnson B, Aurang C, Owen R, Iwamoto T, Carson WH, Correll CU. Long-term Tolerability and Safety of Aripiprazole in the Treatment of Pediatric Patients with Schizophrenia or Bipolar I Disorder. Schizophrenia Bulletin 2009;35(Suppl 1):362-3 [abstract].

36. Correll CU. Patterns and Predictive Value of Early Treatment Response in Adolescents with Schizophrenia-Spectrum Disorders. Schizophrenia Bulletin 2009;35(Suppl 1):368-9 [abstract].

37. Correll CU, Pappadopulos E, Mandel F. Predictors of Metabolic Change in Pediatric Bipolar Patients Treated With Ziprasidone. Bipolar Disord 2009;11 (Suppl 1): 49-50 [abstract].

38. Correll CU, Kane JM. New Research in the Early Prediction of Antipsychotic Response in Schizophrenia. Schizophr Res 2010;117(1-3) (suppl 2): 131 [abstract].

39. Correll CU. Time Course and Relevance of Early Treatment Response in Adolescents With Schizophrenia-Spectrum Disorders. Schizophr Res 2010;117: 131-132 [abstract].

40. Correll CU, Schenk EM. DelBello M. Antipsychotic and Mood Stabilizer Efficacy and Tolerability in Adult and Pediatric Patients with Bipolar I Mania: A Comparative Analysis of Acute, Randomized, Placebo-Controlled Trials. Bipolar Disord 2009;11 (Suppl 1): 49 [abstract]

41. Correll CU. Efficacy and Safety of Antipsychotics in Adolescents with Early-Onset Schizophrenia. Schizophr Res 2010;117: 166-167 [abstract].

42. Cohen D, Correll CU, De Hert M. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010;117: 270 [abstract].

43. Lencz T, Correll CU, Kane JM, Malhotra A. Genome-wide association study of antipsychotic induced weight gain in previously untreated patients. Neuropsychopharmacology. 2010;35:342 [abstract].

44. Stearns W, Olvet D, McLaughlin D, Auther A, Correll CU, Cornblatt BA. The clinical and neurocognitive similarities between the schizophrenia and bipolar prodromes. Neuropsychopharmacology. 2010;35: 118-9 [abstract].

45. Correll CU, Murray S, Zhao J, Manos G, Mankoski R, Forbes R, Marcus R, McQuade R. Weight gain and metabolic changes in studies of aripiprazole for the treatment of pediatric bipolar I disorder and adolescent schizophrenia. Neuropsychopharmacology. 2010;35:387-388 [abstract].

46. Malhotra AK, Correll CU, Kane JM, Lencz T. Genome-wide association study of antipsychotic-induced weight gain in previously untreated patients. Schizophrenia Bulletin 2011;37(Suppl 1):28 [abstract].

47. Malhotra AK, Correll CU, DeRosse P, Burdick KE, Szeszko PR, Lencz T. Genetic approaches to clinical heterogeneity in schizophrenia. Schizophrenia Bulletin 2011;37(Suppl 1):89 [abstract].

48. Correll CU. Treatment of early-onset schizophrenia: a meta-analysis of randomized-controlled trials. Schizophrenia Bulletin 2011;37(Suppl 1):299 [abstract].

Curriculum Vitae Christoph U. Correll, M.D. Page 131

49. Correll CU. Challenges and pitfalls in the implementation and conduct of clinical trials. Schizophrenia Bulletin 2011;37(Suppl 1):299 [abstract].

50. Correll CU, Agarwal V, Kane JM. Gradual and Overlapping Antipsychotic Switch Strategies Are Associated with Less All-Cause Discontinuation in Schizophrenia: Results from a Meta-analysis of Different Switch Strategies. Neuropsychopharmacology. 2011;36: S167-8 [abstract].

51. Cucchiaro J, Hsu J, Ogasa M, Silva R, Simonelli D, Pikalov A, Loebel A, Correll CU. Long-Term Safety and Effectiveness of Lurasidone in Sshizophrenia: Results of a 22-Month, Open-Label Extension Study Neuropsychopharmacology. 2011;36:S168 [abstract].

52. Glick I, Davis J, Correll CU. Mid- And Long-Term Efficacy & Effectiveness of Antipsychotic Medications for Schizophrenia: A Data-Driven, Personalized Clinical Approach. Neuropsychopharmacology. 2011;36: S169 [abstract].

53. Zhang J, Gallego JA, Robinson D, Malhotra AK, Kane JM, Correll CU. Efficacy and Safety of Second- vs First-Generation Antipsychotics in First Episode Schizophrenia: A Systematic Review and Meta-analysis. Neuropsychopharmacology. 2011;36:S175 [abstract].

54. Correll CU, Vieta E, Gitlin M, Grunze H. Making the right decision to prevent recurrence in the long-term treatment of bipolar disorder. Bipolar Disord 2012;14 (Suppl 1):49 [abstract].

55. Correll CU. Paediatric clinical trials: methodological issues and problems. Eur Neuropsychopharmacol. 2014;24(Suppl 2):S133 [abstract].

56. Correll CU. The role of LAI antipsychotics in the maintenance treatment of schizophrenia. Eur Neuropsychopharmacol. 2014;24(Suppl 2):S763 [abstract].

57. Correll CU. Cardiometabolic Risk in First Episode Schizophrenia-Spectrum Disorder Patients: Baseline Results from the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) Study”. Early Interv Psychiatry. 2014 Feb;8(Suppl 1):27.

58. Correll CU. Does a Prodrome Exist in Bipolar Disorder? Early Interv Psychiatry. 2014 Feb;8(Suppl 1):29 [abstract].

59. Correll CU, Kohegy E, Zhao C, Baker RA, McQuade RD, Salzman P, Sanchez R, Nyilas M, Carson WH, Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology. 2014;39:S349-50 [abstract].

60. Zhang JP, Lencz T, Robinson D, Fleichhacker W, Kahn R, Ophoff R, Kane J, Malhorta A, Correll C. Pharmacogenetic Associations of Antipsychotic Drug Induced Weight Gain: A Systematic Review and Meta-analysis. Neuropsychopharmacology. 2014;39:S418-19 [abstract].

61. Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck RA, Kane JM. Medication Prescription Practices for Patients with Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. Neuropsychopharmacology. 2014;39:S455-56 [abstract].

62. Correll CU, Skuban A, Youakim J, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R. Brexpiprazole for the treatment of acute schizophrenia: a randomized, controlled trial. Neuropsychopharmacology. 2014;39:S474 [abstract].

63. Fagerlund B, Pagsber AK, Fink-Jensen A, Jensen MH, Jeppesen P, Nielsen MO, Jensen KG, Andersen GS, Stentebjerg-Olesen M, Klauber DG, Rudå D, Correll CU, The Glenthøj BY, Jepsen JR. impact of age of onset and IQ on cognitive deficits in antipsychotic-naïve adolescents and adults with schizophrenia. Schizophrenia Bulletin 2015;41(Suppl 1):43-44 [abstract].

64. Pagsberg AK, Jensen KG, Rudå D, Klauber DG, Stentebjerg-Olesen M, Stenstrøm AD, Bilenberg N, Jepsen JR, Jantzen P, Fagerlund B, Correll CU, Jeppesen P, Fink-Jensen A. Clinical Characteristics of Children and Adolescents with First Episode Schizophrenia in the Tolerability Tolerability and Efficacy of Antipsychotics (TEA) Trial. Schizophrenia Bulletin 2015;41(Suppl 1):114 [abstract].

65. Rizvi AF, Correll CU, Kane JM, Birnbaum ML,. Role of Social Media and the Internet in Pathways to Care for Youth with Psychosis. Schizophrenia Bulletin 2015;41(Suppl 1):188 [abstract].

66. Silverman BL, Correll CU, Weiden P, Jiang Y, Pathak S, DiPetrillo L, Martin W, Bose A; Stankovic S, Ehrich EW. A Phase 2, Randomized, Olanzapine-Controlled Study of the Safety, Tolerability,

Curriculum Vitae Christoph U. Correll, M.D. Page 132

and Efficacy of ALKS 3831 in Adults with Schizophrenia. Schizophrenia Bulletin 2015;41(Suppl 1):307 [abstract].

67. Correll CU. Cardiometabolic Risk in First-Epsiode Schizophrenia-Spectrum Disorders. Schizophrenia Bulletin 2015;41(Suppl 1):307 [abstract].

68. Correll CU, Skuban A, Ouyang J, Weiller E, Weiss C. Long-term Safety of Brexpiprazole (OPC-34712) in Schizophrenia: Results from Two 52-Week Open-Label Studies. Schizophrenia Bulletin 2015;41(Suppl 1):307 [abstract].

69. Correll CU. Update on the Pharmacological Treatment and clinical Predictors of Therapeutic Response to Antipsychotics in First-Episode Schizophrenia. Schizophrenia Bulletin 2015;41(Suppl 1):307 [abstract].

70. Skuban A, Correll CU, Kane JM, Ouyang J, Weiss C, Weiller E. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies. Schizophrenia Bulletin 2015;41(Suppl 1):333-4 [abstract].

71. Fagerlund B. Pagsberg AK, Fink-Jensen AJensen MH, Jeppesen P, Nielsen ME, Jensen KG, Andersen GS, Stentebjerg-Olesen M, Klauber DG, Ruda D, Correll CU, Glenthoj BY, Jepsen JRM. The impact of age of onset and IQ on cognitive deficits in antipsychotic-naïve adolescents and adults with schizophrenia. Schizophr Bull 2016;41(3) (Suppl 1):S43-44.

72. Pagsberg AK, Jensen KG, Ruda D, Klauber DG, Stentebjerg-Olesen M, Stenstrom AD, Bilenberg N, Jepsen JRM, Fagerlund B, Correll CU, Jeppesen P, Fink-Jensen A. Clinical Characteristics of Children and Adolescents with First-Episode Schizophrenia in the Tolerability and Efficacy of Antipsychotics (TEA) Trial. Schizophr Bull 2016;41(3) (Suppl 1):S114-S115.

73. Rizvi A, Kane JM. Correll CU, Birnbaum ML. The role of social media and the internet in pathways to care for youth with psychosis. Schizophr Bull 2016;41(3) (Suppl 1):S188.

74. Correll CU. Cardiometabolic Risk in First-Episode Schizophrenia-Spectrum Disorders. S307

75. Correll CU, Carbon M. Update on the Pharmacological Treatment and Clinical Predictors of Therapeutic Response to Antipsychotics in First-Episode Schizophrenia. Schizophr Bull 2016;41(3) (Suppl 1):S307-S308.

76. Correll CU, Skuban A, Ouyang J, Weiller E, Weiss C. Long-term Safety of Brexpiprazole (OPC-34712) in Schizophrenia: Results from Two 52-Week Open-Label Studies, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence Italy April 02-06, 2016. Schizophr Bull 2016;41(3) (Suppl 1):S307.

77. Skuban A, Correll CU, Kane JM, Ouyang J, Weiss C, Weiller E. Efficacy of Brexpiprazole (OPC-34712) in Acute Schizophrenia: Results of Two Pooled Pivotal Studies, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence Italy, April 02-06, 2016. Schizophr Bull 2016;41(3) (Suppl 1):S333-S334.

78. Guinart D, Moreno E, Cuenca A, Galindo L, Fernandez C, Perez EJ, Menoyo E, Garcia J, Salgado P, Correll CU, de la Torre R, Perez V, Robledo P: Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium-derived cells of Schizophrenia patients: Clinical and Neuropsychological Correlates. European Neuropsychopharmacology Jan. 2019; 29: S114-S115.

POSTER PRESENTATIONS (SELECTION) 1. Correll CU, Lencz T, Obuchowski M, Shah M, Smith C, Auther A, Olsen R, Kane JM, Cornblatt

BA. Risks of pharmacological interventions in adolescents considered prodromal for schizophrenia. 42nd Annual National Institute of Mental Health New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, June 10–13, 2002.

2. Cornblatt B, Lencz T, Correll C, Author A, Smith C. Treating the prodrome: Naturalistic findings from the RAP Program. Third International Early Psychosis Conference, Copenhagen, Denmark, September 25-28, 2002.

Curriculum Vitae Christoph U. Correll, M.D. Page 133

3. Correll CU, Saito E, Kafantaris V, Kumra S, Malhotra AK. Atypical antipsychotics: nutritional and metabolic effects on children and adolescents. 49th American Academy of Child and Adolescent Psychiatry Meeting, San Francisco, CA, October 22-27, 2002.

4. Saito E, Correll CU, Kafantaris V. A prospective study of hyperprolactinemia secondary to atypical antipsychotic agents. 49th American Academy of Child and Adolescent Psychiatry Meeting, San Francisco, CA, October 22-27, 2002.

5. Correll CU, Parikh UH, Kane JM, Malhotra AK. Novel antipsychotic-induced weight gain and metabolic effects in children and adolescents with psychotic and aggressive disorders. Annual American Federation for Medical Research (AFMR) Clinical Research Meeting, Maryland, Baltimore, March 13-16, 2003.

6. Correll CU, Kane JM, O’Shea D, Razi K, Malhotra AK. Antipsychotic polypharmacy in the treatment of schizophrenia. International Congress on Schizophrenia Research, Colorado Springs, CO, March 29 – April 2, 2003.

7. Correll CU, Parikh UH, Kane JM, Malhotra AK. Novel antipsychotic-induced weight gain and metabolic effects in children and adolescents with psychotic and aggressive disorders. Clinical Research 2003 Meeting, Baltimore, March 14-16, 2003.

8. Correll CU, Parikh UH, Kane JM, Malhotra AK. Novel antipsychotic-induced hyperlipidemia in children and adolescents with psychotic and aggressive disorders. Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003.

9. Saito E, Correll C, Kafantaris V. Hyperprolactinemia in children and adolescents treated with atypical antipsychotics. 43th Annual Meeting of the New Drug Evaluation Unit (NCDEU), Boca Raton, FL, May 27-30, 2003.

10. Correll CU, Parikh UH, John M. Kane, Malhotra AK. Atypical antipsychotic-induced nutritional and metabolic effects during development. 50th American Academy of Child and Adolescent Psychiatry Meeting, Miami Beach, FL, October 14-19, 2003.

11. Trivedi HK, Eisenberg T, Le A, Correll CU. Characteristics and appropriateness of pediatric psychiatry emergency room visits. 50th American Academy of Child and Adolescent Psychiatry Meeting, Miami Beach, FL, October 14-19, 2003.

12. Correll CU, Parikh UH, Olshanskiy V, Chopra B, Kane JM, Malhotra AK. Changes in body composition and serum lipids in children and adolescents treated with second-generation antipsychotics. 16th World Congress of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Germany, August 22 - 26, 2004.

13. Correll CU, Parikh UH, Kane JM, Malhotra AK. Prospective Study of second-generation antipsychotic-induced insulin resistance in antipsychotic-naïve children and adolescents. 16th World Congress of the International Association in Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Germany, August 22 - 26, 2004.

14. Correll CU, Parikh UH, John M. Kane, Malhotra AK. Changes in body composition in children and adolescents treated with second generation antipsychotics. 59th Annual Conference of the Society of Biological Psychiatry, New York, NY, April 27 - May 1, 2004.

15. Saito E, Correll CU, Kafantaris V, Gallelli K, McMeniman M, Parikh U, Malhotra AK. Hyperprolactinemia and sexual side effects in children and adolescents treated with atypical antipsychotic agents. 59th Annual Conference of the Society of Biological Psychiatry, New York, NY, April 27 - May 1, 2004.

16. Correll CU, Parikh UH, John M. Kane, Malhotra AK. Second generation antipsychotic-induced insulin resistance in antipsychotic-naive children and adolescents. 59th Annual Conference of the Society of Biological Psychiatry, New York, NY, April 27 - May 1, 2004.

17. Cornblatt BA, Smith C, Lencz T, Auther A, Nakayama E, Correll C, Siris S. Are Anti-depressants a Possible Treatment for the Schizophrenia Prodrome? 43rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, December 12-16, 2004.

18. Olshanskiy V, Parikh UH, Mughal T, Moroff M, Kane JM, Malhotra AK, Correll CU. Changes in Composition in Children and Adolescents Treated with Second-Generation Antipsychotics. International Congress on Schizophrenia Research (ICOSR), Savannah, GA, April 02-06, 2005.

Curriculum Vitae Christoph U. Correll, M.D. Page 134

19. Parikh UH, Mughal T, Olshanskiy V, Kane JM, Malhotra AK, Correll CU. New-onset Dyslipidemia in Children and Adolescents Treated with Second-Generation Antipsychotics. International Congress on Schizophrenia Research (ICOSR), Savannah, GA, April 02-06, 2005.

20. Cornblatt BA, Lencz T, Smith C, Correll C, Auther A, Nakayama E. Social isolation: a critical intervention target in prodromal research. International Congress on Schizophrenia Research (ICOSR), Savannah, GA, April 02-06, 2005.

21. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Mlhotra AK, Kane JM, Cornblatt BA. The Prodrome in Early-onset Bipolar Disorder: Onset Pattern and Symptom Constellation. 60th Annual Meeting of the Society of Biological Psychiatry, Atlanta, GA, May 19-21, 2005.

22. Correll CU, Parikh UH, Mughal T, Shah M, Pleak RR, Gutkovich Z, Olshanskiy V, Moroff M, Kane JM, Malhotra AK. Development of Insulin Resistance in Antipsychotic-naïve Youngsters Treated with Novel Antipsychotics. 60th Annual Meeting of the Society of Biological Psychiatry, Atlanta, GA, May 19-21, 2005.

23. Correll CU, Parikh UH, Mughal T, Kane JM, Malhotra AK. New-onset Dyslipidemia in Antipsychotic-naïve Youngsters Treated with Atypical Antipsychotics. 60th Annual Meeting of the Society of Biological Psychiatry, Atlanta, GA, May 19-21, 2005.

24. Correll CU, Parikh UH, Mughal T, Olshanskiy V, Moroff M, Pleak RR, Foley C, Shah M, Gutkovich Z, Kane JM, Malhotra AK. Body Composition Changes Associated with Second-Generation Antipsychotics. 60th Annual Meeting of the Society of Biological Psychiatry, Atlanta, GA, May 19-21, 2005.

25. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Malhotra AK, Kane JM, Cornblatt BA. Searching for prodromal Symptoms in Early-onset Bipolar Disorder. Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005.

26. Correll CU, Mughal T, Olshanskiy V, Moroff M, Kane JM, Malhotra AK. Insulin Resistance in Antipsychotic-naïve Youngsters Treated with Novel Antipsychotics. Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005.

27. Zhu B, Ascher-Svanum H, Faries F, Correll C, Kane J. Cost of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26, 2005.

28. Correll CU, Parikh UH, Mughal T, Olshanskiy V, Kane JM, Malhotra AK. Dyslipidemia in Treatment-Naïve Youngsters Treated with Atypical Antipsychotics. Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005.

29. Correll CU, Parikh UH, Mughal T, Olshanskiy V, Shah M, Pleak RR, Gutkovich Z, Kane JM, Malhotra AK. Effect of Atypical Antipsychotics on Body Composition in Children and Adolescents. Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005

30. Lencz T, Kingsley R, Szesko P, Correll CU, Malhotra AK, Cornblatt BA. A simple fMRI probe of fronto-striatal function based on stimulus response incompatibility. 11th Annual Meeting of the Organization for Human Brain Mapping, Toronto, Canada, 12-16 June 2005.

31. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Malhotra AK, Kane JM, Cornblatt BA. Onset pattern and time course of prodromal symptoms in early-onset bipolar disorder. 6th International Conference on Bipolar Disorder, Pittsburgh, PA, June 16-18, 2005.

32. Correll CU, Parikh UH, Mughal T, Kane JM, Malhotra AK. Effect of Atypical Antipsychotics on Hypothalamic Appetite Regulation in Youth. 52nd American Academy of Child and Adolescent Psychiatry Meeting, Toronto, Canada, October 18-22, 2005.

33. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Malhotra AK, Kane JM, Cornblatt BA. Duration and Characteristics of the Bipolar Prodrome in Youth. 52nd American Academy of Child and Adolescent Psychiatry Meeting, Toronto, Canada, October 18-22, 2005.

34. Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. 2nd Asia-Pacific Conference of the International Society for Pharmacoepidemiology and Outcomes Research (ISPOR), Shanghai, China, March 5-7, 2006.

Curriculum Vitae Christoph U. Correll, M.D. Page 135

35. Correll CU, Penzner J, Kafantaris V, Nakayama E, Auther A, Lencz T, Malhotra AK, Kane JM, Cornblatt BA. A Lengthy, Clinically Relevant Prodrome Precedes First Mania in Early-Onset Bipolar Disorder. Fourth Annual NIMH Collaborative Pediatric Bipolar Disorder Conference, Chicago, IL, March 31 – April 1, 2006.

36. Nwaka TO, Dudas M, Parikh UH, Mughal T, Olshanskiy V, Kane JM, Malhotra AK, Correll CU. Aripiprazole for Bipolar Youth. 47th Annual National Student Research Forum, University of Texas Medical Branch, Galveston, TX, April 27-28, 2006.

37. Correll CU, Parikh UH, Mughal T, Olshanskiy V, Kane JM, Malhotra AK. Second-Generation Antipsychotic-Induced Weight Gain, Insulin Resistance and Dyslipidemia in Treatment-Naive Children and Adolescents. 61st Annual Meeting of the Society of Biological Psychiatry, Toronto, Canada, May 18-20, 2006.

38. Correll CU, Parikh UH, Mughal T, Goodwin L, Kane JM, Malhotra AK. Effect of Atypical Antipsychotics on Hypothalamic Key Regulatory Peptides for Appetite and Energy Balance in Treatment-Naïve Youth. 61st Annual Meeting of the Society of Biological Psychiatry, Toronto, Canada, May 18-20, 2006.

39. Frederickson A, Correll CU, Kane JM, Manu P. Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.

40. Penzner JB, Correll CU, Auther A, Smith C, Kane JM, Cornblatt BA. Distal and Proximal Risk Factors For Pediatric Bipolar Disorder. 53rd American Academy of Child and Adolescent Psychiatry Meeting, San Diego, CA, October 24-29, 2006.

41. Correll CU, Mughal T, Dudas M, Kane JM, Malhotra AK. Effect of Atypical Antipsychotics on Prolactin Levels and Reproductive Functioning in Children and Adolescents. Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 3-7, 2006.

42. Cornblatt BA, Smith CW, Auther A, Shah MR, Foley C, Lencz T, Correll CU, Kane JM. Treatment of the schizophrenia prodrome: Do antidepressants work? Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 3-7, 2006.

43. Correll CU, Hanssens. Metabolic risk of atypical antipsychotics: Individualizing treatment to improve mental and physical health. 15th European Congress on Psychiatry, Association of European Psychiatrists, Madrid, Spain, March 17-21, 2007.

44. Mughal T, Dudas M, Kane JM, Malhotra AK, Correll CU. Long-term Effects of Atypical Antipsychotics on Prolactin Levels and Reproductive Functioning in Children and Adolescents. Bi-Annual Meeting of the International Congress on Schizophrenia Research, Cold Springs, CO, March 28- April 1, 2007.

45. Druss B, Correll C, Cuffel B, Loebel A, Giordano S, Siu C. Findings of a national metabolic screening program for psychiatric outpatients. 160th Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19-24, 2007.

46. Correll CU, Penzner JB, Frederickson AM, Richter JJ, Auther A, Smith CW, Kane JM, Cornblatt BA. Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome. 7th International Conference on Bipolar Disorder, Pittsburgh, PA, June 7-9, 2007.

47. Correll CU, Nyilas M, Aurang C, van Beek A, Jin N, Marcus R, Forbes RA, McQuade RD, Iwamoto T, Weller E. Safety And Tolerability Of Aripiprazole In Children With Mania. 54th American Academy of Child and Adolescent Psychiatry Meeting, Boston, MA, October 23-28, 2007.

48. Callahan E, Frederickson A, Trivedi H, Eugene MC, Le A, Eisenberg T, Shekher M, Weiskopf M, Dicker R, Correll CU. Characteristics and Appropriateness of Pediatric Psychiatric Emergency Visits. 54th American Academy of Child and Adolescent Psychiatry Meeting, Boston, MA, October 23-28, 2007.

49. Correll CU, Nyilas M, Aurang C, van Beek A, Jin N, Marcus R, Forbes RA, McQuade RD, Iwamoto T, Carson W. Long-Term Safety And Tolerability Of Aripiprazole In Children (10-17 y/o)

Curriculum Vitae Christoph U. Correll, M.D. Page 136

with Bipolar I Disorder. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Boca Raton, FL, December 9-13, 2007.

50. Cornblatt BA, Smith CW, Auther A, Nagachandran P, McLaughlin D, Rifkin A, Correll CU. Differentiating Between Prodromal Mania and Prodromal Schizophrenia. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Boca Raton, FL, December 9-13, 2007.

51. Manu P, Napolitano B, Tsang J, Martin L. Lesser ML, Correll CU. Insulin-Sensitive Obesity in the United States: Findings From the National Health and Nutrition Examination Survey, 1999-2004. Society of General Internal Medicine, Pittsburgh, PA, April 9-12, 2008.

52. Smith CW, Auther A, Correll C, Baskir L, McLaughlin D, Cornblatt B. Naturalistic treatment of functional deficits in the schizophrenia prodrome. 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May 1-3, 2008.

53. Cornblatt BA, Smith CW, Auther A, Nagachandran P, McLaughlin D, Correll CU. Differences and Overlap Between the Clinical Prodrome of Mania and Schizophrenia. 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May 1-3, 2008.

54. Correll CU, Lops J, Malhotra AK, Kane JM, Manu P. Electrocardiographic Changes with Ziprasidone in Children and Adolescents Treated Within the Adult Dose Range: An Open-Label Prospective Study. 161st Annual Meeting of the American Psychiatric Association, Washington, DC, May 3-8, 2008.

55. Soto EC, Frederickson A, Trivedi H, Eisenberg T, Dicker R, Correll CU. Suicidality and Hospitalization as Cause and Outcome of Pediatric Psychiatric Emergency Room Visits. Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ, May 27-30, 2008.

56. Correll CU, Kane JM, Goff D, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Pikalov A, Assunção-Talbott S. Aripiprazole in Combination with Risperidone or Quetiapine: Results from a 16-Week, Randomized, Double-Blind Study in Patients with Schizophrenia. 1st Annual Meeting of the Schizophrenia International Research Society, Venice, Italy, June 21-25, 2008.

57. Correll CU. How Are Weight Gain And Metabolic Dysfunction Related to Antipsychotic Efficacy in Schizophrenia? 1st Annual Meeting of the Schizophrenia International Research Society, Venice, Italy, June 21-25, 2008.

58. Forbes RA, Nyilas M, Jin N, Owen R, Todorov S, Carson W, Correll CU. A 6-week study of the efficacy and tolerability of aripiprazole in pediatric patients with schizophrenia. 1st Annual Meeting of the Schizophrenia International Research Society, Venice, Italy, June 21-25, 2008.

59. Nyilas M, Forbes RA, Jin N, Aurang C, Johnson B, Owen R, Iwamoto T, Carson W, Correll CU. Long-term tolerability and safety of aripiprazole in the treatment of pediatric patients with schizophrenia or bipolar disorder. 1st Annual Meeting of the Schizophrenia International Research Society, Venice, Italy, June 21-25, 2008.

60. Correll CU, Nyilas M, Forbes RA, Jin N, Aurang C, Owen R, Iwamoto T, McQuade RD, Carson WH, Weller E. Long-term Tolerability and Safety of Aripiprazole in the Treatment of Pediatric Patients with Schizophrenia or Bipolar I Disorder. XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP) conference, Munich, Germany, July 13–17, 2008.

61. Smith CW, Auther A, Correll CU, Baskir L, McLaughlin D, Cornblatt B. Differential relationships between cognition, social and role functioning in the prodromal phase of psychosis. Annual Meeting of the Society for Research in Psychopathology, Pittsburgh, PA, September 25-28, 2008.

62. Soto EC, Dicker R, Correll CU. Frequency and Predictors of Medication Non-adherence in Psychiatrically Ill Children and Adolescents evaluated in the Emergency Room. 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 28-November 2, 2008.

63. Correll CU, Wang P, Pappadopulos E, Stewart M, Mandel F. Predictors of Response to Ziprasidone in Pediatric Patients with Bipolar Disorder. Annual Meeting of the American College of Neuropsychopharmacology, Scottsdale, AZ, December 7-11, 2008.

64. Forbes RA, Nyilas M, Johnson B, Aurang C, Jin N, Owen R, Iwamoto T, Carson WH, Correll CU. Long-term Tolerability and Safety of Aripiprazole in the Treatment of Pediatric Patients with

Curriculum Vitae Christoph U. Correll, M.D. Page 137

Schizophrenia or Bipolar I Disorder. Annual Meeting of the International Congress on Schizophrenia Research (ICOSR), San Diego, CA, March 28 – April 1, 2009.

65. Stewart M, Pappadopulos E, Mandel F, Correll CU. Predictors of Response and Remission in Pediatric Patients With Bipolar Disorder Treated With Ziprasidone. 162nd Annual Meeting of the American Psychiatric Association (APA), San Francisco CA, May 16-May 21, 2009.

66. Correll CU, Carson WH, Nyilas M, Forbes RA, Chen CF, Iwamoto T, Mankoski R, Mathew SJ, Pikalov A. Early Response Predicts Future Treatment Success during Aripiprazole Treatment of Adolescents with Schizophrenia. 162nd Annual Meeting of the American Psychiatric Association (APA), San Francisco, CA, May 16-May 21, 2009.

67. Correll CU, Pappadopulos E, Mandel F. Predictors of Metabolic Change in Pediatric Bipolar Patients Treated With Ziprasidone. 8th International Conference on Bipolar Disorder, Pittsburgh, June 25-27, 2009.

68. Correll CU, Schenk EM. DelBello M. Antipsychotic and Mood Stabilizer Efficacy and Tolerability in Adult and Pediatric Patients with Bipolar I Mania: A Comparative Analysis of Acute, Randomized, Placebo-Controlled Trials. 8th International Conference on Bipolar Disorder, Pittsburgh, PA, June 25-27, 2009.

69. Correll CU, Pappadopulos E, Mandel F. Predictors of Change in Weight and Metabolic Parameters in Pediatric Patients With Bipolar Disorder Treated With Ziprasidone or Placebo. 49th Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 29 - July 2, 2009.

70. Pikalov A, Mathew SJ, Carson WH, Nyilas M, Chen CF, Iwamoto T, Mankoski R, Correll CU. Early Response Predicts Future Treatment Success during Aripiprazole Treatment of Adolescents with Schizophrenia. 49th Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 29 - July 2, 2009.

71. Gallego JA, Bonetti J, Correll CU. Prevalence and Correlates of Antipsychotic Polypharmacy from the 1970s to 2009: A Systematic Review and Metaregression”. 49th Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 29 - July 2, 2009.

72. Correll CU, Pappadopulos E, Karayal O, Mandel F. Predictors of the Development of Cardiometabolic Abnormalities in Youth With Bipolar Disorder Treated With Ziprasidone or Placebo. Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Istanbul, Turkey, September 12-16, 2009.

73. Loze JY, Nyilas M, Aurang C, Jin N, Iwamoto T, Owen R, Carson WH, Forbes RA, Correll CU. Similar efficacy results in short- and long-term studies of aripiprazole in adolescents (ages 15-17) and adults with schizophrenia. Presented at the 2nd European Conference on Schizophrenia Research (ECSR), Berlin, Germany, September 21 – 23, 2009.

74. Soto EC, Frederickson A, Trivedi H, Eisenberg T, Dicker R, Correll CU. Frequency and risk factors for self-injurious behavior in patients seen in a pediatric psychiatric emergency room. 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Honolulu, HI, October 27-November 1, 2009.

75. Lops J, Manu P, Figen V, Malhotra AK, Kane JM, Correll CU. QT Interval Duration and Dispersion in Pediatric Patients Treated With Ziprasidone. 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Honolulu, HI, October 27-November 1, 2009.

76. Nyilas M, Aurang C, Jin N, Loze JY, Iwamoto T, Owen R, Carson WH, Forbes RA, Correll CU. Similar Efficacy Results in Short-Term and Long-Term Studies of Adult and Adolescent Patients with Schizophrenia Treated with Aripiprazole. 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Honolulu, HI, October 27-November 1, 2009.

77. Pikalov A, Mathew SJ, Carson WH, Nyilas M, Chen CF, Iwamoto T, Mankoski R, Correll CU. Early Response Predicts Future Treatment Success during Aripiprazole Treatment of Adolescents with Schizophrenia. 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Honolulu, HI, October 27-November 1, 2009.

78. Correll CU, Nyilas M, Mathew S, Zhao Q, Mankoski R, Carson WH, Iwamoto T, Forbes A. Validity of Early Antipsychotic Response to Aripiprazole in Adolescents with Schizophrenia and Its

Curriculum Vitae Christoph U. Correll, M.D. Page 138

Predictive Value for Clinical Outcomes. Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 6-10, 2009.

79. Maayan L, Vakhrusheva J, Correll CU. Pharmacologic Interventions to Reduce Antipsychotic Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-analysis. Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 6-10, 2009.

80. Cohen D, Correll CU, De Hert M. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. 2nd biannual meeting of the Schizophrenia International Research Society, Florence, Italy, April 10-14, 2010.

81. Nielsen J, Correll CU. Hematological clozapine monitoring with a point-of-care device. Poster presented at the 163rd Annual American Psychiatric Association Meeting, New Orleans, LA, May 22-26, 2010.

82. Maayan L, Vakhrusheva J, Sheridan EM, Correll CU. Risperidone Across the Age Span: A Meta-analytic Comparison of Placebo Controlled Trials. New Clinical Drug Evaluation Unit Meeting (NCDEU), Boca Raton, FL, June 14-17, 2010.

83. Maayan L, Correll CU, Vakhrusheva J, Smith M, Panza KE, Mahmood A, Bloch M. Weight Gain Associated with Mood Stabilizers and Second Generations Antipsychotics In Children: A Comparative Meta-Analysis. 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), New York, NY, October 26-31, 2010.

84. Lencz T, Correll CU, Kane JM, Malhotra A. Genome-wide association study of antipsychotic induced weight gain in previously untreated patients. Annual meeting of the American College of Neuropsychopharmacology (ACNP), Miami Beach, FL, December 5-9, 2010.

85. Stearns W, Olvet D, McLaughlin D, Auther A, Correll CU, Cornblatt BA. The clinical and neurocognitive similarities between the schizophrenia and bipolar prodromes. Annual meeting of the American College of Neuropsychopharmacology (ACNP), Miami Beach, FL, December 5-9, 2010.

86. Correll CU, Murray S, Zhao J, Manos G, Mankoski R, Forbes R, Marcus R, McQuade R. Weight gain and metabolic changes in studies of aripiprazole for the treatment of pediatric bipolar I disorder and adolescent schizophrenia. Annual meeting of the American College of Neuropsychopharmacology (ACNP), Miami Beach, FL, December 5-9, 2010.

87. Kristensen D, Bauer J, Balslev Jørgensen M, Correll CU. Antipsychotic polypharmacy in a treatment-refractory schizophrenic population receiving adjunctive treatment with Electroconvulsive therapy. Collegium Internationale Neuro-Psychopharmacologicum (CINP) conference, Salzburg, Austria, April 1-3, 2011.

88. Correll CU. Treatment of Early-Onset Schizophrenia: A Meta-Analysis of Randomized Controlled Trials International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, April 3-April 6, 2011.

89. Kyriakopoulos M, Samartzis L, Dima D, Hayes D, Corrigall R, Barker G, Correll CU, Frangou S. Effects of antipsychotic medication on white matter in Bipolar Disorder and Schizophrenia: a review of Diffusion Tensor Imaging findings. 66th Society of Biological Psychiatry (SOBP) Annual Meeting, San Francisco, CA, May 12-14, 2011.

90. Kishi T, Fukuo Y, Kawashima K, Moriwaki M, Fujita K, Correll CU, Iwata N. Nicotine addiction, endophenotype-related traits (cognitive function and prepulse inhibition) of schizophrenia, and neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2). 51st Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 13-16, 2011.

91. Kishi T, Fukuo Y, Okochi T, Kawashima K, Kitajima T, Yamanouchi Y, Kinoshita Y, Inada T, Ozaki N, Correll CU, Iwata N. Serotonin 6 receptor gene and schizophrenia: case-control study, meta-analysis and endophenotype-related traits of cognitive function and acoustic startle response. 51st Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 13-16, 2011.

92. Rothman B, Opler M, Correll CU, Zalsman G, Pandurangi A, Kohegyi E, Menlow N. Assessing the reliability of tanner Staging in CNS trials: a cross-cultural comparison of European, US and

Curriculum Vitae Christoph U. Correll, M.D. Page 139

Indian Raters. 51st Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 13-16, 2011.

93. Kishimoto T, Agarwal V, Brody A, Gelmann G, Kane JM, Correll CU. Maintenance Treatment and Relapse Prevention in Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials of First- and Second-Generation Antipsychotics. 51st Annual Meeting of the New Drug Evaluation Unit (NCDEU), Hollywood, FL, June 13-16, 2011.

94. Murray S, Zhao J, Manos G, Mankoski R, Marcus R, McQuade R, Marler S, Forbes RA, Correll CU. Weight Gain and Metabolic Changes in Studies of Aripiprazole for the Treatment of Irritability Associated with Autistic Disorder. 58th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2011.

95. Manu P, Kane JM, Correll CU. Lithium Is Metabolically Safer Than Divalproex in Children and Adolescents with Bipolar Disorder Who Also Receive a Second Generation Antipsychotic. 58th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Toronto, Canada, October 18-23, 2011.

96. Correll CU, Agarwal V, Kane JM. Gradual and Overlapping Antipsychotic Switch Strategies Are Associated with Less All-Cause Discontinuation in Schizophrenia: Results from a Meta-analysis of Different Switch Strategies”. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, December 4-8, 2011.

97. Glick I, Correll CU, Davis J. Mid- And Long-Term Efficacy & Effectiveness of Antipsychotic Medications for Schizophrenia: A Data-Driven, Personalized Clinical Approach. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, December 4-8, 2011.

98. Zhang J, Gallego JG, Robinson D, Malhotra AK, Kane JM, Correll CU. Efficacy and Safety of Second- vs First-Generation Antipsychotics in First Episode Schizophrenia: A Systematic Review and Meta-analysis. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, December 4-8, 2011.

99. Cucchiaro J, Hsu J, Ogasa M, Silva R, Simonelli D, Pikalov A, Loebel A, Correll CU. Long-term Safety and Effectiveness of Lurasidone in Schizophrenia: Results of a 22-Month, Open-Label Extension Study. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, December 4-8, 2011.

100. Agarwal V, Correll CU. Weight Change and Cardiometabolic Risk With Antipsychotic Polypharmacy: Meta-analysis Showing Improved Outcomes with Certain Aripiprazole Combinations. Poster presented at the Annual Meeting of the American Psychiatric Association (APA), Philadelphia, PA, May 5-9, 2012.

101. Yildiz A, Vieta E, Nikodem M, Correll CU, Baldessarini R. Can sophisticated methods of evidence synthesis offer better clinical decision making tools for the treatment of bipolar mania? The 12th International Review of Bipolar Disorders. Nice, France, May 21-23, 2012.

102. Detke HC, Feldman P, Correll CU, Liu C, Landry J, McDonnell DP. Comparison of Outcomes in Patients with Early Phase vs Later Phase Schizophrenia. 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) meeting, Phoenix, AZ, May 29-June 1, 2012.

103. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Kane JM, Correll CU. New Results Alter Balance of Evidence of Long-Acting Injectable vs. Oral Antipsychotics Regarding Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis. 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) meeting, Phoenix, AZ, May 29-June 1, 2012.

104. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long Acting Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image and Cohort Studies, poster presentation, 25th European College of Neuropsychopharmacology (ECNP) Congress, Vienna, Austria, October 3-17, 2012.

105. Kraemer S, Detke HC, Correll CU, Liu C, Landry J, Feldman P, McDonnell DP. Comparison of Outcomes in Patients with Early Phase vs Later Phase Schizophrenia. Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 21-24, 2012.

Curriculum Vitae Christoph U. Correll, M.D. Page 140

106. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long acting injectable vs. oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies, poster presentation, 51st Annual meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 2-6, 2012.

107. McEvoy JP, Citrome L, Hernandez D, Hsu J, Werner P, Pikalov A, Cucchiaro J, Correll CU, Loebel A. Switching to Lurasidone in Patients with Schizophrenia: Tolerability and Effectiveness at 6 Weeks and 6 Months, poster presentation, 51st Annual meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 2-6, 2012.

108. Correll CU, Maayan L, De Hert M, Cohen D. Adjunctive Topiramate in Patients with Schizophrenia-spectrum Disorders” Results from a Meta-Analysis of 9 Randomized Controlled Trials, poster presentation, 51st Annual meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 2-6, 2012.

109. Zhang J, Lencz T, Correll CU, Malhotra A. Multiple Obesity-related Genes are Associated with Antipsychotics-induced Weight Gain in Drug-Naïve Pediatric Patients, poster presentation, 51st Annual meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 2-6, 2012.

110. Correll CU. Predictors of Adverse Cardiometabolic Risk Modification in Youth With Schizophrenia-Spectrum Disorders and Non-Psychotic Disorders Receiving Antipsychotics, poster presentation, 14th International Congress on Schizophrenia Research (ICOSR), 14th International Congress on Schizophrenia Research, Orlando FL, April 11-25, 2013.

111. McEvoy JP, Citrome L, Correll CU, Hsu J, Pikalov A, Cucchiaro J, Loebel A. Switching to Lurasidone in Patients with Schizophrenia: Tolerability and Effectiveness at 6 Weeks and 6 Months, poster presentation at the World Federation of Societies for Biological Psychiatry (WFSBP) meeting, Kyoto, June 23-27, 2013.

112. Correll CU, Werner P, Pikalov A, Hsu J, Cucchiaro J, Loebel A. Early Improvement Predicts Endpoint Response to Lurasidone in Schizophrenia: Pooled Analysis of Five Double-Blind Trials, poster presentation, Annual Meeting of the European College of Neuropsychopharmacology (ACNP), Barcelona, Spain, October 5-9, 2013.

113. Grudnikoff E, Kaliora S, Al-Dhaher S, Mori N, Correll CU, Petrides G. Electroconvulsive Therapy In a Consecutive Cohort Of 41 Adolescents With Severe Psychotic and Mood Disorders: Efficacy, Safety and Correlates Of Response, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

114. Al-Dhaher Z, Kapoor S, Chekuri R, Al-Jadiri A, Ake T, David L, Correll CU. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine and risperidone in youth, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

115. Muir O, Al-Jadiri A, Bhatia P, Kapoor S, JKane JM, Correll CU. Attitudes of Children and Adolescents and their Caregivers Towards Long-Acting Injectable Antipsychotics in a Cohort of Youth Initiating Oral Antipsychotic Treatment, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Orlando, FL, October 22-26, 2013.

116. Correll CU, Werner P, Pikalov A, Hsu J, Cucchiaro J, Loebel A. Early Improvement Predicts Endpoint Response to Lurasidone in Schizophrenia: Pooled Analysis of Five Double-Blind Trials, poster presentation, 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 8-12, 2013.

117. Correll CU, Muir O, Al-Jadiri A, Kapoor S, Kane JM. Attitudes of Children and Adolescents and Their Caregivers Towards Long-Acting Injectable Antipsychotics in a Cohort of Youth Initiating Oral Antipsychotic Treatment, poster presentation, 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 8-12, 2013.

118. Gerstenberg M, Dvosrky D, Maurizia F, Heekeren K, Metzler S, Roessler X, Theodoridou A, Traber-Walker N, Wotruba D, Correll CU, Walitza S. Frequency and characteristics of the Attenuated Psychosis Syndrome and delineation to other risk profiles in a sample of help-seeking

Curriculum Vitae Christoph U. Correll, M.D. Page 141

individuals. Annual Meeting of the Schizophrenia International Reseach Society (SIRS), Florence, Italy, April 5-9, 2014.

119. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-Term Safety and Effectiveness of Lurasidone in Schizophrenia: Results of a 22 Month, Open-Label Extension Study. Annual Meeting of the Schizophrenia International Reseach Society (SIRS), Florence, Italy, April 5-9, 2014.

120. Vernal DL, Kapoor S, Al-Jadiri A, Borenstein Y, Gerstenberg M, Sheridan EM, Borner I, Kane JM, Steinhausen HC, Correll CU. 12-week Naturalistic Study comparing Characteristics and Outcomes of Antipsychotic-Treated Youth with Schizophrenia Spectrum Disorders and Psychosis NOS. Annual Meeting of the Schizophrenia International Reseach Society (SIRS), Florence, Italy, April 5-9, 2014.

121. Jensen KG, Correll CU, Juul K, Fink-Jensen A, Pagsberg AK. QTc-prolongation during antipsychotic treatment in children and adolescents: A Systematic Review. Annual Meeting of the Schizophrenia International Reseach Society (SIRS), Florence, Italy, April 5-9, 2014.

122. Correll CU, Pikalov A, Hsu J, Cucchiaro J, Goldman R, Loebel A. Early Improvement Predicts Endpoint Response to Lurasidone in Schizophrenia: Pooled Analysis of Five Double-Blind Trials, poster presentation, Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), Hollywood, FL, June 16-19, 2014.

123. Birnbaum M, Rizvi A, Kane JM, Correll CU. The Role of Social Media and the Internet in Pathways to Care for Youth with Psychosis, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, FL, October 22-26, 2014.

124. Al-Dhaher Z, Azzo S, Correll CU. Tolerability and Effectiveness of Aripiprazole, Quetiapine and Risperidone in Youth with Autism Spectrum Disorders, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, FL, October 22-26, 2014.

125. Chawla JM, Kishimoto T, Kapoor S, Al-Jadiri A, Azzo S, Correll CU. Effects of Risperidone and Aripiprazole on Prolactin-Mediated Alterations in Sex Hormones, Sexual Functioning, Bone Turnover and Vitamin D in Youth: A Cross-Sectional Study, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, FL, October 22-26, 2014.

126. Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. QTc changes during antipsychotic treatment of children and adolescents: A systematic review and meta-analysis of clinical trials, poster presentation, annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), San Diego, FL, October 22-26, 2014.

127. Zhang JP, Lencz T, Robinson D, Fleichhacker W, Kahn R, Ophoff R, Kane J, Malhorta A, Correll C. Pharmacogenetic Associations of Antipsychotic Drug Induced Weight Gain: A Systematic Review and Meta-analysis, poster presentation, 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 7-11, 2014.

128. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial, poster presentation, 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 7-11, 2014.

129. Correll CU, Kohegy E, Zhao C, Baker RA, McQuade RD, Salzman P, Sanchez R, Nyilas M, Carson WH, Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia: a randomized, double-blind, placebo-controlled trial, poster presentation, 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 7-11, 2014.

130. Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck RA, Kane JM. Medication Prescription Practices for Patients with Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study, poster presentation, 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 7-11, 2014.

Curriculum Vitae Christoph U. Correll, M.D. Page 142

131. Skuban A, Correll CU, Kane JM, Ouyang J, Weiss C, Weiller E. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies. 15th International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2015.

132. Correll CU, Skuban A, Ouyang J, Weiller E, Weiss C. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies, poster presentation, 15th International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2015.

133. Silverman BL, Correll CU, Weiden P, Jiang Y, Pathak S, DiPetrillo L, Martin W, Bose A; Stankovic S, Ehrich EW. A Phase 2, Randomized, Olanzapine-Controlled Study of the Safety, Tolerability, and Efficacy of ALKS 3831 in Adults with Schizophrenia, poster presentation, 15th International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2015.

134. Fagerlund B, Pagsberg AK, Fink-Jensen A, Jensen MH, Jeppesen P, Nielsen MO, Jensen KG, Andersen GS, Stentebjerg-Olesen M, Klauber DG, Rudå D, Correll CU, The Glenthøj BY, Jepsen JR. impact of age of onset and IQ on cognitive deficits in antipsychotic-naïve adolescents and adults with schizophrenia, poster presentation, 15th International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2015.

135. Correll CU, Skuban A, Ouyang J, Weiller E, Weiss C. Long-term Safety of Brexpiprazole (OPC-34712) in Schizophrenia: Results from Two 52-Week Open-Label Studies, poster presentation, 15th International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, March 28-April 01, 2015.

136. Ilzarbe D, Vernal DL, Correll CU. Psychosis NOS in children and adolescents: a systematic review of the “unspecified” gap. 16th International annual meeting of the European Society for Child and Adolescent Psychiatry (ESCAP) , Madrid, Spain, June 20-24, 2015.

137. Abdelkarim Garcia M, Galling B, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis., poster presentation, 28th European College of Neuropsychopharmacology (ECNP) Congress, Amsterdam, Netherlands, August 28 – September 1, 2015).

138. Roldán A, Galling B, Correll CU. Are Antipsychotics a risk factor for Type 2 Diabetes in Youth? A metaanalysis of incidence rates compared to healthy and psychiatric controls, poster presentation, 28th European College of Neuropsychopharmacology (ECNP) Congress, Amsterdam, Netherlands, August 28 – September 1, 2015).

139. Galling B, Roldán A, Correll CU. Efficacy and Safety of Antipsychotic Polypharmacy in Schizophrenia: Results from a Systematic Review and Metaanalysis of Augmentation with a Second Antipsychotic in Patients with Suboptimal Response, poster presentation, 28th European College of Neuropsychopharmacology (ECNP) Congress, Amsterdam, Netherlands, August 28 – September 1, 2015).

140. Silverman BL, Correll CU, Weiden P, Jiang Y, Pathak S, DiPetrillo L, Martin W, Bose A, Stankovic S, Ehrich EW. ALKS 3831 demonstrated equivalent Antipsychotic Efficacy While Addressing Weight Gain: Results From A Phase 2, Randomized, Olanzapine-Controlled Study. 5th biannual meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 2-6, 2016.

141. Ilzarbe D, Ramos Caneda A, Vernal DL, Correll CU. Age Differences in the Diagnostic Stability of Patients with Psychosis NOS: A Meta-Analysis. 5th biannual meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 2-6, 2016.

142. Vanover KE, Davis RE, O’Gorman C, Saillard J, Weingar M, Mates S, Correll CU. Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Safety Results from a Randomized, Double-Blind, Placebo-Controlled Trial. Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 3-7, 2016.

143. Vanover KE, Davis RE, O’Gorman C, Saillard J, Weingar M, Mates S, Correll CU. Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Secondary Endpoints &

Curriculum Vitae Christoph U. Correll, M.D. Page 143

Subgroup Analyses from a Randomized, Double-Blind, Placebo-Controlled Trial. Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy, April 3-7, 2016.

144. Fagerlund B. Pagsberg AK, Fink-Jensen AJensen MH, Jeppesen P, Nielsen ME, Jensen KG, Andersen GS, Stentebjerg-Olesen M, Klauber DG, Ruda D, Correll CU, Glenthoj BY, Jepsen JRM. The impact of age of onset and IQ on cognitive deficits in antipsychotic-naïve adolescents and adults with schizophrenia, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence, Italy, April 02-06, 2016.

145. Pagsberg AK, Jensen KG, Ruda D, Klauber DG, Stentebjerg-Olesen M, Stenstrom AD, Bilenberg N, Jepsen JRM, Fagerlund B, Correll CU, Jeppesen P, Fink-Jensen A. Clinical Characteristics of Children and Adolescents with First-Episode Schizophrenia in the Tolerability and Efficacy of Antipsychotics (TEA) Trial, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence, Italy, April 02-06, 2016.

146. Rizvi A, Kane JM. Correll CU, Birnbaum ML. The role of social media and the internet in pathways to care for youth with psychosis Trial, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence, Italy, April 02-06, 2016.

147. Correll CU, Skuban A, Ouyang J, Weiller E, Weiss C. Long-term Safety of Brexpiprazole (OPC-34712) in Schizophrenia: Results from Two 52-Week Open-Label Studies, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence, Italy, April 02-06, 2016.

148. Skuban A, Correll CU, Kane JM, Ouyang J, Weiss C, Weiller E. Efficacy of Brexpiprazole (OPC-34712) in Acute Schizophrenia: Results of Two Pooled Pivotal Studies, poster presentation, 5th Biennial Schizophrenia International Research Society Conference (ICOSR), Florence, Italy, April 02-06, 2016.

149. Vedtofte L, Larsen JR, Jakobsen MS, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. The GLP-1 analog liraglutide improves glucose tolerance and reduces body weight in schizophrenia spectrum disorder patients treated with clozapine or olanzapine. Annual Meeting in Danish Endocrine Society, Esbjerg, Denmark, January 27-28, 2017

150. Comella CL, Correll CU, Liang GS, Burke J, Yonan C, Le H. Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension), 69th Annual Meeting of the American Academy of Neurology (ANA), Boston, MA, USA, April 22-28, 2017

151. Beck N, Wolter H, Beck JF, Correll CU, Spohr HL, van Noort BM. Criminal behavior and substance abuse in adolescents and adults with fetal alcohol spectrum disorder. European Conference on FASD, Berlin Germany, September 24-26, 2018

152. van Noort BM, Beck JF, Beck N, Wolter H, Spohr HL, Correll CU. Psychiatric symptoms and quality of life in adolescents and adults with fetal alcohol spectrum disorder: results from a longitudinal observational study. European Conference on FASD, Berlin Germany, September 24-26, 2018

153. von Hardenberg L, Krogmann A, Galling B, Correll CU, Pagsberg AK. Early antipsychotic response as outcome predictor in adolescents with psychosis: results from the TEA trial. Annual meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 6-9, 2018.

154. von Hardenberg L, Krogmann A Correll CU, Galling B. Antidepressants vs. Antipsychotics in the Treatment of Patients with High-Risk for Psychosis. Annual Meeting of the German Association of Psychiatry, Psychotherapy and Neurology (DGPPN), Berlin, Germany, November 28 - December 1, 2018.

155. Guinart D, Moreno E, Cuenca A, Galindo L, Fernandez C, Perez EJ, Menoyo E, Garcia J, Salgado P, Correll CU, de la Torre R, Perez V, Robledo P: Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium-derived cells of Schizophrenia patients: Clinical and Neuropsychological Correlates. Annual meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 6-9, 2018.